

Laboratory
Emerging Pathogens Initiative (EPI)
Version 5.2
Roll Up Modifications Technical and User Manual



September 2015

Department of Veterans Affairs (VA)
Office of Information and Technology (OI&T)
Product Development (PD)

Revision History

[illegible]

| Date | Version | Description | Author |
|---------|------------|--|---------|
| | | Installation instructions. Removed Personally Identifiable Information (PII). Changed AAC to Austin Information Technology Center (AITC) throughout manual | |
| 05/2008 | LR*5.2*175 | Initial release | VA OI&T |

Preface

The Veterans Health Information Systems and Architecture (VistA) Laboratory Emerging Pathogens Initiative (EPI) Rollup Modifications Patch LR*5.2*281 Technical and User Manual provides assistance for installing, implementing, and maintaining the EPI software application enhancements.

The International Classification of Diseases, Tenth Revision (ICD-10) Remediation patch LR* 5.2*421 makes the following changes to the Emerging Pathogens Initiative (EPI) application:

- The following fields and screens have been updated to refer to “ICD” rather than “ICD9”:
 - Laboratory Search/Extract Parameters Input screens
 - Enter/Edit Local Pathogens screens
 - Detailed Verification Report
 - Help text
- Within the Enter/Edit Local Pathogens and Laboratory Search/Extract Parameters Input screens, users are prompted to specify a code set on which to search prior to entering an ICD code. Based on this input, the system will only allow ICD-9 entry or ICD-10 entry.
- The Pathogen Inquiry option has been modified to list both ICD-9 and ICD-10 codes.
- The Generate Local Report/Spreadsheet option has been modified to include both the Diagnosis Code Set Designation and the Diagnosis Code.
- Health Level 7 (HL7) Reports that are sent to Austin Information Technical Center (AITC), formerly Austin Automation Center (AAC), have been modified to include ICD-10 Codes and Descriptions, which are included in the DG1 HL7 Segments.

The ICD-10 PTF Modifications patch LR*5.2*442 made changes to the Emerging Pathogens Initiative (EPI) application to ensure the software would accommodate the expanded number of ICD-10 codes that may be contained in a patient record.

Intended Audience

The intended audience for this manual includes the following users and functionalities:

- Veterans Health Administration (VHA) facility Information Resource Management (IRM) staff (will be important for installation and implementation of this package)
- Laboratory Information Manager (LIM) (will be important for installation and implementation of this package)
- Representative from the Microbiology section in support of the Emerging Pathogens Initiative (EPI) Rollup enhancements (i.e., director, supervisor, or technologist) (will be important for installation and implementation of this package especially with parameter and etiology determinations; may also have benefit from local functionality)

- Total Quality Improvement/Quality Improvement/Quality Assurance (TQI/QI/QA) staff or persons at the VHA facility with similar function (will be important for implementation of this package given broad-ranging impact on medical centers and cross-cutting responsibilities that extend beyond traditional service lines; may also have benefit from local functionality)
- Infection Control Practitioner (likely to have benefit from local functionality)

NOTE: It is highly recommend that the Office of the Director (00) at each VHA facility designate a person or persons who will be responsible for the routine implementation of this patch (both at the time of this installation and afterwards) and to take the lead in trouble-shooting issues that arise with the routine functioning of the process. This decision is left at the discretion of the director since the functions that persons perform locally may have different titles and meanings. The definitions of installation and implementation are provided below to help the Office of the Director in assigning the responsibility.

The term installation refers to the process of actually integrating the software into the currently existent VistA system locally. This is usually a process that occurs over a short period of time and does not recur. By default, this process is usually accomplished by personnel in IRM.

The term implementation refers to the process of executing the software after installation, adjusting parameters and maintaining the day-to-day functioning of the data cycle that the Laboratory EPI Rollup Modifications entail. There are two main functionalities that will need to be addressed by implementation (national functionality and local functionality). The national functionality will have limited local resource requirements, but will require periodic, on-going attention. Initial parameter set-up will take about 1-2 hours of time with personnel representing the LIM function, microbiology function and IRM function working in concert to set the parameters appropriately. Thereafter, a once-yearly review of the parameter set-up for all national EPI-specified pathogens is the minimum expected. Day-to-day functioning does not refer to the maintenance of the actual software patch, but, instead, refers to the EPI data cycle to assure that the national pathogen information has been appropriately sent to and received by the central data repository—by this definition, it is not necessarily the IRM function to oversee this. Because this will involve review of information sent, confirmation of information receipt, and, most importantly, troubleshooting of errors received from the processing into the central data repository, a local site function that has experience with numerous areas at the local facility from where the data are extracted (medical administrative services, social work, patient demographic information, laboratory information) and that cuts across multiple lines of authority should be considered by the Office of the Director (00) for this task. The local functionality resource requirements will be dependent upon the use at the local site.

Orientation

This section of the EPI Roll Up Modifications Technical and User Manual addresses package or audience-specific notations or directions pertaining to symbols used to indicate terminal dialogues and user responses, information for accessing the EPI Technical and User Manual via the Office of Information Field Offices (OIFOs) Anonymous Software directories, VistA website, VistA Documentation Library (VDL), EPI software phased installation and implementation procedures, instructions for seeding EPI historical data, and Austin Information Technology Center (AITC) transmission schedule for seeding the EPI historical data.

EPI Roll Up Modifications Technical and User Manual

The EPI Roll Up Modifications Technical and User Manual contains the following sections:

Introduction - conveys the major functions, purposes, and how the software accomplishes the objectives.

Security Information - addresses any legal requirements pertaining to the EPI Patch LR*5.2*281, software product and identifies any security measures necessary to protect the integrity of the product and database.

Pre-Installation Information - contains information that should be acknowledged prior to the installation of Patch LR*5.2*281.

Installation Instructions - provides information regarding the installation process for Patch LR*5.2*281.

Post Installation Instruction - provides all the necessary information required for the IRM and LIM personnel to implement the Laboratory EPI Rollup Modifications software application.

EPI Rollup Modifications User Manual - provides the necessary information for implementing and maintaining the EPI criteria.

Appendix A - provides instructions for editing/printing files, using input screens, linking data, and a Workload and Suffixes Codes Request Form.

Appendix B - suggest helpful hints and examples regarding for EPI preferred methods, transmissions, and data validation suggestions.

Appendix C - provides VistA Health Level Seven (HL7) Protocol tables used to transmit EPI Roll Up Modifications data to the Austin Information Technology Center (AITC)

Appendix D - provides a copy of the IMPLEMENTATION OF LOGICAL OBSERVATION IDENTIFIERS NAMES AND CODES (LOINC®) FOR LABORATORY DATA (VHA Directive 2001-039)

Screen Dialogue

Screen Captures - The computer dialogue appears in courier font, no larger than 10 points. **Example:**
Courier font 10 points

User Response - User entry response appears in boldface type Courier font, no larger than 10 points.
Example: Boldface type

Return Symbol - User response to computer dialogue is followed by the **<Enter>** symbol that appears in Courier font, no larger than 10 points, and bolded. **Example: <Enter>**

Tab Symbol - User response to computer dialogue is followed by the symbol that appears in Courier font, no larger than 10 points, and bolded. **Example: <Tab>**

References

Please review the following guide and manual prior to installing and implementing the VistA Laboratory EPI Rollup Modifications Patch LR*5.2*281:

- Kernel Systems Manual V. 8.0
- VA FileMan V. 21.0
- VA Mailman V. 7.1

EPI Roll Up Modifications Software Phased Installation and Implementation Instructions

Due to extensive historical data transmission requirements and mandated setups required for such, a phased installation and implementation of this patch (LR*5.2*281) is utilized for releasing this patch. The software download information is made available to sites attending one of the following national audio conference training calls:

Tuesday, June 8 at 1:00 - 3:00 PM EST for VISNs 1-2-3-4-5-6
 Thursday, June 10 at 3:00 - 5:00 PM EST for VISNs 7-8-9-10-11
 Tuesday, June 15 at 4:00 - 6:00 PM EST for VISNs 12-15-16-16-23
 Wednesday, June 16 at 2:00 - 4:00 PM EST for VISNs 18-19-20-21-22
 Thursday, June 17 at 2:00 - 4:00 PM EST for those unable to attend the other calls.

The VANTS telephone number is 1 800 767-1750 and the access code for all calls is 13143.

This patch will involve reseeding of the EPI databases for each site to allow the new data created by this patch to be captured. It is imperative that each site attend an audio conference prior to installation and implementation of the EPI patch LR*5.2*281.

Instructions for Seeding EPI Historical Data:

EPI historical data **must** be gathered from October 1, 2000 through June 14, 2004. Use the Lab EPI Manual Run (Enhanced) [LREPI ENHANCE MANUAL RUN] option to extract and transmit 6 manual runs (consecutive runs) at a time.

WARNING: SITES - DO NOT transmit the EPI historical data reports on June 16 or July 4, 2004 to avoid Austin Automation Center (AITC) capacity limitations.

Batch #1: October 1, 2000 -March 31, 2001
 Batch #2: April 1, 2001 - September 30, 2001
 Batch #3: October 1, 2001 - March 31, 2002
 Batch #4: April 1, 2002 - September 30, 2002
 Batch #5: October 1, 2002 - March 31, 2003
 Batch #6: April 1, 2003 - September 30, 2003
 Batch #7: October 1, 2003 - March 31, 2004
 Batch #8: April 1, 2004 - June 14, 2004

Sites will run 8 batches of EPI historical data reports. Each batch should contain 6 separate monthly extracts which are tasked separately by month, (i.e., OCT 2000, NOV 2000, DEC 2000, JAN 2001, FEB 2001, MAR 2001 = 1 batch) and will generate six separate processing reports back to the station and transmit them over a five week period June 10, 2004 – July 12, 2004. You do not have to wait for one monthly extract to run before starting the next in a batch. You do not have to wait for one batch to complete running before queuing the next batch. If you receive any fatal errors and the monthly extract is rejected, you will need to fix the error and retransmit that month.

Austin Information Technology Center (AITC) Schedule for Transmitting EPI Historical Data:

WARNING: SITES - DO NOT transmit the EPI historical data reports on June 16 or July 4, 2004 to avoid Austin Automation Center (AITC) capacity limitations.

Sites may transmit EPI historical data reports to AITC on evenings and weekends following this schedule:

1. VISNs with odd numbers are asked to transmit batches on Tuesday & Thursday during the PM hours and Saturdays.
2. VISNs with even numbers are asked to transmit on Monday & Friday during the PM hours and Sundays.

EPI Roll Up Modifications Manual Retrieval

The VistA Laboratory EPI Rollup Modifications Technical and User Manual (i.e., LR_52_281_EPI_TUM.PDF) file is available for retrieval via the File Transfer Protocol (FTP). All VA medical centers are encouraged to use the Transmission Control Protocol/Internet Protocol (TCP/IP) FTP functionality to obtain the documentation file at the following Office of Information Field Offices (OIFOs) ANONYMOUS SOFTWARE directories:

| OIFOs | FTP ADDRESS | DIRECTORY |
|---------------------|---|----------------------|
| Albany | ftp.fo-albany.med.va.gov | [ANONYMOUS.SOFTWARE] |
| Hines | ftp.fo-hines.med.va.gov | [ANONYMOUS.SOFTWARE] |
| Salt Lake City | ftp.fo-slc.med.va.gov | [ANONYMOUS.SOFTWARE] |
| VistA Download Site | download.vista.med.va.gov | |

EPI Roll Up Modifications Manual Formats

VistA Laboratory EPI Rollup Modifications Technical and User Manual is exported as part of Patch LR*52*281 in the following file name and retrieval format:

| FILE NAME | RETRIEVAL FORMATS |
|-----------------------|----------------------------------|
| LR_52_281_EPI_TUM.PDF | LR EPI Technical and User Manual |

Website Locations:

The VistA Laboratory EPI Rollup Modifications Patch LR*5.2*281 Technical and User Manual is available in MS Word (i.e., LR_52_281_EPI_TUM.DOC) format and Portable Document Format (PDF) (i.e., LR_52_281_EPI_TUM.PDF) at the following website locations:

Laboratory Version 5.2 Home Page

<http://vista.med.va.gov/ClinicalSpecialties/lab/>

VistA Documentation Library (VDL)

<http://www.va.gov/vdl/>

Table of Contents

| | |
|---|-------------|
| <i>Preface</i> | <i>iv</i> |
| Intended Audience | iv |
| <i>Orientation</i> | <i>vi</i> |
| EPI Roll Up Modifications Technical and User Manual | vi |
| Screen Dialogue | vii |
| References | vii |
| EPI Roll Up Modifications Software Phased Installation and Implementation Instructions | vii |
| Instructions for Seeding EPI Historical Data: | viii |
| Austin Information Technology Center (AITC) Schedule for Transmitting EPI Historical Data: | viii |
| EPI Roll Up Modifications Manual Retrieval | ix |
| EPI Roll Up Modifications Manual Formats | ix |
| Website Locations: | ix |
| <i>Table of Contents</i> | <i>x</i> |
| <i>Introduction</i> | <i>1</i> |
| Overview | 1 |
| <i>Enhancements and Modifications</i> | <i>7</i> |
| Enhancements: | 7 |
| Renamed EPI Menu/Options | 7 |
| Lab Search Extract Primary [LREPI SEARCH EXTRACT MENU] menu RENAMED to Lab EPI Primary [LREPI SEARCH EXTRACT MENU] menu: | 7 |
| Lab Search/Extract Manual Run (Enhanced) [LREPI SEARCH/EXTRACT ENHANCED MANUAL RUN] option RENAMED Lab EPI Manual Run (Enhanced) [LREPI ENHANCE MANUAL RUN] option: | 7 |
| Modified Lab EPI Primary [LREPI SEARCH EXTRACT MENU] menu options: | 8 |
| Lab EPI Parameter Setup [LREPI (EPI) PARAMETER SETUP] option: | 8 |
| New Lab EPI Primary [LREPI SEARCH EXTRACT MENU] menu options | 8 |
| Print Detailed Verification Report [LREPI VERIFICATION REPORT] option: | 8 |
| Pathogen Inquiry [LREPI PATHOGEN INQUIRY] option: | 8 |
| New Local Pathogen Submenu and Options: | 8 |
| Local Pathogen [LREPI LOCAL PATHOGEN MENU] Submenu: | 8 |
| Enter/Edit Local Pathogens [LREPI ENTER/EDIT LOCAL PATH] option: | 9 |
| Lab EPI Generate Report/Spreadsheet [LREPI GENERATE REPORT/SP] option: | 9 |
| Lab EPI Print Local Report/Spreadsheet [LREPI PRINT REPORT/SPSHT] option: | 9 |
| Delete Local Pathogen [LREPI DELETE LOCAL PATHOGEN] option | 9 |
| Delete Local Report or Spreadsheet [LREPI DELETE LOCAL REPORT] option | 9 |
| New EPI Reports | 10 |
| New EPI Summary Verification Report of EPI Extracted Data from Site for Nationally Rolled-Up Emerging Pathogens: | 10 |

| | |
|---|------------------|
| New Detailed Verification Report of EPI Extracted Data from Site for Nationally Rolled-Up Emerging Pathogens: | 10 |
| New EPI Processing/Error Report Mailman Message sent from Austin | 11 |
| New EPI Data Extracted: | 11 |
| Logical Observation, Identifiers, Name, and Codes (LOINC) | 11 |
| Master Patient Index (MPI) | 11 |
| Susceptibility Results MIC Values | 11 |
| Site Institution/Division Number | 11 |
| Patient Demographics | 11 |
| Race and Ethnicity | 11 |
| Six New Emerging Pathogens | 12 |
| New Legionella Urinary Antigen Test | 12 |
| New EPI Informational Alert | 12 |
| Modifications | 13 |
| EPI Single Day Transmissions: | 13 |
| LAB EPI Search Criteria | 13 |
| National Center for Health (NCH) Data Screening No Longer Required: | 13 |
| Deletion of National Center for Health (NCH) Protocol | 13 |
| Lab EPI Nightly Task [LREPI NIGHTLY TASK] option | 13 |
| <i>Austin Information Technology Center Database Processing</i> | <i>14</i> |
| Numerator Files: | 14 |
| Denominator File: | 14 |
| AITC EPI Data Transmission | 15 |
| AITC Transmission Reports | 15 |
| EPI Confirmation Mailman Message sent from AITC | 15 |
| New EPI Processing (Error) Report Mailman Message from Austin | 15 |
| <i>Security Information</i> | <i>16</i> |
| Security Management: | 16 |
| Security Features: | 16 |
| EPI Mail Groups | 16 |
| EPI mail group: | 16 |
| EPI-Report mail group: | 16 |
| New EPI Informational Alert | 16 |
| Remote Systems | 17 |
| Archiving/Purging | 17 |
| Contingency Planning | 17 |
| Interfacing | 17 |
| Electronic Signatures | 17 |
| Menus | 17 |
| Security Keys | 17 |
| File Security | 17 |
| References | 17 |
| Official Policies | 17 |
| <i>Pre-Installation Information</i> | <i>18</i> |
| EPI Phased Installation and Implementation | 18 |

| | |
|--|------------------|
| Intended Audience | 18 |
| IRM Staff: | 18 |
| Laboratory Staff: | 18 |
| Quality Management Staff: | 19 |
| Other Staff: | 19 |
| Test Sites: | 19 |
| Hardware and Operating System Requirements: | 19 |
| Digital Equipment Corporation (DEC) Alpha Series: | 19 |
| System Performance Capacity: | 20 |
| Memory Constraints: | 20 |
| Installation Time: | 20 |
| Disabling EPI Menus Not Required: | 20 |
| Users on the System: | 20 |
| Backup Routines: | 20 |
| Namespace: | 20 |
| Software Requirements: | 21 |
| Required Patches: | 21 |
| Health Level Seven (HL7): | 21 |
| Protocols: | 21 |
| Domain | 21 |
| Database Integration Agreements (DBIAs) | 22 |
| 1. DBIA #418 | 22 |
| 2. DBIA #3018 | 22 |
| 3. DBIA #3094: | 22 |
| 4. DBIA #3530 | 23 |
| 5. DBIA 4280 | 23 |
| Data Dictionary Changes | 24 |
| LAB SEARCH/EXTRACT file (#69.5) | 24 |
| Modified Fields: | 24 |
| NAME field (#69.5.,01) | 24 |
| INACTIVE field (#69.5,1) | 25 |
| PROTOCOL field (#69.55,12): | 25 |
| NEW Fields: | 27 |
| PREVIOUS CYCLE field (69.5,19) | 27 |
| INDICATOR field (#69.55,1): | 27 |
| INDICATED VALUE field (#69.55,2): | 28 |
| PROTOCOL file (#101) | 28 |
| Modified Field | 28 |
| Processing Routine field (#771): | 28 |
| Routine Summary | 29 |
| <i>Installation Instructions</i> | <i>30</i> |
| Installation Example: | 32 |

| | |
|---|-----------|
| Post Installation and Implementation Instructions | 34 |
| IRM Post Installation Instructions: | 34 |
| IRM - Step 1: Verify Lower Level Protocol of the HL7 V. 1.6 background job for EPI – LAB | 34 |
| IRM - Step 2: Verify Lab EPI Nightly Task [LREPI NIGHTLY TASK] Option Nightly Run | 36 |
| Example: How to schedule the Lab EPI Nightly Task [LREPI NIGHTLY TASK] option to run nightly. | 36 |
| Example: How to schedule the Lab EPI Nightly Task [LREPI NIGHTLY TASK] option to run nightly <i>continued.</i> | 37 |
| IRM - Step 3: Verify EPI mail group setup entries | 38 |
| Example: How to verify existing EPI mail group setup entries | 38 |
| IRM Step 4: Verify EPI-REPORT mail group setup entries | 39 |
| Example: How to verify EPI-REPORT mail group setup entries | 39 |
| IRM Step 5: Verify XXX@Q-EPI.MED.VA.GOV Remote Member Entries | 40 |
| IRM Step 6: Verify Lab EPI Primary [LREPI SEARCH EXTRACT MENU] menu assignment to all designated users | 41 |
| Example: Lab EPI Primary [LREPI SEARCH EXTRACT MENU] menu | 41 |
| Example: Local Pathogen [LREPI LOCAL PATHOGEN MENU] Menu | 41 |
| LIM Implementation Instructions | 42 |
| LIM - Step 1: Review new EPI Descriptions and Input Screens Examples | 42 |
| LIM - Step 2: Setup new EPI Parameter Descriptions | 43 |
| LIM - Step 3: Link the Logical Observations, Identifiers, Names, and Codes (LOINC) | 43 |
| Office of Director (00) Designated Staff Implementation Instructions: | 44 |
| (00) Designated Staff - Step 1: Review new EPI Descriptions and Input Screens Examples | 44 |
| (00) Designated Staff - Step 2: Setup new EPI Parameter Descriptions | 45 |
| Instructions for Seeding EPI Historical Data: | 46 |
| Austin Automation Center (AITC) Schedule for Transmitting EPI Historical Data: | 46 |
| Use of the Software | 48 |
| EPI Review Requirements: | 48 |
| Six New Emerging Pathogens: | 49 |
| New Legionella Urinary Antigen Test: | 49 |
| New Local Pathogen [LREPI LOCAL PATHOGEN MENU] Menu | 49 |
| Lab EPI Primary (LREPI SEARCH EXTRACT MENU) Menu Diagram | 50 |
| Lab EPI Primary [LREPI SEARCH EXTRACT MENU] Menu | 51 |
| Lab EPI Manual Run (Enhanced) [LREPI ENHANCE MANUAL RUN] option: | 51 |
| Print Detailed Verification Report [LREPI VERIFICATION REPORT] option: | 53 |
| Local Pathogen [LREPI LOCAL PATHOGEN MENU] Menu: | 55 |
| Enter/Edit Local Pathogens [LREPI ENTER/EDIT LOCAL PATH] option: | 55 |
| How to use the Enter/Edit Local Pathogens [LREPI ENTER/EDIT LOCAL PATH] option | 59 |
| Lab EPI Generate Local Report/Spreadsheet [LREPI GENERATE REPORT/SP] option: | 63 |
| Lab EPI Print Local Report/Spreadsheet [LREPI PRINT] option: | 69 |
| How to ENTER local SPREADSHEET captures to a TEXT FILE or EXCEL spreadsheet software: | 80 |
| Delete Local Pathogen [LREPI DELETE LOCAL PATHOGEN] option | 90 |
| Delete Local Report or Spreadsheet [LREPI DELETE LOCAL REPORT] option | 91 |
| Pathogen Inquiry [LREPI PATHOGEN INQUIRY] option: | 92 |
| Lab EPI Parameter Setup [LREPI (EPI) PARAMETER SETUP] option: | 93 |
| Lab EPI Protocol Edit [LREPI PROTOCOL EDIT] option | 94 |
| Antimicrobial Link Update [LREPILK] option: | 94 |

| | |
|--|-----------|
| Emerging Pathogens Names and Reference Numbers | 95 |
| Lab EPI Parameter Setup [LREPI PARAMETER SETUP] option Input Screen Definitions | 96 |
| Lab EPI Parameter Setup [LREPI PARAMETER SETUP] option Input Screen Definitions (continued) | 97 |
| Lab EPI Parameter Setup [LREPI PARAMETER SETUP] option Input Screen Definitions (continued) | 98 |
| Lab EPI Parameter Setup [LREPI PARAMETER SETUP] option | 99 |
| New Legionella Urinary Antigen Test | 100 |
| LAB SEARCH/EXTRACT file (#69.5) Entries and Parameter Setup Examples | 101 |
| All Enterococci (Reference #23) | 102 |
| Example: Lab EPI Parameter Setup for All Enterococci | 103 |
| All Staphylococcus aureus (Reference #18) | 107 |
| Lab EPI Parameter setup for All Staphylococcus aureus (Reference #18) | 108 |
| All Streptococcus pneumoniae (Reference #22) | 111 |
| Lab EPI Parameter setup for All Streptococcus pneumoniae (Reference #22) | 112 |
| Candida (Reference #8) | 115 |
| Lab EPI Parameter Setup for CANDIDA | 116 |
| Clostridium difficile (Reference #4) | 119 |
| Lab EPI Parameter Setup for CLOSTRIDIUM DIFFICILE | 120 |
| Creutzfeldt-Jakob Disease (CJD) (Reference #13) | 123 |
| Example: Lab EPI Parameter Setup for CREUTZFELDT-JAKOB DISEASE | 123 |
| Cryptosporidium (Reference #9) | 126 |
| Example: Lab EPI Parameter Setup for CRYPTOSPORIDIUM | 127 |
| Dengue (Reference #12) | 130 |
| Example: Lab EPI Parameter Setup for DENGUE | 130 |
| E. coli O157:H7 (Reference #10) | 133 |
| Example: Lab EPI Parameter Setup for E. COLI 0157:H7 | 134 |
| Hepatitis A Antibody Positive (Reference #16) | 137 |
| Example: Lab EPI Parameter Setup for HEPATITIS A ANTIBODY POS | 138 |
| Hepatitis B Positive (Reference #17) | 142 |
| Example: Lab EPI Parameter Setup for HEPATITIS B POS | 143 |
| Not Positive for Hepatitis C Antibody OR Hepatitis C Antibody Neg (Reference #15) | 147 |
| Example: Lab EPI Parameter Setup for HEPATITIS C ANTIBODY NEG | 148 |
| Hepatitis C Antibody Positive (Reference #2) | 151 |
| Example: Lab EPI Parameter Setup for Hepatitis C Antibody POS | 152 |
| Legionella (Reference #7) | 155 |
| Example: Lab EPI Parameter Setup for LEGIONELLA | 156 |
| Leishmaniasis (Reference #14) | 159 |
| Example: Lab EPI Parameter Setup for Leishmaniasis | 159 |
| Malaria (Reference #11) | 162 |
| Example: Lab EPI Parameter Setup for Malaria | 162 |
| Methicillin-Resistant Staphylococcus aureus (MRSA) (Reference #19) | 167 |
| Example: Lab EPI Parameter Setup for METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) | 168 |
| Penicillin - Resistant Pneumococcus (Reference #3) | 171 |
| Example: Lab EPI Parameter Setup for Penicillin - Resistant Pneumococcus | 171 |
| Streptococcus-Group A (Reference #6) | 174 |
| Example: Lab EPI Parameter Setup for Streptococcus-Group A | 174 |
| Tuberculosis (TB) (Reference #5) | 178 |
| Example: Lab EPI Parameter Setup for Tuberculosis (TB) | 179 |
| Vancomycin-Resistant Coagulase Negative Staphylococci/Staph epi (VRSE) (Reference #21) | 182 |

| | |
|---|-------------------|
| Example: Lab EPI Parameter Setup for Vancomycin-Resistant Coagulase Negative Staphylococci/Staph epi (VRSE) (Reference #21) | 183 |
| Vancomycin-Resistant Enterococcus (VRE) (Reference #1) | 186 |
| Example: Lab EPI Parameter Setup for Vancomycin-Resistant Enterococcus (VRE) (Reference #1) | 187 |
| Vancomycin-Resistant Staphylococcus Aureus (VRSA) (Reference #20) | 191 |
| Example: Lab EPI Parameter Setup for Vancomycin-Resistant Staphylococcus aureus (VRSA) (Reference #20) | 192 |
| Conclusion | 195 |
| <i>Appendix – A</i> | <i>198</i> |
| <i>Editing/Printing Files, Linking Data, and Editing Input Screens</i> | <i>198</i> |
| Editing/Printing Files, Screens, Linking Data, Request Form | 199 |
| Editing TOPOGRAPHY file (#61): | 199 |
| Printing LAB SEARCH/EXTRACT file (#69.5) Definitions: | 200 |
| How to Link Antimicrobial Entries to Workload Codes Entries: | 202 |
| AUTO function | 202 |
| MANUAL function | 203 |
| SEMI-AUTO function | 203 |
| Delete Entry from Laboratory EPI Parameters Input Screen | 204 |
| How to add an entry to the Laboratory EPI Parameters Input Screen | 205 |
| Lab EPI Generate Local Report/Spreadsheet [LREPI GENERATE REPORT/SP] option Field Definitions: | 206 |
| <i>Appendix – B Helpful Hints</i> | <i>210</i> |
| Preferred Methods for Clostridium difficile Data Capture | 210 |
| Preferred Method #1: | 210 |
| Preferred Method #2: | 211 |
| Validating EPI Data Captures | 211 |
| Required EPI Mail Groups and Descriptions | 213 |
| EPI Mail Group Description | 213 |
| EPI-REPORT Mail Group Description | 213 |
| EPI Data Processing Cycles | 214 |
| EPI HL7 Format Mailman Message | 215 |
| EPI Confirmation Mailman Message | 217 |
| New EPI Summary Verification Report of EPI Extracted Data from Site' HL7 Mailman Message | 218 |
| New EPI Summary Verification Report for prior month - TB only | 223 |
| New Detailed Verification Report of EPI Extracted Data from Site Mailman Message | 226 |
| New EPI Processing Error Report Mailman Message sent from Austin | 253 |
| Table of Reject and Errors and/or Warning Codes | 255 |
| National Laboratory Test (NLT) List | 261 |
| <i>Appendix C - Health Level Seven (HL7) Protocol</i> | <i>348</i> |
| 3. General Specifications | 348 |

| | |
|--|------------|
| Definitions from Austin | 353 |
| 4.0 Transaction Specifications | 357 |
| Table VA011 - Period of Service | 358 |
| Table 0070 - Specimen Source Codes (<i>continued</i>) | 359 |
| Table 0070 - Specimen Source Codes (<i>continued</i>) | 360 |
| Table 0005 – Race: | 361 |
| Table CDC – Race: | 361 |
| Table 0189 - Ethnic Group | 362 |
| Table CDC - Ethnic Group | 362 |
| Table 0001 - Sex | 362 |
| Table 0078 - Abnormal flags | 363 |
| Table Specimen Source ID Code | 363 |
| Table Hepatitis Risk Assessment Resolutions | 363 |
| <i>APPENDIX – D</i> | 365 |
| <i>IMPLEMENTATION OF LOGICAL OBSERVATION IDENTIFIERS NAMES AND CODES (LOINC®) FOR LABORATORY DATA</i> | 365 |

Introduction

Overview

The Infectious Diseases Program Office was tasked by the Under Secretary for Health to retrieve tracking and trending information about emerging and re-emerging infectious diseases (including antibiotic resistance) that are important to VHA. Data would be used for tracking and trending of specified infectious diseases entities, policy decision-making, and resource allocation at the national level. To accomplish this, the VistA Laboratory Emerging Pathogens Initiatives (EPI) software was initially installed at all VAMC facilities in February 1997 via VistA EPI Patch LR*5.2*132, with modifications occurring by means of the VistA Laboratory Search/Extract Patch LR*5.2*175 in March 1998. This software was originally developed by the CIOFO-Dallas in conjunction with the Infectious Diseases Program Office. As this proved to be a successful and beneficial endeavor, the Under Secretary for Health further tasked the Infectious Diseases program Office to retrieve Hepatitis C antibody testing data for a one-day survey nationwide, Hepatitis C Surveillance Day (March 17, 1999). The EPI software application was selected to accomplish this task because data were already stored in the standard VistA data set and linked to patient identifiers. Information retrieved from both the routine running of the EPI, as well as Hepatitis C Surveillance Day was an extremely important component that resulted in the VHA obtaining additional Congressional funding for hepatitis C disease care. Information obtained from the EPI assisted in determining the importance of the emerging pathogen, hepatitis C, as a significant issue for VHA. Data from EPI have been used by the Allocation Resource Center (ARC) in determinations for Veterans Equitable Resource Allocation (VERA) hepatitis C resource allocation to local facilities; EPI data are still provided to ARC for this purpose.


For Hepatitis C Surveillance Day, temporary modifications were necessary to achieve prompt data acquisition. More lasting modifications/enhancements were to occur with the release of the combined process from VistA Laboratory EPI Hepatitis Extract Patch LR*5.2*260, Patch PXR*1.5*1, PSJ*5*48, and Patch PSO*7*45 in August 2000. However, due to significant pressures and time constraints applied to this project to produce the National Hepatitis C Risk Assessment portion of the requests, the Infectious Diseases Program Office agreed to delay the below-listed components of that approved request until this time; one of the key functionalities that was delayed was the ability of local facilities to use the software to extract locally-relevant data.

The following delayed enhancement components were requested and have been addressed with the release of VistA Laboratory Emerging Pathogens Rollup Modifications Patch LR*5.2*281 (note that due to systems constraints and set-ups, not all requested components are deliverable with this patch):



- New EPI Summary Verification Report of EPI-extracted data from site in plain text (human-readable) format for nationally rolled-up pathogen information
- New EPI Detailed Verification Report of EPI-extracted data from site in plain text (human-readable) format for nationally rolled-up pathogen information
- New EPI Processing Report (error report) concerning data processed at the central data repository for the EPI delivered to site in plain text (human-readable) format containing only patients with error/warning codes or indicating that the data were processed into the central data repository without any errors
- New Local Pathogen Menu [LREPI LOCAL PATHOGEN MENU]
- New EPI option to add locally-relevant pathogens using the EPI search/extract backbone, without altering nationally rolled-up pathogen information
- Improvement of the extraction tool to capture and report tuberculosis (due to constraints of long incubation periods in the results reporting, embedded within an accessioning acquisition framework of the EPI extracts)
- Ability to capture and report International Classification of Diseases, ICD-10, codes in association with outpatients who have a reported EPI pathogen (system constraints will not allow this requested component to be completed for this release)
- Ability to capture and report Logical Observations, Identifiers, Names and Codes (LOINC) information along with laboratory-based testing information acquired by EPI (system constraints will not allow this requested component to be fully realized for this release; partial realization will occur for CH-subscribed laboratory tests)
- Ability to capture and report Master Patient Index codes for patients identified as meeting an EPI pathogen parameter
- Ability to capture and report antibiotic susceptibility MIC values

- Ability to use antibiotic susceptibility MIC values as an identification parameter for either national or locally-relevant pathogens (system constraints will not allow this requested component to be completed for this release)
- Ability to capture and report actual site/location (institution and division designations) in which the patient actually received care associated with the EPI pathogen trigger for data acquisition (not just the reporting site) in order to accurately assess where the pathogens are occurring (system constraints will not allow this requested component to be completed for this release)
- Ability to capture and report county and state information from patient's identified by the EPI process
- Ability to capture and report the newly implemented race and ethnicity coding, along with the prior race/ethnicity coding
- Ability to capture and report the actual station location (unit) of care for a patient at the time of EPI pathogen data acquisition (this currently only applies to inpatient information and only for information that is CH-subscribed)
- Six new national EPI Emerging Pathogens to be added for national roll-up
- New documentation of the prior Legionella pathogen to provided guidance for use of recently FDA-approved Legionella Urinary Antigen test that can be used for diagnosis

AUTOMATED EMERGING PATHOGENS INITIATIVE DATA CYCLE FLOW CHART



AUSTIN AUTOMATION CENTER
EMERGINING PATHOGENS INITIATIVE PROCESS FLOWCHART



VistA Blood Bank Software Version 5.2

EFFECT ON BLOOD BANK FUNCTIONAL REQUIREMENTS: Patch LR*5.2*281 does not contain any changes to the VISTA BLOOD BANK Software as defined by VHA DIRECTIVE 99-053 titled VISTA BLOOD BANK SOFTWARE VERSION 5.2.

EFFECT ON BLOOD BANK FUNCTIONAL REQUIREMENTS: Patch LR*5.2*281 does not alter or modify any software design safeguards or safety critical elements functions.

RISK ANALYSIS: Changes made by patch LR*5.2*281 have no effect on Blood Bank software functionality, therefore RISK is none.

VALIDATION REQUIREMENTS BY OPTION: Because of the nature of the changes made, no specific validation requirements exist as a result of installation of this patch.

NOTE: As with previous Lab EPI patches, it is highly recommended that the **Office of the Director** (00) at each facility designate a person or persons to be responsible for the routine implementation of this patch (both at the time of this installation and afterwards) and to take the lead in trouble-shooting issues that arise with the routine functioning of the process

Enhancements and Modifications

VistA Laboratory EPI Rollup Modification patch LR*5.2*281 contain the following software enhancements and modifications:

Enhancements:

Renamed EPI Menu/Options

Lab Search Extract Primary [LREPI SEARCH EXTRACT MENU] menu RENAMED to Lab EPI Primary [LREPI SEARCH EXTRACT MENU] menu:

For consistency of this software release, the Lab Search Extract Primary [LREPI SEARCH EXTRACT MENU] menu is **RENAMED** Lab EPI Primary [LREPI SEARCH EXTRACT MENU] menu. This is the main EPI menu containing four existing options, two **new** options, and one **new** submenu containing 4 **new** options. This **new** submenu may be assigned to users without the Lab EPI Primary [LREPI SEARCH EXTRACT MENU] menu.

Lab Search/Extract Manual Run (Enhanced) [LREPI SEARCH/EXTRACT ENHANCED MANUAL RUN] option RENAMED Lab EPI Manual Run (Enhanced) [LREPI ENHANCE MANUAL RUN] option:

For consistency of this software release, the Lab Search/Extract Manual Run (Enhanced) [LREPI SEARCH/EXTRACT ENHANCED MANUAL RUN] is **RENAMED** Lab EPI Manual Run (Enhanced) [LREPI ENHANCE MANUAL RUN] option. This option is used ONLY to manually extract National EPI data, transmit the manually extracted data to the Austin Information Technology Center (AITC), and to generate the **new** EPI Summary Verification Report. This **new** EPI Summary Verification Report is automatically sent to the EPI-Report mail group after being generated. This option has been **enhanced** to generate the **new** Detailed Verification Report which can be printed using the **new** Print Detailed Verification Report [LREPI VERIFICATION REPORT] option.

NOTE: ONLY national emerging pathogens extract data are transmitted to the AITC, local emerging pathogens extract data will NOT be transmitted.

Modified Lab EPI Primary [LREPI SEARCH EXTRACT MENU] menu options:

Lab EPI Parameter Setup [LREPI (EPI) PARAMETER SETUP] option:

The Lab EPI Parameter Setup [LREPI PARAMETER SETUP] option is used to define the search criteria associated with the National Emerging Pathogen Initiative extract data. This option only allows editing of the EPI Parameter Setup input screens. Local pathogens CANNOT be added using this option. This option has been **enhanced** by adding the **new** PREVIOUS CYCLE field which is automatically defined as '1' for TB ONLY and CANNOT be edit. For all other emerging pathogens the **new** PREVIOUS CYCLE field is blank and CANNOT be EDITED. The existing PROTOCOL field can no longer be EDITED. The ACTIVE: 'YES' has been changed to display INACTIVE: 'NO', and Lag Days for the six new EPIs have been defined as 15 with the release of the new EPI enhancement software.

New Lab EPI Primary [LREPI SEARCH EXTRACT MENU] menu options

Print Detailed Verification Report [LREPI VERIFICATION REPORT] option:

This **new** option is use to print the **new** Detailed Verification Report mailman message.

Pathogen Inquiry [LREPI PATHOGEN INQUIRY] option:

This **new** option is used to inquire into the LAB SEARCH/EXTRACT file (#69.5) parameter description fields (i.e., INACTIVE: NO, LAG DAYS: 15, RUN DATE: OCT 07, 2003, CYCLE: MONTHLY, PROTOCOL: LREPI, FOLLOW PTF: YES, REFERENCE NUMBER: 23, and ETIOLOGIES) for defined emerging pathogen.

New Local Pathogen Submenu and Options:

Local Pathogen [LREPI LOCAL PATHOGEN MENU] Submenu:

This **new** submenu contains four **new** options use to enter/edit local pathogens, generate and print local EPI reports and spreadsheets, and delete local pathogens.

Example: New Local Pathogen [LREPI LOCAL PATHOGEN MENU] Menu

Local Pathogen Menu

| | |
|-----|---|
| ENT | Enter/Edit Local Pathogens |
| GEN | Lab EPI Generate Local Report/Spreadsheet |
| PRT | Lab EPI Print Local Report/Spreadsheet |
| DEL | Delete Local Pathogen |
| DRS | Delete Local Report or Spreadsheet |

Enter/Edit Local Pathogens [LREPI ENTER/EDIT LOCAL PATH] option:

This **new** option is use to enter or edit local pathogens into LAB SEARCH/EXTRACT file (#69.5).

Lab EPI Generate Report/Spreadsheet [LREPI GENERATE REPORT/SP] option:

This **new** option is used to generate Lab EPI reports or spreadsheets for national and local emerging pathogens extract data. After selecting national or local emerging pathogens, time period, segments and fields, report or spreadsheet, the job is automatically tasked. The tasked job will take approximately 2-3 hours to generate. An alert is automatically sent to the requester/user after the tasked job has finished generating. The Lab EPI report or spreadsheet can then be viewed on the screen or printed using the **new** Lab EPI Print Local Report/Spreadsheet [LREPI PRINT] option. **NOTE:** NO data will be transmitted to AITC when using this option.

Lab EPI Print Local Report/Spreadsheet [LREPI PRINT REPORT/SPSHT] option:

This **new** option is used to print a report or spreadsheet that was generated with the Lab EPI Generate Local Report/Spreadsheet [LREPI GENERATE REPORT/SP] option.

Delete Local Pathogen [LREPI DELETE LOCAL PATHOGEN] option

This **new** option is use to delete local pathogens entries ONLY.

NOTE: National emerging pathogens entries CANNOT be deleted.

Delete Local Report or Spreadsheet [LREPI DELETE LOCAL REPORT] option

This **new** option is use to delete local reports or local spreadsheets.

New EPI Reports

New EPI Summary Verification Report of EPI Extracted Data from Site for Nationally Rolled-Up Emerging Pathogens:

The **new** Summary Verification Report of EPI Extracted Data from Site contains the following **new** functionality:

- Automatically sent to EPI-REPORT mail group after EPI extract data transmissions to AITC on the 15th each month
- Displays in a human readable format used for quick reviewing
- Displays reporting site name and station number
- Displays emerging pathogens total number of occurrences during the monthly processing cycle
- Displays emerging pathogens total number of persons with occurrences during the monthly processing cycle
- Displays number of persons with the nationally rolled-up resolutions for the National Hepatitis C Risk Assessment Clinical Reminder that occurred during the monthly processing cycle
- Displays report in several pages
- ENHANCE MANUAL RUN] option (**Note** that each manual run generates HL7 message transmission to the central data repository [AITC])
- Automatically sent to EPI-REPORT mail group after manual generation

New Detailed Verification Report of EPI Extracted Data from Site for Nationally Rolled-Up Emerging Pathogens:

The **new** Detailed Verification Report of EPI Extracted Data from Site' contains the following **new** functionality:

- Displays reporting site station number with Notes and Comment Segments (NTE) findings in a human readable format
- Displays the site reporting NTE findings of 1, 2, 3...23, starting with a new page for each NTE findings.
- Displays listing by emerging pathogens
- Recreation of the report on demand using the Lab EPI Manual Run (Enhanced) [LREPI ENHANCE MANUAL RUN] option
- Recreation of the manually generated EPI extract data is automatically sent to Austin Automation Center.
- Displays Clinical Reminder data transmitted to EPI data stream regarding nationally rolled-up data about Hepatitis C Risk Assessment and associated hepatitis laboratory data.

New EPI Processing/Error Report Mailman Message sent from Austin

The **new** EPI Processing (Error) Report mailman message itemizes all transmissions received by AITC and document the records status as either being accepted or rejected (with the reason and reject code identified). This report will be sent to EPI mail group. (*Examples of the **new** EPI Processing/Error Report mailman message and “Tables of Rejects and Errors and/or Warning Codes” are located in the Appendix - B section of this manual*).

New EPI Data Extracted:

Logical Observation, Identifiers, Name, and Codes (LOINC)

EPI Roll up Modifications software provides the ability to automatically extract LOINC data, transmit the data to the AITC, and display the data on the **new** Verification Detailed Report of EPI Extracted Data from Site.

Master Patient Index (MPI)

EPI Roll Up Modifications software provides the ability to automatically extract MPI values and transmit the data to AITC.

Susceptibility Results MIC Values

EPI Roll Up Modifications software provides the ability to automatically extract Susceptibility Results MIC values from the ANTIMICROBIAL SUSCEPTIBILITY file (#62.06), Susceptibility Result field (#.01), Susceptibility Result subfile (#2), and transmit the data to AITC. These MIC values can be displayed via the **new** Verification Detailed Report of EPI Extracted Data from Site.

Site Institution/Division Number

EPI Rollup Modifications software release provides the ability to automatically capture the patient’s site division number during an encounter.

Patient Demographics

EPI Roll Up Modifications software release provides the ability to extract patient’s demographics county and state data, transmit data to the AITC, and display the demographic data on the **new** Verification Detailed Report of EPI Extracted Data From Site.

Race and Ethnicity

EPI Roll Up modifications software release provide the ability to capture patient’s race and ethnicity data using the new race/ethnicity protocols, transmit data to AITC, and display the data on the **new** Verification Detailed Report of EPI Extracted Data from Site.

Six New Emerging Pathogens

EPI Roll-Up Modifications software provides the ability to automatically extract data for the following **six new** emerging pathogens without the necessity of any manual data entry once the parameter descriptions are set up using the Lab EPI Parameter Setup [LREPI PARAMETER SETUP] option:

- All *Staphylococcus aureus* (Reference #18)
- Methicillin-Resistant *Staphylococcus aureus* (MRSA) (Reference #19)
- Vancomycin-Resistant *Staphylococcus aureus* (VRSA) (Reference #20)
- Vancomycin-Resistant Coagulase Negative *Staphylococci/Staph epi* (VRSE) (Reference #21)
- All *Streptococcus pneumoniae* (Reference #22)
- All Enterococci (Reference #23)

New Legionella Urinary Antigen Test

The Legionella Urinary Antigen test is FDA-approved and available clinical use. Suggestions will be provided for updating parameter setups to capture the results of this testing in the already existent Legionella (Reference #7) EPI national pathogen and allow for national roll-up. This newer test **must** be added for LEGIONELLA using the Lab EPI Parameter Setup [LREPI PARAMETER SETUP] option. The preferred Lab EPI parameter setup for etiology for the **newer** Legionella Urinary Antigen test is *POSITIVE FOR LEGIONELLA PNEUMOPHILA*.

New EPI Informational Alert

This alert is created when the new Lab EPI Generate Local Report/Spreadsheet [LREPI GENERATE REPORT/SP] option is accessed. This alert is sent to the user who generated the report or spreadsheet when the report or spreadsheet is finished generating.

Modifications

VistA Laboratory EPI Roll-Up Modification Patch LR*5.2*281 software contains the following modifications:

EPI Single Day Transmissions:

Date handling for start and stop date was **modified** because it created a problem with EPI single day transmissions. It showed the beginning date and time to be 10:00 a.m. yesterday. The end time is (in effect) midnight tonight. This was corrected by creating a beginning time of one tenth of a second after midnight and the end time is the following midnight.

LAB EPI Search Criteria

Currently, some TB cultures are not being captured because it can require up to six weeks for TB cultures to grow and obtain the results. This delay causes the result to be overlooked in the subsequent EPI reporting. A new search criterion has been added to the Lab EPI engine. The LAB SEARCH/EXTRACT file (#69.5), contains the **new** PREVIOUS CYCLE field (# 19), which is a numeric value of 1, automatically set by the EPI software. This **new** field instructs the LAB SEARCH EXTRACT engine to also look for TB pathogen(s) in previous cycles. **Note:** The **new** PREVIOUS CYCLE field (# 19), is used for the automated run (i.e., 15th day of the month) ONLY. This field CANNOT be EDITED.

National Center for Health (NCH) Data Screening No Longer Required:

NCH data screening is no longer required and NCH transmissions to AITC have been terminated. NCH Cholesterol and NCH Pap smear entries has been removed from the Lab EPI Parameter Setup entries.

Deletion of National Center for Health (NCH) Protocol

The LRNCH AITC and LRNCH SEND CLIENT protocols have been deleted since the NCH data screening is no longer required.

Lab EPI Nightly Task [LREPI NIGHTLY TASK] option

The Lab Search/Extract Nightly Task [LREPI SEARCH/EXTRACT NIGHTLY TASK] option is **renamed** to Lab EPI Nightly Task [LREPI NIGHTLY TASK]. This option builds a HL7 message and sends it to the defined location specified in the EPI Protocols. The EPI Nightly Task [LREPI NIGHTLY TASK] option **must** be scheduled to run each night by TaskMan.

Austin Information Technology Center Database Processing

The Austin Information Technology Center (AITC) serves as the central data repository for the national EPI pathogen data that is rolled-up from sites. AITC creates two file structures, both in Statistical Analysis System (SAS) file format. These two file structures are used as a source of data for the VHA Headquarters Infectious Disease Program Office. The data are available to the VA Central Office Infectious Diseases Program Office to be used for analysis and reporting. The two file structures are referred to as the “Numerator Files” and “Denominator File” because of their planned utilization.

Numerator Files:

The Numerator files contain accumulated data sent by all VHA facilities. The Numerator file information is specific to unique patients with a VA Central Office Infectious Diseases Program Office designated national emerging pathogen. Emerging pathogen data entries are flagged through the *VistA* Laboratory EPI software process. Numerator files data are collected and transmitted to AITC monthly by VHA facilities.

Denominator File:

The Denominator file provides the VHA Headquarters Infectious Diseases Program Office total and unique counts of patients each VHA facility. The individual files that these data elements are extracted from are the National Patient Care (NPC), Inpatient Treatment File (PTF), VHA Work Measurement (VWM), and Cost Distribution Report (CDR) systems.

The data elements are:

- * Unique SSN served (inpatient and outpatient together)
- * Total # of discharges
- * Total unique SSN discharges
- * Inpatient hospital days
- * Inpatient ICU days
- * Unique SSN encounters for both inpatient and outpatient

Unique and total counts are available for the individual months, current month, and previous eleven months for a year's set of totals, current month, and previous three month periods for a quarter's set of totals.

AITC EPI Data Transmission

National emerging Pathogens, as defined by VA Central Office, act as triggers for data acquisition for Patch LR*5.2*281. The software then retrieves relevant, predetermined, and patient-specific data for transmission to the EPI central data repository at the AITC. Once at that location, the data are uploaded into Statistical Analysis System (SAS)-based statistical software accessible files. VA Central Office reports may then be generated for appropriate use and distribution at the national level.

With the installation of patch LR*5.2*281, automated data transmissions will occur. Receipt of this transmission at the AITC queue will trigger a confirmation message back to the originating site to “confirm” that data has been sent. Then at the next processing cycle (~25th of the month), a processing/error report will also be generated and sent back to the originating site. This processing/error report will serve as the definitive “confirmation” that data has been accepted. If there is a fatal error in any segment of the message, the entire message will be rejected and must be resent manually. Warning codes/errors are accepted into the data set, but serve to remind the originating site that a correction of the process generating the error may be needed.

AITC Transmission Reports

EPI Confirmation Mailman Message sent from AITC

An EPI Confirmation mailman message is sent from the AITC upon receipt of the VHA facilities EPI monthly transmission via the EPI mail group. The EPI mail group members are notified that the original EPI HL7 format mailman message data transmission has been received by AITC for processing.

NOTE: This EPI Confirmation mailman message ONLY means that the sending VHA facility data transmission has been received by the AITC for processing.

New EPI Processing (Error) Report Mailman Message from Austin

The **new** EPI Processing Error Report mailman message itemizes all transmissions received by AITC and document the records status as either being accepted or rejected (with the reason and reject code identified). This report will be sent to the EPI mail group. (*Examples of the “Table of Rejects and Errors and/or Warning Codes” are located in the Appendix - B section of this manual.*)

Security Information

This section addresses any legal requirements pertaining to the EPI Patch LR*5.2*281, software product and identifies any security measures necessary to protect the integrity of the product and database.

Security Management:

According to VA Directive 6214, the existing Laboratory EPI software meets the requirements for VA IT Security Certification and Accreditation Program. The Lab EPI Enhancement software (LR*5.2*281) does not constitute a major change that requires new risk assessment and re-accreditation of the Laboratory system. Lab EPI security is maintained through menu assignment and VA FileMan protection.

Security Features:

EPI Mail Groups

EPI mail group:

This mail group is used by the VHA facilities to transmit EPI HL7 format mailman messages to AITC and for AITC to transmit EPI Confirmation mailman messages back to the sending VHA facilities once the EPI HL7 format mailman messages data transmission has been received by AITC.

EPI-Report mail group:

This mail group is used to receive the Emerging Pathogens Verification Report and the EPI Processing Report mailman messages sent from AITC. The members of this mail group will assist in the EPI data validation and corrections process.

New EPI Informational Alert

An alert is created by the Lab EPI Generate Local Report/Spreadsheet [LREPI GENERATE REPORT/SP] option. This alert is sent to the user who generated the report or spreadsheet when the report or spreadsheet is finished generating.

Example: Alert Display

```
The local report/spreadsheet finished generating at JAN 23, 2004@18:45:00
Enter "VA to jump to VIEW ALERTS option
```


Remote Systems

The EPI software retrieves relevant, predetermined patient-specific data for transmission to the Austin Automation Center database repository.

Archiving/Purging

Archiving and Purging utilities are not provided with this software release.

Contingency Planning

Each facility using the **VISTA** Laboratory EPI software application **must** develop a local contingency plan to be used in the event of application problems in a live environment. The facility contingency plan **must** identify procedures used for maintaining the functionality provided by the software in the event of a system outage.

Interfacing

No specialized (not VA-produced) products (hardware and/or software) are embedded within or required by the EPI software product.

Electronic Signatures

There is no electronic signature utilized in the VistA EPI software application.

Menus

The Lab EPI Primary [LREPI SEARCH EXTRACT MENU] menu contains six options. IRM staff assigns the menu to have access to all options and the **new** submenu [Local Pathogen Menu...] that has 4 options. The new [Local Pathogen Menu...] submenu may be assigned independent from the Lab EPI Primary [LREPI SEARCH EXTRACT MENU] menu; this will allow only access to the submenu options.

Security Keys

There are no locks or security keys associated with the EPI Lab EPI Primary [LREPI SEARCH EXTRACT MENU] menu or options.

File Security

EPI changes and enhancements **do not** modify any existing file security schemes. New files exported by the patch installation have no file security applied. However, VA FileMan security access L1 code is recommended if file security is deemed necessary by the facilities.

References

Please review the following guide and manual prior to installing and implementing the Laboratory EPI Rollup Modifications Patch LR*5.2*281:

- Kernel Systems Manual V. 8.0
- VA FileMan V. 21.0
- VA Mailman V. 7.1

Official Policies

EPI software release reference no official policy unique to the product regarding the modification of software and distribution of the product.

Pre-Installation Information

The following information contain recommendations and requirements that should be acknowledged **prior** to installing the VistA Laboratory EPI Rollup Modifications patch LR*5.2*281.

EPI Phased Installation and Implementation

NOTE: Due to extensive historical data transmission requirements and mandated setups required for such, a phased installation and implementation of this patch will be utilized for release of this patch. The software download information will be made available to sites attending one of the following national audio conference training calls:

Tuesday, June 8 at 1:00 - 3:00 PM EST for VISNs 1-2-3-4-5-6

Thursday, June 10 at 3:00 - 5:00 PM EST for VISNs 7-8-9-10-11

Tuesday, June 15 at 4:00 - 6:00 PM EST for VISNs 12-15-16-16-23

Wednesday, June 16 at 2:00 - 4:00 PM EST for VISNs 18-19-20-21-22

Thursday, June 17 at 2:00 - 4:00 PM EST for those unable to attend the other calls.

The VANTS telephone number is 1 800 767-1750 and the access code for all calls is 13143.

This patch will involve reseeding of the EPI databases for each site to allow the new data created by this patch to be captured. It is imperative each site attend an audio conference prior to installation and implementation of LR*5.2*281.

Intended Audience

IRM Staff:

IRM staff is required for the installation, post installation, assignment of mail groups, and menu options for the EPI Rollup Modifications patch LR*5.2*281.

Laboratory Staff:

It is **highly recommended** that the following person(s) jointly participate in reviewing the national EPI pathogen parameter descriptions and set-ups:

- Laboratory Information Manager (LIM)
- Representative from the Microbiology section for the Emerging Pathogens Initiative (i.e., director, supervisor, or technologist)

Quality Management Staff:

It is **highly recommended** that the following person(s) jointly participate in reviewing the national EPI pathogen parameter descriptions and set-ups:

- Total Quality Improvement/Quality Improvement/Quality Assurance (TQI/QI/QA) staff (or person at the facility with similar function)

Other Staff:

It may also be beneficial to have Infection Control Personnel involved in national EPI pathogen parameter set-ups.

Test Sites:

The VistA Laboratory EPI Rollup Modifications patch LR*5.2*281, has been tested at the following VAMCs:

| EPI Test Sites | Operating System |
|---------------------------------------|---|
| Boston, MA HCS (Beta Test) | ALPHA/Digital Standard Mumps (DSM) Oct 2003 DSM VMS - May 15, 2004 |
| Cincinnati, OH VAMC (Alpha/Beta Test) | OS V7.2-1 – DSM V7.2.1, June 2003 |
| Detroit, MI VAMC (Beta Test) | OS V7.3 – DSM V7.2.1, June 2003 |
| Durham, NC VAMC (Beta Test) | OS V7.2-1 – DSM V7.2.1, March 2003: |
| Manchester, NH VAMC (Beta Test) | Windows NT 3.2, June 2003 |
| Togus, ME VAMC (Beta Test) | CACHE V7.3 - DSM V7.2.1, October 2003 |

Hardware and Operating System Requirements:

VistA software operates on two hardware platforms. The hardware platforms are listed in the mini-computer category, which provides multi-tasking and multi-user capabilities. The hardware platforms systems used are:

Digital Equipment Corporation (DEC) Alpha Series:

Digital Equipment Corporation (DEC) Alpha series is using the DEC Open Virtual Memory System (VMS), Version 6.1 or greater, operating system. This platform uses the DEC System Mumps (DSM), Version 6.3 or greater, of American National Standards Institutes (ANSI) of Massachusetts General Hospital Utility Multi-Programming System (MUMPS) also known as 'M' language. MUMPS is a Federal Information Processing Standard (FIPS) language.

System Performance Capacity:

There are no significant changes in the performance capacity of the VistA operating system once the Lab EPI Roll Up Modification Enhancement patch LR*5.2*281 is installed. The software application should not create any appreciable global growth or network transmission problems. There are no memory constraints.

Memory Constraints:

Sufficient memory is required by sites to maintain the growth of the EPI globals.

Installation Time:

Installation time for the VistA Laboratory EPI Rollup Modifications patch LR*5.2*281 is less than 2 minutes during off peak hours and less than 5 minutes during peak hours.

Disabling EPI Menus Not Required:

The Lab EPI Primary (LREPI SEARCH EXTRACT MENU) menu and options are NOT required to be disabled during the EPI installation process.

Users on the System:

Users may remain on system during the installation of patch LR*5.2*281 and all options may remain in service.

Backup Routines:

It is highly recommended that a backup of the transport global be performed before installing patch LR*5.2*281.

Namespace:

The VistA Laboratory EPI Rollup Modifications Patch LR*5.2*281, uses the Laboratory's LR namespace.

Software Requirements:

The following software applications are **must** be installed prior to the installation of Laboratory EPI Rollup Modifications patch LR*5.2*281:

| Software Applications | Versions (or Greater) |
|-----------------------|---------------------------------|
| VA FileMan | v. 21 (with patches installed) |
| Kernel | v. 8.0 (with patches installed) |
| Laboratory | v.5.2 (with patches installed) |
| PIMS | v. 5.3 (with patches installed) |
| HL7 | v.1.6 (with patches installed) |
| Social Work | v.3.0 (with patches installed) |
| Mailman | v.7.1 (with patches installed) |
| Clinical Reminder | v.1.5 (with patches installed) |

Required Patches:

NOTE: For a list of patches required to install patch LR*5.2*442, please refer to the ICD-10 PTF Modifications Installation Guide: <http://www.va.gov/vdl/application.asp?appid=118>

NOTE: For a list of patches required to install patch LR*5.2*421, please refer to the ICD-10 Remediation project Release Notes.

Prior to the installation of Laboratory EPI Rollup Modifications patch LR*5.2*281, the following patches **MUST** be installed:

| Software Applications | Patches |
|--------------------------|--|
| Laboratory V. 5.2 | LR*5.2*175 LR*5.2*242 LR*5.2*260 |
| Clinical Reminder V. 1.5 | PXRM*1.5*1 |

Health Level Seven (HL7):

Laboratory EPI Rollup Modifications patch LR*5.2*281 uses the VistA HL7 V. 1.6 software application to transmit EPI data to the AITC.

Protocols:

LRPEI: This event driver protocol defines the associated parameters required for building HL7 messages that are used to transmit EPI data to the AITC.

LRPEI CLIENT: This subscriber protocol defines the parameter required by the HL7 application that determines where to send the HL7 formatted message containing the emerging pathogens data.

Domain

The Q-EPI-MED.GOV domain is used for transmitting EPI data to AITC.

Database Integration Agreements (DBIAs)

The following new DBIA was approved for VistA Laboratory ICD-10 PTF Modifications patch LR*5.2*442:

- **DBIA#6130**

The following DBIAs were approved for VistA Laboratory EPI Rollup Modifications patch LR*5.2*281:

1. DBIA #418

Laboratory EPI software has been approved to look at the discharge date x-ref in the PTF file (#45). The EPI software gathers lab data to send to Austin.

```

                FILE: 45                      ROOT: DGPT(
DESCRIPTION:                                TYPE: File #45 PTF file

^DGPT("ADS",    cross-reference:
  The routine LREPI5 searches a date range for discharge dates in that range
to gather Lab EPI data to send to Austin.
```

2. DBIA #3018

Laboratory EPI software approved to call the \$\$IN^VAFHLPV1 to create a PV1 segment to send to the Austin Automation Center.

3. DBIA #3094:

AUPNVPOV (PCE PATIENT CARE ENCOUNTER DESCRIPTION: TYPE: File V POV diagnoses are used as a finding in Clinical Reminders. Therefore, Clinical Reminders needs to read the following fields:

```

GLOBAL REFERENCE:
^AUPNVPOV('AA',
GLOBAL REFERENCE:
^AUPNVPOV(D0,0)
.01      POV                      0;1      Direct Global Read
.03      VISIT                    0;3      Direct Global Read
.04      PROVIDER NARRATIVE       0;4      Direct Global Read
.12      PRIMARY/SECONDARY        0;12     Direct Global Read
KEYWORDS: CLINICAL REMINDERS V POV
```

4. DBIA #3530

Laboratory EPI software approved to reference ^AUPNVSIT.

```

3530      NAME: DBIA3530
CUSTODIAL PACKAGE: PCE PATIENT CARE ENCOUNTER      Albany
SUBSCRIBING PACKAGE: INTEGRATED BILLING            Albany
      USAGE: Private      ENTERED: FEB 27, 2002
      STATUS: Active      EXPIRES:
      DURATION: Till Otherwise Agr  VERSION:
      FILE: 9000010      ROOT: AUPNVSIT(
      DESCRIPTION:      TYPE: File
Integrated Billing receives encounters from PCE but screens out many based
on certain criteria. One of these criteria is the Data Source of the
encounter. The following reference is needed to identify the Data Source
of an encounter to determine if the encounter should pass to Integrated
Billing.

GLOBAL REFERENCE:
^AUPNVSIT(D0
81203      DATA SOURCE      812;3      Direct Global Read
Visit's Data Source, pointer to file 839.7
      KEYWORDS:

```

5. DBIA 4280

LAB EPI software approved to do a direct read of the global \$P(^DIC(21,D0,0),U,3) and a direct global read of the "D" cross reference ^DIC(21,"D").

```

NAME: DIC(21
CUSTODIAL PACKAGE: REGISTRATION      Albany
SUBSCRIBING PACKAGE: LAB SERVICE      Dallas
      USAGE: Private      ENTERED: MAY 27,2004
      STATUS:      EXPIRES:
      DURATION: Till Otherwise Agr  VERSION:
      FILE: 21      ROOT: DIC(21
      DESCRIPTION:      TYPE: File
LAB EPI software does a direct read of the global $P(^DIC(21,D0,0),U,3) and
a direct global read of the "D" cross reference ^DIC(21,"D" The software
gathers EPI data for transmission to Austin.
GLOBAL REFERENCE:
^DIC(21

```

Data Dictionary Changes

The following data dictionary changes are required for the EPI Roll-Up Modifications Patch LR*5.2*281 software release:

LAB SEARCH/EXTRACT file (#69.5)

This file contains search criteria used by the Laboratory EPI software. This file should ONLY be edited using the EPI Parameter Setup [LREPI PARAMETER SETUP] option provided with this software. This file contains the following changes:

Modified Fields:

NAME field (#69.5,.01)

The Search/Extract parameter name is converted to upper case and stored in the "D" x-ref for easier lookup (i.e., enter a Name (3 to 30 characters) for the Search/Extract parameter you are defining).

```
69.5,.01      NAME                      0;1 FREE TEXT (Required)

INPUT TRANSFORM:  K:$L(X)>30!($L(X)<3)!'(X'?1P.E)!(X'? .ANP) X
LAST EDITED:     MAR 16, 2004
HELP-PROMPT:     Enter a Name (3 to 30 characters) for the
                  Search/Extract parameter you are defining.
DESCRIPTION:     This is the name of the Search/Extract
                  parameter you are defining.

NOTES:           XXXX--CAN'T BE ALTERED EXCEPT BY PROGRAMMER

CROSS-REFERENCE: 69.5^B
                  1)= S ^LAB(69.5,"B",$E(X,1,30),DA)=" "
                  2)= K ^LAB(69.5,"B",$E(X,1,30),DA)

CROSS-REFERENCE: 69.5^D^MUMPS
                  1)= D UP^LRXREF S ^LAB(69.5,"D",X,DA)=" "
                  2)= D UP^LRXREF K ^LAB(69.5,"D",X,DA)
                  The name is converted to upper case and stored
                  in the "D" x-ref for easier lookup.
                  ^LAB(69.5,"D",UPPERCASE NAME, IEN)
```

This field has also been **modified** to add the following 6 **new** emerging pathogens entries:

- All *Staphylococcus aureus* (Reference #18)
- Methicillin-Resistant *Staphylococcus aureus* (MRSA) (Reference #19)
- Vancomycin-Resistant *Staphylococcus aureus* (VRSA) (Reference #20)
- Vancomycin-Resistant Coagulase Negative *Staphylococci/Staph epi* (VRSE) (Reference #21)
- All *Streptococcus pneumoniae* (Reference #22)
- All Enterococci (Reference #23)

NOTE: For Patch LR*5.2*421, the following changes have been made for File (#69.5) to support ICD-10 implementation. The “ICD-9 Diagnosis” field has been modified to “ICD Diagnosis.” Please refer to the ICD-10 Release Notes for LR*5.2*421.

| | | |
|-----------|------------------|--|
| 69.5,4 | ICD DIAGNOSIS | 3;0 POINTER Multiple #69.54 |
| | LAST EDITED: | JUN 12, 2012 |
| | DESCRIPTION: | This defines the ICD to search for. |
| | | |
| 69.54,.01 | ICD DIAGNOSIS | 0;1 POINTER TO ICD DIAGNOSIS FILE (#80) (Multiply asked) |
| | LAST EDITED: | SEP 17, 2012 |
| | HELP-PROMPT: | Select the ICD standardized code, used nationwide in federal and non-federal private health care facilities, to be included in the search. |
| | DESCRIPTION: | This defines an ICD for use in emerging pathogens data search/extract. |
| | | |
| | CROSS-REFERENCE: | 69.54^B 1)= S LAB(69.5,DA(1),3,"B",\$E(X,1,30),DA)=" " 2)= K ^LAB(69.5,DA(1),3,"B",\$E(X,1,30),DA) |
| | | |
| 69.54,1 | CODING SYSTEM | 0;2 POINTER TO ICD CODING SYSTEMS FILE (#80.4) |
| | LAST EDITED: | AUG 10, 2012 |
| | HELP-PROMPT: | Enter the applicable ICD coding system for this ICD. |

INACTIVE field (#69.5,1)

This field has been renamed from ACTIVE to INACTIVE.

Example: 69.5,1 INACTIVE 0;2 SET

| | |
|--------------|--|
| | '1' FOR YES; |
| | '0' FOR NO; |
| LAST EDITED: | JUN 19, 2002 |
| HELP-PROMPT: | '1' or 'YES' indicates that this is an inactive entry. '0' or 'NO' indicates that this is an active entry. |
| DESCRIPTION: | This defines if this entry is active or not. |

PROTOCOL field (#69.55,12):

This field defines the protocol associated with the parameters. This field has been **changed** to UNEDITABLE.

Example: 69.5,12 PROTOCOL 0;7 POINTER TO LAB
SEARCH/EXTRACT PROTOCOL FILE (#69.4)

| | |
|--------------|--------------|
| LAST EDITED: | NOV 06, 2003 |
|--------------|--------------|

HELP-PROMPT: Select the Protocol to be used to define the
output messages.
DESCRIPTION: This defines what protocol is associated with
the parameters.

UNEDITABLE

NEW Fields:**PREVIOUS CYCLE field (69.5,19)**

This **new** field is defined as a numeric field, (type a number between 1 and 99). By entering a number here the Lab search engine knows to look at a previous cycle for updates to data. How far back it looks is based on the cycle and number entered. For example if the cycle is monthly and the previous cycle is 1, then the search engine will also search 1 month back for data. This **new** field is UNEDITABLE.

Example: 69.5,19

PREVIOUS CYCLE

0;13 NUMBER

INPUT TRANSFORM: K:+X'=X!(X>99)!(X<1)!(X?.E1"."1.N) X
 LAST EDITED: SEP 09, 2003
 HELP-PROMPT: Type a number between 1 and 99.
 DESCRIPTION: By entering a number here the Lab search engine knows to look at a previous cycle for updates to data. How far back it looks is based on the cycle and number entered. For example if the cycle is monthly and the previous cycle is 1 then the search engine will also search 1 month back for data.

UNEDITABLE

INDICATOR field (#69.55,1):

NOTE: The **new** INDICATOR field (#69.55,1) located under ANTIMICROBIL SUSCEPTIBILITY sub-field (#69.55) is NOT being used in this release of the EPI software.

This **new** INDICATOR field (#69.55,1) is defined as a SET of CODES. Select the code that will determine how to match lab results. This indicates if the search for the lab test is conditional.

Example:

69.55,1

INDICATOR

0;2 SET

'1' FOR Use Reference Ranges;
 '2' FOR Contains;
 '3' FOR Greater Than;
 '4' FOR Less Than;
 '5' FOR Equal To;
 LAST EDITED: MAR 24, 2004
 HELP-PROMPT: Select the code that will determine how to match lab results.
 DESCRIPTION: This indicates if the search for the lab test is conditional.

INDICATED VALUE field (#69.55,2):

NOTE: The **new** INDICATED VALUE field (#69.55,2) located under ANTIMICROBIL SUSCEPTIBILITY sub-field (#69.55) is NOT being used in this release of the EPI software.

The **new** INDICATED VALUE field (#69.55,2) is defined as FREE TEXT. When the search indicator is used then use this field to define the criteria. Answer must be 1-30 characters in length.

Example:

```
69.55,2      INDICATED VALUE      0;3 FREE TEXT

INPUT TRANSFORM: K:$L(X)>30!($L(X)<1) X
LAST EDITED:   MAR 24, 2004
HELP-PROMPT:   Enter the data to be compared using the
                INDICATOR field.
DESCRIPTION:   If the search is conditional this defines the
                criteria.
```

PROTOCOL file (#101)**Modified Field**Processing Routine field (#771):

Entry in the Processing Routine field (#771) for the Protocol LREPI CLIENT was changed from PROCESS^LREPIRP to a NULL entry.

NOTE: In the LAB SEARCH/EXTRACT file (#69.5), the PROTOCOL field (#101) and PREVIOUS CYCLE field (69.5, 19) has been changed to be UNEDITABLE.

Routine Summary

Example: Checksum

The following routines are included in this patch. The second line of each of these routines now looks like:
 <tab> ;;5.2;LAB SERVICE;<patchlist>;Sep 27, 1994

| Routine Name | Checksum | | Patch List |
|--------------|--------------|-------------|-------------------------|
| | Before Patch | After Patch | |
| LR281 | N/A | 4418686 | 281(Deleted by KIDS) |
| LREPI | 14217525 | 14182167 | 132,175,260,281 |
| LREPI1 | 10654552 | 11822436 | 132,157,175,260,281 |
| LREPI2 | 7199135 | 8491199 | 132,157,175,242,260,281 |
| LREPI2A | NEW | 7574864 | 281 |
| LREPI3 | 5462995 | 9184652 | 132,175,260,281 |
| LREPI5 | NEW | 2408593 | 281 |
| LREPIPH | 5818757 | 6144410 | 260,281 |
| LREPIPI | NEW | 5220624 | 281 |
| LREPIRM | 5260075 | 7566388 | 175,281 |
| LREPIRP | 5973015 | 20442264 | 132,157,175,260,281 |
| LREPIRP1 | NEW | 15133552 | 281 |
| LREPIRP2 | NEW | 3729823 | 281 |
| LREPIRP3 | NEW | 29061422 | 281 |
| LREPIRP4 | NEW | 1812384 | 281 |
| LREPIRP5 | NEW | 11788836 | 281 |
| LREPIRP6 | NEW | 25502070 | 281 |
| LREPIRP7 | NEW | 17171829 | 281 |
| LREPIRP8 | NEW | 8376752 | 281 |
| LREPIRP9 | NEW | 4718 | 281 |
| LREPIRS | NEW | 8576522 | 281 |
| LREPIRS1 | NEW | 16664999 | 281 |
| LREPIRS2 | NEW | 22133542 | 281 |
| LREPIRS3 | NEW | 16290972 | 281 |
| LREPISRV | 12552990 | 15211664 | 260,281 |
| LREPISV1 | NEW | 4805594 | 281 |

Installation Instructions

NOTE: For patch LR*5.2*442 installation instructions, please refer to the ICD-10 PTF Modifications Installation Guide: <http://www.va.gov/vdl/application.asp?appid=118>

NOTE: For Patch LR*5.2*421 installation instructions, please refer to the ICD-10 Release Notes for LR*5.2*421.

VistA Laboratory EPI Rollup Modifications patch LR*5.2*281 uses the Kernel Installation and Distribution System (KIDS). For further instructions on using KIDS, please refer to the Kernel V. 8.0 Systems Manual.

The install time for this patch is less than 2 minutes. This patch can be installed when Laboratory users are on the system.

NOTE: Kernel patches **must** be current on the target system to avoid problems loading and/or installing this patch.

1. If any of the above routines are mapped, disable mapping for them.
2. Use the 'Load a Distribution' option to load the Host file onto your system.
3. The patch has now been loaded into a Transport global on your system. You now need to use KIDS to install the transport global.
4. On the 'Kernel Installation & Distribution System' Menu (KIDS), select the 'Installation' menu.
5. Use the 'Verify Checksum in Transport Global' option and verify that all routines have the correct checksums.
6. On the KIDS menu, under the 'Installation' menu, use the following options:

- Print Transport Global
- Compare Transport Global to Current System
- Backup a Transport Global

If you wish to preserve a copy of the routines exported in this patch prior to installation, you should use the 'Backup a Transport Global' option at this time. You may also compare the routines in your

production account to the routines in the patch by using the 'Compare a Transport Global to Current System' option.

7. Use the 'Install Package(s)' option under the 'Installation' menu and select the package 'LR*5.2*281'.

If prompted ' Want KIDS to Rebuild Menu Trees Upon Completion of Install? YES/' choose 'NO'.

If prompted ' Want KIDS to INHIBIT LOGONs during the install? YES// ' choose 'NO'.

If prompted 'Want to DISABLE Scheduled Options, Menu Options, and Protocols? YES//', choose 'NO'.

8. On a mapped system, rebuild your map set.

9. Routine LR281 will be deleted after successful patch installation.

Installation Example:

```

Select Kernel Installation & Distribution System Option: INSTallation<Enter>

Select Installation Option: 6  Install Package(s)<Enter>
Select INSTALL NAME: LR*5.2*281 <Enter>          Loaded from Distribution
5/24/04@14:18:24      => LR*5.2*281

This Distribution was loaded on May 24, 2004@14:18:24 with header of
  LR*5.2*281
  It consisted of the following Install(s):
    LR*5.2*281
Checking Install for Package LR*5.2*281
Will first run the Environment Check Routine, LR281

          --- Environment Check is Ok ---

Install Questions for LR*5.2*281

Incoming Files:

    69.5      LAB SEARCH/EXTRACT  (including data)
Note:  You already have the 'LAB SEARCH/EXTRACT' File.
I will MERGE your data with mine.

Want KIDS to Rebuild Menu Trees Upon Completion of Install? YES// NO<Enter>

Want KIDS to INHIBIT LOGONs during the install? YES// NO<Enter>
Want to DISABLE Scheduled Options, Menu Options, and Protocols? YES//
NO<Enter>

Enter the Device you want to print the Install messages.
You can queue the install by enter a 'Q' at the device prompt.
Enter a '^' to abort the install.

DEVICE: HOME//<Enter>      UCX/TELNET

Install Started for LR*5.2*281 :
      May 24, 2004@14:19:41

Build Distribution Date: May 20, 2004

Installing Routines:
      May 24, 2004@14:19:41

Running Pre-Install Routine: PRE^LR281

      Deleting NCH entries from LAB/SEARCH EXTRACT file (#69.5)

          *** Preinstall completed ***

```


Installing Data Dictionaries:
May 24, 2004@14:19:42

Installing Data:
May 24, 2004@14:19:43

Installing PACKAGE COMPONENTS:

Installing FORM
LR*5.2*281

Installing PROTOCOL

Installing OPTION
May 24, 2004@14:19:46

Running Post-Install Routine: POST^LR281

Updating Routine file...

Updating KIDS files...

LR*5.2*281 Installed.
May 24, 2004@14:19:47

Install Message sent #10960

100%
Complete

255075

Install Completed

Post Installation and Implementation Instructions

NOTE: There are no post installation instructions for patch LR*5.2*442.

NOTE: For Patch LR*5.2*421 post installation instructions, please refer to the ICD-10 Release Notes for LR*5.2*421.

The following post installation and implementation instructions **must** be completed to ensure a successful performance of the EPI Roll up Modification software enhancements:

IRM Post Installation Instructions:

IRM - Step 1: Verify Lower Level Protocol of the HL7 V. 1.6 background job for EPI – LAB

Example: How to verify that the Lower Level Protocol of the HL7 V. 1.6 background job EPI – LAB is running.

```
Select HL7 Main Menu Option: ?<Enter>
```

```
Event monitoring menu ...
Systems Link Monitor
Filer and Link Management Options ...
Message Management Options ...
Interface Developer Options ...
Site Parameter Edit
```

```
Enter ?? for more options, ??? for brief descriptions, ?OPTION for help text.
```

```
Select HL7 Main Menu Option: FILER and Link Management Options<Enter>
```

```
Select Filer and Link Management Options Option: ?<Enter>
```

```
SM      Systems Link Monitor
FM      Monitor, Start, Stop Filers
LM      TCP Link Manager Start/Stop
SA      Stop All Messaging Background Processes
RA      Restart/Start All Links and Filers
DF      Default Filers Startup
SL      Start/Stop Links
PI      Ping (TCP Only)
ED      Link Edit
ER      Link Errors ...
```

```
Enter ?? for more options, ??? for brief descriptions, ?OPTION for help text.
```

Select HL7 Main Menu Option: **FILER and Link Management Options**<Enter>

Select Filer and Link Management Options Option: **START/Stop Links**<Enter>

This option is used to launch the lower level protocol for the appropriate device. Please select the node with which you want to communicate

Select HL LOGICAL LINK NODE: **EPI-LAB**<Enter>

The LLP was last shutdown on JUL 14, 2000 08:52:58.

Select one of the following:

| | |
|---|------------|
| F | FOREGROUND |
| B | BACKGROUND |
| Q | QUIT |

Method for running the receiver: **B**// BACKGROUND

Job was queued as 130212.

IRM - Step 2: Verify Lab EPI Nightly Task [LREPI NIGHTLY TASK] Option Nightly Run

The Lab EPI Nightly Task [LREPI NIGHTLY TASK] option **must** be scheduled to run nightly. This option will build HL7 messages and send them to the defined locations specified by the LREPI protocol.

Example: How to schedule the Lab EPI Nightly Task [LREPI NIGHTLY TASK] option to run nightly.

```
Select Systems Manager Menu
```

```
Core Applications ...
Device Management ...
FM VA FileMan ...
Manage Mailman ...
Menu Management ...
Programmer Options ...
Operations Management ...
Spool Management ...
Information Security Officer Menu ...
Taskman Management ...
User Management ...
Application Utilities ...
Capacity Management ...
HL7 Main Menu ...
```

```
You have 89 new messages. (Last arrival: 03/17/04@15:30)
```


```
Select Systems Manager Menu Option: TASKman Management<Enter>
```

```
Schedule/Unschedule Options
One-time Option Queue
Taskman Management Utilities ...
List Tasks
Dequeue Tasks
Requeue Tasks
Delete Tasks
Print Options that are Scheduled to run
Cleanup Task List
Print Options Recommended for Queueing
```

```
Select Taskman Management Option: SCHEDULE/UnscheduleOptions<Enter>
```

```
Select OPTION to schedule or reschedule: LREPI NIGHTLY TASK<Enter>
```

Example: How to schedule the Lab EPI Nightly Task [LREPI NIGHTLY TASK] option to run nightly *continued*.



IRM - Step 3: Verify EPI mail group setup entries

This mail group is used by VHA facilities to transmit EPI HL7 format mailman messages **to** Austin Information Technology Center (AITC) and for AITC to transmit EPI Confirmation mailman messages back to the sending VHA facilities once the EPI HL7 format mailman messages data transmission has been received by AITC. The **Office of Director (00)**-designated staff for EPI process implementation should be assigned to this mail group and kept current as personnel assume this responsibility. This/these staff member(s) is/are responsible for that the monthly EPI process has run and generated the appropriately formatted HL7 messages that are transmitted to the AITC. Receipt of the HL7 message series by this mail group is a means of ascertaining that this process has occurred. Installation of this patch provides opportunity to review this EPI mail group and update as needed.

NOTE: It is highly recommended that the **Office of the Director (00)** at each facility initially designate the member(s) responsible for overseeing the EPI mail group data.

Example: How to verify existing EPI mail group setup entries

```
OUTPUT FROM WHAT FILE: LAB EPI// MAIL GROUP<Enter>
                                     (1441 entries)
Select MAIL GROUP NAME: EPI<Enter>
ANOTHER ONE:<Enter>
STANDARD CAPTIONED OUTPUT? Yes//<Enter>    (Yes)
Include COMPUTED fields: (N/Y/R/B): NO//<Enter> - No record number (IEN), no
Computed Fields

NAME: EPI                                TYPE: public
  ALLOW SELF ENROLLMENT?: NO              REFERENCE COUNT: 8499
  LAST REFERENCED: AUG 15, 2000           RESTRICTIONS: UNRESTRICTED
MEMBER: EPI, USER

DESCRIPTION: This mail group is used to deliver a formatted report taken from the HL7 message that is
created to assist in the verification of data.
```

IRM Step 4: Verify EPI-REPORT mail group setup entries

This mail group **receives** the **new** EPI Summary Verification Report that is automatically generated on the 15th day of each month at each VHA facility. The **Office of Director (00)**-designated staff for EPI process implementation should be assigned to this mail group and kept current as personnel assume this responsibility. Other members of this mail group should be personnel who can assist the Office of Director-designated staff validate that the data contained in the **new** EPI Summary Verification Report accurately reflect what has occurred at the facility during the prior month. If the data do not accurately reflect facility activity regarding the national EPI Pathogens, corrections should be undertaken and coordinated by the Office of Director-designated staff; once the corrections are made, it is the responsibility of this designated staff to re-transmit the EPI data to the AITC using the Lab EPI Manual Run (Enhanced) option. Other personnel at the site may have interest in this summary overview of occurrences at the local site and should be permitted to join this mail group—these personnel may include the Infection Control Practitioners, Infectious Diseases physicians, hospital epidemiologists and Quality Managers. Installation of this patch provides opportunity to review this EPI-REPORT mail group and update as needed.

Example: How to verify EPI-REPORT mail group setup entries

```
OUTPUT FROM WHAT FILE: LAB EPI// MAIL GROUP<Enter>
                                     (1441 entries)
Select MAIL GROUP NAME: EPI-REPORT<Enter>
ANOTHER ONE:<Enter>
STANDARD CAPTIONED OUTPUT? Yes//<Enter>    (Yes)
Include COMPUTED fields: (N/Y/R/B): NO//<Enter> - No record number (IEN), no
Computed Fields

NAME: EPI-REPORT                                TYPE: public
  ALLOW SELF ENROLLMENT?: NO                     REFERENCE COUNT: 8499
  LAST REFERENCED: AUG 15, 2000                  RESTRICTIONS: UNRESTRICTED
MEMBER: EPI, USER
DESCRIPTION: This mail group is used to deliver a formatted report taken from the HL7 message that is
created to assist in the verification of data.
```

IRM Step 5: Verify XXX@Q-EPI.MED.VA.GOV Remote Member Entries

Verify designated remote members entries in the MAIL GROUP file (#3.8), MEMBERS - REMOTE field (#12), for the EPI mail group.

Example: How to verify EPI mail groups remote member XXX@Q-EPI.MED.VA.GOV entries:

```
Select VA FileMan 22.0

Select OPTION: 1<Enter>ENTER OR EDIT FILE ENTRIES

INPUT TO WHAT FILE: MAIL GROUP//<Enter>
EDIT WHICH FIELD: ALL// MEMBERS - REMOTE      (multiple)
      EDIT WHICH MEMBERS - REMOTE SUB-FIELD: ALL//<Enter>
THEN EDIT FIELD:<Enter>

Select MAIL GROUP NAME: EPI<Enter>
      1   EPI
      2   EPI-REPORT
CHOOSE 1-2: 1   EPI<Enter>
Select REMOTE MEMBER: S.HL V16 SERVER@DEV// XXX@Q-EPI.MED.VA.GOV<Enter>
      Are you adding 'XXX@Q-EPI.MED.VA.GOV' as a new REMOTE MEMBER (the2ND
for this MAIL GROUP)? No// Y<Enter>(Yes)
```


IRM Step 6: Verify Lab EPI Primary [LREPI SEARCH EXTRACT MENU] menu assignment to all designated users

NOTE: The **Office of Director (00)**-designated staff for EPI process implementation should be assigned to the EPI mail group and kept current as personnel assume this responsibility. It is highly recommended that the Laboratory Information Manager (LIM), a representative from the Microbiology section (director, supervisor, or technologist) and a Total Quality Improvement/Quality Improvement/Quality Assurance (TQI/QI/QA) staff (or person at the facility with similar function) also be assigned the Lab EPI Primary Menu [LREPI SEARCH EXTRACT MENU]. These will be the individual(s) responsible for initially setting the national Lab EPI parameters descriptions and doing periodic reviews of the parameters descriptions to assure they are current.

Example: Lab EPI Primary [LREPI SEARCH EXTRACT MENU] menu

Lab EPI Primary Menu

```
ENH   Lab EPI Manual Run (Enhanced)
VR     Print Detailed Verification Report
LO     Local Pathogen Menu ...
PI     Pathogen Inquiry
UP     Lab EPI Parameter Setup
       Lab EPI Protocol Edit
LK     Antimicrobial Link Update
```

Example: Local Pathogen [LREPI LOCAL PATHOGEN MENU] Menu

```
ENT...Enter/Edit Local Pathogens
GEN   Lab EPI Generate Local Report/Spreadsheet
PRT   Lab EPI Print Local Report/Spreadsheet
DEL   Delete Local Pathogen
DRS   Delete Local Report or Spreadsheet
```

NOTE: Assignment of the Local Pathogen [LREPI Local Pathogen Menu] submenu is automatic with assignment of the Lab EPI Primary Menu. However, this submenu may be assigned independent of the primary menu; this independent assignment allows only access to the local pathogen menu functions. This provides one way of limiting access to functionality to only those personnel truly needing access and preventing personnel from inadvertently changing national EPI pathogen parameters.

LIM Implementation Instructions

The following implementation instructions **must** be completed to achieve a successful performance of the EPI Roll up Modification software enhancements:

NOTE: It is highly recommended that the Laboratory Information Manager (LIM), a representative from the Microbiology section (director, supervisor, or technologist) and a Total Quality Improvement/Quality Improvement/Quality Assurance (TQI/QI/QA) staff (or person at the facility with similar function) be assigned the Lab EPI Primary Menu [LREPI SEARCH EXTRACT MENU]. These will be the individual(s) responsible for initially setting the national Lab EPI parameters descriptions and doing periodic reviews of the parameters descriptions to assure they are current.

LIM - Step 1: Review new EPI Descriptions and Input Screens Examples

Review the following 6 **new** emerging pathogens descriptions and input screens examples **prior** to setting up the Lab EPI parameters. Also review the exiting Legionella (Reference #7) pathogen regarding descriptions and input screen examples to capture the Legionella Urinary Antigen) (*i.e., Descriptions and input screens examples are located in the EPI Roll-Up Modifications User Manual ‘Use of the Software’ section of this manual*):

- All *Staphylococcus aureus* (Reference #18)
- Methicillin-Resistant *Staphylococcus aureus* (MRSA) (Reference #19)
- Vancomycin-Resistant *Staphylococcus aureus* (VRSA) (Reference #20)
- Vancomycin-Resistant Coagulase Negative *Staphylococci/Staph epi* (VRSE) (Reference #21)
- All *Streptococcus pneumoniae* (Reference #22)
- All Enterococci (Reference #23)

LIM - Step 2: Setup new EPI Parameter Descriptions

Use the Lab EPI Parameter Setup [LREPI PARAMETER SETUP] option to setup the 6 **new** emerging pathogens parameter descriptions (i.e., as specified by the VAHQ Infectious Disease Program Office). *(See the EPI Roll Up Modifications User Manual section of this manual for examples on setting up the six new EPI parameters).*

NOTE: Take this opportunity to perform the expected annual review of the already existing EPI parameter set-ups for the other 17 pathogens to assure that they are up-to-date and correct. Should there be corrections that need to be made, they should be made at this time with the following exception: the 4 hepatitis pathogens (Hepatitis C Antibody Positive, Hepatitis C Antibody Negative, Hepatitis A Antibody Positive and Hepatitis B Positive) are tightly integrated with the Clinical Reminder data stream that the EPI national roll-up accomplishes (see combined products VistA Laboratory EPI Hepatitis Extract Patch LR*5.2*260, PXR*1.5*1, PSJ*5*48 and Patch PSO*7*45) and changes in the EPI parameters may need to have concomitant changes in the Clinical Reminder data being passed over to the EPI national roll-up—concurrent review (and changes, if necessary), should be undertaken in conjunction with the local Clinical Applications Coordinator for the Clinical Reminder package to assure that appropriate mapping of Health factors to the national pathogens has occurred.

NOTE: LAG DAYS **must** be set at **15** for all EPI-defined pathogens, including the 6 **new** EPI.

LIM - Step 3: Link the Logical Observations, Identifiers, Names, and Codes (LOINC)

For instructions on linking LOINC please refer to the following web site to obtain a copy of the VistA NLT Mapping to LOINC Technical, Installation, and User Guide.

<http://www.va.gov/vdl/Clinical.asp?appID=119>

Office of Director (00) Designated Staff Implementation Instructions:

The following implementation instructions **must** be completed to achieve a successful performance of the EPI Roll up Modification software enhancements:

NOTE: It is highly recommended that the Laboratory Information Manager (LIM), a representative from the Microbiology section (director, supervisor, or technologist), and a Total Quality Improvement/Quality Improvement/Quality Assurance (TQI/QI/QA) staff (or person at the facility with similar function) be assigned the Lab EPI Primary Menu [LREPI SEARCH EXTRACT MENU]. These will be the individual(s) responsible for initially setting the national Lab EPI parameters descriptions and doing periodic reviews of the parameters descriptions to assure they are current.

(00) Designated Staff - Step 1: Review new EPI Descriptions and Input Screens Examples

Review the following 6 **new** emerging pathogens descriptions and input screens examples **prior** to setting up the Lab EPI parameters. Also review the exiting Legionella (Reference #7) pathogen regarding descriptions and input screen examples to capture the Legionella Urinary Antigen) (*i.e., Descriptions and input screens examples are located in the EPI Roll Up Modifications User Manual 'Use of the Software' section of this manual*):

- All *Staphylococcus aureus* (Reference #18)
- Methicillin-Resistant *Staphylococcus aureus* (MRSA) (Reference #19)
- Vancomycin-Resistant *Staphylococcus aureus* (VRSA) (Reference #20)
- Vancomycin-Resistant Coagulase Negative *Staphylococci/Staph epi* (VRSE) (Reference #21)
- All *Streptococcus pneumoniae* (Reference #22)
- All Enterococci (Reference #23)

(00) Designated Staff - Step 2: Setup new EPI Parameter Descriptions

Use the Lab EPI Parameter Setup [LREPI PARAMETER SETUP] option to setup the 6 **new** emerging pathogens parameter descriptions (i.e., as specified by the VAHQ Infectious Disease Program Office). *(See the EPI Roll Up Modifications User Manual section of this manual for examples on setting up the 6 new EPI parameters).*

NOTE: Take this opportunity to perform the expected annual review of the already existing EPI parameter set-ups for the other 17 pathogens to assure that they are up-to-date and correct. Should there be corrections that need to be made, they should be made at this time with the following exception: the 4 hepatitis pathogens (Hepatitis C Antibody Positive, Hepatitis C Antibody Negative, Hepatitis A Antibody Positive and Hepatitis B Positive) are tightly integrated with the Clinical Reminder data stream that the EPI national roll-up accomplishes (see combined products VistA Laboratory EPI Hepatitis Extract Patch LR*5.2*260, PXR*1.5*1, PSJ*5*48 and Patch PSO*7*45) and changes in the EPI parameters may need to have concomitant changes in the Clinical Reminder data being passed over to the EPI national roll-up—concurrent review (and changes, if necessary), should be undertaken in conjunction with the local Clinical Applications Coordinator for the Clinical Reminder package to assure that appropriate mapping of Health factors to the national pathogens has occurred.

NOTE: LAG DAYS **must** be set at **15** for all EPI-defined pathogens, including the 6 **new** EPI.

Instructions for Seeding EPI Historical Data:

EPI historical data **must** be gathered from October 1, 2000 through June 14, 2004. Use the Lab EPI Manual Run (Enhanced) [LREPI ENHANCE MANUAL RUN] option to extract and transmit 6 manual runs (consecutive runs) at a time.

WARNING: SITES - DO NOT transmit the EPI historical data reports on June 16 or July 4, 2004 to avoid Austin Information Technology Center (AITC) capacity limitations.

Batch #1: October 1, 2000 -March 31, 2001
Batch #2: April 1, 2001 - September 30, 2001
Batch #3: October 1, 2001 - March 31, 2002
Batch #4: April 1, 2002 - September 30, 2002
Batch #5: October 1, 2002 - March 31, 2003
Batch #6: April 1, 2003 - September 30, 2003
Batch #7: October 1, 2003 - March 31, 2004
Batch #8: April 1, 2004 - June 14, 2004

Sites will run 8 batches of EPI historical data reports. Each batch should contain 6 separate monthly extracts which are tasked separately by month, (i.e., OCT 2000, NOV 2000, DEC 2000, JAN 2001, FEB 2001, MAR 2001 = 1 batch) and will generate six separate processing reports back to the station and transmit them over a five week period June 10, 2004 – July 12, 2004. You do not have to wait for one monthly extract to run before starting the next in a batch. You do not have to wait for one batch to complete running before queuing the next batch. If you receive any fatal errors and the monthly extract is rejected, you will need to fix the error and retransmit that month.

Austin Automation Center (AITC) Schedule for Transmitting EPI Historical Data:

WARNING: SITES - DO NOT transmit the EPI historical data reports on June 16 or July 4, 2004 to avoid Austin Automation Center (AITC) capacity limitations.

Sites may transmit EPI historical data reports to AITC on evenings and weekends following this schedule:

1. VISNs with odd numbers are asked to transmit batches on Tuesday & Thursday during the PM hours and Saturdays.
2. VISNs with even numbers are asked to transmit on Monday & Friday during the PM hours and Sundays.

VistA LABORATORY EPI ROLLUP MODIFICATIONS USER MANUAL

Use of the Software

VistA Laboratory Emerging Pathogens Initiative (EPI) Rollup Modifications User Manual (Patch LR*5.2*281) section provides all the necessary information, instructions, illustrations, and examples required for the EPI coordinators, Laboratory personnel, and other users to implement and maintain the 23 emerging pathogens parameter descriptions:

NOTE: It is **highly recommended** that the following person(s) jointly participate in the review and parameter descriptions setup process for the 23 EPI descriptions at the time of this installation and at least once annually thereafter:

- Laboratory Information Manager (LIM)
- Total Quality Improvement/Quality Improvement/Quality Assurance (TQI/QI/QA) staff (e.g., or person at the facility with similar function)
- Representative from the Microbiology (i.e., director, supervisor, or technologist)

EPI Review Requirements:

The 23 emerging pathogens will require an ongoing review process (i.e., as specified by the VA Central Office Infectious Disease Program Office). The expected minimum for review is once annually. The person(s) participating in the ongoing review process is(are) responsible for ensuring the following requirements are kept current.

- Periodic reviews of ICD codes.
- Periodic reviews of the Lab EPI Parameter Setup [LREPI PARAMETER SETUP] option for the defined EPI parameter description setups.

NOTE: Remember that if the parameter set up needs to be changed for any of the four hepatitis entities, that a concomitant change needs to be made in the corresponding Reminder logic.

- Annual review of the national EPI pathogen descriptions (i.e., as specified by the VA Central Office Infectious Disease Program Office).

NOTE: To request additional LOINC, Workload, and Suffixes codes access the VistA Laboratory website, National Lab Tests (NLT) Documentation Set and LOINC Request Forms link:

<http://vista.med.va.gov/ClinicalSpecialties/lab/>

Six New Emerging Pathogens:

The EPI Roll-Up Modifications software release exports the following 6 **new** Emerging Pathogens Initiative and parameter descriptions:

1. All *Staphylococcus aureus* (Reference #18)
2. Methicillin - resistant *Staphylococcus aureus* (MRSA) (Reference #19)
3. Vancomycin-Resistant *Staphylococcus aureus* (VRSA) (Reference #20)
4. Vancomycin-Resistant Coagulase Negative *Staphylococci/Staph epi* (VRSE) (Reference #21)
5. All *Streptococcus pneumoniae* (Reference #22)
6. All Enterococci (Reference #23)

New Legionella Urinary Antigen Test:


The **new** Food and Drug Administration (FDA)-approved Legionella Urinary Antigen test may be added to the existing Legionella pathogen criteria.

New Local Pathogen [LREPI LOCAL PATHOGEN MENU] Menu

The **new** submenu contains four **new** options use to enter/edit local pathogens, generate and print local EPI reports and spreadsheets, and delete local pathogens

Lab EPI Primary (LREPI SEARCH EXTRACT MENU) Menu Diagram

Example: Lab EPI Primary [LREPI SEARCH EXTRACT MENU] menu diagram



Lab EPI Primary [LREPI SEARCH EXTRACT MENU] Menu

For consistency of this software release, the Lab Search Extract Primary [LREPI SEARCH EXTRACT MENU] menu is **RENAMED** Lab EPI Primary [LREPI SEARCH EXTRACT MENU] menu. This is the main EPI menu containing four existing options, two **new** options, and one **new** submenu containing four **new** options.

Example: Lab Search Extract Primary [LREPI SEARCH EXTRACT MENU] menu screen

| Lab EPI Primary Menu | |
|----------------------|------------------------------------|
| ENH | Lab EPI Manual Run (Enhanced) |
| VR | Print Detailed Verification Report |
| LO | Local Pathogen Menu ... |
| PI | Pathogen Inquiry |
| UP | Lab EPI Parameter Setup |
| | Lab EPI Protocol Edit |
| LK | Antimicrobial Link Update |

Lab EPI Manual Run (Enhanced) [LREPI ENHANCE MANUAL RUN] option:

This option is used **ONLY** to manually extract National EPI data, transmit manually extracted data to the Austin Information Technology Center (AITC), and to generate the **new** EPI Summary Verification Report. The **new** EPI Summary Verification Report is automatically sent to the EPI-Report mail group after being generated. This option has been **enhanced** to generate the **new** Detailed Verification Report which can be printed using the **new** Print Detailed Verification Report [LREPI VERIFICATION REPORT] option.

NOTES:

ONLY national emerging pathogens extract data are transmitted to the AITC, local pathogens extract data will **NOT** be transmitted.

Lab EPI Transmissions to AITC after 6:00 p.m. are processed the next day.

DO NOT use the Lab EPI Manual Run (Enhanced) [LREPI ENHANCED MANUAL RUN] option to transmit EPI data on Wednesdays of PAY ROLL weeks. These transmissions may cause a delay in processing PAY ROLL data.

Example: How to use the Lab EPI Manual Run (Enhanced) [LREPI ENHANCE MANUAL RUN] option.

NOTES:

In the following Laboratory Search rerun option example 'Override Any Inactive indicators: ? NO//' prompt requires a YES or NO answer. However, ALL National Emerging Pathogens are automatically set by the EPI software as ACTIVE, so either answer is correct.
THIS PROMPT WILL BE REMOVED IN A FUTURE PATCH.

At the 'Select Search Date' prompt choose the month/date/year that you wish to manually re-submit and press ENTER. At this point you should get a message regarding queuing of the task that will run at the queued time.

Laboratory Search rerun option

```
Select Protocol: LREPI <Enter>    EMERGING PATHOGEN    Emerging Pathogens
Initiative (EPI)
Override Any Inactive indicators: ? NO//<Enter>
Include All Search Parameters? YES// <Enter>
Select Search Date: 1/15/04 <Enter>
Requested Start Time: NOW// <Enter> (JAN 27, 2004@12:08:10)
```

```
The Task has been queued
Task # 54381
```

Print Detailed Verification Report [LREPI VERIFICATION REPORT] option:

This **new** option is use to print the **new** Detailed Verification Report.

Example: How to use the Print Detailed Verification Report [LREPI VERIFICATION REPORT] option

```

                                Lab EPI Primary Menu

    ENH   Lab EPI Manual Run (Enhanced)
    VR     Print Detailed Verification Report
    LO     Local Pathogen Menu ...
    PI     Pathogen Inquiry
    UP     Lab EPI Parameter Setup
          Lab EPI Protocol Edit
    LK     Antimicrobial Link Update

    <TEST ACCOUNT> Select Lab EPI Primary Menu Option: VR Print Detailed
Verification Report <ENTER>
    Print Detailed Verification Report Option

1 JAN 15,2004@16:07:41
2 JAN 16,2004@01:23:25
3 JAN 17,2004@17:19:28
4 JAN 18,2004@19:36:33
5 JAN 22,2004@22:42:01
6 JAN 23,2004@13:01:50
7 JAN 23,2004@16:15:31
8 JAN 23,2004@20:27:36
9 JAN 24,2004@17:56:01
10 JAN 30,2004@21:27:40
11 FEB 4,2004@01:49:41
12 FEB 4,2004@11:07:52
13 FEB 4,2004@11:59:16
14 FEB 4,2004@15:27
15 FEB 4,2004@18:16:41
16 FEB 8,2004@21:32:11
Choose the number for the report you wish to print: (1-16): 16<Enter>

This report will contain Confidential Information.
Do you wish to continue/proceed? NO// y YES<Enter>
Include All Pathogens? NO// y YES<Enter>
DEVICE: HOME// <Enter>WAN

                                PAGE 1

    DETAILED VERIFICATION REPORT OF EPI EXTRACTED DATA
    FROM STATION (your site station number and name
will be displayed)
    PROCESSING PERIOD: 01-01-2003 through 01-31-2003

NTE~1-Report of Vancomycin-resistant Enterococcus
These data note persons at your facility during the month that had a positive
result for Vancomycin-resistant Enterococcus. Identifying information, along
with specimen and culture results has been provided.

```

| | | | | |
|---|-----------------|-----------------|----------------|-------------------|
| PATIENT NAME | LAST 4 | DOB | SEX | PERIOD OF SERVICE |
| LABPATIENT~ONE | 0001 | 02-05-1949 | M | VIETNAM ERA |
| Outpatient Accession Date: 01-09-2003@1600 | | | | |
| 01-09-2003@1600 | BACT 03 275 | MICRO CULTURE | URINE | |
| 1 | | 01-12-2003 | ENTEROCOCCUS | FAECIUM |
| ORG # 1 | 01-09-2003@1600 | ANTIBIOTIC MIC | URINE | |
| PENICILLIN | | R | | R |
| VANCOMYCIN | | R | | R |
| NITROFURANTOIN | | S | | S |
| CIPROFLOXACIN | | R | | R |
| LEVOFLOXACIN | | R | | R |
| GENTAMICIN HP | | SYN-R | | SYN-R |
| STREPTOMYCIN HP | | SYN-R | | SYN-R |
| | | | | PAGE 2 |
| DETAILED VERIFICATION REPORT OF EPI EXTRACTED DATA | | | | |
| FROM STATION (your site station number and name | | | | |
| will be displayed) | | | | |
| PROCESSING PERIOD: 01-01-2003 through 01-31-2003 | | | | |
| NTE~2 Report of Hepatitis C antibody positive | | | | |
| This represents a line listing of persons reported during the month who had a | | | | |
| positive test for hepatitis C antibody (based on accession date and not | | | | |
| results reported date). Definitions for data to be extracted are provided in | | | | |
| Technical and User Manual documentation for Laboratory EPI LR*5.2*281. | | | | |
| Name | LAST 4 | Accession Date | Test Name | Test Result |
| LABPATIENT~TWO | 0002 | 01-16-2003@0700 | HEP C ANTIBODY | STRONG POSITIVE |
| LABPATIENT~THREE | 0003 | 01-14-2003@0909 | HEP C ANTIBODY | STRONG POSITIVE |
| LABPATIENT~FOUR | 0004 | 01-22-2003@1833 | HEP C ANTIBODY | STRONG POSITIVE |
| LABPATIENT~FIVE | 0005 | 01-30-2003@1137 | HEP C ANTIBODY | STRONG POSITIVE |
| LABPATIENT~SIX | 0006 | 01-13-2003@1653 | HEP C ANTIBODY | STRONG POSITIVE |
| LABPATIENT~SEVEN | 0007 | 01-17-2003@0941 | HEP C ANTIBODY | STRONG POSITIVE |
| LABPATIENT~EIGHT | 0008 | 01-30-2003@1246 | HEP C ANTIBODY | STRONG POSITIVE |
| LABPATIENT~NINE | 0009 | 01-13-2003@1516 | HEP C ANTIBODY | STRONG POSITIVE |
| LABPATIENT~TEN | 0010 | 01-23-2003@1153 | HEP C ANTIBODY | STRONG POSITIVE |
| LABPATIENT1~ONE | 0011 | 01-16-2003@1147 | HEP C ANTIBODY | STRONG POSITIVE |
| LAPPATIENT1~TWO | 0012 | 01-16-2003@1317 | HEP C ANTIBODY | STRONG POSITIVE |
| LABPATIENT1~THREE | 0013 | 01-29-2003@0700 | HEP C ANTIBODY | STRONG POSITIVE |
| LABPATIENT1~THREE | 0013 | 01-15-2003@0700 | HEP C ANTIBODY | STRONG POSITIVE |
| LABPATIENT1~FOUR | 0014 | 01-06-2003@0725 | HEP C ANTIBODY | STRONG POSITIVE |
| LABPATIENT1~FIVE | 0015 | 01-24-2003@1433 | HEP C ANTIBODY | STRONG POSITIVE |
| LABPATIENT1~SIX | 0016 | 01-01-2003@0700 | HEP C ANTIBODY | STRONG POSITIVE |
| LABPATIENT1~SEVEN | 0017 | 01-08-2003@1334 | HEP C ANTIBODY | STRONG POSITIVE |
| LABPATIENT1~EIGHT | 0018 | 01-08-2003@0901 | HEP C ANTIBODY | STRONG POSITIVE |
| LABPATIENT1~NINE | 0019 | 01-21-2003@1708 | HEP C ANTIBODY | STRONG POSITIVE |
| LABPATIENT1~TEN | 0110 | 01-28-2003@1618 | HEP C ANTIBODY | STRONG POSITIVE |
| LABPATIENT2~ONE | 0021 | 01-13-2003@0700 | HEP C ANTIBODY | STRONG POSITIVE |
| LABPATIENT2~TWO | 0022 | 01-30-2003@1108 | HEP C ANTIBODY | STRONG POSITIVE |
| LABPATIENT2~THREE | 0023 | 01-15-2003@1653 | HEP C ANTIBODY | STRONG POSITIVE |

NOTE: This Detailed Verification Report will include a subsequent page for each national pathogen as well as one for each National Hepatitis C Risk Assessment Clinical Reminder Data element that is integrated into the EPI data stream.

Local Pathogen [LREPI LOCAL PATHOGEN MENU] Menu:

This new submenu contains 5 new options used to enter/edit local pathogens, generate and print local reports and spreadsheets, and delete local pathogens.

Example: New Local Pathogen [LREPI LOCAL PATHOGEN MENU] Menu

Local Pathogen Menu

| | |
|-----|---|
| ENT | Enter/Edit Local Pathogens |
| GEN | Lab EPI Generate Local Report/Spreadsheet |
| PRT | Lab EPI Print Local Report/Spreadsheet |
| DEL | Delete Local Pathogen |
| DRS | Delete Local Report or Spreadsheet |

Enter/Edit Local Pathogens [LREPI ENTER/EDIT LOCAL PATH] option:

This **new** option is use to enter or edit local pathogens into LAB SEARCH/EXTRACT file (#69.5).

Example: How to use the Enter/Edit Local Pathogens [LREPI ENTER/EDIT LOCAL PATH] option to **ENTER** local pathogens.

NOTE: The following LABORATORY EPI PARAMETERS INPUT SCREEN under the Topography Selection screen, Include, Exclude, and Sex prompts are FOR FUTURE USE ONLY.

Select Lab EPI Primary Menu

| | |
|-----|--|
| ENH | Lab Search/Extract Manual Run (Enhanced) |
| VR | Print Detailed Verification Report |
| LO | Local Pathogen Menu ... |
| PI | Pathogen Inquiry |
| UP | Lab EPI Parameter Setup |
| | Lab EPI Protocol Edit |
| LK | Antimicrobial Link Update |

Select Lab EPI Primary Menu Option: **lo** Local Pathogen Menu<ENTER>

| | |
|-----|---|
| ENT | Enter/Edit Local Pathogens |
| GEN | Lab EPI Generate Local Report/Spreadsheet |
| PRT | Lab EPI Print Local Report/Spreadsheet |
| DEL | Delete Local Pathogen |
| DRS | Delete Local Report or Spreadsheet |

Select Local Pathogen Menu Option: **Enter/Edit Local Pathogens**<

Example: How to use the Enter/Edit Local Pathogens [LREPI ENTER/EDIT LOCAL PATH] option to ENTER local pathogens continued.

| | | |
|--|--|--------------|
| LABORATORY EPI PARAMETERS INPUT SCREEN | | Page 1 of 5 |
| NAME: Herpes virus539 | | INACTIVE: NO |

| | | |
|--------------------|-----------|-------|
| Laboratory Test(s) | Indicator | Value |
| < > | | |

ICD Coding System [ICD-9 or ICD-10]? (9/10):<RET>

| | | |
|----------|--------|-----------------|
| ICD Code | Cd Set | ICD Description |
| < > | | |

| | | | |
|------|------|-----------|---------|
| Exit | Save | Next Page | Refresh |
|------|------|-----------|---------|

Enter a command or '^' followed by a caption to jump to a specific field.

COMMAND: **n** Press <PF1>H for help Insert

| | | |
|--|--|--------------|
| LABORATORY EPI PARAMETERS INPUT SCREEN | | Page 2 of 5 |
| NAME: Herpes virus539 | | INACTIVE: NO |

| | |
|------------------------|-----------------------|
| Selected Etiology | Selected Snomed Codes |
| HERPES SIMPLEX VIRUS 1 | |
| HERPES SIMPLEX VIRUS 2 | |
| < > | |

| | | |
|------------------------------|----------|-----------------|
| Antimicrobial Susceptibility | NLT Code | NLT Description |
| < > | | |

| | | | |
|------|------|-----------|---------|
| Exit | Save | Next Page | Refresh |
|------|------|-----------|---------|

Enter a command or '^' followed by a caption to jump to a specific field.

COMMAND: **n** Press <PF1>H for help Insert

Example: How to use the Enter/Edit Local Pathogens [LREPI ENTER/EDIT LOCAL PATH] option to ENTER local pathogens continued.

NOTE: The following LABORATORY EPI PARAMETERS INPUT SCREEN under the Topography Selection screen, Include, Exclude, and Sex prompts are FOR FUTURE USE ONLY.

| | | |
|---|----------------|-----------------------------------|
| LABORATORY EPI PARAMETERS INPUT SCREEN | | Page 3 of 5 |
| NAME: Herpes virus539 | | INACTIVE: NO |
| Topography Selection | | |
| Include < > | Exclude < > | |
| Exit Save Next Page Refresh | | |
| Enter a command or '^' followed by a caption to jump to a specific field. | | |
| COMMAND: n | | Press <PF1>H for help Insert |

| | | |
|---|--|-----------------------------------|
| LABORATORY EPI PARAMETERS INPUT SCREEN | | Page 4 of 5 |
| NAME: Herpes virus539 | | INACTIVE: NO |
| FIRST ENCOUNTER: < > FOLLOW PTF: < > | | |
| BEFORE DATE OF BIRTH: < > | | AFTER DATE OF BIRTH: < > |
| Select SEX: < > | | |
| Exit Save Next Page Refresh | | |
| Enter a command or '^' followed by a caption to jump to a specific field. | | |
| COMMAND: n | | Press <PF1>H for help Insert |

Example: How to use the Enter/Edit Local Pathogens [LREPI ENTER/EDIT LOCAL PATH] option to **ENTER** local pathogens continued.

| | | |
|---|---------------------|---------------------------------|
| LABORATORY EPI PARAMETERS INPUT SCREEN | | Page 5 of 5 |
| NAME: Herpes virus539 | | INACTIVE: NO |
| <hr/> | | |
| Run Date: < > | Protocol: LREPI < > | |
| Run Cycle: < > | Lag Days: < > | |
| Previous Cycle: < > | | |
| General Description: < > | | |
| <hr/> | | |
| Exit | Save | Next Page Refresh |
| Enter a command or '^' followed by a caption to jump to a specific field. | | |
| COMMAND: n | | Press <PF1>H for help Insert |

How to use the Enter/Edit Local Pathogens [LREPI ENTER/EDIT LOCAL PATH] option

Example: How to use the Enter/Edit Local Pathogens [LREPI ENTER/EDIT LOCAL PATH] option to **EDIT LOCAL** pathogens.

NOTE: The following LABORATORY EPI PARAMETERS INPUT SCREEN under the Topography Selection screen, Include, Exclude, and Sex prompt will NOT be used in this release.

Select Lab EPI Primary Menu

| | |
|-----|------------------------------------|
| ENH | Lab EPI Manual Run (Enhanced) |
| VR | Print Detailed Verification Report |
| LO | Local Pathogen Menu ... |
| PI | Pathogen Inquiry |
| UP | Lab EPI Parameter Setup |
| | Lab EPI Protocol Edit |
| LK | Antimicrobial Link Update |

Select Lab EPI Primary Menu Option: **lo** Local Pathogen Menu<ENTER>

| | |
|-----|---|
| ENT | Enter/Edit Local Pathogens |
| GEN | Lab EPI Generate Local Report/Spreadsheet |
| PRT | Lab EPI Print Local Report/Spreadsheet |
| DEL | Delete Local Pathogen |
| DRS | Delete Local Report or Spreadsheet |

Select Local Pathogen Menu Option: **Enter/Edit Local Pathogens**<

```

LABORATORY EPI PARAMETERS INPUT SCREEN
Page 2 of 5

NAME: Herpes virus539
INACTIVE: NO

-----
Selected Etiology
HERPES SIMPLEX VIRUS 1
HERPES SIMPLEX VIRUS 2
< >

Selected Snomed Codes

Antimicrobial Susceptibility
NLT Code
NLT Description
< >

-----
Exit      Save      Next Page      Refresh

Enter a command or '^' followed by a caption to jump to a specific field.

COMMAND: n
Press <PF1>H for help      Insert

```

Example: How to use the Enter/Edit Local Pathogens [LREPI ENTER/EDIT LOCAL PATH] option to **EDIT** local pathogens continued.

NOTE: The following LABORATORY EPI PARAMETERS INPUT SCREEN under the Topography Selection screen, Include, Exclude, and Sex prompts are for FUTURE USE.

| | | |
|---|---------|-----------------------------------|
| LABORATORY EPI PARAMETERS INPUT SCREEN | | Page 3 of 5 |
| NAME: Herpes virus539 | | INACTIVE: NO |
| Topography Selection | | |
| Include | Exclude | |
| SKIN < > | | |
| SKIN APPENDAGE < > | | |
| URETHRA | | |
| < > | | |
| Exit | Save | Next Page Refresh |
| Enter a command or '^' followed by a caption to jump to a specific field. | | |
| COMMAND: n | | Press <PF1>H for help Insert |

| | | |
|---|--------------------------|-----------------------------------|
| LABORATORY EPI PARAMETERS INPUT SCREEN | | Page 4 of 5 |
| NAME: Herpes virus539 | | INACTIVE: NO |
| Topography Selection | | |
| FIRST ENCOUNTER: < > | FOLLOW PTF: < > | |
| BEFORE DATE OF BIRTH: < > | AFTER DATE OF BIRTH: < > | |
| Select SEX: < > | | |
| Exit | Save | Next Page Refresh |
| Enter a command or '^' followed by a caption to jump to a specific field. | | |
| COMMAND: n | | Press <PF1>H for help Insert |

Example: How to use the Enter/Edit Local Pathogens [LREPI ENTER/EDIT LOCAL PATH] option to **EDIT** local pathogens continued.

| | | |
|---|---------------------|------------------------|
| LABORATORY EPI PARAMETERS INPUT SCREEN | | Page 5 of 5 |
| NAME: Herpes virus539 | | INACTIVE: NO |
| <hr/> | | |
| Run Date: < > | Protocol: LREPI < > | |
| Run Cycle: < > | Lag Days: < > | |
| Previous Cycle: < > | | |
| General Description: < > | | |
| <hr/> | | |
| Exit | Save | Next Page Refresh |
| Enter a command or '^' followed by a caption to jump to a specific field. | | |

Lab EPI Generate Local Report/Spreadsheet [LREPI GENERATE REPORT/SP] option:

This **new** option is used to generate Lab EPI reports or spreadsheets for national and local emerging pathogens extract data. After selecting national or local emerging pathogens, time period, segments and fields, report or spreadsheet, the job is automatically tasked. The tasked job will take approximately 2-3 hours to generate. An alert is automatically sent to the requester/user after the tasked job has finished generating. The Lab EPI report or spreadsheet can then be viewed on the screen or printed using the **new** Lab EPI Print Local Report/Spreadsheet [LREPI PRINT] option.

NOTE: NO data will be transmitted to AITC when using this option. (*See the EPI Roll Up Modifications User Manual Appendix-A section of this manual for the local Report/Spreadsheet field definitions*).

Example: How to use the **new** Lab EPI Generate Local Report/Spreadsheet [LREPI GENERATE REORT/SP] option to **GENERATE** a local **REPORT**.

NOTE: In the following Lab EPI Generate Local Report/Spreadsheet [LREPI GENERATE REORT/SP] option, the prompt 'Include All Pathogens?' when answered "YES" will generate ALL NATIONAL and LOCAL Pathogens.

```
Select Lab EPI Primary Menu Option: lo Local Pathogen Menu<ENTER>

ENT    Enter/Edit Local Pathogens
GEN    Lab EPI Generate Local Report/Spreadsheet
PRT    Lab EPI Print Local Report/Spreadsheet
DEL    Delete Local Pathogen
DRS    Delete Local Report or Spreadsheet

Select Local Pathogen Menu Option: gen Lab EPI Generate Local<ENTER>
Report/Spreadsheet

        Laboratory Generate Local Report/Spreadsheet option

Include All Pathogens? NO//<ENTER>
Include All Local Pathogens? NO//<ENTER>
```

```

Select Pathogens: ?
Answer with LAB SEARCH/EXTRACT NAME, or REFERENCE NUMBER
Do you want the entire LAB SEARCH/EXTRACT List? y (Yes)<ENTER>
Choose from:
ALL ENTEROCOCCI
ALL STAPH AUREUS
ALL STREP PNEUMO
CANDIDA
CLOSTRIDIUM DIFFICILE
CREUTZFELDT-JAKOB DISEASE
CRYPTOSPORIDIUM
CRYPTOSPORIDIUM
DENGUE
E. COLI 0157:H7
Gonorrhea539
HCV Genotype539
HEPATITIS A ANTIBODY POS
HEPATITIS B POS
HEPATITIS C ANTIBODY NEG
HEPATITIS C ANTIBODY POS
Hepatitis C RNA tests539
Herpes virus539
Influenza A isolates539
LEGIONELLA
LEISHMANIASIS
MALARIA
METH-RES STAPH AUREUS
MRSA Bloodstream isolates539
Mycobacterium avium
Mycobacterium fortuitum
PEN-RES PNEUMOCOCCUS
STREPTOCOCCUS GROUP A
Salmonella539
TUBERCULOSIS
VANC-RES COAG NEG STAPH
VANC-RES ENTEROCOCCUS
VANC-RES STAPH AUREUS

Select Pathogens: sal<ENTER>
Answer with LAB SEARCH/EXTRACT NAME, or REFERENCE NUMBER
Do you want the entire LAB SEARCH/EXTRACT List? n (No)<ENTER>

Select Pathogens: salm<ENTER>
Answer with LAB SEARCH/EXTRACT NAME, or REFERENCE NUMBER
Do you want the entire LAB SEARCH/EXTRACT List? n (No)<ENTER>

Select Pathogens: s
1 STREPTOCOCCUS GROUP A
2 Salmonella539
CHOOSE 1-2: 2 Salmonella539<ENTER>
Select Pathogens: <ENTER>
Select Start Date: 1/1/1995<ENTER>
Select End Date: 12/31/2003<ENTER>

```


Select one of the following:

- | | |
|---|-------------|
| 1 | REPORT |
| 2 | SPREADSHEET |

Enter response: **1** REPORT<ENTER>

Choose the segments to capture for report.

1-PID

2-PV1

3-DG1

4-NTE

5-OBR

6-OBX

Enter a list or range of numbers (1-7): **1,2,6,7**<ENTER>

Choose the fields from the PID segment to capture for report.

1-Set Id

2-SSN

3-MPI

4-Patient Name

5-Date of Birth

6-Sex

7-Race

8-Homeless

9-State

10-Zip Code

11-County

12-Ethnicity

13-Period of Service

Enter a list or range of numbers (1-13): **1,2,4**<ENTER>

Choose the fields from the PV1 segment to capture for report.

1-Set Id

2-Patient Class

3-Hospital Location

4-Discharge Disposition

5-Facility

6-Admit Date/Time

7-Discharge Date/Time

```
Enter a list or range of numbers (1-7): 1,2,3,5<ENTER>
Choose the fields from the OBR segment to capture for report.
1-Set Id
2-Test Name
3-Accession Date
4-Specimen
5-Accession Number

Enter a list or range of numbers (1-5): 1,2,3,4<ENTER>
Choose the fields from the OBX segment to capture for report.
1-Set Id
2-Value Type
3-Test Name
4-LOINC Code
5-LOINC Name
6-Test Result
7-Units
8-Abnormal Flags
9-Verified Date/Time
Enter a list or range of numbers (1-9): 1,3,6,9<ENTER>
DOCUMENT TITLE: Sam+Ella 1995 thru 2003<ENTER>
Requested Start Time: NOW//<ENTER>(MAR 08, 2004@10:39:54)

The Task has been queued
Task # 75028
```

Example: How to use the **new** Lab EPI Generate Report/Spreadsheet [LREPI GENERATE REORT/SP] option to **GENERATE** a local **SPREADSHEET**.

NOTE: In the following Lab EPI Generate Local Report/Spreadsheet [LREPI GENERATE REORT/SP] option, a 'YES' response at the 'Include All Pathogens? NO//' prompt will include ALL NATIONAL and LOCAL Pathogens.

```

ENT      Enter/Edit Local Pathogens
GEN      Lab EPI Generate Local Report/Spreadsheet
PRT      Lab EPI Print Local Report/Spreadsheet
DEL      Delete Local Pathogen
DRS      Delete Local Report or Spreadsheet

```

Select Local Pathogen Menu Option: **gen** Lab EPI Generate Local Report/Spreadsheet<ENTER>

Laboratory Generate Local Report/Spreadsheet option
 Include All Pathogens? NO//<ENTER>
 Include All Local Pathogens? NO//<ENTER>

Select Pathogens: **S**<ENTER>

- 1 STREPTOCOCCUS GROUP A
- 2 Salmonella539

CHOOSE 1-2: **2** Salmonella539<ENTER>

Select Pathogens: <ENTER>

Select Start Date: **1/1/1995**<ENTER>

Select End Date: **12/31/2003**<ENTER>

Select one of the following:<ENTER>

- 1 REPORT
- 2 SPREADSHEET

Enter response: **2** SPREADSHEET<ENTER>

Choose the segments to capture for spreadsheet.

- 1-PID
- 2-PV1
- 3-DG1
- 4-DSP
- 5-NTE
- 6-OBR
- 7-OBX

Enter a list or range of numbers (1-7): **1,2,6,7**<ENTER>

Choose the fields from the PID segment to capture for spreadsheet.

1-Set Id
 2-SSN
 3-MPI
 4-Patient Name
 5-Date of Birth
 6-Sex
 7-Race
 8-Homeless
 9-State
 10-Zip Code
 11-County
 12-Ethnicity
 13-Period of Service

Enter a list or range of numbers (1-13): **1,2,4<ENTER>**

Choose the fields from the PVI segment to capture for spreadsheet.

1-Set Id
 2-Patient Class
 3-Hospital Location
 4-Discharge Disposition
 5-Facility
 6-Admit Date/Time
 7-Discharge Date/Time

Enter a list or range of numbers (1-7): **1,2,3,5<ENTER>**

Choose the fields from the OBR segment to capture for spreadsheet.

1-Set Id
 2-Test Name
 3-Accession Date
 4-Specimen
 5-Accession Number

Enter a list or range of numbers (1-5): **1,2,3,4<ENTER>**

Choose the fields from the OBX segment to capture for spreadsheet.

1-Set Id
 2-Value Type
 3-Test Name
 4-LOINC Code
 5-LOINC Name
 6-Test Result
 7-Units
 8-Abnormal Flags
 9-Verified Date/Time

Enter a list or range of numbers (1-9): **1,3,6,9<ENTER>**

DOCUMENT TITLE: **Sam+Ella 1995 thru 2003<ENTER>**

Requested Start Time: NOW//**<ENTER>** (MAR 08, 2004@10:41:29)

The Task has been queued
 Task # 75030

Lab EPI Print Local Report/Spreadsheet [LREPI PRINT] option:

This **new** option is used to PRINT a report or spreadsheet which has been generated using the **new** Lab EPI Generate Local Report/Spreadsheet [LREPI GENERATE REPORT/SP] option.

Example: How to use the **new** Lab EPI Print Local Report/Spreadsheet [LREPI PRINT] option to **PRINT** a local **REPORT**.

```
Select Lab EPI Primary Menu Option: lo Local Pathogen Menu<ENTER>

ENT    Enter/Edit Local Pathogens
GEN    Lab EPI Generate Local Report/Spreadsheet
PRT    Lab EPI Print Local Report/Spreadsheet
DEL    Delete Local Pathogen
DRS    Delete Local Report or Spreadsheet

Select Local Pathogen Menu Option: prt Lab EPI Print Local
Report/Spreadsheet<ENTER>
Print Local Report/Spreadsheet Option

Select one of the following:

1          REPORT
2          SPREADSHEET

Which one do you wish to print: 1 REPORT<ENTER>
1 JAN 14,2004@14:50:29 Loc1 EPI 1-09 thru 12-02
2 JAN 14,2004@15:02:02 Cipro Res 1995 thru 2002
3 JAN 14,2004@20:38:46 Histoplasma Jan 90 - Dec 99
4 JAN 14,2004@20:40:58 CiprResPseud 1-99 - 12-02
5 JAN 14,2004@20:43:25 Mfortuitum 01-85 - 12-02
6 JAN 24,2004@15:08:06 TEST REPORT
7 FEB 4,2004@20:56:48 Gonorrhea report
8 FEB 9,2004@11:15:52 Influenza A 1995 thru 2003
9 FEB 11,2004@13:51:27 Flu A 1995 thru 2003
10 FEB 15,2004@14:33:30 HCV Genotyping
11 FEB 26,2004@23:52:09 HCV RNA Jan 96 thru Dec 02
12 MAR 8,2004@10:37:31 Sam+Ella 1995 thru 2003
Choose the number for the report you wish to print: (1-12): 12<ENTER>

This report will contain Confidential Information.
Do you wish to continue/proceed? NO// y YES<ENTER>
DEVICE: HOME//<ENTER> WAN
***THIS REPORT CONTAINS CONFIDENTIAL INFORMATION***
EMERGING PATHOGENS LOCAL REPORT MAR 8,2004 PAGE 1
FROM STATION (Your station number is displayed)
PROCESSING PERIOD FROM 01-01-1995 THROUGH 12-31-2003
Reported Local Pathogens:Salmonella539<ENTER>
```

```

Set Id SSN      Patient Name
Set Id Patient Class Hospital Location  Facility
Set ID Test Name      Accession Date  Specimen
Set Id  Test Name      Test Result  Verified Date/Time
*****
1      000000024 LABPATIENT2, FOUR
1      Outpatient
1      MICRO CULTURE      04-25-2002@0041  BLOOD
1      SALMONELLA SP  05-08-2002
2      ANTIBIOTIC MIC      04-25-2002@0041  BLOOD
1      AMPICILLIN  R
2      TRIMETHOPRIM+SULFAMETHOXAZOLE  S
3      CEFOTAXIME  S
Enter RETURN to continue or '^' to exit:

***THIS REPORT CONTAINS CONFIDENTIAL INFORMATION***
      EMERGING PATHOGENS LOCAL REPORT      MAR 8,2004      PAGE 2
      FROM STATION (Your station number is displayed here)
      PROCESSING PERIOD FROM 01-01-1995 THROUGH 12-31-2003
Reported Local Pathogens:Salmonella539

Set Id SSN      Patient Name
Set Id Patient Class Hospital Location  Facility
Set ID Test Name      Accession Date  Specimen
Set Id  Test Name      Test Result  Verified Date/Time
4      LEVOFLOXACIN  S
2      Inpatient      6 NORTH~A612~1      539
1      MICRO CULTURE      05-01-2002@0000  FECES
1      SALMONELLA SP  05-08-2002
*****
2      000000025 LABPATIENT2, FIVE
1      Outpatient
1      MICRO CULTURE      12-30-2002@0000  BLOOD
1      SALMONELLA SP  01-13-2003

***THIS REPORT CONTAINS CONFIDENTIAL INFORMATION.***
      EMERGING PATHOGENS LOCAL REPORT      MAR 8,2004      PAGE 3
      FROM STATION (Your station number is displayed)
      PROCESSING PERIOD FROM 01-01-1995 THROUGH 12-31-2003
Reported Local Pathogens: Salmonella539

Set Id SSN      Patient Name
Set Id Patient Class Hospital Location  Facility
Set ID Test Name      Accession Date  Specimen
Set Id  Test Name      Test Result  Verified Date/Time
2      ANTIBIOTIC MIC      12-30-2002@0000  BLOOD
1      AMPICILLIN  S
2      TRIMETHOPRIM+SULFAMETHOXAZOLE  S
3      CEFOTAXIME  S
4      LEVOFLOXACIN  S
2      Inpatient      6 SOUTH~A667~1      539
1      MICRO CULTURE      12-31-2002@0000  FECES
1      SALMONELLA SP  01-03-2003
*****

```

THIS REPORT CONTAINS CONFIDENTIAL INFORMATION.
 EMERGING PATHOGENS LOCAL REPORT MAR 8,2004 PAGE 4
 FROM STATION (Your station number is displayed here)
 PROCESSING PERIOD FROM 01-01-1995 THROUGH 12-31-2003
 Reported Local Pathogens:Salmonella539

| Set Id | SSN | Patient Name | Set Id | Patient Class | Hospital Location | Facility | |
|--------|-------------------------------|------------------|----------|---------------|-------------------|-------------|--------------------|
| Set ID | Test Name | Accession Date | Specimen | Set Id | Test Name | Test Result | Verified Date/Time |
| 3 | 000000026 | LABPATIENT2, SIX | | | | | |
| 1 | Inpatient | MICU/CCU~B608~8 | 539 | | | | |
| 1 | MICRO CULTURE | 05-06-2002@0220 | BLOOD | | | | |
| 1 | SALMONELLA SP | 05-24-2002 | | | | | |
| 2 | ANTIBIOTIC MIC | 05-06-2002@0220 | BLOOD | | | | |
| 1 | AMPICILLIN | S | | | | | |
| 2 | TRIMETHOPRIM+SULFAMETHOXAZOLE | S | | | | | |
| 3 | CEFOTAXIME | S | | | | | |
| 4 | LEVOFLOXACIN | S | | | | | |

THIS REPORT CONTAINS CONFIDENTIAL INFORMATION.
 EMERGING PATHOGENS LOCAL REPORT MAR 8,2004 PAGE 5
 FROM STATION (Your station number is displayed here)
 PROCESSING PERIOD FROM 01-01-1995 THROUGH 12-31-2003
 Reported Local Pathogens:Salmonella539

| Set Id | SSN | Patient Name | Set Id | Patient Class | Hospital Location | Facility | |
|--------|-------------------------------|--------------------|----------|---------------|-------------------|-------------|--------------------|
| Set ID | Test Name | Accession Date | Specimen | Set Id | Test Name | Test Result | Verified Date/Time |
| 4 | 000000027 | LABPATIENT2, SEVEN | | | | | |
| 1 | Outpatient | | | | | | |
| 1 | MICRO CULTURE | 11-03-2000@0000 | FECES | | | | |
| 1 | SALMONELLA SP | 11-22-2000 | | | | | |
| 2 | ANTIBIOTIC MIC | 11-03-2000@0000 | FECES | | | | |
| 1 | AMPICILLIN | S | | | | | |
| 2 | TRIMETHOPRIM+SULFAMETHOXAZOLE | S | | | | | |
| 3 | LEVOFLOXACIN | S | | | | | |

THIS REPORT CONTAINS CONFIDENTIAL INFORMATION.
 EMERGING PATHOGENS LOCAL REPORT MAR 8,2004 PAGE 6
 FROM STATION (Your station number is displayed here)
 PROCESSING PERIOD FROM 01-01-1995 THROUGH 12-31-2003
 Reported Local Pathogens:Salmonella539

```

Set Id SSN      Patient Name
Set Id Patient Class Hospital Location Facility
Set ID Test Name      Accession Date Specimen
Set Id Test Name      Test Result Verified Date/Time
2      Outpatient
1      MICRO CULTURE      12-29-2000@1400 FECES
1      SALMONELLA SP      01-03-2001
2      ANTIBIOTIC MIC      12-29-2000@1400 FECES
1      GENTAMICIN
2      CEFAZOLIN
3      AMPICILLIN S
4      POLYMXIN B
5      TRIMETHOPRIM+SULFAMETHOXAZOLE S

***THIS REPORT CONTAINS CONFIDENTIAL INFORMATION.***
      EMERGING PATHOGENS LOCAL REPORT      MAR 8,2004      PAGE 7
      FROM STATION (Your station number is displayed here)
      PROCESSING PERIOD FROM 01-01-1995 THROUGH 12-31-2003
Reported Local Pathogens:Salmonella539

Set Id SSN      Patient Name
Set Id Patient Class Hospital Location Facility
Set ID Test Name      Accession Date Specimen
Set Id Test Name      Test Result Verified Date/Time
6      PIPERACILLIN
7      CEFOTAXIME
8      CIPROFLOXACIN
9      IMIPENUM
10     CEFTAZIDIME
11     TIMENTIN
12     AMPICILLIN+SULBACTAM
13     CEFOTETAN
14     CEFTRIAXONE

***THIS REPORT CONTAINS CONFIDENTIAL INFORMATION.***
      EMERGING PATHOGENS LOCAL REPORT      MAR 8,2004      PAGE 8
      FROM STATION (Your station number is displayed here)
      PROCESSING PERIOD FROM 01-01-1995 THROUGH 12-31-2003
Reported Local Pathogens:Salmonella539

Set Id SSN      Patient Name
Set Id Patient Class Hospital Location Facility
Set ID Test Name      Accession Date Specimen
Set Id Test Name      Test Result Verified Date/Time
15     CEFUROXIME-SODIUM
16     CEFUROXIME-AXETIL
17     LEVOFLOXACIN S

```



```

*****
5      000000028 LABPATIENT2, EIGHT
1      Outpatient
1      MICRO CULTURE      06-18-1997      FECES
1      SALMONELLA SP      06-23-1997
2      ANTIBIOTIC MIC      06-18-1997      FECES
***THIS REPORT CONTAINS CONFIDENTIAL INFORMATION.***
      EMERGING PATHOGENS LOCAL REPORT      MAR 8,2004      PAGE 9
      FROM STATION (Your station number is displayed here)
      PROCESSING PERIOD FROM 01-01-1995 THROUGH 12-31-2003
Reported Local Pathogens:Salmonella539

Set Id SSN      Patient Name
Set Id Patient Class Hospital Location Facility
Set ID Test Name      Accession Date Specimen
Set Id Test Name      Test Result Verified Date/Time
1      GENTAMICIN
2      CEFZOLIN
3      AMPICILLIN S
4      POLYMICIN B
5      TRIMETHOPRIM+SULFAMETHOXAZOLE S
6      AMIKACIN
7      CEFOTITIN
8      PIPERACILLIN
9      CEFOTAXIME
***THIS REPORT CONTAINS CONFIDENTIAL INFORMATION.***
      EMERGING PATHOGENS LOCAL REPORT      MAR 8,2004      PAGE 10
      FROM STATION (Your station number is displayed here)
      PROCESSING PERIOD FROM 01-01-1995 THROUGH 12-31-2003
Reported Local Pathogens:Salmonella539

Set Id SSN      Patient Name
Set Id Patient Class Hospital Location Facility
Set ID Test Name      Accession Date Specimen
Set Id Test Name      Test Result Verified Date/Time
10     NITROFURANTOIN
11     CEFOPERAZONE
12     MEZLOCILLIN
13     CEPHALOTHIN
14     CEFUROXIME
15     TICARCILLIN
16     CIPROFLOXACIN S
17     AZTREONAM
18     IMIPENUM

```

```

***THIS REPORT CONTAINS CONFIDENTIAL INFORMATION.***
      EMERGING PATHOGENS LOCAL REPORT                MAR 8,2004    PAGE 11
      FROM STATION (Your station number is displayed here)
      PROCESSING PERIOD FROM 01-01-1995 THROUGH 12-31-2003
Reported Local Pathogens:Salmonella539

Set Id SSN      Patient Name
Set Id Patient Class Hospital Location  Facility
Set ID Test Name      Accession Date  Specimen
Set Id  Test Name      Test Result   Verified Date/Time
19      CEFTAZIDIME
20      TIMENTIN
21      AMPICILLIN+SULBACTAM
22      NORFLOXACIN
*****
6      000000029 LABPATIENT2, NINE
1      Inpatient      6 NORTH~A624~1      539
1      MICRO CULTURE      01-23-2003@0000  FECES
1      SALMONELLA SP  02-07-2003

***THIS REPORT CONTAINS CONFIDENTIAL INFORMATION.***
      EMERGING PATHOGENS LOCAL REPORT                MAR 8,2004    PAGE 12
      FROM STATION (Your station number is displayed here)
      PROCESSING PERIOD FROM 01-01-1995 THROUGH 12-31-2003
Reported Local Pathogens:Salmonella539

Set Id SSN      Patient Name
Set Id Patient Class Hospital Location  Facility
Set ID Test Name      Accession Date  Specimen
Set Id  Test Name      Test Result   Verified Date/Time
2      ANTIBIOTIC MIC      01-23-2003@0000  FECES
1      AMPICILLIN  S
2      TRIMETHOPRIM+SULFAMETHOXAZOLE  S
3      LEVOFLOXACIN  S
*****
7      000000210 LABPATIENT2, TEN
1      Outpatient
1      MICRO CULTURE      04-03-1996@0000  FECES
1      SALMONELLA SP  04-07-1996

```

```

***THIS REPORT CONTAINS CONFIDENTIAL INFORMATION.***
      EMERGING PATHOGENS LOCAL REPORT          MAR 8, 2004    PAGE 13
      FROM STATION (Your station number is displayed here)
      PROCESSING PERIOD FROM 01-01-1995 THROUGH 12-31-2003
Reported Local Pathogens:Salmonella539

Set Id SSN      Patient Name
Set Id Patient Class Hospital Location  Facility
Set ID Test Name      Accession Date  Specimen
Set Id  Test Name      Test Result  Verified Date/Time
2      ANTIBIOTIC MIC      04-03-1996@0000  FECES
1      AMPICILLIN  S
2      TRIMETHOPRIM+SULFAMETHOXAZOLE  S
3      CIPROFLOXACIN  S
*****
8      000000031 LABPATIENT3, ONE
1      Outpatient
1      MICRO CULTURE      06-27-2002@0000  FECES
1      SALMONELLA SP  07-24-2002

***THIS REPORT CONTAINS CONFIDENTIAL INFORMATION.***
      EMERGING PATHOGENS LOCAL REPORT          MAR 8, 2004    PAGE 14
      FROM STATION (Your station number is displayed here)
      PROCESSING PERIOD FROM 01-01-1995 THROUGH 12-31-2003
Reported Local Pathogens:Salmonella539

Set Id SSN      Patient Name
Set Id Patient Class Hospital Location  Facility
Set ID Test Name      Accession Date  Specimen
Set Id  Test Name      Test Result  Verified Date/Time
2      ANTIBIOTIC MIC      06-27-2002@0000  FECES
1      AMPICILLIN  S
2      TRIMETHOPRIM+SULFAMETHOXAZOLE  S
3      LEVOFLOXACIN  S

ENT      Enter/Edit Local Pathogens
GEN      Lab EPI Generate Local Report/Spreadsheet
PRT      Lab EPI Print Local Report/Spreadsheet
DEL      Delete Local Pathogen
DRS      Delete Local Report or Spreadsheet

```

Example: How to use the **new** Lab EPI Print Local Report/Spreadsheet [LREPI PRINT] option to **PRINT** a local **SPREADSHEET**.

```

ENT      Enter/Edit Local Pathogens
GEN      Lab EPI Generate Local Report/Spreadsheet
PRT      Lab EPI Print Local Report/Spreadsheet
DEL      Delete Local Pathogen
DRS      Delete Local Report or Spreadsheet

```

Select Local Pathogen Menu Option: **prt** Lab EPI Print Local Report/Spreadsheet<Enter>

Print Local Report/Spreadsheet Option

Select one of the following:

```

1          REPORT
2          SPREADSHEET

```

Which one do you wish to print: **2** SPREADSHEET<Enter>

1 JAN 16,2004@16:31:40 Mfortuitum 1-97 thru 12-02

2 JAN 24,2004@15:09:13 TEST SPSHT

3 FEB 4,2004@20:59:04 Myfortuitum report

4 FEB 26,2004@23:49:13 MRSA BSI Jan 00 thru Dec 02

5 FEB 29,2004@14:29:54 Sam+Ella 4 subfield results

6 MAR 8,2004@10:40:05 Sam+Ella 1995 thru 2003

Choose the number for the spreadsheet you wish to print: (1-6): **6**<Enter>

This option will print the selected fields.

You will need to capture this printout in a text document.

Using a text editor, remove any extraneous lines from the beginning and the end of the file so that only the data to be imported remains.

Save the edited file. Use this file in the import function of your spreadsheet program.

This report will contain Confidential Information.

Do you wish to continue/proceed? NO// **y** YES<ENTER>

Ready to Capture? **y** YES<ENTER>

Set Id|SSN|Patient Name|

Set Id|Patient Class|Hospital Location|Facility|

Set Id|Test Name|Accession Date/Time|Specimen|

Set Id|Test Name|Test Result|Verified Date/Time|

```

*****
1|000000024|LABPATIENT2, FOUR|
1|Outpatient|||
1|MICRO CULTURE|04-25-2002@0041|BLOOD|
1||SALMONELLA SP|05-08-2002|
2|ANTIBIOTIC MIC|04-25-2002@0041|BLOOD|
1|AMPICILLIN|R||
2|TRIMETHOPRIM+SULFAMETHOXAZOLE|S||
3|CEFOTAXIME|S||
4|LEVOFLOXACIN|S||
2|Inpatient|6 NORTH~A612~1|539|
1|MICRO CULTURE|05-01-2002@0000|FECES|
1||SALMONELLA SP|05-08-2002|
*****
2|000000025|LABPATIENT2, FIVE|
1|Outpatient|||
1|MICRO CULTURE|12-30-2002@0000|BLOOD|
1||SALMONELLA SP|01-13-2003|
2|ANTIBIOTIC MIC|12-30-2002@0000|BLOOD|
1|AMPICILLIN|S||
2|TRIMETHOPRIM+SULFAMETHOXAZOLE|S||
3|CEFOTAXIME|S||
4|LEVOFLOXACIN|S||
2|Inpatient|6 SOUTH~A667~1|539|
1|MICRO CULTURE|12-31-2002@0000|FECES|
1||SALMONELLA SP|01-03-2003|
*****
3|000000026|LABPATIENT2, SIX|
1|Inpatient|MICU/CCU~B608~8|539|
1|MICRO CULTURE|05-06-2002@0220|BLOOD|
1||SALMONELLA SP|05-24-2002|
2|ANTIBIOTIC MIC|05-06-2002@0220|BLOOD|
1|AMPICILLIN|S||
2|TRIMETHOPRIM+SULFAMETHOXAZOLE|S||
3|CEFOTAXIME|S||
4|LEVOFLOXACIN|S||
*****
4|000000027|LABPATIENT2, SEVEN|
1|Outpatient|||
1|MICRO CULTURE|11-03-2000@0000|FECES|
1||SALMONELLA SP|11-22-2000|
2|ANTIBIOTIC MIC|11-03-2000@0000|FECES|
1|AMPICILLIN|S||
2|TRIMETHOPRIM+SULFAMETHOXAZOLE|S||
3|LEVOFLOXACIN|S||
2|Outpatient|||
1|MICRO CULTURE|12-29-2000@1400|FECES|
1||SALMONELLA SP|01-03-2001|
2|ANTIBIOTIC MIC|12-29-2000@1400|FECES|
1|GENTAMICIN|||
2|CEFAZOLIN|||

```

```

3|AMPICILLIN|S||
4|POLYMIXIN B|||
5|TRIMETHOPRIM+SULFAMETHOXAZOLE|S||
6|PIPERACILLIN|||
7|CEFOTAXIME|||
8|CIPROFLOXACIN|||
9|IMIPENUM|||
10|CEFTAZIDIME|||
11|TIMENTIN|||
12|AMPICILLIN+SULBACTAM|||
13|CEFOTETAN|||
14|CEFTRIAZONE|||
15|CEFUROXIME-SODIUM|||
16|CEFUROXIME-AXETIL|||
17|LEVOFLOXACIN|S||
*****
5|000000028|LABPATIENT2, EIGHT|
1|Outpatient|||
1|MICRO CULTURE|06-18-1997|FECES|
1||SALMONELLA SP|06-23-1997|
2|ANTIBIOTIC MIC|06-18-1997|FECES|
1|GENTAMICIN|||
2|CEFAZOLIN|||
3|AMPICILLIN|S||
4|POLYMIXIN B|||
5|TRIMETHOPRIM+SULFAMETHOXAZOLE|S||
6|AMIKACIN|||
7|CEFOXITIN|||
8|PIPERACILLIN|||
9|CEFOTAXIME|||
10|NITROFURANTOIN|||
11|CEFOPERAZONE|||
12|MEZLOCILLIN|||
13|CEPHALOTHIN|||
14|CEFUROXIME|||
15|TICARCILLIN|||
16|CIPROFLOXACIN|S||
17|AZTREONAM|||
18|IMIPENUM|||
19|CEFTAZIDIME|||
20|TIMENTIN|||
21|AMPICILLIN+SULBACTAM|||
22|NORFLOXACIN|||

```

```

*****
6|000000029|LABPATIENT2, NINE|
1|Inpatient|6 NORTH~A624~1|539|
1|MICRO CULTURE|01-23-2003@0000|FECES|
1||SALMONELLA SP|02-07-2003|
2|ANTIBIOTIC MIC|01-23-2003@0000|FECES|
1|AMPICILLIN|S||
2|TRIMETHOPRIM+SULFAMETHOXAZOLE|S||
3|LEVOFLOXACIN|S||
*****
7|000000210|LABPATIENT2, TEN|
1|Outpatient|||
1|MICRO CULTURE|04-03-1996@0000|FECES|
1||SALMONELLA SP|04-07-1996|
2|ANTIBIOTIC MIC|04-03-1996@0000|FECES|
1|AMPICILLIN|S||
2|TRIMETHOPRIM+SULFAMETHOXAZOLE|S||
3|CIPROFLOXACIN|S||
*****
8|000000031|LABPATIENT3, ONE|
1|Outpatient|||
1|MICRO CULTURE|06-27-2002@0000|FECES|
1||SALMONELLA SP|07-24-2002|
2|ANTIBIOTIC MIC|06-27-2002@0000|FECES|
1|AMPICILLIN|S||
2|TRIMETHOPRIM+SULFAMETHOXAZOLE|S||
3|LEVOFLOXACIN|S||


```

How to ENTER local SPREADSHEET captures to a TEXT FILE or EXCEL spreadsheet software:

1. Start the KEA Emulator. From the menu bar, click on the “Tools” menu, and select the “Capture Incoming Data” command.

NOTE: Other emulators will have similar menu options that will provide the same functionality.


Example: KEA emulator setup for screen capture.



How to **ENTER** local SPREADSHEET captures to a TEXT FILE or EXCEL spreadsheet software continued.


2. After indicating the preferred capture, you **must** define the location you want the capture file to be stored in (important... remember where you indicated). **Note:** It may be a good idea to create a special folder for this purpose and always route the captured data to this particular folder. Name the capture file something that will be meaningful to you later on). From the “Save as type:” command to be a Text Files (*.TXT) AND “checkmark” the “Save as text” box at the bottom, uncheck the “Append data to existing file” if it is checked.

Example: Saving local SPREADSHEET captures as a Text Files (*.TXT).



How to **ENTER** local SPREADSHEET captures to a TEXT FILE or EXCEL spreadsheet software continued:


Example: Captured data folder location. **Note:** It may be helpful to see the full folder location path in order to find it again.



How to **ENTER** local SPREADSHEET captures to a TEXT FILE or EXCEL spreadsheet software continued:


3. After the data capture has finished scrolling to the screen, from the KEA emulator menu bar, click on the “Tools” menu, and select the “End Capture” command to decrease the amount of unwanted text that will appear in the saved file.

NOTE: The data capture will need to be edited prior to opening the TEXT file in your spreadsheet program. Use the wizard to finish importing the data into a spreadsheet format.



How to **ENTER** local SPREADSHEET captures to a TEXT FILE or EXCEL spreadsheet software continued.


4. Select the basic Notepad program to open the saved text file folder (remember the location of the saved text file folder). Navigate to the folder via the Notepad program and then open saved text file. Do any required editing and resave the edited text file under the same file name.



How to **ENTER** local SPREADSHEET captures to a TEXT FILE or EXCEL spreadsheet software continued.


Example: This is an example of the saved text file folder location where the particular screen captures were stored in this example.

NOTE: This will be different on your system; therefore, it is a good idea to establish a known, standard downloading folder where you can easily find your downloaded text files.



How to **ENTER** local SPREADSHEET captures to a TEXT FILE or EXCEL spreadsheet software continued.

Example: A unique file name in a specific download folder



How to **ENTER** local SPREADSHEET captures to a TEXT FILE or EXCEL spreadsheet software continued.

5. The saved text file may look similar to the following example. Edit the beginning and end of the captured text so that only text with the “bar” delimiters are left.

NOTE: If the text download “wrapped” (lines at 80 columns), edit the lines to “unwrap” the text. Usually this can be done via Notepad by putting the cursor at the end of the first line that is wrapped and press “delete” once or twice to get the next line down that is wrapped. The text **must** appear as one continuous line for the spreadsheet import to work correctly.

Example: Saved Text File Download

```

localmethreststaph - Notepad
File Edit Format Help
Choose the number for the spreadsheet you wish to print: (1-32): 32

This option will print the selected fields.
You will need to capture this printout in a text document.
Using a text editor, remove any extraneous lines from the beginning
and the end of the file so that only the data to be imported remains.
Save the edited file. Use this file in the import function of
your spreadsheet program.

This report will contain confidential information.
Do you wish to continue/proceed? No// y YES
Ready to Capture? y YES
[0] Set ID|SSN|MPI|Patient Name|Date of Birth|Sex|
[1] Set ID|Patient Class|Hospital Location|Discharge Disposition|Facility|Admit
Date/Time|Discharge Date/Time|
[2] Set ID|Comment|
[3] Set ID|Test Name|Accession Date/Time|Specimen|Accession Number|OBR SUBID
[4] Set ID|Value Type|Test Name|LOINC Code|LOINC Name|Test Result|Units|Abnorma
Flags|verified date/Time|OBX SUBID
[2] R-REPORTING DATE FROM 20031002 TO 20031031~V3|

1|0| |000000033|""| LABPATIENT3.TWO |04-04-1923|M|
1|1| |Outpatient|||10-03-2003||
1|2|1|111~LOCALMETHREISTSTAPH558|
1|3|1|MICRO CULTURE|10-03-2003|URINE|MICRO 03 7431|
1|4|1|1|CE|||STAPHYLOCOCCUS AUREUS||10-05-2003|1|
1|4|1|2|CE|||STAPHYLOCOCCUS AUREUS (METHICILLIN RESIST.)||10-05-2003|2|
1|3|2|ANTIBIOTIC MIC|10-03-2003|URINE||2|
1|4|2|1|ST|CLINDAMYCIN|||R||R||
1|4|2|2|ST|VANCOMYCIN|||S||S||
1|4|2|3|ST|TRIMETHOPRIM+SULFAMETHOXAZOLE|||S||S||
1|4|2|4|ST|CEFOXITIN|||R||R||
1|4|2|5|ST|ERYTHROMYCIN|||R||R||
1|4|2|6|ST|RIFAMPIN|||S||S||
1|4|2|7|ST|OXACILLIN|||R||R||
1|4|2|8|ST|AMPICILLIN|||R||R||
1|4|2|9|ST|LEVOFLOXACIN|||R||R||
1|4|2|10|ST|ANTIMICROBIC ASSAY|||S||S||

2|0| |000000033|""| LABPATIENT3.THREE |04-29-1946|M|
2|1|1|Inpatient|MICU-A5054-1|REGULAR|558|10-08-2003#1733|10-14-2003#1957|
2|2|1|111~LOCALMETHREISTSTAPH558|
2|3|1|MICRO CULTURE|10-12-2003#0001|VEIN|MICRO 03 7686|
2|4|1|1|CE|||STAPHYLOCOCCUS AUREUS||10-15-2003|1|
2|4|1|2|CE|||STAPHYLOCOCCUS SP||10-15-2003|2|
2|4|1|3|CE|||STAPHYLOCOCCUS (COAGULASE NEGATIVE)||10-15-2003|3|
2|4|1|4|CE|||STAPHYLOCOCCUS AUREUS (METHICILLIN RESIST.)||10-15-2003|4|
2|3|2|ANTIBIOTIC MIC|10-12-2003#0001|VEIN||3|
2|4|2|1|ST|CLINDAMYCIN|||R||R||
2|4|2|2|ST|VANCOMYCIN|||S||S||
  
```

How to **ENTER** local SPREADSHEET captures to a TEXT FILE or EXCEL spreadsheet software continued.

Example: This is screen capture example of how the text file should appear after being edited. This will make the text file ready to import into a spreadsheet file via the import wizard.


```

0|Set Id|SSN|MPI|Patient Name|Date of Birth|Sex|
1|Set Id|Patient Class|Hospital Location|Discharge disposition|Facility|Admit Date/Time|Discharge Date/Time|
2|Set Id|Comment|
3|Set Id|Test Name|Accession date/Time|Specimen|Accession Number|OBR SUBID
4|Set Id|Value|Tvn|Test Name|LOINC Code|LOINC Name|Test Result|Units|Abnormal|Flags|Verified Date/Time|OBX SUBID
1|0|000000032|LABPATIENT3, TWO|01-04-1923|M|
1|1|1|Outpatient|||10-03-2003||
1|2|1|111-LOCALMETHREISTSTAPH558|
1|3|1|MICRO CULTURE|10-03-2003|URINE|MICRO 03 7431|
1|4|1|1|CE|||STAPHYLOCOCCUS AUREUS|||10-05-2003|1|
1|4|1|2|CE|||STAPHYLOCOCCUS AUREUS (METHICILLIN RESIST.)|||10-05-2003|2|
1|3|2|ANTIBIOTIC MIC|10-03-2003|URINE||2|
1|4|2|1|ST CLINDAMYCIN|||R||R||
1|4|2|2|ST VANCOMYCIN|||S||S||
1|4|2|3|ST TRIMETHOPRIM+SULFAMETHOXAZOLE|||S||S||
1|4|2|4|ST CEFOTAXIME|||R||R||
1|4|2|5|ST ERYTHROMYCIN|||R||R||
1|4|2|6|ST RIFAMPIN|||S||S||
1|4|2|7|ST OXACILLIN|||R||R||
1|4|2|8|ST AMPICILLIN|||R||R||
1|4|2|9|ST LEVOFLOXACIN|||R||R||
1|4|2|10|ST ANTIMICROBIC ASSAY|||S||S||
2|0|000000033|LABPATIENT3, THREE|04-29-1946|M|
2|1|1|Inpatient|MICU-A5054-1|REGULAR|558|10-06-2003@1733|10-14-2003@1957|
2|2|1|111-LOCALMETHREISTSTAPH558|
2|3|1|MICRO CULTURE|10-12-2003@0001|VEIN|MICRO 03 7686|
2|4|1|1|CE|||STAPHYLOCOCCUS AUREUS|||10-15-2003|1|
2|4|1|2|CE|||STAPHYLOCOCCUS SP|||10-15-2003|2|
2|4|1|3|CE|||STAPHYLOCOCCUS (COAGULASE NEGATIVE)|||10-15-2003|3|
2|4|1|4|CE|||STAPHYLOCOCCUS AUREUS (METHICILLIN RESIST.)|||10-15-2003|4|
2|3|2|ANTIBIOTIC MIC|10-12-2003@0001|VEIN||3|
2|4|2|1|ST CLINDAMYCIN|||R||R||
2|4|2|2|ST VANCOMYCIN|||S||S||
2|4|2|3|ST TRIMETHOPRIM+SULFAMETHOXAZOLE|||R||R||
2|4|2|4|ST CEFOTAXIME|||R||R||
2|4|2|5|ST ERYTHROMYCIN|||R||R||
2|4|2|6|ST RIFAMPIN|||R||R||
2|4|2|7|ST OXACILLIN|||R||R||
2|4|2|8|ST LEVOFLOXACIN|||R||R||
2|4|2|9|ST ANTIMICROBIC ASSAY|||S||S||
2|3|3|ANTIBIOTIC MIC|10-12-2003@0001|VEIN||4|
2|4|3|1|ST CLINDAMYCIN|||R||R||
2|4|3|2|ST VANCOMYCIN|||S||S||
2|4|3|3|ST TRIMETHOPRIM+SULFAMETHOXAZOLE|||R||R||
2|4|3|4|ST CEFOTAXIME|||R||R||
2|4|3|5|ST ERYTHROMYCIN|||R||R||
2|4|3|6|ST RIFAMPIN|||S||S||
2|4|3|7|ST OXACILLIN|||R||R||
2|4|3|8|ST LEVOFLOXACIN|||R||R||
2|4|3|9|ST ANTIMICROBIC ASSAY|||S||S||
3|0|000-00-0034|LABPATIENT3, FOUR|02-18-1943|M|
3|1|1|Inpatient|7A -A7004-3|REGULAR|558|10-06-2003@2120|10-23-2003@1111|
  
```


How to **ENTER** local SPREADSHEET captures to a TEXT FILE or EXCEL spreadsheet software continued.

6. After editing the ASCII text, click on “File”, then select the “Save” command and close the text file. Then start up the spreadsheet program.

Example: Saving the ASCII text file data.



Delete Local Pathogen [LREPI DELETE LOCAL PATHOGEN] option

This **new** option allows deletion of local pathogens entries ONLY.

NOTE: National emerging pathogens entries CANNOT be deleted using the **new** Delete Local Pathogen [LREPI DELETE LOCAL PATHOGEN] option.

Example: How to use the **new** Delete Local Pathogen [LREPI DELETE LOCAL PATHOGEN] option to **DELETE** a local pathogen.

```
ENT   Enter/Edit Local Pathogens
GEN   Lab EPI Generate Local Report/Spreadsheet
PRT   Lab EPI Print Local Report/Spreadsheet
DEL   Delete Local Pathogen
DRS   Delete Local Report or Spreadsheet
```

Select Local Pathogen Menu Option: **DELETE Local Pathogen <ENTER>**

LOCAL PATHOGEN NAME: **HISTOPLASMA428<ENTER>**

Do you really want to delete this pathogen? **YES<ENTER>**

Entry HISTOPLASMA428 deleted.

Delete Local Report or Spreadsheet [LREPI DELETE LOCAL REPORT] option

This option is used to delete local reports or local spreadsheets.

Example: How to use the **new** Delete Local Report or Spreadsheet [LREPI DELETE LOCAL REPORT] option to **DELETE** a local report.

```
Select Lab EPI Primary Menu Option: LO Local Pathogen Menu<ENTER>
```

```

ENT    Enter/Edit Local Pathogens
GEN    Lab EPI Generate Local Report/Spreadsheet
PRT    Lab EPI Print Local Report/Spreadsheet
DEL    Delete Local Pathogen
DRS    Delete Local Report or Spreadsheet
```

```
Select Local Pathogen Menu Option: DRS Delete Local Report or Spreadsheet<ENTER>
```

```
Delete a Local Report/Spreadsheet Option
```

```
Select one of the following: <ENTER>
```

```

1      REPORT
2      SPREADSHEET
```

```
Which one do you wish to delete: 1 REPORT<ENTER>
```

```
1 APR 14,2004@11:02:11 REPORT 1
```

```
Choose the number for the report you wish to delete: (1-1): 1<ENTER>
Report deleted.
```

```
Select one of the following:
```

```

1      REPORT
2      SPREADSHEET
```

```
Which one do you wish to delete: 2 SPREADSHEET<ENTER>
```

```
1 APR 14,2004@11:02:11 SPSHT 1
```

```
Choose the number for the spreadsheet you wish to delete: (1-1): 1<ENTER>
Spreadsheet deleted.
```

Pathogen Inquiry [LREPI PATHOGEN INQUIRY] option:

This **new** option is used to inquire into the LAB SEARCH/EXTRACT file (#69.5) parameter description fields (i.e., INACTIVE: NO, LAG DAYS: 15, RUN DATE: OCT 07, 2003, CYCLE: MONTHLY, PROTOCOL: LREPI, FOLLOW PTF: YES, REFERENCE NUMBER: 23, and ETIOLOGIES) for defined emerging pathogen.

Example: How to use the **new** Pathogen Inquiry [LREPI PATHOGEN INQUIRY] option

```
Select Lab EPI Primary Menu Option: PI <Enter> Pathogen Inquiry
Select Pathogen: ALL ENTEROCOCCI <Enter>
NAME: ALL ENTEROCOCCI                INACTIVE: NO
LAG DAYS: 15                        RUN DATE: OCT 07, 2003
CYCLE: MONTHLY                     PROTOCOL: LREPI
FOLLOW PTF: YES                     REFERENCE NUMBER: 23
ETIOLOGY: ENTEROCOCCUS
ETIOLOGY: STREP D ENTEROCOCCUS
ETIOLOGY: ENTEROCOCCUS (STREPT. FAECALIS-GROUP D)
ETIOLOGY: STREPTOCOCCUS FAECALIS
ETIOLOGY: STREPTOCOCCUS FAECIUM
```

Description: The enterococci are a group of bacteria that can cause serious disease in humans, including blood stream infections, urinary tract infections, wound infections, endocarditis and even death. As with many other organisms that cause disease in humans, resistance to antibiotics is emerging in the enterococci. The presence of antibiotic resistance creates a challenge in treatment of infections with this organism. In order to determine the prevalence of antibiotic resistance, a baseline of occurrence of ALL enterococci needs to be obtained. This particular EPI pathogen setting has been created to identify ALL culture positive isolates of enterococci from any specimen site in any patient/client receiving care within the VHA. **Note:** Even specimens that have been obtained from patients (not the environment) as part of an epidemiologic prevalence study or survey should be included if they are present in the VistA laboratory package results from your site. The results from this EPI pathogen setting will be coupled with the results from Reference #1 (Vancomycin-Resistant Enterococci [VRE]) to help determine the percentage of all isolates of enterococci that have vancomycin.

Lab EPI Parameter Setup [LREPI (EPI) PARAMETER SETUP] option:

The Lab EPI Parameter Setup [LREPI PARAMETER SETUP] option is used to define the search criteria associated with the National Emerging Pathogens Initiative (EPI) extract data. This option allows editing of the National EPI ONLY. **Note:** Local pathogens CANNOT be added using this option. This option has been **enhanced** by adding the **new** PREVIOUS CYCLE field. This **new** field is automatically defined as '1' for TB ONLY and CANNOT be edited (as highlighted in the example below). For all other emerging pathogens the **new** PREVIOUS CYCLE field is blank and CANNOT be EDITED. The existing PROTOCOL field has been modified and can NO longer be EDITED. The field displaying ACTIVE "YES" has been modified to display INACTIVE "NO". The following input screen example new functionality changes are highlighted.

Example: Laboratory EPI Parameters Input Screen Page 5 of 5 field changes

| | | |
|--|------------------------|---------------------------------|
| LABORATORY EPI PARAMETERS INPUT SCREEN | | Page 5 of 5 |
| NAME: TUBERCULOSIS | | INACTIVE: NO |
| <hr/> | | |
| Run Date: <Enter> | Protocol: LREPI<Enter> | |
| Run Cycle: MONTHLY <Enter> | Lag Days: 15 <Enter> | |
| Previous Cycle: 1 <TAB> | | |
| General Description: <TAB> | | |
| <hr/> | | |
| Exit | Save | Refresh |
| COMMAND: E <Enter> | | Press <PF1>H for help Insert |
| Save changes before leaving form (Y/N)? Y <Enter> | | |

Lab EPI Protocol Edit [LREPI PROTOCOL EDIT] option

This option is use to edit the LAB SEARCH/EXTRACT PROTOCOL file. The option is located on the Lab EPI Primary Menu [LREPI SEARCH EXTRACT MENU].

Example: How to use the Lab EPI Protocol Edit [LREPI PROTOCOL EDIT] option

```
Protocol Parameters Setup Definition
```

```
PROTOCOL: LREPI<Enter>
```

```
Title: Emerging Pathogens Initiative (EPI)
```

```
Message Size: 32000
```

```
Report Mail Group: EPI-REPORT
```

```
Send Alert: YES
```

```
Send Alert To
```

```
DOE,Jane
```

Antimicrobial Link Update [LREPILK] option:

This option is use to link the ANTIMICROBIAL SUSCEPIBILITY file (#62.06) with the WKLD CODE file (#64). *(See the EPI Roll Up Modifications User Manual, Appendix-A section of this manual for an example on how to use this option).*

Emerging Pathogens Names and Reference Numbers

This chart lists the 23 emerging pathogens names and reference numbers:

| EMERGING PATHOGENS | EMERGING PATHOGENS |
|---|---|
| All Enterococci (Reference #23) (NEW) | Hepatitis C Antibody Positive (Reference #2) |
| All <i>Staphylococcus aureus</i> (Reference #18) (NEW) | Legionella (Reference #7) Note: The new Legionella Urinary Antigen test has been added to the existing Legionella test criteria. |
| All <i>Streptococcus pneumoniae</i> (Reference #22) (NEW) | Leishmaniasis (Reference #14) |
| Candida (Reference #8) | Malaria (Reference #11) |
| Clostridium difficile (Reference #4) | Methicillin - resistant <i>Staphylococcus aureus</i> (MRSA) (Reference #19) (NEW) |
| Creutzfeldt-Jakob Disease (CJD) (Reference #13) | Penicillin - Resistant Pneumococcus (Reference #3) |
| Cryptosporidium (Reference #9) | Streptococcus-Group A (Reference #6) |
| Dengue (Reference #12) | Tuberculosis (Reference #5) |
| E. coli O157:H7 (Reference #10) | Vancomycin-Resistant Coagulase Negative <i>Staphylococci/Staph epi</i> (VRSE) (Reference #21) (NEW) |
| Hepatitis A Antibody Positive (Reference #16) | Vancomycin-Resistant Enterococcus (VRE) (Reference #1) |
| Hepatitis B Positive (Reference #17) | Vancomycin-Resistant <i>Staphylococcus aureus</i> (VRSA) (Reference #20) (NEW) |
| Not Positive for Hepatitis C Antibody OR Hepatitis C Antibody NEG (Reference #15) | |

Lab EPI Parameter Setup [LREPI PARAMETER SETUP] option Input Screen Definitions

| LABORATORY EPI PARAMETERS INPUT SCREEN PROMPTS: | LABORATORY EPI PARAMETERS INPUT SCREEN PROMPTS DEFINITIONS: |
|---|---|
| Name: | <p>The LAB SEARCH/EXTRACT file (#69.5), Name field (#69.5.01) is modified to include the following 6 new emerging pathogens entries.</p> <ul style="list-style-type: none"> • All <i>Staphylococcus aureus</i> (Reference #18) • Methicillin-Resistant <i>Staphylococcus aureus</i> (MRSA) (Reference #19) • Vancomycin-Resistant <i>Staphylococcus aureus</i> (VRSA) (Reference #20) • Vancomycin-Resistant Coagulase Negative <i>Staphylococci/Staph</i> EPI (VRSE) (Reference #21) • All <i>Streptococcus pneumoniae</i> (Reference #22) • All Enterococci (Reference #23) <p>Answer with the EPI name or reference number</p> |
| Inactive: | <p>This prompt is renamed from ACTIVE to INACTIVE. This prompt is used to define if this entry is active or not. '1' or 'YES' indicates that this is an inactive entry. '0' or 'NO' indicates that this is an active entry.</p> |
| Laboratory Test (s): | <p>Consider these synonymous with, chemistry, serology, hematology, and “blood/serum” tests. Results anticipated to be found here would have had a test done under the chemistry/hematology accession areas, even if physically performed in microbiology and other areas. Select tests from the LABORATORY TEST file (#60).</p> |
| Indicator: | <p>Select the code that will determine how to match lab results.</p> <p>‘1’ FOR Use Reference Ranges ‘2’ FOR Contains ‘3’ FOR Greater Than ‘4’ FOR Less Than ‘5’ FOR Equal To</p> <p>Note: This new INDICATOR field (#69.55,1), located under ANTIMICROBIL SUSCEPTIBILITY sub-field (#69.55) is FOR FUTURE USE ONLY.</p> |
| Value: | <p>Positive, etc. Answer must be 1-15 characters in length. This is a Free Text field.</p> |
| ICD-9: | <p>ICD-9 standardized code used nationwide in federal and non-federal/private health care facilities. Select from the ICDM-9 DIAGNOSIS file (#80).</p> |
| ICD9 Description: | <p>Title of ICD diagnosis</p> |
| ICD10 Description: | <p>Title of ICD diagnosis</p> |
| ICD-10: | <p>ICD-10 standardized code used nationwide in federal and non-federal/private health care facilities. Select from the ICDM-10 DIAGNOSIS file (#80).</p> |

Lab EPI Parameter Setup [LREPI PARAMETER SETUP] option Input Screen Definitions (continued)

| LABORATORY EPI PARAMETERS INPUT SCREEN PROMPTS: | LABORATORY EPI PARAMETERS INPUT SCREEN PROMPTS DEFINITIONS: |
|---|--|
| Selected Etiology: | Consider synonymous with organism, final microbial diagnosis/isolate. Select from the ETIOLOGY FIELD file (#61.2). |
| Selected SNOMED codes: | Answer with SNOMED CODES You may enter a new SNOMED CODE, if you wish. Answer must be 1-15 characters in length. |
| Antimicrobial Susceptibility: | Enter the Antimicrobial that will be used in screening out sensitive Etiologies (e.g., "Vancomycin" for Vancomycin Resistant Enterococcus). Select from the ANTIMICROBIAL SUSCEPTIBILITY file (#62.6). |
| NLT Code: | Displays the associated NLT code if linked. If no NLT Code is displayed use the Antimicrobial Link Update option. |
| NLT Description: | Displays the Description of the linked NLT code. |
| Topography Selection: | Enter a date to screen out patients born before the date entered. Examples of Valid Dates: JAN 20 1957 or 20 JAN 57 or 1/20/57 or 012057 T (for TODAY), T+1 (for TOMORROW), T+2, T+7, etc. T-1 (for YESTERDAY), T-3W (for 3 WEEKS AGO), etc. |
| Include: | Selection of Topography screens all others out except the ones selected. For "ALL" leave blank. Not to be used in conjunction with the exclude Topography selection. Select from the TOPOGRAPHY file (#61). |
| Exclude: | Select the Topography to screen out. Not to be used in conjunction with the Include Topography selection. Select from the TOPOGRAPHY file (#61). |
| First Encounter: | Limits the output to the first encounter for the patient. Otherwise list all encounters. Choose: '1' FOR YES '0' FOR NO |
| Follow PTF: | Indicates if the PTF record will be followed until a discharge has been entered. Choose: '1' FOR YES '0' FOR NO |
| Before Date Of Birth: | Enter a date to screen out patients born before the date entered. Examples of Valid Dates: JAN 20 1957 or 20 JAN 57 or 1/20/57 or 012057 T (for TODAY), T+1 (for TOMORROW), T+2, T+7, etc. T-1 (for YESTERDAY), T-3W (for 3 WEEKS AGO), etc. |

Lab EPI Parameter Setup [LREPI PARAMETER SETUP] option Input Screen Definitions (continued)

| LABORATORY EPI PARAMETERS INPUT SCREEN PROMPTS: | LABORATORY EPI PARAMETERS INPUT SCREEN PROMPTS DEFINITIONS: |
|--|---|
| After Date Of Birth: | A birthrate to screen patients (i.e., patients DOB after 1/1/1950). |
| Select SEX: | FOR FUTURE USE ONLY. |
| Run Date: | Date that the last Auto EPI processed. |
| Protocol: | This defines the protocol associated with the parameters. This prompt has been modified to be UNEDITABLE. |
| Run Cycle: | Enter the date that the last Auto EPI processed. |
| Previous Cycle: | This new field is displayed on input screen page 5 of 5. By entering a number here the Lab search engine knows to look at a previous cycle for updates to data. How far back it looks is based on the cycle and number entered. For example if the cycle is monthly and the previous cycle is 1, then the search engine will also search 1 month back for data. This new field is UNEDITABLE. |
| Lag Days: | Defines the Lag Days parameter as 15 for all 23 emerging pathogens. Lag Days for the six new EPIs has been defined as 15 with the release of the new EPI software. |
| General Description: | To review or edit the General Description prompt use the <Tab> key. |

Lab EPI Parameter Setup [LREPI PARAMETER SETUP] option

The following information **must** be adhered to as recommended to ensure a successful implementation and utilization of the software:

NOTE: There may be more etiologies that fit the description/definition than just the ones that load automatically as part of the EPI Roll Up Modification software.

NOTE: It is highly recommended that the Laboratory Information Manager (LIM), a representative from the Microbiology section (director, supervisor, or technologist) and a Total Quality Improvement/Quality Improvement/Quality Assurance (TQI/QI/QA) staff (or person at the facility with similar function) be assigned the Lab EPI Primary Menu [LREPI SEARCH EXTRACT MENU]. These will be the individual(s) responsible for initially setting the Lab EPI parameters descriptions and doing periodic reviews of the parameters descriptions to assure they are current.

The Lab EPI Parameter Setup [LREPI PARAMETER SETUP] option is used to setup local parameters for the national emerging pathogens. Each emerging pathogen descriptions **must** be reviewed **prior** to setting up the Lab EPI parameters.

NOTES:

There are a number of different ways that sites have chosen to enter results into the VistA database. As long as the results are in a retrievable format (straight from the VistA database without additional manual input needed), how it is entered is **not** of significance to the Emerging Pathogen Initiative. However, two preferred methods make it easy to capture the data. Please reference the Helpful Hints section of this guide for the two preferred methods.

Site-specific spelling or alternate spelling for data entries **must** be consistent to guarantee accurate data capture.

The Lab EPI Parameter Setup [LREPI PARAMETER SETUP] option, Lag Day parameter **MUST** be pre-defined as **15** for ALL national emerging pathogens.

NOTE: If a lab test needs to be entered more than once in the parameter set up for a particular lab EPI pathogen name (e.g., because there is more than one test result that may meet the definition), the second and subsequent tests must be placed in quotes (“ ”). Even though the “ ” marks are used to enter the data, they don’t appear in the final product. This process can be done unlimited times for one set-up.

The Lab EPI Parameter Setup [LREPI PARAMETER SETUP] option input screen examples display how to setup EPI parameters (i.e., including the 6 **new** emerging pathogens. Several of the Lab EPI Parameter Setup [LREPI PARAMETER SETUP] option input screen examples display partially pre-populated entries. The ETIOLOGY FIELD file (#61.2) site-specific data entries are used to partially pre-populate the fields in the LAB SEARCH/EXTRACT file (#69.5). However, further data entries are required for site-specific data. Additional data entries can be added or deleted to meet your site-specific needs.

New Legionella Urinary Antigen Test

The **newer** Legionella Urinary Antigen test is available with this release of EPI. The LAB EPI parameter setup for the newer test is POSITIVE FOR LEGIONELLA PNEUMOPHILA. (see helpful hints for *Clostridium difficile* in Appendix B.)

LAB SEARCH/EXTRACT file (#69.5) Entries and Parameter Setup Examples

The following table (first column) contains the **6 new** emerging pathogens added to LAB SEARCH/EXTRACT file (#69.5). The (second column) contains the Lab EPI parameter setup example entries for the emerging pathogens: **Note:** The LAB EPI parameter setup entries are ONLY examples, as sites may have different names for tests. The table (second column) examples DOES NOT use the indicator mechanism of whether the result CONTAINS the POS or is EQUAL TO the POS, etc.

| LAB SEARCH/EXTRACT file (#69.5) Emerging Pathogen 6 New Entries: | LAB EPI Parameter Setup Example Entries: |
|--|--|
| All Enterococci (Reference #23) | ENTEROCOCCUS STREP D ENTEROCOCCUS ENTEROCOCCUS (STREPT. FAECALIS-GROUP) ENTEROCOCCUS FAECALIS ENTEROCOCCUS DURANS ENTEROCOCCUS FAECIUM ENTEROCOCCUS AVIUM Note: These are just samples. There are many other named species of coagulase negative staphylococci. |
| All <i>Staphylococcus aureus</i> (Reference #18): | STAPHYLOCOCCUS AUREUS STAPHYLOCOCCUS AUREUS (MRSA) STAPHYLOCOCCUS AUREUS (VRSA) |
| All <i>Streptococcus pneumoniae</i> (Reference #22): | STREPTOCOCCUS PNEUMONIAE DIPLOCOCCUS PNEUMOCOCCUS |
| Methicillin - Resistant <i>Staphylococcus aureus</i> (MRSA) (Reference #19): | STAPHYLOCOCCUS AUREUS STAPHYLOC+ OCCUS AUREUS (MRSA) |
| Vancomycin-Resistant Coagulase Negative <i>Staphylococci/Staph epi</i> (VRSE) (Reference #21): | STAPHYLOCOCCUS (COAGULASE NEGATIVE) STAPHYLOCOCCUS (COAGULASE NEGATIVE) STAPHYLOCOCCUS EPIDERMIDIS STAPHYLOCOCCUS HAEMOLYTICUS STAPHYLOCOCCUS SAPROPHYTICUS STAPHYLOCOCCUS SALIVARIUS STAPHYLOCOCCUS SIMULANS STAPHYLOCOCCUS SP Note: These are just samples. There are many other named species of coagulase negative staphylococci. |
| Vancomycin-Resistant <i>Staphylococcus aureus</i> (VRSA) (Reference #20) | STAPHYLOCOCCUS AUREUS STAPHYLOCOCCUS AUREUS (VRSA) |

All Enterococci (Reference #23)

The *enterococci* are a group of bacteria that can cause serious disease in humans, including blood stream infections, urinary tract infections, wound infections, endocarditis and even death. As with many other organisms that cause disease in humans, resistance to antibiotics is emerging in the enterococci. The presence of antibiotic resistance creates a challenge in treatment of infections with this organism. In order to determine the prevalence of antibiotic resistance, a baseline of occurrence of ALL enterococci needs to be obtained. This particular EPI pathogen setting has been created to identify ALL culture positive isolates of enterococci from any specimen site in any patient/client receiving care within the Veterans Health Administration (VHA).

NOTE: Even specimens that have been obtained from patients (not the environment) as part of an epidemiologic prevalence study or survey should be included if they are present in the VistA laboratory package results from your site.

The results from this EPI pathogen setting will be coupled with the results from Reference #1 (Vancomycin-Resistant Enterococci [VRE]) to help determine the percentage of all isolates of enterococci that have vancomycin resistance.

Example: Lab EPI Parameter Setup for All Enterococci

```

                                Lab EPI Primary Menu

ENH      Lab EPI Manual Run (Enhanced)
VR       Print Detailed Verification Report
LO       Local Pathogen Menu ...
PI       Pathogen Inquiry
UP       Lab EPI Parameter Setup
         Lab EPI Protocol Edit
LK       Antimicrobial Link Update

Select Lab EPI Primary menu Option: UP<Enter> Lab EPI Parameter Setup

Select LAB EPI NAME: ?<Enter>
  Answer with LAB EPI NAME, or REFERENCE NUMBER
  Do you want the entire 23-Entry LAB EPI List? Y (Yes)<Enter>
  Choose from:

    ALL ENTEROCOCCI
    ALL STAPHYLOCOCCUS AUREUS
    ALL STREPTOCOCCUS PNEUMONIAE
    CANDIDA
    CLOSTRIDIUM DIFFICILE
    CREUTZFELDT-JAKOB DISEASE
    CRYPTOSPORIDIUM
    DENGUE
    E. COLI 0157:H7
    HEPATITIS A ANTIBODY POS
    HEPATITIS B POS
    HEPATITIS C ANTIBODY NEG
    HEPATITIS C ANTIBODY POS
    LEGIONELLA
    LEISHMANIASIS
    MALARIA
    METH-RES STAPH AUREUS
    PEN-RES PNEUMOCOCCUS
    STREPTOCOCCUS GROUP A
    TUBERCULOSIS
    VANC-RES COAG NEG STAPH
    VANC-RES ENTEROCOCCUS
    VANC-RES STAPH AUREUS (VRSA)

Select LAB EPI NAME: ALL ENTEROCOCCI<Enter>

```

| | | |
|--|--|--------------|
| LABORATORY EPI PARAMETERS INPUT SCREEN | | Page 1 of 5 |
| NAME: ALL ENTEROCOCCI | | INACTIVE: NO |

| | | |
|---|-----------|-----------------|
| Laboratory Test(s) | Indicator | Value |
| <Enter> | | |
| ICD Coding System [ICD-9 or ICD-10]? (9/10):<RET> | | |
| ICD Code | Cd Set | ICD Description |
| <Enter> | | |

| | | | |
|------|------|-----------|---------|
| Exit | Save | Next Page | Refresh |
|------|------|-----------|---------|

Enter a command or '^' followed by a caption to jump to a specific field.

COMMAND: **N<Enter>** Press <PF1>H for help

Insert

| | | |
|--|--|--------------|
| LABORATORY EPI PARAMETERS INPUT SCREEN | | Page 2 of 5 |
| NAME: ALL ENTEROCOCCI | | INACTIVE: NO |

| | |
|-------------------|-----------------------|
| Selected Etiology | Selected Snomed Codes |
|-------------------|-----------------------|

ENTEROCOCCUS
 STREP D ENTEROCOCCUS
 ENTEROCOCCUS (STREPT. FAECALIS-GROUP)
 ENTEROCOCCUS FAECALIS
 ENTEROCOCCUS DURANS
 ENTEROCOCCUS FAECIUM
 ENTEROCOCCUS AVIUM

Note: These are just samples; there are many other named species eneterococci. You should review these and add/delete as appropriate based on the description definition provided in the EPI Technical and User Guide. To enter additional etiologies please see (Appendix-A, How to add an entry using the Lab EPI Parameter Setup [LREPI PARAMTER SETUP] option).

| | | |
|------------------------------|----------|-----------------|
| Antimicrobial Susceptibility | NLT Code | NLT Description |
| <Enter> | | |

| | | | |
|------|------|-----------|---------|
| Exit | Save | Next Page | Refresh |
|------|------|-----------|---------|

Enter a command or '^' followed by a caption to jump to a specific field.

COMMAND: **N<Enter>** Press <PF1>H for help Insert

Example: How to add additional etiology/etiologies

NOTE: The following LABORATORY EPI PARAMETERS INPUT SCREEN (i. e., Page 2 of 5) is an example on how to add additional etiology/etiologies (organisms) entries for this emerging pathogen. This functionality causes the added etiology (organism) to appear and the next line will be a blinking cursor. At this point if you have additional etiologies (organisms) to add, just type them in and repeat the process. OR, if you have finished adding etiology/etiologies (organisms) entries, just press the <Enter>key to proceed with the process.

| | |
|--|-------------|
| LABORATORY EPI PARAMETERS INPUT SCREEN | Page 2 of 5 |
|--|-------------|

NAME: ALL ENTEROCOCCI ACTIVE: NO

| | |
|-------------------|-----------------------|
| Selected Etiology | Selected Snomed Codes |
|-------------------|-----------------------|

Note: To add additional etiology/etiologies for this emerging pathogen type in the following etiology and select from the following entries.

Example: Enteroc<RET

| Antimicrobial Susceptibility | NLT Code | NLT Description |
|------------------------------|---|-----------------|
| 1 | ENTEROCOCCUS 49990P | |
| 2 | ENTEROCOCCUS (STREPT. FAECALIS-GROUP D) | 6789 |
| 3 | ENTEROCOCCUS AVIUM L1E603 | |
| 4 | ENTEROCOCCUS CASSELI FLAVUS L1E604 | |
| 5 | ENTEROCOCCUS DURANS L1E605 | |
| 6 | ENTEROCOCCUS FAECALIS L1E601 | |
| 7 | ENTEROCOCCUS FAECIUM L1E602 | |
| 8 | ENTEROCOCCUS GALLINARUM L1E606 | |

Choose 1-8 or '^' to quit: **8 <Enter>**

ENTEROCOCCUS GALLINARUM L1E606

Are you adding 'ENTEROCOCCUS GALLINARUM' as a new ETIOLOGY? No//**Y <Enter>**

| | |
|--|--------------|
| LABORATORY EPI PARAMETERS INPUT SCREEN | Page 3 of 5 |
| NAME: ALL ENTEROCOCCI | INACTIVE: NO |

Topography Selection

| | |
|---------------------------------|---------|
| Include <Enter> | Exclude |
|---------------------------------|---------|

Exit Save Next Page Refresh

Enter a command or '^' followed by a caption to jump to a specific field.

COMMAND: **N<Enter>** Press <PF1>H for help Insert

| | |
|--|--------------|
| LABORATORY EPI PARAMETERS INPUT SCREEN | Page 4 of 5 |
| NAME: ALL ENTEROCOCCI | INACTIVE: NO |

| | |
|--|---|
| FIRST ENCOUNTER: <Enter> | FOLLOW PTF: YES<Enter> |
| BEFORE DATE OF BIRTH: <Enter> | AFTER DATE OF BIRTH: <Enter> |

Select SEX: **<Enter>**

Exit Save Next Page Refresh

Enter a command or '^' followed by a caption to jump to a specific field.

COMMAND: **N<Enter>** Press <PF1>H for help Insert

| | |
|--|--------------|
| LABORATORY EPI PARAMETERS INPUT SCREEN | Page 5 of 5 |
| NAME: ALL ENTEROCOCCI | INACTIVE: NO |

| | |
|--|--------------------------------------|
| Run Date: <Enter> | Protocol: LREPI <Enter> |
| Run Cycle: MONTHLY<Enter> | Lag Days: 15 <Enter> |

Previous Cycle: **<Enter>**

General Description: **<Enter>**

Exit Save Next Page Refresh

Enter a command or '^' followed by a caption to jump to a specific field.

COMMAND: **E<Enter>** Press <PF1>H for help Insert

All *Staphylococcus aureus* (Reference #18)

Staphylococcus aureus is a bacterium that causes much disease in humans, including furunculosis, boils, acne, cellulites, pneumonia, toxic shock syndrome, and even death. It has always been a significant pathogen in the community setting, as well as in the healthcare setting where transmission can occur through contact and from the hands of healthcare personnel. The presence of antibiotic resistance creates a challenge in treatment of infections with this organism. In order to determine the prevalence of antibiotic resistance, a baseline of occurrence of ALL *Staphylococcus aureus* needs to be obtained. This particular EPI pathogen setting has been created to identify ALL culture positive isolates of *Staphylococcus aureus* from any specimen site in any patient/client receiving care within the VHA.

NOTE: Even specimens that have been obtained from patients (not the environment) as part of an epidemiologic prevalence study or survey should be included if they are present in the VistA laboratory package results from your site.

The results from this EPI pathogen setting will be coupled with the results from Reference #19 (MRSA) and Reference #20 (VRSA) to help determine the percentage of all isolates of *Staphylococcus aureus* that have methicillin (oxacillin) resistance and vancomycin resistance.

Lab EPI Parameter setup for All Staphylococcus aureus (Reference #18)

| Lab EPI Primary Menu | |
|----------------------|------------------------------------|
| ENH | Lab EPI Manual Run (Enhanced) |
| VR | Print Detailed Verification Report |
| LO | Local Pathogen Menu ... |
| PI | Pathogen Inquiry |
| UP | Lab EPI Parameter Setup |
| | Lab EPI Protocol Edit |
| LK | Antimicrobial Link Update |

Select Lab EPI Primary menu Option: **UP<Enter>** Lab EPI Parameter Setup

Select LAB EPI NAME: **?<Enter>**
 Answer with LAB EPI NAME, or REFERENCE NUMBER
 Do you want the entire 23-Entry LAB EPI List? **Y (Yes)<Enter>**
 Choose from:

- ALL ENTEROCOCCI
- ALL STAPHYLOCOCCUS AUREUS
- ALL STREPTOCOCCUS PNEUMONIAE
- CANDIDA
- CLOSTRIDIUM DIFFICILE
- CREUTZFELDT-JAKOB DISEASE
- CRYPTOSPORIDIUM
- DENGUE
- E. COLI 0157:H7
- HEPATITIS A ANTIBODY POS
- HEPATITIS B POS
- HEPATITIS C ANTIBODY NEG
- HEPATITIS C ANTIBODY POS
- LEGIONELLA
- LEISHMANIASIS
- MALARIA
- METH-RES STAPH AUREUS
- PEN-RES PNEUMOCOCCUS
- STREPTOCOCCUS GROUP A
- TUBERCULOSIS
- VANC-RES COAG NEG STAPH
- VANC-RES ENTEROCOCCUS
- VANC-RES STAPH AUREUS (VRSA)

Select LAB EPI NAME: ALL STAPHYLOCOCCUS AUREUS**<Enter>**

| | |
|--|--------------|
| LABORATORY EPI PARAMETERS INPUT SCREEN | Page 1 of 5 |
| NAME: ALL STAPHYLOCOCCUS AUREUS | INACTIVE: NO |

| | | |
|---|-----------|-----------------|
| Laboratory Test(s) | Indicator | Value |
| <Enter> | | |
| ICD Coding System [ICD-9 or ICD-10]? (9/10):<RET> | | |
| ICD Code | Cd Set | ICD Description |
| <Enter> | | |

| | | | |
|------|------|-----------|---------|
| Exit | Save | Next Page | Refresh |
|------|------|-----------|---------|

Enter a command or '^' followed by a caption to jump to a specific field.

| | | |
|--------------------------------|-----------------------|--------|
| COMMAND: N<Enter> | Press <PF1>H for help | Insert |
|--------------------------------|-----------------------|--------|

| | |
|--|--------------|
| LABORATORY EPI PARAMETERS INPUT SCREEN | Page 2 of 5 |
| NAME: ALL STAPH AUREUS | INACTIVE: NO |

| | |
|---|-----------------------|
| Selected Etiology | Selected Snomed Codes |
| STAPHYLOCOCCUS AUREUS | |
| STAPHYLOCOCCUS AUREUS (MRSA) | |
| STAPHYLOCOCCUS AUREUS (VRSA) <Enter> | |

Note: You may enter a new etiology, if you wish.
 If your facility uses a separate "selected etiology" designation to report *Staphylococcus aureus* with resistance to an antibiotic (e.g. *Staphylococcus aureus* (MRSA)), be sure to include this etiology in your list of names here so that the EPI process will acquire all *Staphylococcus aureus* isolates.

| | | |
|------------------------------|----------|-----------------|
| Antimicrobial Susceptibility | NLT Code | NLT Description |
| <Enter> | | |

| | | | |
|------|------|-----------|---------|
| Exit | Save | Next Page | Refresh |
|------|------|-----------|---------|

Enter a command or '^' followed by a caption to jump to a specific field.

| | | |
|--------------------------------|-----------------------|--------|
| COMMAND: N<Enter> | Press <PF1>H for help | Insert |
|--------------------------------|-----------------------|--------|

| | | |
|---|-----------------------|------------------------|
| LABORATORY EPI PARAMETERS INPUT SCREEN | | Page 3 of 5 |
| NAME: ALL STAPH AUREUS | | INACTIVE: NO |
| <hr/> | | |
| Topography Selection | | |
| Include <Enter> | Exclude <Enter> | |
| <hr/> | | |
| Exit | Save | Next Page Refresh |
| Enter a command or '^' followed by a caption to jump to a specific field. | | |
| COMMAND: N<Enter> | Press <PF1>H for help | Insert |

| | | |
|---|------------------------------|------------------------|
| LABORATORY EPI PARAMETERS INPUT SCREEN | | Page 4 of 5 |
| NAME: ALL STAPH AUREUS | | INACTIVE: NO |
| <hr/> | | |
| FIRST ENCOUNTER: <Enter> | FOLLOW PTF: YES <Enter> | |
| BEFORE DATE OF BIRTH: <Enter> | AFTER DATE OF BIRTH: <Enter> | |
| Select SEX: <Enter> | | |
| <hr/> | | |
| Exit | Save | Next Page Refresh |
| Enter a command or '^' followed by a caption to jump to a specific field. | | |
| COMMAND: N<Enter> | Press <PF1>H for help | Insert |

| | | |
|---|------------------------|------------------------|
| LABORATORY EPI PARAMETERS INPUT SCREEN | | Page 5 of 5 |
| NAME: ALL STAPH AUREUS | | INACTIVE: NO |
| <hr/> | | |
| Run Date: <Enter> | Protocol: LREPI<Enter> | |
| Run Cycle: MONTHLY<Enter> | Lag Days: 15<Enter> | |
| Previous Cycle: <TAB> | | |
| General Description: <TAB> | | |
| <hr/> | | |
| Exit | Save | Next Page Refresh |
| Enter a command or '^' followed by a caption to jump to a specific field. | | |
| COMMAND: S<Enter> | Press <PF1>H for help | Insert |

All *Streptococcus pneumoniae* (Reference #22)

Streptococcus pneumoniae is a bacterium that causes serious disease in humans, including pneumonia, bacteremia, meningitis and even death. It is an important pathogen to monitor in that many of the more serious sequelae of infection may be ameliorated with preventive vaccination. As with many other organisms that cause disease in humans, resistance to antibiotics is emerging in this *S. pneumoniae*. The presence of antibiotic resistance creates a challenge in treatment of infections with this organism. In order to determine the prevalence of antibiotic resistance, a baseline of occurrence of ALL *Streptococcus pneumoniae* needs to be obtained. This particular EPI pathogen setting has been created to identify ALL culture positive isolates of *Streptococcus pneumoniae* from any specimen site in any patient/client receiving care within the VHA.

NOTE: Even specimens that have been obtained from patients (not the environment) as part of an epidemiologic prevalence study or survey should be included if they are present in the VistA Laboratory Package results from your site.

The results from this EPI pathogen setting will be coupled with the results from Penicillin-Resistant Pneumococcus (Reference #3) to help determine the percentage of all isolates of *Streptococcus pneumoniae* that have penicillin resistance.

Lab EPI Parameter setup for All Streptococcus pneumoniae (Reference #22)

```

                                Lab EPI Primary Menu

ENH      Lab EPI Manual Run (Enhanced)
VR       Print Detailed Verification Report
LO       Local Pathogen Menu ...
PI       Pathogen Inquiry
UP       Lab EPI Parameter Setup
         Lab EPI Protocol Edit
LK       Antimicrobial Link Update

Select Lab EPI Primary menu Option: UP<Enter> Lab EPI Parameter Setup

Select LAB EPI NAME: ?<Enter>
  Answer with LAB EPI NAME, or REFERENCE NUMBER
  Do you want the entire 23-Entry LAB EPI List? Y (Yes)<Enter>
Choose from:

  ALL ENTEROCOCCI
  ALL STAPHYLOCOCCUS AUREUS
  ALL STREPTOCOCCUS PNEUMONIAE
  CANDIDA
  CLOSTRIDIUM DIFFICILE
  CREUTZFELDT-JAKOB DISEASE
  CRYPTOSPORIDIUM
  DENGUE
  E. COLI 0157:H7
  HEPATITIS A ANTIBODY POS
  HEPATITIS B POS
  HEPATITIS C ANTIBODY NEG
  HEPATITIS C ANTIBODY POS
  LEGIONELLA
  LEISHMANIASIS
  MALARIA
  METH-RES STAPH AUREUS
  PEN-RES PNEUMOCOCCUS
  STREPTOCOCCUS GROUP A
  TUBERCULOSIS
  VANC-RES COAG NEG STAPH
  VANC-RES ENTEROCOCCUS
  VANC-RES STAPH AUREUS (VRSA)

Select LAB EPI NAME: ALL STREPTOCOCCUS PNEUMONIAE<Enter>

```


| | | |
|--|--|--------------|
| LABORATORY EPI PARAMETERS INPUT SCREEN | | Page 1 of 5 |
| NAME: ALL STREP PNEUMO | | INACTIVE: NO |

| | | |
|---|-----------|-----------------|
| Laboratory Test(s) | Indicator | Value |
| <Enter> | | |
| ICD Coding System [ICD-9 or ICD-10]? (9/10):<RET> | | |
| ICD Code | Cd Set | ICD Description |
| <Enter> | | |

| | | | |
|------|------|-----------|---------|
| Exit | Save | Next Page | Refresh |
|------|------|-----------|---------|

Enter a command or '^' followed by a caption to jump to a specific field.

COMMAND: **N<Enter>** Press <PF1>H for help Insert

| | | |
|--|--|--------------|
| LABORATORY EPI PARAMETERS INPUT SCREEN | | Page 2 of 5 |
| NAME: ALL STREP PNEUMO | | INACTIVE: NO |

| | |
|--------------------------|-----------------------|
| Selected Etiology | Selected Snomed Codes |
| STREPTOCOCCUS PNEUMONIAE | |
| DIPLOCOCCUS | |
| PNEUMOCOCCUS | |
| <Enter> | |

Note: You may enter a new etiology, if you wish.
Are you adding a new ETIOLOGY? No//**<Enter>**

| | | |
|------------------------------|----------|-----------------|
| Antimicrobial Susceptibility | NLT Code | NLT Description |
| <Enter> | | |

| | | | |
|------|------|-----------|---------|
| Exit | Save | Next Page | Refresh |
|------|------|-----------|---------|

Enter a command or '^' followed by a caption to jump to a specific field.

COMMAND: **N<Enter>** Press <PF1>H for help Insert

| | |
|--|--------------|
| LABORATORY EPI PARAMETERS INPUT SCREEN | Page 3 of 5 |
| NAME: ALL STREP PNEUMO | INACTIVE: NO |

Topography Selection

| | |
|--------------------|--------------------|
| Include <Enter> | Exclude <Enter> |
|--------------------|--------------------|

Exit Save Next Page Refresh

Enter a command or '^' followed by a caption to jump to a specific field.

COMMAND: **N**<Enter> Press <PF1>H for help Insert

| | |
|--|--------------|
| LABORATORY EPI PARAMETERS INPUT SCREEN | Page 4 of 5 |
| NAME: ALL STREP PNEUMO | INACTIVE: NO |

| | |
|-------------------------------|--------------------------------|
| FIRST ENCOUNTER: <Enter> | FOLLOW PTF: YES <Enter> |
| BEFORE DATE OF BIRTH: <Enter> | AFTER DATE OF BIRTH: <Enter> |

Select SEX: <Enter>

Exit Save Next Page Refresh

Enter a command or '^' followed by a caption to jump to a specific field.

COMMAND: **N**<Enter> Press <PF1>H for help Insert

| | |
|--|--------------|
| LABORATORY EPI PARAMETERS INPUT SCREEN | Page 5 of 5 |
| NAME: ALL STREP PNEUMO | INACTIVE: NO |

| | |
|-----------------------------------|-----------------------------|
| Run Date: <Enter> | Protocol: LREPI<Enter> |
| Run Cycle: MONTHLY <Enter> | Lag Days: 15 <Enter> |

Previous Cycle: <TAB>

General Description: <TAB>

Exit Save Next Page Refresh

Enter a command or '^' followed by a caption to jump to a specific field.

COMMAND: **S**<Enter> Press <PF1>H for help Insert

Candida (Reference #8)

Fungal infections are rising in significance especially in severely ill patients. The same is true for bloodstream infections acquired in the hospital, especially those associated with intravenous lines. Fungal bloodstream infections are increasing in prevalence.

As a marker of bloodstream infections, the fungus *Candida* (and *Torulopsis*) has been chosen as an initial indicator organism. This organism may **not** be a prevalent or significant entity at your site; however, its presence is more likely to be indicative of serious or true infection than other organisms. The fungus *Candida* (and *Torulopsis*) may commonly be isolated from the blood in association with IV lines. Additionally, this yeast is more likely to be associated with nosocomial acquisition than other organisms (i.e., *Staphylococcus aureus* and coagulase negative *Staphylococcus*), which can cause a number of community acquired syndromes **not** at all related to IV lines.

All episodes of *Candida* (*Torulopsis*, yeast) isolation from blood or a blood source (central line, IV catheter tip, etc.) are being tracked. The VistA Laboratory EPI software has provided a partial pre-populated list of (etiologies/organisms) that fit the description for *Candida* (*Torulopsis*, yeast) to choose. These (etiologies/organisms) should be used, in addition to any site specific (etiologies/organisms) that may also fit the description.

Lab EPI Parameter Setup for CANDIDA

```

                                Lab EPI Primary Menu

ENH      Lab EPI Manual Run (Enhanced)
VR        Print Detailed Verification Report
LO        Local Pathogen Menu ...
PI        Pathogen Inquiry
UP        Lab EPI Parameter Setup
          Lab EPI Protocol Edit
LK        Antimicrobial Link Update

Select Lab EPI Primary menu Option: UP<Enter> Lab EPI Parameter Setup

Select LAB EPI NAME: ?<Enter>
  Answer with LAB EPI NAME, or REFERENCE NUMBER
  Do you want the entire 23-Entry LAB EPI List? Y (Yes)<Enter>
Choose from:

  ALL ENTEROCOCCI
  ALL STAPHYLOCOCCUS AUREUS
  ALL STREPTOCOCCUS PNEUMONIAE
  CANDIDA
  CLOSTRIDIUM DIFFICILE
  CREUTZFELDT-JAKOB DISEASE
  CRYPTOSPORIDIUM
  DENGUE
  E. COLI 0157:H7
  HEPATITIS A ANTIBODY POS
  HEPATITIS B POS
  HEPATITIS C ANTIBODY NEG
  HEPATITIS C ANTIBODY POS
  LEGIONELLA
  LEISHMANIASIS
  MALARIA
  METH-RES STAPH AUREUS
  PEN-RES PNEUMOCOCCUS
  STREPTOCOCCUS GROUP A
  TUBERCULOSIS
  VANC-RES COAG NEG STAPH
  VANC-RES ENTEROCOCCUS
  VANC-RES STAPH AUREUS (VRSA)

Select LAB EPI NAME: CANDIDA<Enter>

```

| LABORATORY EPI PARAMETERS INPUT SCREEN | | Page 1 of 5 |
|---|-----------|-----------------------|
| NAME: Candida | | INACTIVE: NO |
| <hr/> | | |
| Laboratory Test(s) | Indicator | Value |
| <Enter> | | |
| ICD Coding System [ICD-9 or ICD-10]? (9/10):<RET> | | |
| ICD Code | Cd Set | ICD Description |
| <Enter> | | |
| <hr/> | | |
| Exit | Save | Next Page |
| Refresh | | |
| COMMAND: N<Enter> | | Press <PF1>H for help |
| | | Insert |

| LABORATORY EPI PARAMETERS INPUT SCREEN | | Page 2 of 5 |
|--|-----------------------|-----------------------|
| NAME: CANDIDA | | INACTIVE: NO |
| <hr/> | | |
| Selected Etiology | Selected Snomed Codes | |
| Examples: CANDIDA | | |
| CANDIDA GUILLIERMONDII | | |
| CANDIDA KRUSEI | | |
| CANDIDA PARAPSILOSIS | | |
| CANDIDA PSEUDOTROPICALIS | | |
| CANDIDA STELLATOIDEA | | |
| CANDIDA TROPICALIS | | |
| CANDIDA, NOS | | |
| <Enter> | | |
| <p>Note: During the post Init, the ETIOLOGY FIELD file (#61.2) was searched to pre-populate the Etiology field (#3) in the EMERGING PATHOGENS file (#69.5). Listed above are examples of etiology entries which may have been populated from your site's file. Additional etiologies may be added or deleted at the <u>Selected Etiology</u> prompt to meet your site specific needs.</p> | | |
| <p>Note: If spelling differences occur within your ETIOLOGY FIELD file (#61.2), be consistent with your local file and spell the results here, as it is spelled in your file (even if it is spelled differently in the example). We are concerned more importantly with data <u>recovery</u>.</p> | | |
| Antimicrobial Susceptibility | NLT Code | NLT Description |
| <Enter> | | |
| <hr/> | | |
| Exit | Save | Next Page |
| Refresh | | |
| COMMAND: N<Enter> | | Press <PF1>H for help |
| | | Insert |

| | |
|--|-----------------------------------|
| LABORATORY EPI PARAMETERS INPUT SCREEN | Page 3 of 5 |
| NAME: Candida | INACTIVE: NO |
| <hr/> | |
| Topography Selection | |
| Include | Exclude |
| Blood<Enter> | <Enter> |
| Bloodstream<Enter> | |
| Catheter Tip<Enter> | |
| Note: These are only suggestions from specimen source code table 007 (see table 007 in Appendix C). Please add accordingly to your site definition. | |
| <hr/> | |
| Exit | Save Next Page Refresh |
| COMMAND: N<Enter> | Press <PF1>H for help Insert |

| | |
|---|-----------------------------------|
| LABORATORY EPI PARAMETERS INPUT SCREEN | Page 4 of 5 |
| NAME: Candida | INACTIVE: NO |
| <hr/> | |
| FIRST ENCOUNTER:<Enter> | Follow PTF:YES<Enter> |
| BEFORE DATE OF BIRTH:<Enter> | AFTER DATE OF BIRTH:<Enter> |
| Select SEX:<Enter> | |
| <hr/> | |
| Exit | Save Refresh |
| COMMAND: E<Enter> | Press <PF1>H for help Insert |
| Save changes before leaving form (Y/N)?Y<Enter> | |

| | |
|--|-----------------------------------|
| LABORATORY EPI PARAMETERS INPUT SCREEN | Page 5 of 5 |
| NAME: Candida | INACTIVE: NO |
| <hr/> | |
| Run Date:<Enter> | Protocol: LREPI<Enter> |
| Run Cycle: MONTHLY<Enter> | Lag Days: 15<Enter> |
| Previous Cycle: | |
| General Description: <TAB> | |
| <hr/> | |
| Exit | Save Refresh |
| COMMAND: E<Enter> | Press <PF1>H for help Insert |
| Save changes before leaving form (Y/N)?<Enter> | |

Clostridium difficile (Reference #4)

Disease associated with the presence of *Clostridium difficile* enterotoxin A can cause significant morbidity, as well as mortality. It is of importance, as its predominant acquisition seems to occur nosocomially. Presence of Clostridial toxin (either enterotoxin A or cytotoxin L) by assay (whether it be EIA, latex agglutination, cytotoxicity of cell culture \pm neutralization, or culture of organism with subsequent colony testing) is the best indicator that an inflammatory diarrheal disease is due to presence of *Clostridium difficile*.

Laboratory Services are quite varied as to how they identify the presence of *Clostridium difficile*. Some labs are set up to identify *C. difficile* as the final microbiological (bacterial) etiology of a culture, even if a culture method was not used. Other labs use a final etiology of “see comment” and then enter the results in a free text format. Still others enter the text under a hematology or chemistry format where a reference range and “positive” and “negative” result values can be entered. Wherever the facility lab places the results which are used to demonstrate the presence of toxin-producing *C. difficile*, we need to be able to track them (that means it **must** occur as a retrievable “positive” or “negative” result, or as a “bacterial etiology”). Results in a “Comments” or “Free-text” section are **not** acceptable.

There are a number of different ways that sites have chosen to enter *Clostridium difficile* toxin assay results into the **VISTA** database. As long as the toxin assay results are in a retrievable format (straight from the **VISTA** database without additional manual input needed), how it is entered is **not** of significance to the Emerging Pathogen Initiative. However, there are two preferred methods that make it easy to capture the data. Please reference the Appendix-B section of this guide for the two methods.

Lab EPI Parameter Setup for CLOSTRIDIUM DIFFICILE

```

                                Lab EPI Primary Menu

ENH      Lab EPI Manual Run (Enhanced)
VR       Print Detailed Verification Report
LO       Local Pathogen Menu ...
PI       Pathogen Inquiry
UP       Lab EPI Parameter Setup
         Lab EPI Protocol Edit
LK       Antimicrobial Link Update

Select Lab EPI Primary menu Option: UP<Enter> Lab EPI Parameter Setup

Select LAB EPI NAME: ?<Enter>
  Answer with LAB EPI NAME, or REFERENCE NUMBER
  Do you want the entire 23-Entry LAB EPI List? Y (Yes)<Enter>
  Choose from:

    ALL ENTEROCOCCI
    ALL STAPHYLOCOCCUS AUREUS
    ALL STREPTOCOCCUS PNEUMONIAE
    CANDIDA
    CLOSTRIDIUM DIFFICILE
    CREUTZFELDT-JAKOB DISEASE
    CRYPTOSPORIDIUM
    DENGUE
    E. COLI 0157:H7
    HEPATITIS A ANTIBODY POS
    HEPATITIS B POS
    HEPATITIS C ANTIBODY NEG
    HEPATITIS C ANTIBODY POS
    LEGIONELLA
    LEISHMANIASIS
    MALARIA
    METH-RES STAPH AUREUS
    PEN-RES PNEUMOCOCCUS
    STREPTOCOCCUS GROUP A
    TUBERCULOSIS
    VANC-RES COAG NEG STAPH
    VANC-RES ENTEROCOCCUS
    VANC-RES STAPH AUREUS (VRSA)

Select LAB EPI NAME: CLOSTRIDIUM DIFFICILE<Enter>
  
```


| | | |
|--|--|--------------|
| LABORATORY EPI PARAMETERS INPUT SCREEN | | Page 1 of 5 |
| NAME: CLOSTRIDIUM DIFFICILE | | INACTIVE: NO |

| | | |
|------------------------------------|-----------------|-------|
| Laboratory Test(s) | Indicator | Value |
| Clostridium<Enter> difficile toxin | Contains<Enter> | |
| Pos<Enter> | | |

Note: This example is only a suggestion. Please add accordingly to your site definition.

ICD Coding System [ICD-9 or ICD-10]? (9/10):<RET>

| | | |
|----------|--------|-----------------|
| ICD Code | Cd Set | ICD Description |
| <Enter> | | |

| | | | |
|------|------|-----------|---------|
| Exit | Save | Next Page | Refresh |
|------|------|-----------|---------|

COMMAND: N<Enter> Press <PF1>H for help Insert

| | | |
|--|--|--------------|
| LABORATORY EPI PARAMETERS INPUT SCREEN | | Page 2 of 5 |
| NAME: CLOSTRIDIUM DIFFICILE | | INACTIVE: NO |

| | |
|---|-----------------------|
| Selected Etiology | Selected Snomed Codes |
| Clostridium difficile toxin positive<Enter> | |

Note: This is only a suggestion. Please add accordingly to your site definition.

| | | |
|------------------------------|----------|-----------------|
| Antimicrobial Susceptibility | NLT Code | NLT Description |
| <Enter> | | |

| | | | |
|------|------|-----------|--------|
| Exit | Save | Next Page | Refres |
|------|------|-----------|--------|

COMMAND: N<Enter> Press <PF1>H for help Insert

| | | |
|--|------|-----------------------------------|
| LABORATORY EPI PARAMETERS INPUT SCREEN | | Page 3 of 5 |
| NAME: CLOSTRIDIUM DIFFICILE | | INACTIVE: NO |
| <hr/> | | |
| Topography Selection | | |
| Include <Enter> | | Exclude <Enter> |
| <hr/> | | |
| Exit | Save | Next Page Refresh |
| COMMAND: N<Enter> | | Press <PF1>H for help Insert |

| | | |
|--|------|-----------------------------|
| LABORATORY EPI PARAMETERS INPUT SCREEN | | Page 4 of 5 |
| NAME: CLOSTRIDIUM DIFFICILE | | INACTIVE: NO |
| <hr/> | | |
| First Encounter:<Enter> | | Follow PTF: YES<Enter> |
| BEFORE DATE OF BIRTH:<Enter> | | AFTER DATE OF BIRTH:<Enter> |
| Selected SEX:<Enter> | | |
| <hr/> | | |
| Exit | Save | Refresh |
| COMMAND: E<Enter> | | Press <PF1>H for help |

| | | |
|---|------|-----------------------------------|
| LABORATORY EPI PARAMETERS INPUT SCREEN | | Page 5 of 5 |
| NAME: CLOSTRIDIUM DIFFICILE | | INACTIVE: NO |
| <hr/> | | |
| Run Date: <Enter> | | Protocol: LREPI<Enter> |
| Run Cycle: MONTHLY<Enter> | | Lag Days: 15<Enter> |
| Previous Cycle: <TAB> | | |
| General Description: <TAB> | | |
| <hr/> | | |
| Exit | Save | Refresh |
| COMMAND: E<Enter> | | Press <PF1>H for help Insert |
| Save changes before leaving form (Y/N)?Y<Enter> | | |

Creutzfeldt-Jakob Disease (CJD) (Reference #13)

Creutzfeldt-Jakob Disease (CJD) disease is a rare illness associated with prions. The DVA has chosen to follow this entity because of historic problems with certain blood products used in the private and public health care sectors. The data will be one of a number of ways used to identify changes in trends of incidence of this illness. This task is remarkably complex because of the long incubation period of CJD. There are no specific tests for diagnosis other than central nervous system histology combined with clinical presentation. As such, this entity is followed through ICD coding.

Example: Lab EPI Parameter Setup for CREUTZFELDT-JAKOB DISEASE

```

                                Lab EPI Primary Menu

ENH      Lab EPI Manual Run (Enhanced)
VR       Print Detailed Verification Report
LO       Local Pathogen Menu ...
PI       Pathogen Inquiry
UP       Lab EPI Parameter Setup
         Lab EPI Protocol Edit
LK       Antimicrobial Link Update

Select Lab EPI Primary menu Option: UP<Enter> Lab EPI Parameter Setup

Select LAB EPI NAME: ?<Enter>
  Answer with LAB EPI NAME, or REFERENCE NUMBER
  Do you want the entire 23-Entry LAB EPI List? Y (Yes)<Enter>
Choose from:

  ALL ENTEROCOCCI
  ALL STAPHYLOCOCCUS AUREUS
  ALL STREPTOCOCCUS PNEUMONIAE
  CANDIDA
  CLOSTRIDIUM DIFFICILE
  CREUTZFELDT-JAKOB DISEASE
  CRYPTOSPORIDIUM
  DENGUE
  E. COLI 0157:H7
  HEPATITIS A ANTIBODY POS
  HEPATITIS B POS
  HEPATITIS C ANTIBODY NEG
  HEPATITIS C ANTIBODY POS
  LEGIONELLA
  LEISHMANIASIS
  MALARIA
  METH-RES STAPH AUREUS
  PEN-RES PNEUMOCOCCUS
  STREPTOCOCCUS GROUP A
  TUBERCULOSIS
  VANC-RES COAG NEG STAPH
  VANC-RES ENTEROCOCCUS
  VANC-RES STAPH AUREUS (VRSA)

Select LAB EPI NAME: CREUTZFELDT-JAKOB DISEASE<Enter>

```

| | | |
|--|--|--------------|
| LABORATORY EPI PARAMETERS INPUT SCREEN | | Page 1 of 5 |
| NAME: CREUTZFELDT-JAKOB DISEASE | | INACTIVE: NO |

| | | |
|---|-----------|-----------------------|
| Laboratory Test(s) | Indicator | Value |
| <Enter> | | |
| ICD Coding System [ICD-9 or ICD-10]? (9/10):<RET> | | |
| ICD Code | Cd Set | ICD Description |
| 046.1 | ICD-9 | JAKOB-CREUTZFELDT DIS |
| <Enter> | | |

| | | | |
|--------------------------------|------|-----------------------|---------|
| Exit | Save | Next Page | Refresh |
| COMMAND: N<Enter> | | Press <PF1>H for help | Insert |
| Press <PF1>H for help | | Insert | |

| | | |
|--|--|--------------|
| LABORATORY EPI PARAMETERS INPUT SCREEN | | Page 2 of 5 |
| NAME: CREUTZFELDT-JAKOB DISEASE | | INACTIVE: NO |

| | | |
|------------------------------|--|-----------------|
| Selected Etiology | Selected Snomed Codes <Enter> | |
| Antimicrobial Susceptibility | NLT Code | NLT Description |
| <Enter> | | |

| | | | |
|--------------------------------|------|-----------------------|---------|
| Exit | Save | Next Page | Refresh |
| COMMAND: N<Enter> | | Press <PF1>H for help | Insert |

| | | |
|--|--------------------|-----------------------------------|
| LABORATORY EPI PARAMETERS INPUT SCREEN | | Page 3 of 5 |
| NAME: CREUTZFELDT-JAKOB DISEASE | | INACTIVE: NO |
| <hr/> | | |
| Topography Selection | | |
| Include <Enter> | Exclude <Enter> | |
| <hr/> | | |
| Exit | Save | Next Page Refresh |
| COMMAND: N<Enter> | | Press <PF1>H for help Insert |

| | | |
|--|------------------------------|-----------------------------------|
| LABORATORY EPI PARAMETERS INPUT SCREEN | | Page 4 of 5 |
| NAME: CREUTZFELDT-JAKOB DISEASE | | INACTIVE: NO |
| <hr/> | | |
| First Encounter: <Enter> | Follow PTF: YES<Enter> | |
| BEFORE DATE OF BIRTH: <Enter> | AFTER DATE OF BIRTH: <Enter> | |
| Select SEX: <Enter> | | |
| <hr/> | | |
| Exit | Save | Refresh |
| COMMAND: E<Enter> | | Press <PF1>H for help Insert |

| | | |
|---|------------------------|-----------------------------------|
| LABORATORY EPI PARAMETERS INPUT SCREEN | | Page 5 of 5 |
| NAME: CREUTZFELDT-JAKOB DISEASE | | INACTIVE: NO |
| <hr/> | | |
| Run Date:<Enter> | Protocol: LREPI<Enter> | |
| Run Cycle: MONTHLY<Enter> | Lag Days:15<Enter> | |
| Previous Cycle: <TAB> | | |
| General Description: <TAB> | | |
| <hr/> | | |
| Exit | Save | Refresh |
| COMMAND: E<Enter> | | Press <PF1>H for help Insert |
| Save changes before leaving form (Y/N)?Y<Enter> | | |

Cryptosporidium (Reference #9)

The parasite *Cryptosporidium parvum* is a cause of water-borne diarrheal disease. It has gained recent prominence after evaluation of the outbreak in the greater Milwaukee area in 1993 which is estimated to have affected <400,000 persons. In addition to affecting HIV-infected persons and young children, information exists which demonstrates that the chronically ill, elderly are also a higher risk group than the general population. Microbiology laboratory data (parasitology for most laboratories) as well as ICD coding is used to track this disease, both are narrowly defined parameters.

NOTE: Microsporidiosis is a similar disease; however, the EPI does **not** currently wish to follow this disease process. Microsporidian etiologies should **not** be entered.

NOTE: If a lab test needs to be entered in the parameter set up for a particular lab EPI pathogen name (e.g. because there is more than one test result that may meet the definition), the second and subsequent tests must be placed in quotes (“ ”). Even though the “ ” marks are used to enter the data, they don't appear in the final product. This process can be done unlimited times for one set-up.

A **new** antigen test for *Cryptosporidium* is FDA approved. If your laboratory uses this test, but does not report the result as an etiology of just the organism name, please refer to Appendix B Helpful Hints for *Clostridium difficile* to review ways by which these data may be captured.

Example: Lab EPI Parameter Setup for CRYPTOSPORIDIUM

```

                                Lab EPI Primary Menu

ENH      Lab EPI Manual Run (Enhanced)
VR       Print Detailed Verification Report
LO       Local Pathogen Menu ...
PI       Pathogen Inquiry
UP       Lab EPI Parameter Setup
         Lab EPI Protocol Edit
LK       Antimicrobial Link Update

Select Lab EPI Primary menu Option: UP<Enter> Lab EPI Parameter Setup

Select LAB EPI NAME: ?<Enter>
  Answer with LAB EPI NAME, or REFERENCE NUMBER
  Do you want the entire 23-Entry LAB EPI List? Y (Yes)<Enter>
Choose from:

  ALL ENTEROCOCCI
  ALL STAPHYLOCOCCUS AUREUS
  ALL STREPTOCOCCUS PNEUMONIAE
  CANDIDA
  CLOSTRIDIUM DIFFICILE
  CREUTZFELDT-JAKOB DISEASE
  CRYPTOSPORIDIUM
  DENGUE
  E. COLI 0157:H7
  HEPATITIS A ANTIBODY POS
  HEPATITIS B POS
  HEPATITIS C ANTIBODY NEG
  HEPATITIS C ANTIBODY POS
  LEGIONELLA
  LEISHMANIASIS
  MALARIA
  METH-RES STAPH AUREUS
  PEN-RES PNEUMOCOCCUS
  STREPTOCOCCUS GROUP A
  TUBERCULOSIS
  VANC-RES COAG NEG STAPH
  VANC-RES ENTEROCOCCUS
  VANC-RES STAPH AUREUS (VRSA)

Select LAB EPI NAME: CRYPTOSPORIDIUM<Enter>

```

| | | |
|---|-----------|-----------------------------------|
| LABORATORY EPI PARAMETERS INPUT SCREEN | | Page 1 of 5 |
| NAME: CRYPTOSPORIDIUM | | INACTIVE: NO |
| <hr/> | | |
| Laboratory Test(s) | Indicator | Value |
| <Enter> | | |
| ICD Coding System [ICD-9 or ICD-10]? (9/10):<RET> | | |
| ICD Code | Cd Set | ICD Description |
| 007.8 | ICD-9 | PROTOZOAL INTEST DIS N |
| <Enter> | | |
| <hr/> | | |
| Exit | Save | Next Page Refresh |
| COMMAND: N <Enter> | | Press <PF1>H for help Insert |

| | | |
|---|-----------------------|-----------------------------------|
| LABORATORY EPI PARAMETERS INPUT SCREEN | | Page 2 of 5 |
| NAME: CRYPTOSPORIDIUM | | INACTIVE: NO |
| <hr/> | | |
| Selected Etiology | Selected Snomed Codes | |
| Cryptosporidium <Enter> | | |
| Note: If Cryptosporidium is reported under parasitology, add Cryptosporidium species at the Etiology prompt. | | |
| Antimicrobial Susceptibility | NLT Code | NLT Description |
| <Enter> | | |
| <hr/> | | |
| Exit | Save | Next Page Refresh |
| COMMAND: N <Enter> | | Press <PF1>H for help Insert |

| | | |
|--|----------------------|-----------------------------------|
| LABORATORY EPI PARAMETERS INPUT SCREEN | | Page 3 of 5 |
| NAME: CRYPTOSPORIDIUM | | INACTIVE: NO |
| <hr/> | | |
| Topography Selection | | |
| Include | Exclude | |
| <Enter> | <Enter> | |
| <hr/> | | |
| Exit | Save | Next Page Refresh |
| COMMAND: N <Enter> | | Press <PF1>H for help Insert |

| | |
|--|------------------------------|
| LABORATORY EPI PARAMETERS INPUT SCREEN | Page 4 of 5 |
| NAME: CRYPTOSPORIDIUM | INACTIVE: NO |
| <hr/> | |
| First Encounter: <Enter> | Follow PTF: YES<Enter> |
| BEFORE DATE OF BIRTH: <Enter> | AFTER DATE OF BIRTH: <Enter> |
| Select SEX: <Enter> | |
| <hr/> | |
| Exit Save Refresh | |
| COMMAND: E<Enter> | Press <PF1>H for help |

| | |
|--|---------------------------------|
| LABORATORY EPI PARAMETERS INPUT SCREEN | Page 5 of 5 |
| NAME: CRYPTOSPORIDIUM | INACTIVE: NO |
| <hr/> | |
| Run Date: | Protocol: LREPI<Enter> |
| Run Cycle: MONTHLY<Enter> | Lag Days: 15<Enter> |
| Previous Cycle: <TAB> | |
| General Description: <TAB> | |
| <hr/> | |
| Exit Save Refresh | |
| COMMAND: E<Enter> | Press <PF1>H for help Insert |
| Save changes before leaving form (Y/N)? Y<Enter> | |

Dengue (Reference #12)

The mosquito-borne disease of Dengue Hemorrhagic Fever is a rare but re-emerging infection, especially in the Caribbean. The VA has seen cases of Dengue Hemorrhagic Fever over the last several years. Most of these cases have been in Dengue endemic areas served by the VA. However, as our society becomes more mobile, and the area of Dengue endemicity expands, more cases are likely to occur. Because microbiologic culture is not routinely done and serology can be difficult to track, initially ICD coded diagnoses are used to track this entity.

Example: Lab EPI Parameter Setup for DENGUE

| Lab EPI Primary Menu | |
|--|------------------------------------|
| ENH | Lab EPI Manual Run (Enhanced) |
| VR | Print Detailed Verification Report |
| LO | Local Pathogen Menu ... |
| PI | Pathogen Inquiry |
| UP | Lab EPI Parameter Setup |
| | Lab EPI Protocol Edit |
| LK | Antimicrobial Link Update |
| Select Lab EPI Primary menu Option: UP<Enter> Lab EPI Parameter Setup | |
| Select LAB EPI NAME: ?<Enter> | |
| Answer with LAB EPI NAME, or REFERENCE NUMBER | |
| Do you want the entire 23-Entry LAB EPI List? Y (Yes) <Enter> | |
| Choose from: | |
| ALL ENTEROCOCCI | |
| ALL STAPHYLOCOCCUS AUREUS | |
| ALL STREPTOCOCCUS PNEUMONIAE | |
| CANDIDA | |
| CLOSTRIDIUM DIFFICILE | |
| CREUTZFELDT-JAKOB DISEASE | |
| CRYPTOSPORIDIUM | |
| DENGUE | |
| E. COLI 0157:H7 | |
| HEPATITIS A ANTIBODY POS | |
| HEPATITIS B POS | |
| HEPATITIS C ANTIBODY NEG | |
| HEPATITIS C ANTIBODY POS | |
| LEGIONELLA | |
| LEISHMANIASIS | |
| MALARIA | |
| METH-RES STAPH AUREUS | |
| PEN-RES PNEUMOCOCCUS | |
| STREPTOCOCCUS GROUP A | |
| TUBERCULOSIS | |
| VANC-RES COAG NEG STAPH | |
| VANC-RES ENTEROCOCCUS | |
| VANC-RES STAPH AUREUS (VRSA) | |
| Select LAB EPI NAME: DENGUE<Enter> | |

| | | |
|--|--|--------------|
| LABORATORY EPI PARAMETERS INPUT SCREEN | | Page 1 of 5 |
| NAME: DENGUE | | INACTIVE: NO |

| | | |
|----------------------|-----------|-------|
| Laboratory Test(s) | Indicator | Value |
| <Enter> | | |

ICD Coding System [ICD-9 or ICD-10]? (9/10):<RET>

| | | |
|----------------------|--------|--------------------------|
| ICD Code | Cd Set | ICD Description |
| 061. | ICD-9 | DENGUE |
| 065.4 | ICD-9 | MOSQUITO-BORNE HEM FEVER |
| <Enter> | | |

| | | | |
|------|------|-----------|---------|
| Exit | Save | Next Page | Refresh |
|------|------|-----------|---------|

COMMAND: N**<Enter>** Press <PF1>H for help Insert

| | | |
|--|--|--------------|
| LABORATORY EPI PARAMETERS INPUT SCREEN | | Page 2 of 5 |
| NAME: DENGUE | | INACTIVE: NO |

| | |
|----------------------|-----------------------|
| Etiology | Selected Snomed Codes |
| <Enter> | |

| | | |
|------------------------------|----------|-----------------|
| Antimicrobial Susceptibility | NLT Code | NLT Description |
| <Enter> | | |

| | | | |
|------|------|-----------|---------|
| Exit | Save | Next Page | Refresh |
|------|------|-----------|---------|

COMMAND: N**<Enter>** Press <PF1>H for help Insert

| | | |
|--|--|--------------|
| LABORATORY EPI PARAMETERS INPUT SCREEN | | Page 3 of 5 |
| NAME: DENGUE | | INACTIVE: NO |

Topography Selection

| | |
|----------------------|----------------------|
| Include | Exclude |
| <Enter> | <Enter> |

| | | | |
|------|------|-----------|---------|
| Exit | Save | Next Page | Refresh |
|------|------|-----------|---------|

COMMAND: N**<Enter>** Press <PF1>H for help Insert

| | |
|--|-----------------------------|
| LABORATORY EPI PARAMETERS INPUT SCREEN | Page 4 of 5 |
| NAME: DENGUE | INACTIVE: NO |
| <hr/> | |
| First Encounter: <Enter> | Follow PTF: YES <Enter> |
| BEFORE DATE OF BIRTH:<Enter> | AFTER DATE OF BIRTH:<Enter> |
| Select SEX:<Enter> | |
| <hr/> | |
| Exit Save Refresh | |
| COMMAND: E<Enter> | Press <PF1>H for help |

| | |
|--|---------------------------------|
| LABORATORY EPI PARAMETERS INPUT SCREEN | Page 5 of 5 |
| NAME: DENGUE | INACTIVE: NO |
| <hr/> | |
| Run Date:<Enter> | Protocol: LREPI<Enter> |
| Run Cycle: MONTHLY<Enter> | Lag Days: 15<Enter> |
| Previous Cycle: <TAB> | |
| General Description: <TAB> | |
| <hr/> | |
| Exit Save Refresh | |
| COMMAND: E<Enter> | Press <PF1>H for help Insert |
| Save changes before leaving form (Y/N)? Y<Enter> | |

E. coli O157:H7 (Reference #10)

Escherichia coli serotype O157 (*E. coli* O157) has gained prominence as a food-borne illness with potentially life threatening complications coming from the associated Hemolytic Uremic Syndrome. Not all sites routinely culture for the presence of *E. coli* O157 in stool specimens submitted for culture. In addition, *E. coli* O157 is not a microbiologic (bacterial) etiology pre-existing in the most recent - national microbiology lab package. In order to nationally track cultures positive for this organism, each site will need to make an etiology specific for *E. coli* O157 (e.g. *Escherichia coli* O157, *E. coli* O157, *E. coli* serotype O157, etc.). Some sites have already done this and will **not** need to generate a new entry.

NOTE: Entering *Escherichia coli* or *E. coli* from the bacterial etiology and then entering “serotype O157” or “O157”, under the “Comments” or “Free Text” section is **not** acceptable, as it will **not** allow the data to be retrieved nationally.

All subsequent positive cultures for this organism **must** then be entered under the new etiology.

Other serotypes of *E. coli* will also cause disease, but we will not currently track these as O157 causes by far, the majority of cases of interest for the national database.

The EPI criterion is dependent on your site. If your site already has an etiology that will select positive cultures for *E. coli* O157, then enter that etiology. However, if your site had to enter a new etiology to accommodate the EPI criteria, be sure to enter this new etiology here.

NOTE: If a lab test needs to be entered in the parameter set up for a particular lab EPI pathogen name (e.g. because there is more than one test result that may meet the definition), the second and subsequent tests must be placed in quotes (“”). Even though the “” marks are used to enter the data, they don't appear in the final product. This process can be done unlimited times for one set-up.

Example: Lab EPI Parameter Setup for E. COLI 0157:H7

```

                                Lab EPI Primary Menu

ENH      Lab EPI Manual Run (Enhanced)
VR       Print Detailed Verification Report
LO       Local Pathogen Menu ...
PI       Pathogen Inquiry
UP       Lab EPI Parameter Setup
         Lab EPI Protocol Edit
LK       Antimicrobial Link Update

Select Lab EPI Primary menu Option: UP<Enter> Lab EPI Parameter Setup

Select LAB EPI NAME: ?<Enter>
  Answer with LAB EPI NAME, or REFERENCE NUMBER
  Do you want the entire 23-Entry LAB EPI List? Y (Yes)<Enter>
  Choose from:

    ALL ENTEROCOCCI
    ALL STAPHYLOCOCCUS AUREUS
    ALL STREPTOCOCCUS PNEUMONIAE
    CANDIDA
    CLOSTRIDIUM DIFFICILE
    CREUTZFELDT-JAKOB DISEASE
    CRYPTOSPORIDIUM
    DENGUE
    E. COLI 0157:H7
    HEPATITIS A ANTIBODY POS
    HEPATITIS B POS
    HEPATITIS C ANTIBODY NEG
    HEPATITIS C ANTIBODY POS
    LEGIONELLA
    LEISHMANIASIS
    MALARIA
    METH-RES STAPH AUREUS
    PEN-RES PNEUMOCOCCUS
    STREPTOCOCCUS GROUP A
    TUBERCULOSIS
    VANC-RES COAG NEG STAPH
    VANC-RES ENTEROCOCCUS
    VANC-RES STAPH AUREUS (VRSA)

Select LAB EPI NAME: E. COLI 0157:H7<Enter>

```

| | | |
|---|-----------|------------------------|
| LABORATORY EPI PARAMETERS INPUT SCREEN | | Page 1 of 5 |
| NAME: E. COLI 0157:H7 | | INACTIVE: NO |
| <hr/> | | |
| Laboratory Test(s) | Indicator | Value |
| <Enter> | | |
| ICD Coding System [ICD-9 or ICD-10]? (9/10):<RET> | | |
| ICD Code | Cd Set | ICD Description |
| <Enter> | | |
| <hr/> | | |
| Exit | Save | Next Page Refresh |
| COMMAND: N <Enter> | | Press <PF1>H for help |

| | | |
|---|----------|------------------------|
| LABORATORY EPI PARAMETERS INPUT SCREEN | | Page 2 of 5 |
| NAME: E. COLI 0157:H7 | | INACTIVE: NO |
| <hr/> | | |
| Selected Etiology | | |
| Example: Escherichia coli 0157 <Enter> | | |
| <p>Note: Entering <i>Escherichia coli</i> or <i>E. coli</i> from the bacterial etiology and then entering "serotype 0157" or "0157", under the Comments section or in free text is not acceptable as it will not allow the data to be retrieved nationally).</p> | | |
| Antimicrobial Susceptibility | NLT Code | NLT Description |
| <Enter> | | |
| <hr/> | | |
| Exit | Save | Next Page Refresh |
| COMMAND: N <Enter> | | Press <PF1>H for help |

| | | |
|--|----------------------|-----------------------------------|
| LABORATORY EPI PARAMETERS INPUT SCREEN | | Page 3 of 5 |
| NAME: E. COLI 0157:H7 | | INACTIVE: NO |
| <hr/> | | |
| Topography Selection | | |
| Include | Exclude | |
| <Enter> | <Enter> | |
| <hr/> | | |
| Exit | Save | Next Page Refresh |
| COMMAND: N <Enter> | | Press <PF1>H for help Insert |

| | |
|--|------------------------------|
| LABORATORY EPI PARAMETERS INPUT SCREEN | Page 4 of 5 |
| NAME: E. COLI 0157:H7 | INACTIVE: NO |
| <hr/> | |
| First Encounter: <Enter> | Follow PTF: YES<Enter> |
| BEFORE DATE OF BIRTH: <Enter> | AFTER DATE OF BIRTH: <Enter> |
| Select SEX: <Enter> | |
| <hr/> | |
| Exit Save Refresh | |
| COMMAND: E<Enter> | Press <PF1>H for help |

| | |
|--|---------------------------------|
| LABORATORY EPI PARAMETERS INPUT SCREEN | Page 5 of 5 |
| NAME: E. COLI 0157:H7 | INACTIVE: NO |
| <hr/> | |
| Run Date: <Enter> | Protocol: LREPI<Enter> |
| Run Cycle: MONTHLY<Enter> | Lag Days: 15<Enter> |
| Previous Cycle: <TAB> | |
| General Description: <TAB> | |
| <hr/> | |
| Exit Save Refresh | |
| COMMAND: E<Enter> | Press <PF1>H for help Insert |
| Save changes before leaving form (Y/N)? Y<Enter> | |

Hepatitis A Antibody Positive (Reference #16)

One of the goals of the Healthy People 2000 and 2010 initiatives of the Department of Health and Human Services is to decrease certain infectious diseases, especially those that are vaccine preventable. Acute infection with Hepatitis A is one such disease that has specific objectives present in the Healthy People objectives.

The purpose of surveillance for this disease is to record all cases as diagnosed by the laboratory. A positive laboratory test for the presence of Hepatitis A virus is needed. Usually this criterion is met by presence of antibodies to the Hepatitis A virus. In particular, the IgM antibody against hepatitis A is the test most commonly used for determining acute hepatitis A infection. There are other antibody tests available for Hepatitis A. These tests usually indicate past infection with hepatitis A (or in some circumstances may indicate evidence of previous vaccination); usually the IgG antibody against Hepatitis A, OR the Total antibody against Hepatitis A (a test that does not discriminate between IgM or IgG, but can show evidence of exposure) are the tests done for this purpose.

What we are looking for is evidence of presence of ANY antibody to Hepatitis A, whether it is recorded as “weakly positive,” “strongly positive,” “positive,” or “present.” If other phrases are used to describe a test result, one should be able to differentiate responses upon entry into the program. As an example, the words “present” and “not present” might be used to designate “positive” vs. “negative”, however, they would not allow retrieval of only the positive cases as both phrases contain the word, “present.” Also, numerical values of results (e.g. at titer value) are not readily useable. Therefore, parameters for this are to be laboratory based and should include all tests for antibodies against hepatitis A (see examples above).

Also, some institutions will use ICD-9 coding and problem lists as a means to abstract data on this disease. DO NOT use these methods for this particular program. We are only abstracting laboratory confirmed cases of antibodies against Hepatitis A.

NOTE: If a lab test needs to be entered in the parameter set up for a particular lab EPI pathogen name (e.g. because there is more than one test result that may meet the definition), the second and subsequent tests must be placed in quotes (“ ”). Even though the “ ” marks are used to enter the data, they don't appear in the final product. This process can be done unlimited times for one set-up.

Example: Lab EPI Parameter Setup for HEPATITIS A ANTIBODY POS

| Lab EPI Primary Menu | |
|----------------------|------------------------------------|
| ENH | Lab EPI Manual Run (Enhanced) |
| VR | Print Detailed Verification Report |
| LO | Local Pathogen Menu... |
| PI | Pathogen Inquiry |
| UP | Lab EPI Parameter Setup |
| | Lab EPI Protocol Edit |
| LK | Antimicrobial Link Update |

Select Lab EPI Primary menu Option: **UP<Enter>** Lab EPI Parameter Setup

Select LAB EPI NAME: **?<Enter>**
 Answer with LAB EPI NAME, or REFERENCE NUMBER
 Do you want the entire 23-Entry LAB EPI List? **Y (Yes)<Enter>**
 Choose from:

- ALL ENTEROCOCCI
- ALL STAPHYLOCOCCUS AUREUS
- ALL STREPTOCOCCUS PNEUMONIAE
- CANDIDA
- CLOSTRIDIUM DIFFICILE
- CREUTZFELDT-JAKOB DISEASE
- CRYPTOSPORIDIUM
- DENGUE
- E. COLI 0157:H7
- HEPATITIS A ANTIBODY POS
- HEPATITIS B POS
- HEPATITIS C ANTIBODY NEG
- HEPATITIS C ANTIBODY POS
- LEGIONELLA
- LEISHMANIASIS
- MALARIA
- METH-RES STAPH AUREUS
- PEN-RES PNEUMOCOCCUS
- STREPTOCOCCUS GROUP A
- TUBERCULOSIS
- VANC-RES COAG NEG STAPH
- VANC-RES ENTEROCOCCUS
- VANC-RES STAPH AUREUS (VRSA)

Select LAB EPI NAME: **HEPATITIS A ANTIBODY POS<Enter>**

Note: The four hepatitis pathogens (Hepatitis C Antibody Positive, Hepatitis C Antibody Negative, Hepatitis A Antibody Positive and Hepatitis B Positive) are tightly integrated with the Clinical Reminder data stream that the EPI national roll-up accomplishes (see combined products VistA Laboratory EPI Hepatitis Extract Patch LR*5.2*260, PXR*1.5*1, PSJ*5*48 and Patch PSO*7*45) and changes in the EPI parameters may need to have concomitant changes in the Clinical Reminder data being passed over to the EPI national roll-up—concurrent review (and changes, if necessary), should be undertaken in conjunction with the local Clinical Applications Coordinator for the Clinical Reminder package to assure that appropriate mapping of Health factors to the national pathogens has occurred.

| | | |
|--|--|--------------|
| LABORATORY EPI PARAMETERS INPUT SCREEN | | Page 1 of 5 |
| NAME: HEPATITIS A ANTIBODY POS | | INACTIVE: NO |

| | | |
|---------------------------------------|-----------------|------------|
| Laboratory Test(s) | Indicator | Value |
| HEP A ANTIBODY-TOTAL<Enter> | Equal To<Enter> | |
| REACTIVE<Enter> | | |
| HEP A ANTIBODY(IgM)<Enter> | Contains<Enter> | POS<Enter> |
| HEPATITIS A AB(IGG)D/C(2/99)<Enter> | Contains<Enter> | POS<Enter> |
| "HEPATITIS A AB(IGG)D/C(2/99)"<Enter> | Contains<Enter> | Pos<Enter> |
| "HEPATITIS A AB(IGG)D/C(2/99)"<Enter> | Contains<Enter> | P<Enter> |
| "HEPATITIS A AB(IGG)D/C(2/99)"<Enter> | Contains<Enter> | p<Enter> |
| "HEP A ANTIBODY-TOTAL"<Enter> | Equal To<Enter> | R<Enter> |

Note: Enter the appropriate test for your site, and how the results are reported.

ICD Coding System [ICD-9 or ICD-10]? (9/10):<RET>

| | | |
|----------|--------|-----------------|
| ICD Code | Cd Set | ICD Description |
| <Enter> | | |

| | | | |
|------|------|-----------|---------|
| Exit | Save | Next Page | Refresh |
|------|------|-----------|---------|

COMMAND: N<Enter> Press <PF1>H for help Insert

| | | |
|--|--|--------------|
| LABORATORY EPI PARAMETERS INPUT SCREEN | | Page 2 of 5 |
| NAME: HEPATITIS A ANTIBODY POS | | INACTIVE: NO |

| | |
|-------------------|-----------------------|
| Selected Etiology | Selected Snomed Codes |
| <Enter> | |

| | | |
|------------------------------|----------|-----------------|
| Antimicrobial Susceptibility | NLT Code | NLT Description |
| <Enter> | | |

| | | | |
|------|------|-----------|---------|
| Exit | Save | Next Page | Refresh |
|------|------|-----------|---------|

COMMAND: N<Enter> Press <PF1>H for help Insert

| | | |
|--|--|--------------|
| LABORATORY EPI PARAMETERS INPUT SCREEN | | Page 3 of 5 |
| NAME: HEPATITIS A ANTIBODY POS | | INACTIVE: NO |

Topography Selection

| | |
|---------|---------|
| Include | Exclude |
| <Enter> | <Enter> |

| | | | |
|------|------|-----------|---------|
| Exit | Save | Next Page | Refresh |
|------|------|-----------|---------|

COMMAND: **N<Enter>**

Press <PF1>H for help

Insert

| | | |
|--|------------------------------|-----------------------|
| LABORATORY EPI PARAMETERS INPUT SCREEN | | Page 4 of 5 |
| NAME: HEPATITIS A ANTIBODY POS | | INACTIVE: NO |
| <hr/> | | |
| First Encounter: <Enter> | Follow PTF: YES<Enter> | |
| BEFORE DATE OF BIRTH: <Enter> | AFTER DATE OF BIRTH: <Enter> | |
| Select SEX: <Enter> | | |
| <hr/> | | |
| Exit | Save | Refresh |
| COMMAND: E<Enter> | | Press <PF1>H for help |

| | | |
|---|------------------------|-----------------------|
| LABORATORY EPI PARAMETERS INPUT SCREEN | | Page 5 of 5 |
| NAME: HEPATITIS A ANTIBODY POS | | INACTIVE: NO |
| <hr/> | | |
| Run Date: <Enter> | Protocol: LREPI<Enter> | |
| Run Cycle: MONTHLY<Enter> | Lag Days: 15<Enter> | |
| Previous Cycle: <TAB> | | |
| General Description: <TAB> | | |
| <hr/> | | |
| Exit | Save | Refresh |
| COMMAND: E<Enter> | | Press <PF1>H for help |
| Save changes before leaving form (Y/N)? Y <Enter> | | |

Hepatitis B Positive (Reference #17)

One of the goals of the Healthy People 2000 and 2010 initiatives of the Department of Health and Human Services is to decrease certain infectious diseases, especially those that are vaccine preventable. Acute and chronic infection with Hepatitis B is one such disease that has specific objectives present in the Healthy People objectives.

Both acute and chronic diseases have significant morbidity and can contribute to mortality. Further, infection with hepatitis B can complicate the medical course of persons with other liver ailments. As such, surveillance for both acute and chronic disease is important. In order for the VHA to do surveillance for these diseases, we are looking for laboratory evidence of infection with hepatitis B. This laboratory evidence of infection includes the following standard serological markers:

- Presence of the Hepatitis B surface antigen
- Presence of antibodies against the Hepatitis B core antigen (in particular, the IgM antibody)
- Presence of antibodies against the Hepatitis B surface antigen
- Presence of the hepatitis B e antigen.

These are not all of the tests that can be done for hepatitis B, but they are the ones likely to pick up acute cases (new) or those chronic cases that are likely to be infectious to other persons. Please list only those tests at your facility that is in keeping with what we are looking for— acute cases or those cases likely to be infectious to others.

NOTE: There are advanced PCR based tests that can measure amount of virus in the bloodstream; these are not done at all sites and have not yet been FDA approved. As such, these PCR tests should not be used for case determination.

NOTE: If a lab test needs to be entered in the parameter set up for a particular lab EPI pathogen name (e.g. because there is more than one test result that may meet the definition), the second and subsequent tests must be placed in quotes (“ ”). Even though the “ ” marks are used to enter the data, they don't appear in the final product. This process can be done unlimited times for one set-up.

Example: Lab EPI Parameter Setup for HEPATITIS B POS

```

                                Lab EPI Primary Menu

ENH      Lab EPI Manual Run (Enhanced)
VR       Print Detailed Verification Report
LO       Local Pathogen Menu ...
PI       Pathogen Inquiry
UP       Lab EPI Parameter Setup
         Lab EPI Protocol Edit
LK       Antimicrobial Link Update

Select Lab EPI Primary menu Option: UP<Enter> Lab EPI Parameter Setup

Select LAB EPI NAME: ?<Enter>
  Answer with LAB EPI NAME, or REFERENCE NUMBER
  Do you want the entire 23-Entry LAB EPI List? Y (Yes)<Enter>
Choose from:

  ALL ENTEROCOCCI
  ALL STAPHYLOCOCCUS AUREUS
  ALL STREPTOCOCCUS PNEUMONIAE
  CANDIDA
  CLOSTRIDIUM DIFFICILE
  CREUTZFELDT-JAKOB DISEASE
  CRYPTOSPORIDIUM
  DENGUE
  E. COLI 0157:H7
  HEPATITIS A ANTIBODY POS
  HEPATITIS B POS
  HEPATITIS C ANTIBODY NEG
  HEPATITIS C ANTIBODY POS
  LEGIONELLA
  LEISHMANIASIS
  MALARIA
  METH-RES STAPH AUREUS
  PEN-RES PNEUMOCOCCUS
  STREPTOCOCCUS GROUP A
  TUBERCULOSIS
  VANC-RES COAG NEG STAPH
  VANC-RES ENTEROCOCCUS
  VANC-RES STAPH AUREUS (VRSA)

Select LAB EPI NAME: HEPATITIS B POS<Enter>

Note: The four hepatitis pathogens (Hepatitis C Antibody Positive, Hepatitis C
Antibody Negative, Hepatitis A Antibody Positive and Hepatitis B Positive) are
tightly integrated with the Clinical Reminder data stream that the EPI
national roll-up accomplishes (see combined products VistA Laboratory EPI
Hepatitis Extract Patch LR*5.2*260, PXR*1.5*1, PSJ*5*48 and Patch PSO*7*45)
and changes in the EPI parameters may need to have concomitant changes in the
Clinical Reminder data being passed over to the EPI national roll-up-
concurrent review (and changes, if necessary), should be undertaken in
conjunction with the local Clinical Applications Coordinator for the Clinical
Reminder package to assure that appropriate mapping of Health factors to the
national pathogens has occurred.

```

| LABORATORY EPI PARAMETERS INPUT SCREEN | | Page 1 of 5 |
|--|-----------------|---------------------------------|
| NAME: HEPATITIS B POS | | INACTIVE: NO |
| Laboratory Test(s) | Indicator | Value |
| HEP B SURFACE Ag<Enter> | Contains<Enter> | |
| POS<Enter> | | |
| HEP B SURFACE AB<Enter> | Contains<Enter> | |
| POS<Enter> | | |
| HEP B CORE AB(IgM)<Enter> | Contains<Enter> | |
| POS<Enter> | | |
| HEP Be ANTIGEN<Enter> | Contains<Enter> | |
| POS<Enter> | | |
| "HEP Be ANTIGEN"<Enter> | Contains<Enter> | |
| Pos<Enter> | | |
| "HEP Be ANTIGEN"<Enter> | Contains<Enter> | p<Enter> |
| "HEP Be ANTIGEN"<Enter> | Contains<Enter> | P<Enter> |
| Note: Enter the appropriate test for your site, and how the results are reported. | | |
| ICD Coding System [ICD-9 or ICD-10]? (9/10):<RET> | | |
| ICD Code | Cd Set | ICD Description |
| <Enter> | | |
| Exit | Save | Next Page |
| Refresh | | |
| COMMAND: N<Enter> | | Press <PF1>H for help Insert |

| LABORATORY EPI PARAMETERS INPUT SCREEN | | Page 2 of 5 |
|--|-----------------------|---------------------------------|
| NAME: HEPATITIS B POS | | INACTIVE: NO |
| Selected Etiology | Selected Snomed Codes | |
| <Enter> | | |
| Antimicrobial Susceptibility | NLT Code | NLT Description |
| <Enter> | | |
| Exit | Save | Next Page |
| Refresh | | |
| COMMAND: N<Enter> | | Press <PF1>H for help Insert |

| LABORATORY EPI PARAMETERS INPUT SCREEN | | Page 3 of 5 |
|--|---------|--------------|
| NAME: HEPATITIS B POS | | INACTIVE: NO |
| Topography Selection | | |
| Include | Exclude | |
| <Enter> | <Enter> | |
| Exit | Save | Next Page |
| Refresh | | |

COMMAND: **N<Enter>**

Press <PF1>H for help

Insert

| | |
|--|------------------------------|
| LABORATORY EPI PARAMETERS INPUT SCREEN | Page 4 of 5 |
| NAME: HEPATITIS B POS | INACTIVE: NO |
| <hr/> | |
| First Encounter: <Enter> | Follow PTF: YES<Enter> |
| BEFORE DATE OF BIRTH: <Enter> | AFTER DATE OF BIRTH: <Enter> |
| Select SEX: <Enter> | |
| <hr/> | |
| Exit Save Refresh | |
| COMMAND: E<Enter> | Press <PF1>H for help |

| | |
|--|------------------------|
| LABORATORY EPI PARAMETERS INPUT SCREEN | Page 5 of 5 |
| NAME: HEPATITIS B POS | INACTIVE: NO |
| <hr/> | |
| Run Date: <Enter> | Protocol: LREPI<Enter> |
| Run Cycle: MONTHLY<Enter> | Lag Days: 15<Enter> |
| Previous Cycle: <TAB> | |
| General Description: <TAB> | |
| <hr/> | |
| Exit Save Refresh | |
| COMMAND: E<Enter> | Press <PF1>H for help |
| Save changes before leaving form (Y/N)? Y<Enter> | |

Not Positive for Hepatitis C Antibody OR Hepatitis C Antibody Neg (Reference #15)

The first version of the EPI gathered data on persons who were positive for antibody against Hepatitis C. This version will continue to gather such data. However, there are many cases, and it is important to try to find out what differences there are in those persons who are positive for Hepatitis C antibody as opposed to those who do not have Hepatitis C antibody present. Therefore, please review those results that you have designated to be placed into the Hepatitis C Antibody Positive portion of the EPI. Be sure that they truly meet the definition, as noted in Lab EPI Patch LR*5.2*175 Technical and User Guide (distributed August 1998).

All the results of Hepatitis C antibody testing that are not considered “positive” should be reported in this area. Therefore, all of the hepatitis C results that your facility reports should be mapped to either the hepatitis C Antibody Positive file or the Not Positive for Hepatitis C Antibody File. Not positive terms may include “negative,” “indeterminant,” “indeterminate,” “undetectable.” As with the Hepatitis C Antibody Positive component, be sure that phrases that truly differentiate results are used (e.g. the results of “present” and “not present” are not truly differentiated by computer retrieval as both contain the word “present”).

NOTE: There are PCR based tests utilized for Hepatitis C. These tests are not used at all facilities and are not yet FDA approved for identification of hepatitis C disease. As such, they should not be used for reporting purposes with this iteration of EPI.

NOTE: If a lab test needs to be entered in the parameter set up for a particular lab EPI pathogen name (e.g. because there is more than one test result that may meet the definition), the second and subsequent tests must be placed in quotes (“ ”). Even though the “ ” marks are used to enter the data, they don't appear in the final product. This process can be done unlimited times for one set-up.

Example: Lab EPI Parameter Setup for HEPATITIS C ANTIBODY NEG

```

                                Lab EPI Primary Menu

ENH      Lab EPI Manual Run (Enhanced)
VR       Print Detailed Verification Report
LO       Local Pathogen Menu ...
PI       Pathogen Inquiry
UP       Lab EPI Parameter Setup
         Lab EPI Protocol Edit
LK       Antimicrobial Link Update

Select Lab EPI Primary menu Option: UP<Enter> Lab EPI Parameter Setup

Select LAB EPI NAME: ?<Enter>
  Answer with LAB EPI NAME, or REFERENCE NUMBER
  Do you want the entire 23-Entry LAB EPI List? Y (Yes)<Enter>
  Choose from:

    ALL ENTEROCOCCI
    ALL STAPHYLOCOCCUS AUREUS
    ALL STREPTOCOCCUS PNEUMONIAE
    CANDIDA
    CLOSTRIDIUM DIFFICILE
    CREUTZFELDT-JAKOB DISEASE
    CRYPTOSPORIDIUM
    DENGUE
    E. COLI 0157:H7
    HEPATITIS A ANTIBODY POS
    HEPATITIS B POS
    HEPATITIS C ANTIBODY NEG
    HEPATITIS C ANTIBODY POS
    LEGIONELLA
    LEISHMANIASIS
    MALARIA
    METH-RES STAPH AUREUS
    PEN-RES PNEUMOCOCCUS
    STREPTOCOCCUS GROUP A
    TUBERCULOSIS
    VANC-RES COAG NEG STAPH
    VANC-RES ENTEROCOCCUS
    VANC-RES STAPH AUREUS (VRSA)

Select LAB EPI NAME: HEPATITIS C ANTIBODY NEG<Enter>

Note: The four hepatitis pathogens (Hepatitis C Antibody Positive, Hepatitis C
Antibody Negative, Hepatitis A Antibody Positive and Hepatitis B Positive) are
tightly integrated with the Clinical Reminder data stream that the EPI
national roll-up accomplishes (see combined products VistA Laboratory EPI
Hepatitis Extract Patch LR*5.2*260, PXR*1.5*1, PSJ*5*48 and Patch PSO*7*45)
and changes in the EPI parameters may need to have concomitant changes in the
Clinical Reminder data being passed over to the EPI national roll-up-
concurrent review (and changes, if necessary), should be undertaken in
conjunction with the local Clinical Applications Coordinator for the Clinical
Reminder package to assure that appropriate mapping of Health factors to the
national pathogens has occurred.

```

| | | |
|--|--|--------------|
| LABORATORY EPI PARAMETERS INPUT SCREEN | | Page 1 of 5 |
| NAME: HEPATITIS C ANTIBODY NEG | | INACTIVE: NO |

| | | |
|-------------------------|-----------------|------------|
| Laboratory Test(s) | Indicator | Value |
| HEP C ANTIBODY<Enter> | Contains<Enter> | NEG<Enter> |
| "HEP C ANTIBODY"<Enter> | Contains<Enter> | SEE |
| COMMENTS<Enter> | | |
| "HEP C ANTIBODY"<Enter> | Contains<Enter> | *<Enter> |
| "HEP C ANTIBODY"<Enter> | Contains<Enter> | #<Enter> |

Note: Enter the appropriate test for your site, and how the results are reported.

ICD Coding System [ICD-9 or ICD-10]? (9/10):<RET>

| | | |
|----------|--------|-----------------|
| ICD Code | Cd Set | ICD Description |
| <Enter> | | |

Exit Save Next Page Refresh

COMMAND: N<Enter> Press <PF1>H for help Insert

| | | |
|--|--|--------------|
| LABORATORY EPI PARAMETERS INPUT SCREEN | | Page 2 of 5 |
| NAME: HEPATITIS C ANTIBODY NEG | | INACTIVE: NO |

| | |
|-------------------|-----------------------|
| Selected Etiology | Selected Snomed Codes |
| <Enter> | |

| | | |
|------------------------------|----------|-----------------|
| Antimicrobial Susceptibility | NLT Code | NLT Description |
| <Enter> | | |

Exit Save Next Page Refresh

COMMAND: N<Enter> Press <PF1>H for help Insert

| | | |
|--|--|--------------|
| LABORATORY EPI PARAMETERS INPUT SCREEN | | Page 3 of 5 |
| NAME: HEPATITIS C ANTIBODY Neg | | INACTIVE: NO |

Topography Selection

| | |
|---------|---------|
| Include | Exclude |
| <Enter> | <Enter> |

Exit Save Next Page Refresh

COMMAND: N<Enter> Press <PF1>H for help Insert

| | |
|--|-----------------------------|
| LABORATORY EPI PARAMETERS INPUT SCREEN | Page 4 of 5 |
| NAME: HEPATITIS C ANTIBODY NEG | INACTIVE: NO |
| <hr/> | |
| First Encounter:<Enter> | Follow PTF: YES<Enter> |
| BEFORE DATE OF BIRTH:<Enter> | AFTER DATE OF BIRTH:<Enter> |
| Select SEX:<Enter> | |
| <hr/> | |
| Exit Save Refresh | |
| COMMAND: E<Enter> | Press <PF1>H for help |

| | |
|--|------------------------|
| LABORATORY EPI PARAMETERS INPUT SCREEN | Page 5 of 5 |
| NAME: HEPATITIS C ANTIBODY NEG | INACTIVE: NO |
| <hr/> | |
| Run Date:<Enter> | Protocol: LREPI<Enter> |
| Run Cycle: MONTHLY<Enter> | Lag Days: 15<Enter> |
| Previous Cycle: <TAB> | |
| General Description: <TAB> | |
| <hr/> | |
| Exit Save Refresh | |
| COMMAND: E<Enter> | Press <PF1>H for help |
| Save changes before leaving form (Y/N)? Y<Enter> | |

Hepatitis C Antibody Positive (Reference #2)

Hepatitis C is much more prevalent than originally thought at least in certain key patient sub-populations. As new and more sensitive assays come into use, we seem to find more evidence of this pathogen. We are looking for evidence of exposure to Hepatitis C in patients as demonstrated by Hepatitis C antibody positivity. The need for confirmatory testing or demonstration of active disease is not currently necessary in gathering data for this program. Different facilities may use different assays for this test. What we are looking for is evidence of presence of antibody to Hepatitis C, whether it be recorded as “weakly positive”, “strongly positive”, “positive”, or “present”. If other phrases are used to describe a test result, one should be able to differentiate the results upon entry into the program. As an example, the words, “present” and “not present” would not allow retrieval of only positive cases as both phrases contain the word, “present”.

NOTE: There are PCR based tests utilized for Hepatitis C. These tests are not used at all facilities and are not yet FDA approved for identification of hepatitis C disease. As such, they should not be used for reporting purposes with this iteration of EPI.

Example: Lab EPI Parameter Setup for Hepatitis C Antibody POS

```

                                Lab EPI Primary Menu

ENH      Lab EPI Manual Run (Enhanced)
VR       Print Detailed Verification Report
LO       Local Pathogen Menu ...
PI       Pathogen Inquiry
UP       Lab EPI Parameter Setup
         Lab EPI Protocol Edit
LK       Antimicrobial Link Update

Select Lab EPI Primary menu Option: UP<Enter> Lab EPI Parameter Setup

Select LAB EPI NAME: ?<Enter>
  Answer with LAB EPI NAME, or REFERENCE NUMBER
  Do you want the entire 23-Entry LAB EPI List? Y (Yes)<Enter>
  Choose from:
    ALL ENTEROCOCCI
    ALL STAPHYLOCOCCUS AUREUS
    ALL STREPTOCOCCUS PNEUMONIAE
    CANDIDA
    CLOSTRIDIUM DIFFICILE
    CREUTZFELDT-JAKOB DISEASE
    CRYPTOSPORIDIUM
    DENGUE
    E. COLI 0157:H7
    HEPATITIS A ANTIBODY POS
    HEPATITIS B POS
    HEPATITIS C ANTIBODY NEG
    HEPATITIS C ANTIBODY POS
    LEGIONELLA
    LEISHMANIASIS
    MALARIA
    METH-RES STAPH AUREUS
    PEN-RES PNEUMOCOCCUS
    STREPTOCOCCUS GROUP A
    TUBERCULOSIS
    VANC-RES COAG NEG STAPH
    VANC-RES ENTEROCOCCUS
    VANC-RES STAPH AUREUS (VRSA)

Select LAB EPI NAME: HEPATITIS C ANTIBODY POS<Enter>

Note: The four hepatitis pathogens (Hepatitis C Antibody Positive, Hepatitis C Antibody Negative,
Hepatitis A Antibody Positive and Hepatitis B Positive) are tightly integrated with the Clinical Reminder
data stream that the EPI national roll-up accomplishes (see combined products VistA Laboratory EPI
Hepatitis Extract Patch LR*5.2*260, PXR*1.5*1, PSJ*5*48 and Patch PSO*7*45) and changes in the
EPI parameters may need to have concomitant changes in the Clinical Reminder data being passed over to
the EPI national roll-up—concurrent review (and changes, if necessary), should be undertaken in
conjunction with the local Clinical Applications Coordinator for the Clinical Reminder package to assure
that appropriate mapping of Health factors to the national pathogens has occurred.

```


| | | |
|--|-----------------|---------------------------------|
| LABORATORY EPI PARAMETERS INPUT SCREEN | | Page 1 of 5 |
| NAME: HEPATITIS C ANTIBODY POS | | INACTIVE: NO |
| <hr/> | | |
| Laboratory Test(s) | Indicator | Value |
| HEPATITIS C ANTIBODY<Enter> | Contains<Enter> | |
| POS<Enter> | | |
| Note: Enter the appropriate test for your site, and how the results are reported. | | |
| ICD Coding System [ICD-9 or ICD-10]? (9/10):<RET> | | |
| ICD Code | Cd Set | ICD Description |
| <Enter> | | |
| <hr/> | | |
| Exit | Save | Next Page |
| | | Refresh |
| COMMAND: N<Enter> | | Press <PF1>H for help Insert |

| | | |
|--|-----------------------|---------------------------------|
| LABORATORY EPI PARAMETERS INPUT SCREEN | | Page 2 of 5 |
| NAME: HEPATITIS C ANTIBODY POS | | INACTIVE: NO |
| <hr/> | | |
| Selected Etiology | Selected Snomed Codes | |
| <Enter> | | |
| Antimicrobial Susceptibility | NLT Code | NLT Description |
| <Enter> | | |
| <hr/> | | |
| Exit | Save | Next Page |
| | | Refresh |
| COMMAND: N<Enter> | | Press <PF1>H for help Insert |

| | | |
|--|---------|---------------------------------|
| LABORATORY EPI PARAMETERS INPUT SCREEN | | Page 3 of 5 |
| NAME: HEPATITIS C ANTIBODY POS | | INACTIVE: NO |
| <hr/> | | |
| Topography Selection | | |
| Include | Exclude | |
| <Enter> | <Enter> | |
| <hr/> | | |
| Exit | Save | Next Page |
| | | Refresh |
| COMMAND: N<Enter> | | Press <PF1>H for help Insert |

| | |
|--|-----------------------------|
| LABORATORY EPI PARAMETERS INPUT SCREEN | Page 4 of 5 |
| NAME: HEPATITIS C ANTIBODY POS | INACTIVE: NO |
| <hr/> | |
| First Encounter:<Enter> | Follow PTF: YES<Enter> |
| BEFORE DATE OF BIRTH:<Enter> | AFTER DATE OF BIRTH:<Enter> |
| Select SEX:<Enter> | |
| <hr/> | |
| Exit Save Refresh | |
| COMMAND: E<Enter> | Press <PF1>H for help |

| | |
|--|------------------------|
| LABORATORY EPI PARAMETERS INPUT SCREEN | Page 5 of 5 |
| NAME: HEPATITIS C ANTIBODY POS | INACTIVE: NO |
| <hr/> | |
| Run Date:<Enter> | Protocol: LREPI<Enter> |
| Run Cycle: MONTHLY<Enter> | Lag Days: 15<Enter> |
| Previous Cycle: <TAB> | |
| General Description: <TAB> | |
| <hr/> | |
| Exit Save Refresh | |
| COMMAND: E<Enter> | Press <PF1>H for help |
| Save changes before leaving form (Y/N)? Y<Enter> | |

Legionella (Reference #7)

Since the American Legion Convention in Philadelphia in the 1970's, Legionnaires' disease has been an illness of keen interest to the DVA. Because diagnosis is complex, we have chosen to review for presence of *Legionella* in culture and in ICD DIAGNOSIS file (#80). We will not look at *Legionella* direct fluorescent antibody positivity because of the potential high false positivity of this test. Likewise, serology is not easy to interpret or easily extracted from the VistA database for our purposes and will **not** be included as a marker in this first iteration of the EPI program. Because it is not yet approved, the newer test of *Legionella* urinary antigen will not be used either. The Selected Etiology screen display has been partially pre-populated.

NOTE: The **new** FDA-Approved Legionella Urinary Antigen test is available; as such the ability to capture the result with this release of EPI is addressed. This newer test **must** be added for LEGIONELLA via the Lab EPI Parameter Setup [LREPI PARAMETER SETUP] option. The preferred method to capture this is to have the Etiology (result) of the accessioned microbiology be POSITIVE FOR LEGIONELLA PNEUMOPHILA (or something similar). This issue is similar to one encountered in with the Clostridium difficile pathogen and samples of how to address this are provided in Appendix B Helpful Hints.

Example: Lab EPI Parameter Setup for LEGIONELLA

```

                                Lab EPI Primary Menu

ENH      Lab EPI Manual Run (Enhanced)
VR       Print Detailed Verification Report
LO       Local Pathogen Menu ...
PI       Pathogen Inquiry
UP       Lab EPI Parameter Setup
         Lab EPI Protocol Edit
LK       Antimicrobial Link Update

Select Lab EPI Primary menu Option: UP<Enter> Lab EPI Parameter Setup

Select LAB EPI NAME: ?<Enter>
  Answer with LAB EPI NAME, or REFERENCE NUMBER
  Do you want the entire 23-Entry LAB EPI List? Y (Yes)<Enter>
  Choose from:

    ALL ENTEROCOCCI
    ALL STAPHYLOCOCCUS AUREUS
    ALL STREPTOCOCCUS PNEUMONIAE
    CANDIDA
    CLOSTRIDIUM DIFFICILE
    CREUTZFELDT-JAKOB DISEASE
    CRYPTOSPORIDIUM
    DENGUE
    E. COLI 0157:H7
    HEPATITIS A ANTIBODY POS
    HEPATITIS B POS
    HEPATITIS C ANTIBODY NEG
    HEPATITIS C ANTIBODY POS
    LEGIONELLA
    LEISHMANIASIS
    MALARIA
    METH-RES STAPH AUREUS
    PEN-RES PNEUMOCOCCUS
    STREPTOCOCCUS GROUP A
    TUBERCULOSIS
    VANC-RES COAG NEG STAPH
    VANC-RES ENTEROCOCCUS
    VANC-RES STAPH AUREUS (VRSA)

Select LAB EPI NAME: LEGIONELLA <Enter>

```

| | | |
|--|--|--------------|
| LABORATORY EPI PARAMETERS INPUT SCREEN | | Page 1 of 5 |
| NAME: LEGIONELLA | | INACTIVE: NO |

| | | |
|----------------------|-----------|-------|
| Laboratory Test(s) | Indicator | Value |
| <Enter> | | |

ICD Coding System [ICD-9 or ICD-10]? (9/10):<RET>

| | | |
|----------|--------|-----------------------|
| ICD Code | Cd Set | ICD Description |
| 482.80 | ICD-9 | LEGIONNARIE'S DISEASE |
| 482.84 | ICD-9 | LEGIONNARIE'S DISEASE |

<Enter>

| | | | | |
|------|------|-----------|---------|--|
| Exit | Save | Next Page | Refresh | |
|------|------|-----------|---------|--|

COMMAND: **N<Enter>** Press <PF1>H for help Insert

| | | |
|--|--|--------------|
| LABORATORY EPI PARAMETERS INPUT SCREEN | | Page 2 of 5 |
| NAME: LEGIONELLA | | INACTIVE: NO |

Selected Etiology

Examples: LEGIONELLA BOZEMANII
 LEGIONELLA DUMOFFII
 LEGIONELLA GORMANII
 LEGIONELLA JORDANIS
 LEGIONELLA LONGBEACHAE
 LEGIONELLA MICDADEI
 LEGIONELLA OAKRIDGENSIS
 LEGIONELLA PNEUMOPHILIA
 LEGIONELLA SP
 LEGIONELLA WADSWORTHII
 POSITIVE FOR LEGIONELLA PNEUMOPHILA

<Enter>

Note: During the post Init, the ETIOLOGY FIELD file (#61.2) was searched to pre-populate the Etiology field (#3) in the EMERGING PATHOGENS file (#69.5). Listed above are examples of etiology entries which may have been populated from your site's file. Additional etiologies may be added or deleted at the Selected Etiology prompt to meet your site-specific needs.

Note: If spelling differences occur within your ETIOLOGY FIELD file (#61.2) be consistent with your local file and spell the results here, as it is spelled in your file (even if it is spelled differently in the example). We are concerned more importantly with data recovery.

| | | |
|------------------------------|----------|-----------------|
| Antimicrobial Susceptibility | NLT Code | NLT Description |
| <Enter> | | |

| | | | | |
|------|------|-----------|---------|--|
| Exit | Save | Next Page | Refresh | |
|------|------|-----------|---------|--|

COMMAND: **N<Enter>** Press <PF1>H for help Insert

| | | |
|--|--------------------|-----------------------------------|
| LABORATORY EPI PARAMETERS INPUT SCREEN | | Page 3 of 5 |
| NAME: LEGIONELLA | | INACTIVE: NO |
| <hr/> | | |
| Topography Selection | | |
| Include <Enter> | Exclude <Enter> | |
| <hr/> | | |
| Exit | Save | Next Page Refresh |
| COMMAND: N<Enter> | | Press <PF1>H for help Insert |

| | | |
|--|------------------------------|-----------------------|
| LABORATORY EPI PARAMETERS INPUT SCREEN | | Page 4 of 5 |
| NAME: LEGIONELLA | | INACTIVE: NO |
| <hr/> | | |
| First Encounter: <Enter> | Follow PTF: YES<Enter> | |
| BEFORE DATE OF BIRTH: <Enter> | AFTER DATE OF BIRTH: <Enter> | |
| Select SEX: <Enter> | | |
| <hr/> | | |
| Exit | Save | Refresh |
| COMMAND: E<Enter> | | Press <PF1>H for help |

| | | |
|---|------------------------|-----------------------------------|
| LABORATORY EPI PARAMETERS INPUT SCREEN | | Page 5 of 5 |
| NAME: E. LEGIONELLA | | INACTIVE: NO |
| <hr/> | | |
| Run Date: <Enter> | Protocol: LREPI<Enter> | |
| Run Cycle: MONTHLY<Enter> | Lag Days: 15<Enter> | |
| Previous Cycle: <TAB> | | |
| General Description: <TAB> | | |
| <hr/> | | |
| Exit | Save | Refresh |
| COMMAND: E<Enter> | | Press <PF1>H for help Insert |
| Save changes before leaving form (Y/N)? Y <Enter> | | |

Leishmaniasis (Reference #14)

Leishmaniasis is a significant tropical disease that can cause serious complications. It is of interest to the Department of Veterans Affairs as *Leishmania* has caused illness among military personnel for many years. In addition, the Persian Gulf War occurred in an area of the world where the parasite is endemic. Because no simple, straightforward serology exists and no standard culture techniques exist, we have chosen to follow this entity through ICD diagnosis codes.

Example: Lab EPI Parameter Setup for Leishmaniasis

```

                                Lab EPI Primary Menu

ENH      Lab EPI Manual Run (Enhanced)
VR        Print Detailed Verification Report
LO        Local Pathogen Menu ...
PI        Pathogen Inquiry
UP        Lab EPI Parameter Setup
          Lab EPI Protocol Edit
LK        Antimicrobial Link Update

Select Lab EPI Primary menu Option: UP<Enter> Lab EPI Parameter Setup

Select LAB EPI NAME: ?<Enter>
  Answer with LAB EPI NAME, or REFERENCE NUMBER
  Do you want the entire 23-Entry LAB EPI List? Y (Yes) <Enter>
Choose from:

  ALL ENTEROCOCCI
  ALL STAPHYLOCOCCUS AUREUS
  ALL STREPTOCOCCUS PNEUMONIAE
  CANDIDA
  CLOSTRIDIUM DIFFICILE
  CREUTZFELDT-JAKOB DISEASE
  CRYPTOSPORIDIUM
  DENGUE
  E. COLI 0157:H7
  HEPATITIS A ANTIBODY POS
  HEPATITIS B POS
  HEPATITIS C ANTIBODY NEG
  HEPATITIS C ANTIBODY POS
  LEGIONELLA
  LEISHMANIASIS
  MALARIA
  METH-RES STAPH AUREUS
  PEN-RES PNEUMOCOCCUS
  STREPTOCOCCUS GROUP A
  TUBERCULOSIS
  VANC-RES COAG NEG STAPH
  VANC-RES ENTEROCOCCUS
  VANC-RES STAPH AUREUS (VRSA)

Select LAB EPI NAME: LEISHMANIASIS <Enter>

```

| | | |
|--|--|--------------|
| LABORATORY EPI PARAMETERS INPUT SCREEN | | Page 1 of 5 |
| NAME: LEISHMANIASIS | | INACTIVE: NO |

| | | |
|----------------------|-----------|-------|
| Laboratory Test(s) | Indicator | Value |
| <Enter> | | |

ICD Coding System [ICD-9 or ICD-10]? (9/10):<RET>

| | | |
|----------|--------|--------------------------|
| ICD Code | Cd Set | ICD Description |
| 085.0 | ICD-9 | VISCERAL LEISHMANIASIS |
| 085.1 | ICD-9 | CUTAN LEISHMANIAS URBAN |
| 085.2 | ICD-9 | CUTAN LEISHMANIAS ASIAN |
| 085.3 | ICD-9 | CUTAN LEISHMANIAS ETHIOP |
| 085.4 | ICD-9 | CUTAN LEISHMANIAS AMER |
| 085.5 | ICD-9 | MUCOCUTAN LEISHMANIASIS |
| 085.9 | ICD-9 | LEISHMANIASIS NOS |

<Enter>

| | | | |
|------|------|-----------|---------|
| Exit | Save | Next Page | Refresh |
|------|------|-----------|---------|

COMMAND: **N<Enter>** Press <PF1>H for help Insert

| | | |
|--|--|--------------|
| LABORATORY EPI PARAMETERS INPUT SCREEN | | Page 2 of 5 |
| NAME: LEISHMANIASIS | | INACTIVE: NO |

| | |
|----------------------|-----------------------|
| Selected Etiology | Selected Snomed Codes |
| <Enter> | |

| | | |
|------------------------------|----------|-----------------|
| Antimicrobial Susceptibility | NLT Code | NLT Description |
| <Enter> | | |

| | | | |
|------|------|-----------|---------|
| Exit | Save | Next Page | Refresh |
|------|------|-----------|---------|

COMMAND: **N<Enter>** Press <PF1>H for help Insert

| | | |
|--|--|--------------|
| LABORATORY EPI PARAMETERS INPUT SCREEN | | Page 3 of 5 |
| NAME: LEISHMANIASIS | | INACTIVE: NO |

Topography Selection

| | | |
|----------------------|--|----------------------|
| Include | | Exclude |
| <Enter> | | <Enter> |

| | | | |
|------|------|-----------|---------|
| Exit | Save | Next Page | Refresh |
|------|------|-----------|---------|

COMMAND: **N<Enter>** Press <PF1>H for help Insert

| | | |
|--|------------------------------|-----------------------|
| LABORATORY EPI PARAMETERS INPUT SCREEN | | Page 4 of 5 |
| NAME: LEISHMANIASIS | | INACTIVE: NO |
| <hr/> | | |
| First Encounter: <Enter> | FOLLOW PTF: YES<Enter> | |
| BEFORE DATE OF BIRTH: <Enter> | AFTER DATE OF BIRTH: <Enter> | |
| Select SEX: RET> | | |
| <hr/> | | |
| Exit | Save | Refresh |
| COMMAND: E<Enter> | | Press <PF1>H for help |

| | | |
|--|------------------------|--------------|
| LABORATORY EPI PARAMETERS INPUT SCREEN | | Page 5 of 5 |
| NAME: E. LEISHMANIASIS | | INACTIVE: NO |
| <hr/> | | |
| Run Date: <Enter> | Protocol: LREPI<Enter> | |
| Run Cycle: MONTHLY<Enter> | Lag Days: 15<Enter> | |
| Previous Cycle: <TAB> | | |
| General Description: <TAB> | | |
| <hr/> | | |
| Exit | Save | Refresh |
| COMMAND: E<Enter> | Press <PF1>H for help | Insert |
| Save changes before leaving form (Y/N)? Y<Enter> | | |

Malaria (Reference #11)

The plasmodial parasite is responsible for the blood-borne disease of *malaria*. *Malaria* can cause acute as well as chronic, relapsing disease. Occasionally, U.S. troops are deployed in malaria endemic areas. This placement could potentially put troops at risk for acquiring this disease. For the Emerging Pathogens Initiative program, we are interested in tracking patients with malaria, acute or chronic, relapsing, and in either inpatient or outpatient status. No standardized serologic test allows for easy identification. Since not all sites consistently code and record malarial parasites seen histologically or on blood smears (not all of these interpretations are done through the Pathology and Laboratory Service), we have currently decided to track malaria based on ICD coding.

Example: Lab EPI Parameter Setup for Malaria

```

                                Lab EPI Primary Menu

ENH      Lab EPI Manual Run (Enhanced)
VR       Print Detailed Verification Report
LO       Local Pathogen Menu ...
PI       Pathogen Inquiry
UP       Lab EPI Parameter Setup
         Lab EPI Protocol Edit
LK       Antimicrobial Link Update

Select Lab EPI Primary menu Option: UP<Enter> Lab EPI Parameter Setup

Select LAB EPI NAME: ?<Enter>
  Answer with LAB EPI NAME, or REFERENCE NUMBER
  Do you want the entire 23-Entry LAB EPI List? Y (Yes)<Enter>
  Choose from:

    ALL ENTEROCOCCI
    ALL STAPHYLOCOCCUS AUREUS
    ALL STREPTOCOCCUS PNEUMONIAE
    CANDIDA
    CLOSTRIDIUM DIFFICILE
    CREUTZFELDT-JAKOB DISEASE
    CRYPTOSPORIDIUM
    DENGUE
    E. COLI 0157:H7
    HEPATITIS A ANTIBODY POS
    HEPATITIS B POS
    HEPATITIS C ANTIBODY NEG
    HEPATITIS C ANTIBODY POS
    LEGIONELLA
    LEISHMANIASIS
    MALARIA
    METH-RES STAPH AUREUS
    PEN-RES PNEUMOCOCCUS
    STREPTOCOCCUS GROUP A
    TUBERCULOSIS
    VANC-RES COAG NEG STAPH
    VANC-RES ENTEROCOCCUS
    VANC-RES STAPH AUREUS (VRSA)
  
```

Select LAB EPI NAME: **MALARIA** <Enter>

| LABORATORY EPI PARAMETERS INPUT SCREEN | | Page 1 of 5 |
|---|--------------------|---------------------------------|
| NAME: MALARIA | | INACTIVE: NO |
| <div style="display: flex; justify-content: space-between;"> Laboratory Test(s) Indicator Value </div> | | |
| <div style="display: flex; justify-content: space-between;"> <Enter> </div> | | |
| ICD Coding System [ICD-9 or ICD-10]? (9/10):<RET> | | |
| ICD Code | Cd Set | ICD Description084.0 |
| ICD-9 | FALCIPARUM MALARIA | |
| 084.1 | ICD-9 | VIVAX MALARIA |
| 084.2 | ICD-9 | QUARTAN MALARIA |
| 084.3 | ICD-9 | OVALE MALARIA |
| 084.4 | ICD-9 | MALARIA NEC |
| 084.5 | ICD-9 | MIXED MALARIA |
| 084.6 | ICD-9 | MALARIA NOS |
| 084.7 | ICD-9 | INDUCED MALARIA |
| 084.8 | ICD-9 | BLACKWATER FEVER |
| 084.9 | ICD-9 | MALARIA COMPLICATED NEC |
| <Enter> | | |
| <div style="display: flex; justify-content: space-between;"> Exit Save Next Page Refresh </div> | | |
| COMMAND: N<Enter> | | Press <PF1>H for help Insert |

| LABORATORY EPI PARAMETERS INPUT SCREEN | | Page 2 of 5 |
|---|----------|---------------------------------|
| NAME: MALARIA | | INACTIVE: NO |
| <div style="display: flex; justify-content: space-between;"> Selected Etiology Selected Snomed Codes </div> | | |
| <Enter> | | |
| Antimicrobial Susceptibility | NLT Code | NLT Description |
| <Enter> | | |
| <div style="display: flex; justify-content: space-between;"> Exit Save Next Page Refresh </div> | | |
| COMMAND: N<Enter> | | Press <PF1>H for help Insert |

| LABORATORY EPI PARAMETERS INPUT SCREEN | | Page 3 of 5 |
|---|---------|--------------|
| NAME: MALARIA | | INACTIVE: NO |
| Topography Selection | | |
| Include | Exclude | |
| <Enter> | <Enter> | |
| <div style="display: flex; justify-content: space-between;"> Exit Save Next Page Refresh </div> | | |

COMMAND: **N<Enter>**

Press <PF1>H for help Insert

| | | |
|--|------------------------------|-----------------------|
| LABORATORY EPI PARAMETERS INPUT SCREEN | | Page 4 of 5 |
| NAME: MALARIA | | INACTIVE: NO |
| <hr/> | | |
| First Encounter: <Enter> | FOLLOW PTF: YES<Enter> | |
| BEFORE DATE OF BIRTH: <Enter> | AFTER DATE OF BIRTH: <Enter> | |
| Selected SEX: <Enter> | | |
| Exit | Save | Refresh |
| COMMAND: E<Enter> | | Press <PF1>H for help |

| | | |
|--|------------------------|-----------------------|
| LABORATORY EPI PARAMETERS INPUT SCREEN | | Page 5 of 5 |
| NAME: MALARIA | | INACTIVE: NO |
| <hr/> | | |
| Run Date: <Enter> | Protocol: LREPI<Enter> | |
| Run Cycle: MONTHLY<Enter> | Lag Days: 15<Enter> | |
| Previous Cycle: <TAB> | | |
| General Description: <TAB> | | |
| <hr/> | | |
| Exit | Save | Refresh |
| COMMAND: E<Enter> | | Press <PF1>H for help |
| Save changes before leaving form (Y/N)? Y<Enter> | | |

Methicillin-Resistant *Staphylococcus aureus* (MRSA) (Reference #19)

Methicillin (or oxacillin)-resistant *Staphylococcus aureus* (MRSA) is a pathogen of continuing importance for healthcare facilities. It is also an emerging pathogen from community-acquired sources. It is an organism that can be transmitted easily within facilities and in the community. It can produce a spectrum of illness from asymptomatic colonization to severe, life-threatening disease in those patients who acquire it. Whether this organism is causing disease or not, it can contribute to spread within a healthcare facility. The purpose of this pathogen on the EPI list is to capture all cultures that have MRSA present (whether the patient has disease or is just colonized). This should capture all methicillin non-Susceptible isolates of *Staphylococcus aureus*.

NOTE: This includes all positive cultures for MRSA, both clinical cultures and those done as part of epidemiologic prevalence studies or surveys (such as nasal and rectal swabs) at your facility.

Any *Staphylococcus aureus* isolate that is resistant to methicillin (or oxacillin) should be captured for this. Laboratories may use different methods to capture these data. An appropriate National Committee on Clinical Laboratory Standards (NCCLS) testing schema used and captured in VistA should be adequate.

Example: Lab EPI Parameter Setup for METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (MRSA)

```

                                Lab EPI Primary Menu

ENH      Lab EPI Manual Run (Enhanced)
VR       Print Detailed Verification Report
LO       Local Pathogen Menu ...
PI       Pathogen Inquiry
UP       Lab EPI Parameter Setup
         Lab EPI Protocol Edit
LK       Antimicrobial Link Update

Select Lab EPI Primary menu Option: UP<Enter> Lab EPI Parameter Setup

Select LAB EPI NAME: ?<Enter>
  Answer with LAB EPI NAME, or REFERENCE NUMBER
  Do you want the entire 23-Entry LAB EPI List? Y (Yes) <Enter>
  Choose from:

    ALL ENTEROCOCCI
    ALL STAPHYLOCOCCUS AUREUS
    ALL STREPTOCOCCUS PNEUMONIAE
    CANDIDA
    CLOSTRIDIUM DIFFICILE
    CREUTZFELDT-JAKOB DISEASE
    CRYPTOSPORIDIUM
    DENGUE
    E. COLI 0157:H7
    HEPATITIS A ANTIBODY POS
    HEPATITIS B POS
    HEPATITIS C ANTIBODY NEG
    HEPATITIS C ANTIBODY POS
    LEGIONELLA
    LEISHMANIASIS
    MALARIA
    METH-RES STAPH AUREUS
    PEN-RES PNEUMOCOCCUS
    STREPTOCOCCUS GROUP A
    TUBERCULOSIS
    VANC-RES COAG NEG STAPH
    VANC-RES ENTEROCOCCUS
    VANC-RES STAPH AUREUS (VRSA)

Select LAB EPI NAME: METH-RES STAPH AUREUS <Enter>

```


| | | | | | | | | | | | | | | | | | |
|---|-----------|-----------------------------------|--------------------|-----------|-------|----------------------|--|--|---|--|--|----------|--------|-----------------|----------------------|--|--|
| LABORATORY EPI PARAMETERS INPUT SCREEN | | Page 1 of 5 | | | | | | | | | | | | | | | |
| NAME: METH-RES STAPH AUREUS | | INACTIVE: NO | | | | | | | | | | | | | | | |
| <table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 40%;">Laboratory Test(s)</td> <td style="width: 30%;">Indicator</td> <td style="width: 30%;">Value</td> </tr> <tr> <td colspan="3"><Enter></td> </tr> <tr> <td colspan="3">ICD Coding System [ICD-9 or ICD-10]? (9/10):<RET></td> </tr> <tr> <td>ICD Code</td> <td>Cd Set</td> <td>ICD Description</td> </tr> <tr> <td colspan="3"><Enter></td> </tr> </table> | | | Laboratory Test(s) | Indicator | Value | <Enter> | | | ICD Coding System [ICD-9 or ICD-10]? (9/10):<RET> | | | ICD Code | Cd Set | ICD Description | <Enter> | | |
| Laboratory Test(s) | Indicator | Value | | | | | | | | | | | | | | | |
| <Enter> | | | | | | | | | | | | | | | | | |
| ICD Coding System [ICD-9 or ICD-10]? (9/10):<RET> | | | | | | | | | | | | | | | | | |
| ICD Code | Cd Set | ICD Description | | | | | | | | | | | | | | | |
| <Enter> | | | | | | | | | | | | | | | | | |
| Exit Save Next Page Refresh | | | | | | | | | | | | | | | | | |
| Enter a command or '^' followed by a caption to jump to a specific field. | | | | | | | | | | | | | | | | | |
| COMMAND: N<Enter> | | Press <PF1>H for help Insert | | | | | | | | | | | | | | | |

| | | | | | | | | | | | | | | | | | |
|---|-----------------------|--|------------------------------|-----------------------|-----------------------|-------------------------------|------------|--|---|--|--|-----------|------------|-----------|-----------|------------|-----------|
| LABORATORY EPI PARAMETERS INPUT SCREEN | | Page 2 of 5 | | | | | | | | | | | | | | | |
| NAME: METH-RES STAPH AUREUS | | INACTIVE: NO | | | | | | | | | | | | | | | |
| <table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%;">Selected Etiology</td> <td style="width: 50%;">Selected Snomed Codes</td> </tr> <tr> <td>STAPHYLOCOCCUS AUREUS</td> <td></td> </tr> <tr> <td>STAPHYLOC+</td> <td></td> </tr> <tr> <td>OCCUS AUREUS (MRSA STAPHYLOCOCCUS AUREUS</td> <td></td> </tr> </table> <p>NOTE: In addition to Staphylococcus aureus as an etiology, some laboratories may specifically indicate MRSA as a separate etiology. If that is the case with your laboratory, please be sure to include that naming convention in the EPI parameter for "Selected Etiology" also.</p> <p>Note: You may enter a new etiology, if you wish STAPHYLOCOCCUS AUREUS (MRSA) <Enter></p> <p>Are you adding a new ETIOLOGY? No// Y<Enter></p> | | | Selected Etiology | Selected Snomed Codes | STAPHYLOCOCCUS AUREUS | | STAPHYLOC+ | | OCCUS AUREUS (MRSA STAPHYLOCOCCUS AUREUS | | | | | | | | |
| Selected Etiology | Selected Snomed Codes | | | | | | | | | | | | | | | | |
| STAPHYLOCOCCUS AUREUS | | | | | | | | | | | | | | | | | |
| STAPHYLOC+ | | | | | | | | | | | | | | | | | |
| OCCUS AUREUS (MRSA STAPHYLOCOCCUS AUREUS | | | | | | | | | | | | | | | | | |
| <table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 40%;">Antimicrobial Susceptibility</td> <td style="width: 20%;">NLT Code</td> <td style="width: 40%;">NLT Description</td> </tr> <tr> <td>OXACILLIN<Enter></td> <td></td> <td>NOTE: For this, place the antibiotic (oxacillin, methicillin, or nafcillin) that your lab utilizes to determine methicillin-resistance.</td> </tr> <tr> <td colspan="3">Are you adding a new ANTIMICROBIAL SUSCEPTIBILITY? No// Y<Enter></td> </tr> <tr> <td>OXACILLIN</td> <td>81844.0000</td> <td>Oxacillin</td> </tr> <tr> <td>NAFCILLIN</td> <td>81808.0000</td> <td>Nafcillin</td> </tr> </table> | | | Antimicrobial Susceptibility | NLT Code | NLT Description | OXACILLIN<Enter> | | NOTE: For this, place the antibiotic (oxacillin, methicillin, or nafcillin) that your lab utilizes to determine methicillin-resistance. | Are you adding a new ANTIMICROBIAL SUSCEPTIBILITY? No// Y<Enter> | | | OXACILLIN | 81844.0000 | Oxacillin | NAFCILLIN | 81808.0000 | Nafcillin |
| Antimicrobial Susceptibility | NLT Code | NLT Description | | | | | | | | | | | | | | | |
| OXACILLIN<Enter> | | NOTE: For this, place the antibiotic (oxacillin, methicillin, or nafcillin) that your lab utilizes to determine methicillin-resistance. | | | | | | | | | | | | | | | |
| Are you adding a new ANTIMICROBIAL SUSCEPTIBILITY? No// Y<Enter> | | | | | | | | | | | | | | | | | |
| OXACILLIN | 81844.0000 | Oxacillin | | | | | | | | | | | | | | | |
| NAFCILLIN | 81808.0000 | Nafcillin | | | | | | | | | | | | | | | |
| Exit Save Next Page Refresh | | | | | | | | | | | | | | | | | |
| Enter a command or '^' followed by a caption to jump to a specific field. | | | | | | | | | | | | | | | | | |
| COMMAND: N<Enter> | | Press <PF1>H for help Insert | | | | | | | | | | | | | | | |

| | |
|--|--------------|
| LABORATORY EPI PARAMETERS INPUT SCREEN | Page 3 of 5 |
| NAME: METH-RES STAPH AUREUS | INACTIVE: NO |

Topography Selection

| | |
|---------|---------|
| Include | Exclude |
| <Enter> | <Enter> |

Exit Save Next Page Refresh

Enter a command or '^' followed by a caption to jump to a specific field.

COMMAND: **N**<Enter> Press <PF1>H for help Insert

| | |
|--|--------------|
| LABORATORY EPI PARAMETERS INPUT SCREEN | Page 4 of 5 |
| NAME: METH-RES STAPH AUREUS | INACTIVE: NO |

| | |
|-------------------------------|--------------------------------|
| FIRST ENCOUNTER: <Enter> | FOLLOW PTF: YES <Enter> |
| BEFORE DATE OF BIRTH: <Enter> | AFTER DATE OF BIRTH: <Enter> |

Select SEX: <Enter>

Exit Save Next Page Refresh

Enter a command or '^' followed by a caption to jump to a specific field.

COMMAND: **N**<Enter> Press <PF1>H for help Insert

| | |
|--|--------------|
| LABORATORY EPI PARAMETERS INPUT SCREEN | Page 5 of 5 |
| NAME: METH-RES STAPH AUREUS | INACTIVE: NO |

| | |
|-----------------------------------|------------------------|
| Run Date: <Enter> | Protocol: LREPI<Enter> |
| Run Cycle: MONTHLY <Enter> | Lag Days: 15<Enter> |

Previous Cycle: <TAB>

General Description: <TAB>

Exit Save Next Page Refresh

Enter a command or '^' followed by a caption to jump to a specific field.

COMMAND: **S**<Enter> Press <PF1>H for help Insert

Penicillin - Resistant Pneumococcus (Reference #3)

The emergence of antibiotic resistance in microbial agents is of great interest and concern for health care. Penicillin (PCN) was once the mainstay of therapy for *Streptococcus pneumoniae* infections but resistance to this agent is becoming more prominent. Different therapeutic strategies need to be developed once the prevalence of PCN-resistant *S. pneumoniae* reaches a critical threshold in a community. In order to monitor this, we are looking for the presence of any resistance in the pneumococci (either “moderate/intermediate” or “frank/high” level resistance). As such, any *S. pneumoniae*, which is not fully susceptible to PCN on PCN susceptibility testing, should be recorded.

Example: Lab EPI Parameter Setup for Penicillin - Resistant Pneumococcus

```

                                Lab EPI Primary Menu

ENH      Lab EPI Manual Run (Enhanced)
VR        Print Detailed Verification Report
LO        Local Pathogen Menu ...
PI        Pathogen Inquiry
UP        Lab EPI Parameter Setup
          Lab EPI Protocol Edit
LK        Antimicrobial Link Update

Select Lab EPI Primary menu Option: UP<Enter> Lab EPI Parameter Setup

Select LAB EPI NAME: ?<Enter>
  Answer with LAB EPI NAME, or REFERENCE NUMBER
  Do you want the entire 23-Entry LAB EPI List? Y (Yes) <Enter>
  Choose from:

    ALL ENTEROCOCCI
    ALL STAPHYLOCOCCUS AUREUS
    ALL STREPTOCOCCUS PNEUMONIAE
    CANDIDA
    CLOSTRIDIUM DIFFICILE
    CREUTZFELDT-JAKOB DISEASE
    CRYPTOSPORIDIUM
    DENGUE
    E. COLI 0157:H7
    HEPATITIS A ANTIBODY POS
    HEPATITIS B POS
    HEPATITIS C ANTIBODY NEG
    HEPATITIS C ANTIBODY POS
    LEGIONELLA
    LEISHMANIASIS
    MALARIA
    METH-RES STAPH AUREUS
    PEN-RES PNEUMOCOCCUS
    STREPTOCOCCUS GROUP A
    TUBERCULOSIS
    VANC-RES COAG NEG STAPH
    VANC-RES ENTEROCOCCUS
    VANC-RES STAPH AUREUS (VRSA)

Select LAB EPI NAME: PEN-RES PNEUMOCOCCUS<Enter>

```

| | | |
|---|-----------|---------------------------------|
| LABORATORY EPI PARAMETERS INPUT SCREEN | | Page 1 of 5 |
| NAME: PEN-RES PNEUMOCOCCUS | | INACTIVE: NO |
| <hr/> | | |
| Laboratory Test(s) | Indicator | Value |
| <Enter> | | |
| ICD Coding System [ICD-9 or ICD-10]? (9/10):<RET> | | |
| ICD Code | Cd Set | ICD Description |
| <Enter> | | |
| <hr/> | | |
| Exit | Save | Next Page |
| Refresh | | |
| COMMAND: <Enter> | | Press <PF1>H for help Insert |

| | | |
|--|-----------------------|---------------------------------|
| LABORATORY EPI PARAMETERS INPUT SCREEN | | Page 2 of 5 |
| NAME: PEN-RES PNEUMOCOCCUS | | INACTIVE: NO |
| <hr/> | | |
| Selected Etiology | Selected Snomed Codes | |
| NOTE: You may enter a new ETIOLOGY, if you wish. | | |
| STREPTOCOCCUS PNEUMONIAE 12 | | |
| Are you adding 'STREPTOCOCCUS PNEUMONIAE' as | | |
| a new ETIOLOGY (the 1ST for this EMERGING PATHOGENS)? Y<Enter> | | |
| Antimicrobial Susceptibility | NLT Code | NLT Description |
| Penicillin <Enter> | | |
| Are you adding ' Penicillin ' as a new Antimicrobial Susceptibility (the 1ST | | |
| for this EMERGING PATHOGENS)? Y <Enter> | | |
| <hr/> | | |
| Exit | Save | Next Page |
| Refresh | | |
| COMMAND: <Enter> | | Press <PF1>H for help Insert |

| | | |
|--|----------------------|---------------------------------|
| LABORATORY EPI PARAMETERS INPUT SCREEN | | Page 3 of 5 |
| NAME: PEN-RES PNEUMOCOCCUS | | INACTIVE: NO |
| <hr/> | | |
| Topography Selection | | |
| Include | Exclude | |
| <Enter> | <Enter> | |
| <hr/> | | |
| Exit | Save | Next Page |
| Refresh | | |
| COMMAND: N<Enter> | | Press <PF1>H for help Insert |

| | | |
|--|------------------------------|-----------------------|
| LABORATORY EPI PARAMETERS INPUT SCREEN | | Page 4 of 5 |
| NAME: PEN-RES PNEUMOCOCCUS | | INACTIVE: NO |
| <hr/> | | |
| First Encounter: <Enter> | FOLLOW PTF: YES<Enter> | |
| BEFORE DATE OF BIRTH: <Enter> | AFTER DATE OF BIRTH: <Enter> | |
| Selected SEX: <Enter> | | |
| Exit | Save | Refresh |
| COMMAND: E<Enter> | | Press <PF1>H for help |

| | | |
|---|------------------------|-----------------------------------|
| LABORATORY EPI PARAMETERS INPUT SCREEN | | Page 5 of 5 |
| NAME: PEN-RES PNEUMOCOCCUS | | INACTIVE: NO |
| <hr/> | | |
| Run Date: <Enter> | Protocol: LREPI<Enter> | |
| Run Cycle: MONTHLY<Enter> | Lag Days: 15<Enter> | |
| Previous Cycle: <TAB> | | |
| General Description: <TAB> | | |
| <hr/> | | |
| Exit | Save | Refresh |
| COMMAND: E<Enter> | | Press <PF1>H for help Insert |
| Save changes before leaving form (Y/N)? Y <Enter> | | |

Streptococcus-Group A (Reference #6)

Streptococcus-Group A can be associated with or cause significant disease such as severe fasciitis and streptococcal toxic shock syndrome. We are especially interested to find out how much severe/deep seated disease the VA is experiencing, but other disease entities are of interest also. To this end, we are looking for all episodes of culture positivity for *Streptococcus*-Group A, regardless of site and regardless of inpatient or outpatient status of the person from whom the specimen is obtained. We are aware that some sites may use rapid screenings for *Streptococcus*-Group A, especially from pharyngeal sources. These rapid screens may be difficult to capture, so we are not asking for them on this first iteration of the EPI program. However, if you do capture them in a retrievable format they should be included (see Helpful Hints for *Clostridium difficile* in Appendix B for suggestions on how capture may be possible).

Example: Lab EPI Parameter Setup for Streptococcus-Group A

| Lab EPI Primary Menu | |
|--|------------------------------------|
| ENH | Lab EPI Manual Run (Enhanced) |
| VR | Print Detailed Verification Report |
| LO | Local Pathogen Menu ... |
| PI | Pathogen Inquiry |
| UP | Lab EPI Parameter Setup |
| | Lab EPI Protocol Edit |
| LK | Antimicrobial Link Update |
| Select Lab EPI Primary menu Option: UP<Enter> Lab EPI Parameter Setup | |
| Select LAB EPI NAME: ?<Enter> | |
| Answer with LAB EPI NAME, or REFERENCE NUMBER | |
| Do you want the entire 23-Entry LAB EPI List? Y (Yes) <Enter> | |
| Choose from: | |
| ALL ENTEROCOCCI | |
| ALL STAPHYLOCOCCUS AUREUS | |
| ALL STREPTOCOCCUS PNEUMONIAE | |
| CANDIDA | |
| CLOSTRIDIUM DIFFICILE | |
| CREUTZFELDT-JAKOB DISEASE | |
| CRYPTOSPORIDIUM | |
| DENGUE | |
| E. COLI 0157:H7 | |
| HEPATITIS A ANTIBODY POS | |
| HEPATITIS B POS | |
| HEPATITIS C ANTIBODY NEG | |
| HEPATITIS C ANTIBODY POS | |
| LEGIONELLA | |
| LEISHMANIASIS | |
| MALARIA | |
| METH-RES STAPH AUREUS | |
| PEN-RES PNEUMOCOCCUS | |
| STREPTOCOCCUS GROUP A | |
| TUBERCULOSIS | |
| VANC-RES COAG NEG STAPH | |
| VANC-RES ENTEROCOCCUS | |
| VANC-RES STAPH AUREUS (VRSA) | |

Select LAB EPI NAME: **STREPTOCOCCUS-GROUP A** <Enter>

| | | |
|---|-----------|---------------------------------|
| LABORATORY EPI PARAMETERS INPUT SCREEN | | Page 1 of 5 |
| NAME: STREPTOCOCCUS-GROUP A | | INACTIVE: NO |
| <hr/> | | |
| Laboratory Test(s) <Enter> | Indicator | Value |
| ICD Coding System [ICD-9 or ICD-10]? (9/10):<RET> | | |
| ICD Code <Enter> | Cd Set | ICD Description |
| <hr/> | | |
| Exit | Save | Next Page |
| Refresh | | |
| COMMAND: N<Enter> | | Press <PF1>H for help Insert |

| | | |
|---|-----------------------|---------------------------------|
| LABORATORY EPI PARAMETERS INPUT SCREEN | | Page 2 of 5 |
| NAME: STREPTOCOCCUS-GROUP A | | INACTIVE: NO |
| <hr/> | | |
| Selected Etiology STREPTOCOCCUS-GROUP A <Enter> | Selected Snomed Codes | |
| Antimicrobial Susceptibility <Enter> | NLT Code | NLT Description |
| <hr/> | | |
| Exit | Save | Next Page |
| Refresh | | |
| COMMAND: N<Enter> | | Press <PF1>H for help Insert |

| | | |
|--|---------------------------------|---------------------------------|
| LABORATORY EPI PARAMETERS INPUT SCREEN | | Page 3 of 5 |
| NAME: STREPTOCOCCUS-GROUP A | | INACTIVE: NO |
| <hr/> | | |
| Topography Selection | | |
| Include <Enter> | Exclude <Enter> | |
| <hr/> | | |
| Exit | Save | Next Page |
| Refresh | | |
| COMMAND: N<Enter> | | Press <PF1>H for help Insert |

| | |
|--|------------------------------|
| LABORATORY EPI PARAMETERS INPUT SCREEN | Page 4 of 5 |
| NAME: STREPTOCOCCUS-GROUP A | INACTIVE: NO |
| <hr/> | |
| First Encounter: <Enter> | FOLLOW PTF: YES<Enter> |
| BEFORE DATE OF BIRTH: <Enter> | AFTER DATE OF BIRTH: <Enter> |
| Select SEX: <Enter> | |
| <hr/> | |
| Exit Save Refresh | |
| COMMAND: E<Enter> | Press <PF1>H for help |

| | |
|---|-----------------------------------|
| LABORATORY EPI PARAMETERS INPUT SCREEN | Page 5 of 5 |
| NAME: STREPTOCOCCUS-GROUP A | INACTIVE: NO |
| <hr/> | |
| Run Date:<Enter> | Protocol: LREPI<Enter> |
| Run Cycle: MONTHLY<Enter> | Lag Days: 15<Enter> |
| Previous Cycle: <TAB> | |
| General Description: <TAB> | |
| <hr/> | |
| Exit Save Refresh | |
| COMMAND: E<Enter> | Press <PF1>H for help Insert |
| Save changes before leaving form (Y/N)? Y <Enter> | |

Tuberculosis (TB) (Reference #5)

Mycobacterium tuberculosis infection is an important public health concern. Recent increases in incidence of disease, and occurrence of multiply-drug resistant strains in outbreak situations along with the increased susceptibility of HIV-infected persons for this disease has generated renewed interest in this entity. Since the national data show that 80-85% of all reported active tuberculosis cases are culture positive (with acid fast bacilli smear-only positive cases increasing the reporting by 2-5% more) we have decided to use culture positivity for *Mycobacterium tuberculosis* to track tuberculosis infections in the current iteration of the EPI software application. Information regarding susceptibility will be tracked as well.

For the national EPI program, there will be no need to enter specific antimycobacterial agents to be tracked; it will be done automatically. ICD coding is complex and confusing for many cases of tuberculosis and therefore will **not** be used.

NOTE: The **new** PREVIOUS CYCLE field displayed on screen Page 1 of 5 is automatically defined as '1' for TB ONLY and CAN NOT be EDIT.

Example: Lab EPI Parameter Setup for Tuberculosis (TB)

```

                                Lab EPI Primary Menu

ENH      Lab EPI Manual Run (Enhanced)
VR       Print Detailed Verification Report
LO       Local Pathogen Menu ...
PI       Pathogen Inquiry
UP       Lab EPI Parameter Setup
         Lab EPI Protocol Edit
LK       Antimicrobial Link Update

Select Lab EPI Primary menu Option: UP<Enter> Lab EPI Parameter Setup

Select LAB EPI NAME: ?<Enter>
  Answer with LAB EPI NAME, or REFERENCE NUMBER
  Do you want the entire 23-Entry LAB EPI List? Y (Yes)<Enter>
  Choose from:

    ALL ENTEROCOCCI
    ALL STAPHYLOCOCCUS AUREUS
    ALL STREPTOCOCCUS PNEUMONIAE
    CANDIDA
    CLOSTRIDIUM DIFFICILE
    CREUTZFELDT-JAKOB DISEASE
    CRYPTOSPORIDIUM
    DENGUE
    E. COLI 0157:H7
    HEPATITIS A ANTIBODY POS
    HEPATITIS B POS
    HEPATITIS C ANTIBODY NEG
    HEPATITIS C ANTIBODY POS
    LEGIONELLA
    LEISHMANIASIS
    MALARIA
    METH-RES STAPH AUREUS
    PEN-RES PNEUMOCOCCUS
    STREPTOCOCCUS GROUP A
    TUBERCULOSIS
    VANC-RES COAG NEG STAPH
    VANC-RES ENTEROCOCCUS
    VANC-RES STAPH AUREUS (VRSA)

Select LAB EPI NAME: TUBERCULOSIS <Enter>

```

| | | |
|---|-----------|-----------------------------------|
| LABORATORY EPI PARAMETERS INPUT SCREEN | | Page 1 of 5 |
| NAME: TUBERCULOSIS | | INACTIVE: NO |
| <hr/> | | |
| Laboratory Test(s) | Indicator | Value |
| <Enter> | | |
| ICD Coding System [ICD-9 or ICD-10]? (9/10):<RET> | | |
| ICD Code | Cd Set | ICD Description |
| <Enter> | | |
| <hr/> | | |
| Exit | Save | Next Page Refresh |
| COMMAND: N <Enter> | | Press <PF1>H for help Insert |

| | | |
|---|-----------------------|-----------------------------------|
| LABORATORY EPI PARAMETERS INPUT SCREEN | | Page 2 of 5 |
| NAME:TUBERCULOSIS | | INACTIVE: NO |
| <hr/> | | |
| Selected Etiology | Selected Snomed Codes | |
| Mycobacterium tuberculosis <Enter> | | |
| Antimicrobial Susceptibility | NLT Code | NLT Description |
| <Enter> | | |
| <hr/> | | |
| Exit | Save | Next Page Refresh |
| COMMAND: N <Enter> | | Press <PF1>H for help Insert |

| | | |
|--|----------------------|-----------------------------------|
| LABORATORY EPI PARAMETERS INPUT SCREEN | | Page 3 of 5 |
| NAME: TUBERCULOSIS | | INACTIVE: NO |
| <hr/> | | |
| Topography Selection | | |
| Include | Exclude | |
| <Enter> | <Enter> | |
| <hr/> | | |
| Exit | Save | Next Page Refresh |
| COMMAND: N <Enter> | | Press <PF1>H for help Insert |

| | | |
|--|-----------------------------|-----------------------|
| LABORATORY EPI PARAMETERS INPUT SCREEN | | Page 4 of 5 |
| NAME: TUBERCULOSIS | | INACTIVE: NO |
| <hr/> | | |
| First Encounter:<Enter> | FOLLOW PTF:YES<Enter> | |
| BEFORE DATE OF BIRTH:<Enter> | AFTER DATE OF BIRTH:<Enter> | |
| Select SEX:<Enter> | | |
| <hr/> | | |
| Exit | Save | Refresh |
| COMMAND: E<Enter> | | Press <PF1>H for help |

| | | |
|---|------------------------|---------------------------------|
| LABORATORY EPI PARAMETERS INPUT SCREEN | | Page 5 of 5 |
| NAME: TUBERCULOSIS | | INACTIVE: NO |
| <hr/> | | |
| Run Date: <Enter> | Protocol: LREPI<Enter> | |
| Run Cycle: MONTHLY<Enter> | Lag Days: 15 <Enter> | |
| Previous Cycle: 1<TAB> | | |
| General Description: <TAB> | | |
| <hr/> | | |
| Exit | Save | Refresh |
| COMMAND: E<Enter> | | Press <PF1>H for help Insert |
| Save changes before leaving form (Y/N)? Y <Enter> | | |

Vancomycin-Resistant Coagulase Negative Staphylococci/Staph epi (VRSE) (Reference #21)

Staphylococci are significant contributors to disease in humans. *Staphylococcus aureus* is the most virulent of the staphylococci, but the non-*aureus* staphylococci can also cause disease. As a general group, these non-*aureus* staphylococci are referred to as coagulase negative staphylococci; some refer to this group of organisms as *Staphylococcus epidermidis* because the staphylococcal species *S. epidermidis* is one of the more common members of this group to cause disease. However, to be accurate, the group of organisms called coagulase negative staphylococci includes many different species, even if the generic terminology of *Staphylococcus epidermidis* (a.k.a. *Staph epi*) has been applied.

The coagulase negative staphylococci are important emerging pathogens in that they contribute to many infections acquired while in a healthcare facility. As a general rule, the coagulase negative staphylococci have lesser virulence than *Staphylococcus aureus*, but they can still cause serious, life-threatening disease in certain settings. As with other organisms, antibiotic resistance is occurring among the coagulase negative staphylococci. There is concern in particular for resistance to vancomycin among this group of organisms, as it is currently the only antibiotic that has consistently shown activity against infections caused by this group of organisms; however, decreased susceptibility and even resistance to vancomycin has been identified in rare cases.

The purpose of this EPI pathogen entry is to capture all isolates from all specimens that contain a coagulase negative staphylococcus that is not Susceptible to vancomycin (whether your facility calls it coagulase negative staphylococcus, *Staphylococcus epidermidis*, *Staphylococcus saprophyticus* or the myriad of other staphylococcal species that comprise this group).

Example: Lab EPI Parameter Setup for Vancomycin-Resistant Coagulase Negative Staphylococci/Staph epi (VRSE) (Reference #21)

```

                                Lab EPI Primary Menu

ENH      Lab EPI Manual Run (Enhanced)
VR        Print Detailed Verification Report
LO        Local Pathogen Menu ...
PI        Pathogen Inquiry
UP        Lab EPI Parameter Setup
          Lab EPI Protocol Edit
LK        Antimicrobial Link Update

Select Lab EPI Primary menu Option: UP<Enter> Lab EPI Parameter Setup

Select LAB EPI NAME: ?<Enter>
  Answer with LAB EPI NAME, or REFERENCE NUMBER
  Do you want the entire 23-Entry LAB EPI List? Y (Yes) <Enter>
  Choose from:

    ALL ENTEROCOCCI
    ALL STAPHYLOCOCCUS AUREUS
    ALL STREPTOCOCCUS PNEUMONIAE
    CANDIDA
    CLOSTRIDIUM DIFFICILE
    CREUTZFELDT-JAKOB DISEASE
    CRYPTOSPORIDIUM
    DENGUE
    E. COLI 0157:H7
    HEPATITIS A ANTIBODY POS
    HEPATITIS B POS
    HEPATITIS C ANTIBODY NEG
    HEPATITIS C ANTIBODY POS
    LEGIONELLA
    LEISHMANIASIS
    MALARIA
    METH-RES STAPH AUREUS
    PEN-RES PNEUMOCOCCUS
    STREPTOCOCCUS GROUP A
    TUBERCULOSIS
    VANC-RES COAG NEG STAPH
    VANC-RES ENTEROCOCCUS
    VANC-RES STAPH AUREUS (VRSA)

Select LAB EPI NAME: VANC-RES COAG NEG STAPH <Enter>

```

| | | |
|--|--|--------------|
| LABORATORY EPI PARAMETERS INPUT SCREEN | | Page 1 of 5 |
| NAME: VANC-RES COAG NEG STAPH | | INACTIVE: NO |

| | | |
|----------------------|-----------|-------|
| Laboratory Test(s) | Indicator | Value |
| <Enter> | | |

ICD Coding System [ICD-9 or ICD-10]? (9/10):<RET>

| | | |
|----------------------|--------|-----------------|
| ICD Code | Cd Set | ICD Description |
| <Enter> | | |

| | | | |
|------|------|-----------|---------|
| Exit | Save | Next Page | Refresh |
|------|------|-----------|---------|

Enter a command or '^' followed by a caption to jump to a specific field.

COMMAND: **N<Enter>** Press <PF1>H for help Insert

| | | |
|--|--|--------------|
| LABORATORY EPI PARAMETERS INPUT SCREEN | | Page 2 of 5 |
| NAME: VANC-RES COAG NEG STAPH | | INACTIVE: NO |

| | |
|-------------------|-----------------------|
| Selected Etiology | Selected Snomed Codes |
|-------------------|-----------------------|

STAPHYLOCOCCUS (COAGULASE NEGATIVE)
STAPHYLOCOCCUS (COAGULASE NEGATIVE)
STAPHYLOCOCCUS EPIDERMIDIS
STAPHYLOCOCCUS HAEMOLYTICUS
STAPHYLOCOCCUS SAPROPHYTICUS
STAPHYLOCOCCUS SALIVARIUS
STAPHYLOCOCCUS SIMULANS
STAPHYLOCOCCUS SP

Note: These are just samples. There are many other named species of coagulase negative staphylococci. Do not include the Staphylococcus aureus, etc.)
Note: You may enter a new etiology, is you wish
STAPHYLOCOCCUS SP**<Enter>**

Are you adding a new ETIOLOGY? No// **Y<Enter>**

| | | |
|------------------------------|----------|-----------------|
| Antimicrobial Susceptibility | NLT Code | NLT Description |
|------------------------------|----------|-----------------|

VANCOMYCIN**<Enter>**

Are you adding a new ANTIMICROBIAL SUSCEPTIBILITY? No// **Y<Enter>**

| | | |
|---------|------------|------------|
| VANCMCN | 81485.0000 | Vancomycin |
|---------|------------|------------|

| | | | |
|------|------|-----------|---------|
| Exit | Save | Next Page | Refresh |
|------|------|-----------|---------|

Enter a command or '^' followed by a caption to jump to a specific field.

COMMAND: **N<Enter>** Press <PF1>H for help Insert

| | |
|--|--------------|
| LABORATORY EPI PARAMETERS INPUT SCREEN | Page 3 of 5 |
| NAME: VANC-RES COAG NEG STAPH | INACTIVE: NO |

Topography Selection

| | |
|---------------------------------|---------------------------------|
| Include <Enter> | Exclude <Enter> |
|---------------------------------|---------------------------------|

Exit Save Next Page Refresh

Enter a command or '^' followed by a caption to jump to a specific field.

COMMAND: **N<Enter>** Press <PF1>H for help Insert

| | |
|--|--------------|
| LABORATORY EPI PARAMETERS INPUT SCREEN | Page 4 of 5 |
| NAME: VANC-RES COAG NEG STAPH | INACTIVE: NO |

| | |
|--|---|
| FIRST ENCOUNTER: <Enter> | FOLLOW PTF: YES <Enter> |
| BEFORE DATE OF BIRTH: <Enter> | AFTER DATE OF BIRTH: <Enter> |

Select SEX: **<Enter>**

Exit Save Next Page Refresh

Enter a command or '^' followed by a caption to jump to a specific field.

COMMAND: **N<Enter>** Press <PF1>H for help Insert

| | |
|--|--------------|
| LABORATORY EPI PARAMETERS INPUT SCREEN | Page 5 of 5 |
| NAME: VANC-RES COAG NEG STAPH | INACTIVE: NO |

| | |
|--|--------------------------------------|
| Run Date: <Enter> | Protocol: LREPI <Enter> |
| Run Cycle: MONTHLY<Enter> | Lag Days: 15 <Enter> |

Previous Cycle: **<TAB>**

General Description: **<TAB>**

Exit Save Next Page Refresh

Enter a command or '^' followed by a caption to jump to a specific field.

Vancomycin-Resistant Enterococcus (VRE) (Reference #1)

Vancomycin-Resistant Enterococcus (VRE) is a pathogen of increasing importance. Not only can it cause significant disease, but also it can be spread within facilities. It is important to capture all positive cultures for VRE (not just disease). As such, all positive cultures for VRE will be reported.

In addition to *Enterococcus sp.* as an etiology, some laboratories may specifically indicate VRE as a separate etiology. If that is the case with your laboratory, please be sure to include that naming convention in your EPI parameter for “Selected Etiology” also.

NOTE: This includes cultures positive for prevalence and surveillance review, including specimens of stool and rectal swabs.

Vancomycin-resistant *Enterococcus faecalis* and *E. faecium* are most common, but we wish to look at all vancomycin resistant enterococci whether speciated or not. Therefore, it is important to be sure to list all the places in the Micro Lab package where *Enterococcus* are found, either as *Enterococcus*, *E. (sp.)*, Group D-*Streptococcus*, *E. faecalis*, *E. faecium*, *E. durans*, *E. gallinarum*, *E. casseliflavus*, etc.

NOTE: Only a partial pre-populated Etiology list is shown in the screen display example at the Selected Etiology prompt. Please be sure to review the entire Etiology list. If you have other etiology results at your site, they can be added to this Etiology list. Again, if alternate spellings are present in your site’s ETIOLOGY FIELD file (#61.2), be certain those spellings assure capture of all data points possible.

Example: Lab EPI Parameter Setup for Vancomycin-Resistant Enterococcus (VRE) (Reference #1)

```

                                Lab EPI Primary Menu

ENH      Lab EPI Manual Run (Enhanced)
VR        Print Detailed Verification Report
LO        Local Pathogen Menu ...
PI        Pathogen Inquiry
UP        Lab EPI Parameter Setup
          Lab EPI Protocol Edit
LK        Antimicrobial Link Update

Select Lab EPI Primary menu Option: UP<Enter> Lab EPI Parameter Setup

Select LAB EPI NAME: ?<Enter>
  Answer with LAB EPI NAME, or REFERENCE NUMBER
  Do you want the entire 23-Entry LAB EPI List? Y (Yes) <Enter>
  Choose from:

    ALL ENTEROCOCCI
    ALL STAPHYLOCOCCUS AUREUS
    ALL STREPTOCOCCUS PNEUMONIAE
    CANDIDA
    CLOSTRIDIUM DIFFICILE
    CREUTZFELDT-JAKOB DISEASE
    CRYPTOSPORIDIUM
    DENGUE
    E. COLI 0157:H7
    HEPATITIS A ANTIBODY POS
    HEPATITIS B POS
    HEPATITIS C ANTIBODY NEG
    HEPATITIS C ANTIBODY POS
    LEGIONELLA
    LEISHMANIASIS
    MALARIA
    METH-RES STAPH AUREUS
    PEN-RES PNEUMOCOCCUS
    STREPTOCOCCUS GROUP A
    TUBERCULOSIS
    VANC-RES COAG NEG STAPH
    VANC-RES ENTEROCOCCUS
    VANC-RES STAPH AUREUS (VRSA)

Select LAB EPI NAME: VANC-RES ENTEROCOCCUS <Enter>

```

| | | |
|--|--|--------------|
| LABORATORY EPI PARAMETERS INPUT SCREEN | | Page 1 of 5 |
| NAME: VANC-RES ENTEROCOCCUS | | INACTIVE: NO |

| | | |
|---|-----------|-----------------|
| Laboratory Test(s) | Indicator | Value |
| <Enter> | | |
| ICD Coding System [ICD-9 or ICD-10]? (9/10):<RET> | | |
| ICD Code | Cd Set | ICD Description |
| <Enter> | | |

| | | | |
|------|------|-----------|---------|
| Exit | Save | Next Page | Refresh |
|------|------|-----------|---------|

COMMAND: **N<Enter>** Press <PF1>H for help Insert

| | | |
|--|--|--------------|
| LABORATORY EPI PARAMETERS INPUT SCREEN | | Page 2 of 5 |
| NAME: VANC-RES ENTEROCOCCUS | | INACTIVE: NO |

| | |
|---|---------------------------|
| Selected Etiology | Selected Snomed Codes |
| Examples: Enterococcus | |
| Enterococcus (Strept. faecalis-Group D) | |
| Streptococcus faecalis | Enterococcus durans |
| Streptococcus faecium | Streptococcus sp. Group D |
| Enterococcus avium | |
| Enterococcus avium - (Group D) | |
| Enterococcus casseliflavus | |
| Enterococcus faecalis | |
| Enterococcus gallinarum | |
| Enterococcus malodoratus | Enterococcus |
| Enterococcus hirae | solitarius |
| Enterococcus mundtii | Enterococcus |
| Enterococcus raffinosus | pseudoavium |
| Enterococcus sp. | Enterococcus faecium |
| Enterococcus species | Enterococcus durans |
| Enterococcus (VRE) | |

<Enter>

Note: During the post Init, the ETIOLOGY FIELD file (#61.2) was searched to pre-populate the Etiology field (#3) in the EMERGING PATHOGENS file (#69.5). Listed above are examples of etiology entries which may have been populated from your site's file. Additional etiologies may be added or deleted at the Selected Etiology prompt to meet your site specific needs.

Note: If spelling differences occur within your ETIOLOGY FIELD file (#61.2) be consistent with your local file and spell the results here, as it is spelled in your file (even if it is spelled differently in the example). We are concerned more importantly with data recovery.

| | | |
|---------------------------------|----------|-----------------|
| Antimicrobial Susceptibility | NLT Code | NLT Description |
| VANCOMYCIN <Enter> | | |

| | | | |
|------|------|-----------|---------|
| Exit | Save | Next Page | Refresh |
|------|------|-----------|---------|

COMMAND: **N<Enter>**

Press <PF1>H for help

Insert

| | | |
|--|--------------------|-----------------------------------|
| LABORATORY EPI PARAMETERS INPUT SCREEN | | Page 3 of 5 |
| NAME: VANC-RES ENTEROCOCCUS | | INACTIVE: NO |
| <hr/> | | |
| Topography Selection | | |
| Include <Enter> | Exclude <Enter> | |
| <hr/> | | |
| Exit | Save | Next Page Refresh |
| COMMAND: N<Enter> | | Press <PF1>H for help Insert |

| | | |
|---|-----------------------------|-----------------------------------|
| LABORATORY EPI PARAMETERS INPUT SCREEN | | Page 4 of 5 |
| NAME: VANC-RES ENTEROCOCCUS | | INACTIVE: NO |
| <hr/> | | |
| First Encounter:<Enter> | FOLLOW PTF:YES<Enter> | |
| BEFORE DATE OF BIRTH:<Enter> | AFTER DATE OF BIRTH:<Enter> | |
| Select SEX:<Enter> | | |
| <hr/> | | |
| Exit | Save | Refresh |
| COMMAND: E<Enter> | | Press <PF1>H for help Insert |
| Save changes before leaving form (Y/N)?Y<Enter> | | |

| | | |
|---|------------------------|-----------------------------------|
| LABORATORY EPI PARAMETERS INPUT SCREEN | | Page 5 of 5 |
| NAME: VANC-RES ENTEROCOCCUS | | INACTIVE: NO |
| <hr/> | | |
| Run Date: <Enter> | Protocol: LREPI<Enter> | |
| Run Cycle: MONTHLY<Enter> | Lag Days: 15<Enter> | |
| Previous Cycle: <TAB> | | |
| General Description: <TAB> | | |
| <hr/> | | |
| Exit | Save | Refresh |
| COMMAND: E<Enter> | | Press <PF1>H for help Insert |
| Save changes before leaving form (Y/N)?Y<Enter> | | |

Vancomycin-Resistant Staphylococcus Aureus (VRSA) (Reference #20)

Vancomycin-resistant *Staphylococcus aureus* (VRSA) is a rare but emerging pathogen for healthcare facilities. It is of concern because the resistance to this antibiotic can be combined with resistance to other antibiotics; it is this multiple resistance that will make infection with this organism difficult to treat. Staphylococci can be transmitted easily within facilities; the easy transmission is of concern for this organism should it occur in a patient. The staphylococci can produce a spectrum of illness from asymptomatic colonization to severe, life-threatening disease in those patients who acquire them. Whether this organism is causing disease or not, it can contribute to spread within a healthcare facility. The purpose of this pathogen on the EPI list is to capture all cultures that have VRSA present (whether the patient has disease or is just colonized). This should capture all vancomycin non-Susceptible strains of *Staphylococcus aureus*, whether the susceptibility interpretation is Intermediate or Resistant.

NOTE: This includes all positive cultures for VRSA, both clinical cultures and those done as part of epidemiologic prevalence studies or surveys (such as nasal and rectal swabs) at your facility.

Any *Staphylococcus aureus* isolate that is resistant to vancomycin should be captured for this. Laboratories may use different methods to capture these data. An appropriate National Committee on Clinical Laboratory Standards (NCCLS) testing schema used and captured in VistA should be adequate.

Example: Lab EPI Parameter Setup for Vancomycin-Resistant *Staphylococcus aureus* (VRSA) (Reference #20)

Lab EPI Primary Menu

```

ENH      Lab EPI Manual Run (Enhanced)
VR       Print Detailed Verification Report
LO       Local Pathogen Menu ...
PI       Pathogen Inquiry
UP       Lab EPI Parameter Setup
         Lab EPI Protocol Edit
LK       Antimicrobial Link Update

```

Select Lab EPI Primary menu Option: **UP**<Enter> Lab EPI Parameter Setup

Select LAB EPI NAME: **?<Enter>**

Answer with LAB EPI NAME, or REFERENCE NUMBER

Do you want the entire 23-Entry LAB EPI List? **Y** (Yes) <Enter>

Choose from:

```

ALL ENTEROCOCCI
ALL STAPHYLOCOCCUS AUREUS
ALL STREPTOCOCCUS PNEUMONIAE
CANDIDA
CLOSTRIDIUM DIFFICILE
CREUTZFELDT-JAKOB DISEASE
CRYPTOSPORIDIUM
DENGUE
E. COLI 0157:H7
HEPATITIS A ANTIBODY POS
HEPATITIS B POS
HEPATITIS C ANTIBODY NEG
HEPATITIS C ANTIBODY POS
LEGIONELLA
LEISHMANIASIS
MALARIA
METH-RES STAPH AUREUS
PEN-RES PNEUMOCOCCUS
STREPTOCOCCUS GROUP A
TUBERCULOSIS
VANC-RES COAG NEG STAPH
VANC-RES ENTEROCOCCUS
VANC-RES STAPH AUREUS (VRSA)

```

Select LAB EPI NAME: **VANC-RES STAPH AUREUS (VRSA)**<Enter>

| | | |
|---|-----------|------------------------------|
| LABORATORY EPI PARAMETERS INPUT SCREEN | | Page 1 of 5 |
| NAME: VANC-RES STAPH AUREUS (VRSA) | | INACTIVE: NO |
| Laboratory Test(s) | Indicator | Value |
| <Enter> | | |
| ICD Coding System [ICD-9 or ICD-10]? (9/10):<RET> | | |
| ICD Code | Cd Set | ICD Description |
| <Enter> | | |
| Exit | Save | Next Page Refresh |
| Enter a command or '^' followed by a caption to jump to a specific field. | | |
| COMMAND: N<Enter> | | Press <PF1>H for help Insert |

| | | |
|--|--|-----------------------|
| LABORATORY EPI PARAMETERS INPUT SCREEN | | Page 2 of 5 |
| NAME: VANC-RES STAPH AUREUS (VRSA) | | INACTIVE: NO |
| Selected Etiology | | Selected Snomed Codes |

| | | |
|---|------------|------------------------------|
| STAPHYLOCOCCUS AUREUS | | |
| STAPHYLOCOCCUS AUREUS (MRSA) | | |
| STAPHYLOCOCCUS AUREUS (VRSA) | | |
| NOTE: In addition to Staphylococcus aureus as an etiology, some laboratories may specifically indicate VRSA as a separate etiology. If that is the case with your laboratory, please be sure to include that naming convention in your EPI parameter for "Selected Etiology" also. | | |
| Note: You may enter a new etiology, is you wish STAPHYLOCOCCUS AUREUS (VRSA)<Enter> | | |
| Are you adding a new ETIOLOGY? No// Y<Enter> | | |
| Antimicrobial Susceptibility | NLT Code | NLT Description |
| VANCOMYCIN<Enter> | | |
| Are you adding a new ANTIMICROBIAL SUSCEPTIBILITY? No// Y<Enter> | | |
| VANCMCN | 81485.0000 | Vancomycin |
| Exit | Save | Next Page Refresh |
| Enter a command or '^' followed by a caption to jump to a specific field. | | |
| COMMAND: N<Enter> | | Press <PF1>H for help Insert |

| | | |
|---|--------------------|-----------------------------------|
| LABORATORY EPI PARAMETERS INPUT SCREEN | | Page 3 of 5 |
| NAME: VANC-RES STAPH AUREUS | | INACTIVE: NO |
| <hr/> | | |
| Topography Selection | | |
| Include <Enter> | Exclude <Enter> | |
| <hr/> | | |
| Exit | Save | Next Page Refresh |
| Enter a command or '^' followed by a caption to jump to a specific field. | | |
| COMMAND: N<Enter> | | Press <PF1>H for help Insert |

| | | |
|---|------------------------------|-----------------------------------|
| LABORATORY EPI PARAMETERS INPUT SCREEN | | Page 4 of 5 |
| NAME: VANC-RES STAPH AUREUS | | INACTIVE: NO |
| <hr/> | | |
| FIRST ENCOUNTER: <Enter> | FOLLOW PTF: YES <Enter> | |
| BEFORE DATE OF BIRTH: <Enter> | AFTER DATE OF BIRTH: <Enter> | |
| Select SEX: <Enter> | | |
| <hr/> | | |
| Exit | Save | Next Page Refresh |
| Enter a command or '^' followed by a caption to jump to a specific field. | | |
| COMMAND: N<Enter> | | Press <PF1>H for help Insert |

| | | |
|---|------------------------|-----------------------------------|
| LABORATORY EPI PARAMETERS INPUT SCREEN | | Page 5 of 5 |
| NAME: VANC-RES STAPH AUREUS | | INACTIVE: NO |
| <hr/> | | |
| Run Date: <Enter> | Protocol: LREPI<Enter> | |
| Run Cycle: MONTHLY<Enter> | Lag Days: 15<Enter> | |
| Previous Cycle: <TAB> | | |
| General Description: <TAB> | | |
| <hr/> | | |
| Exit | Save | Next Page Refresh |
| Enter a command or '^' followed by a caption to jump to a specific field. | | |
| COMMAND: S<Enter> | | Press <PF1>H for help Insert |

Conclusion

Once you have finished entering the information as directed by the National Infectious Diseases Program Office, these fields should **not** be changed again except for the following conditions:

1. As requested nationally via the Veterans Affairs Central Office (VACO) Infectious Disease Program Office to update, modify, add, or delete data from the existing files used by the Laboratory EPI software or an addition of a new entity to be tracked.
2. The yearly review must ensure that the entry is acceptable and to update the EPI files with any changes in etiology, lab tests or results parameters that may have occurred locally at the site during the previous year.
3. If your laboratory alters its accessioning or results procedures for one or more other parameters for one of the national EPI pathogens. An update should occur to the EPI to reflect these changes as appropriate.

Annually the EPI national program materials should be reviewed by the VAMCs and updated. It is suggested that this review occur in February of each year. If no changes have occurred in lab practices, etiologies, sites, or results parameters leave the information as is until the next review period. If changes did occur, then enter them as appropriate in order to capture the data requested for each EPI national entity (disease/organism) to be tracked.

As entities (diseases/organisms) are no longer to be tracked nationally (“dropped from the list”), or a new entity is to be tracked (“added to the list”), revision will be forwarded to the sites to assist in updating your site files.

NOTE: Remember that if the parameter setup needs to be changed for any of the four hepatitis entities, that a concomitant change needs to be made in the corresponding Clinical Reminder logic.

APPENDIX - A

EDITING/PRINTING FILES, LINKING DATA, and EDITING INPUT SCREENS

Appendix – A

Editing/Printing Files, Linking Data, and Editing Input Screens

This section contains instructions and examples for editing/adding entries the TOPOGRAPHY file (#61), printing LAB SEARCH/EXTRACT file (#69.5) site definitions, linking the ANTIMICROBIAL SUSCEPTIBILITY file (#62.06) data entries to the WKLD CODE file (#64) data entries, and deleting entries from the Laboratory EPI Parameters Input Screen.

NOTE: To request additional LOINC, Workload, and Suffixes codes access the VistA Laboratory website, National Lab Tests (NLT) Documentation Set and LOINC Request Forms link:

<http://vista.med.va.gov/ClinicalSpecialties/lab/>

Editing/Printing Files, Screens, Linking Data, Request Form

Editing TOPOGRAPHY file (#61):

Specific HL7 codes **must** be added to the TOPOGRAPHY file (#61). The HL7 Code field (#08) in this file is used to add the entries. Specific HL7 codes that **must** be added to TOPOGRAPHY file (#61) is located in the HL7 section of this guide, Table 0070 (Specimen Source Codes). The following is an example of how to add the specific HL7 codes to the TOPOGRAPHY file (#61) using VA FileMan Version 21 - Enter or Edit File Entries option.

Example: How to ADD specific HL7 codes to TOPOGRAPHY file (#61)

```
Select OPTION:      ENTER OR EDIT FILE ENTRIES<Enter>

INPUT TO WHAT FILE: TOPOGRAPHY FIELD// <Enter>
EDIT WHICH FIELD:  ALL// .08 HL7 CODE <Enter>
THEN EDIT FIELD:   <Enter>

Select TOPOGRAPHY FIELD NAME: ? <Enter>
  Answer with TOPOGRAPHY FIELD NAME, or SNOMED CODE, or ABBREVIATION, or
  SYNONYM
  Do you want the entire 8575-Entry TOPOGRAPHY FIELD List? NO<Enter>
  You may enter a new TOPOGRAPHY FIELD, if you wish
  ANSWER MUST BE 2-80 CHARACTERS IN LENGTH
Select TOPOGRAPHY FIELD NAME:      AMNIOTIC FLUID          8Y300
HL7 CODE: ? <Enter>
  Answer must be 2-4 characters in length.

Enter the two to four character codes from the left column:

ABS      ABCs
AMN      Amniotic fluid
ASP      Aspirate
BPH      Basophils
ABLD     Blood arterial
BBL      Blood bag
BON      Bone
BRTH     Breath
BRO      Bronchial
BRN      Burn
```

Printing LAB SEARCH/EXTRACT file (#69.5) Definitions:

Use the following VA FileMan print option to print your local sites definitions from the LAB SEARCH/EXTRACT file (#69.5).

Examples: How to PRINT LAB SEARCH/EXTRACT file (#69.5) local sites definitions:

```
Select VA FileMan 22.0

Select OPTION: 2  PRINT FILE ENTRIES<Enter>

OUTPUT FROM WHAT FILE: REMINDER TERM// LAB SEARCH<Enter>
    1  LAB SEARCH/EXTRACT (19 entries)
    2  LAB SEARCH/EXTRACT PROTOCOL (2 entries)
CHOOSE 1-2: 1 <Enter> LAB SEARCH/EXTRACT (19 entries)
SORT BY: NAME//<Enter>
START WITH NAME: FIRST// HEPATITIS<Enter>
GO TO NAME: LAST// HEPATITIS Z<Enter>
    WITHIN NAME, SORT BY:
FIRST PRINT FIELD: ? <Enter>
    Answer with FIELD NUMBER, or LABEL
    Do you want the entire 21-Entry FIELD List? Y<Enter> (Yes)
Choose from:
    .01      NAME
    .05      REFERENCE NUMBER
    1        ACTIVE
    2        LAB TEST (multiple)
    3        ETIOLOGY (multiple)
    4        ICD DIAGNOSIS (multiple)
    5        ANTIMICROBIAL SUSCEPTIBILITY (multiple)
    6        INCLUDED SITES (multiple)
    7        EXCLUDED SITES (multiple)
    8        SNOMED CODES (multiple)
    9        RUN DATE
    10       CYCLE
    10.5     LAG DAYS
    11       FIRST ENCOUNTER
    12       PROTOCOL
    13       FOLLOW PTF
    14       PTF (multiple)
    15       Description (word-processing)
    16       SEX
    17       BEFORE DATE OF BIRTH
    18       AFTER DATE OF BIRTH
            ^
            TYPE '&' IN FRONT OF FIELD NAME TO GET TOTAL FOR THAT FIELD,
            '!' TO GET COUNT, '+' TO GET TOTAL & COUNT, '#' TO GET MAX & MIN, ']'
TO FORCE SAVING PRINT TEMPLATE
    TYPE '[TEMPLATE NAME]' IN BRACKETS TO USE AN EXISTING PRINT TEMPLATE
    YOU CAN FOLLOW FIELD NAME WITH ';' AND FORMAT SPECIFICATION(S)
FIRST PRINT FIELD: .01;C1;L30 NAME<Enter>
THEN PRINT FIELD: ACTIVE;C35;L5<Enter>
THEN PRINT FIELD: LAG DAYS;C45;L5<Enter>
```



```

THEN PRINT FIELD: LAB TEST      (multiple)<Enter>
  THEN PRINT LAB TEST SUB-FIELD: .01;C5;L30  LAB TEST<Enter>
  THEN PRINT LAB TEST SUB-FIELD: INDICATOR;C38;L15<Enter>
  THEN PRINT LAB TEST SUB-FIELD: INDICATED VALUE;C55;L23<Enter>
  THEN PRINT LAB TEST SUB-FIELD: <Enter>
THEN PRINT FIELD: <Enter>
Heading (S/C): LAB SEARCH/EXTRACT LIST  Replace L With site name_L
  Replace site name_LAB SEARCH/EXTRACT LIST
STORE PRINT LOGIC IN TEMPLATE:
START AT PAGE: 1//
DEVICE: ;;999999  WAN      Right Margin: 80//<Enter>

site name_LAB SEARCH/EXTRACT LIST      AUG 18,2000  12:21      PAGE 1
                                LAG
NAME      ACTIVE      DAYS
  LAB TEST      INDICATOR      INDICATED VALUE
-----
HEPATITIS A ANTIBODY POS      NO      15
  HEP A ANTIBODY-TOTAL      Equal To      Reactive
  HEP A ANTIBODY(IgM)
  HEP A ANTIBODY(IgM)      Contains      POS
  HEPATITIS A AB(IGG)D/C(2/99)      Contains      POS
  HEPATITIS A AB(IGG)D/C(2/99)      Contains      Pos
  HEPATITIS A AB(IGG)D/C(2/99)      Contains      p
  HEPATITIS A AB(IGG)D/C(2/99)      Equal To      Reactive
  HEPATITIS A AB(IGG)D/C(2/99)      Contains      p
  HEPATITIS A AB(IGG)D/C(2/99)      Equal To      Pos
HEPATITIS B POS      NO      15
  HEP B SURFACE Ag      Contains      POS
  HEP B SURFACE AB      Contains      POS
  HEP B CORE AB(IgM)      Contains      POS
  HEP Be ANTIGEN      Contains      POS
  HEP Be ANTIGEN      Contains      Pos
  HEP Be ANTIGEN      Contains      p
  HEP Be ANTIGEN      Contains      P
HEPATITIS C ANTIBODY NEG      NO      15
  HEP C ANTIBODY      Contains      NEG
  HEP C ANTIBODY      Contains      SEE COMMENT
HEPATITIS C ANTIBODY POS      NO      15
  HEP C ANTIBODY      Contains      POS

```

How to Link Antimicrobial Entries to Workload Codes Entries:

The Laboratory EPI software automatically links as many of the ANTIMICROBIAL SUSCEPTIBILITY file (#62.06) data entries to the WKLD CODE file (#64) data entries that are identified in your site files. However, the ANTIMICROBIAL SUSCEPTIBILITY file (#62.06) data entries that were **not** linked (i.e. no match found) to the WKLD CODE file (#64) will require linking. The Antimicrobial Link Update [LREPILK] option contains three functionalities that can be used to identify and link data entries that were **not** linked by the EPI software installation post-INIT process.

Examples: Antimicrobial Link Update [LREPILK] options

```
Select Lab EPI Primary Menu<Enter>
```

```
ENH    Lab Search/Extract Manual Run (Enhanced)
VR      Print Detailed Verification Report
LO      Local Pathogen Menu ...
PI      Pathogen Inquiry
UP      Lab EPI Parameter Setup
        Lab EPI Protocol Edit
LK      Antimicrobial Link Update
```

```
Select Lab EPI Primary Menu Option: LK<Enter>Antimicrobial Link Update
```

This option will allow you to link file '62.06 ANTIMICROBIAL SUSCEPTIBILITY' file with file '64 WKLD CODE'.

Select one of the following:

```
A      AUTO
M      MANUAL
S      SEMI-AUTO
```

AUTO function

The AUTO function identifies and attempts to link data entries that are **not** currently linked. This option also displays linked and non-linked data entries.

Example: AUTO function

```
Enter response: A<Enter>UTO
```

| | | |
|-------------|----------------------|----------------|
| AMIKACN | <----Linked----> | Amikacin |
| AMPICLN | <----Linked----> | Ampicillin |
| CLINDAM | <----Linked----> | Clindamycin |
| POLYMYXIN B | <----Not Linked----> | No Match Found |
| RIFAMPIN | <----Linked----> | Rifampin |

MANUAL function

The MANUAL function is use to add or delete linked entries. **Note:** Examples are from entries in the ANTIMICROBIAL SUSCEPTIBILITY file (#62.06).

Example: Deleting an Entry

```
Enter response: MANUAL<Enter>
Select ANTIMICROBIAL SUSCEPTIBILITY NAME: PENICLIN<Enter>      PENICILLIN
NATIONAL VA LAB CODE: Substance P// PEN<Enter>
  1  PENFIELD AND CONE STAIN                88010.0000
  2  PENICILLIN Penicillin                   81852.0000
  3  PENTAZOCINE Pentazocine                 81854.0000
  4  PENTOBARBITAL Pentobarbital             81856.0000
CHOOSE 1-4: 2 Penicillin<Enter>
Select ANTIMICROBIAL SUSCEPTIBILITY NAME: VANCMCN<Enter>      VANCOMYCIN
NATIONAL VA LAB CODE: Shell Vial Technique// VANCOMYCIN<Enter> Vancomycin
81485.0000<Enter>
Select ANTIMICROBIAL SUSCEPTIBILITY NAME: Ampicillin/sulbactam<Enter>
Ampicillin/subalctam
NATIONAL VA LAB CODE: Ampicillin// @<Enter>
  SURE YOU WANT TO DELETE? Y (Yes)<Enter>
Select ANTIMICROBIAL SUSCEPTIBILITY NAME: <Enter>
```

SEMI-AUTO function

The SEMI-AUTO function looks for entries that are not currently linked and prompts the user to select the corresponding entry in the WKLD CODE file (#64).

Example: SEMI-AUTO function

```
Enter response: SEMI-AUTO<Enter>

AMIKACN      AMIKACIN
NATIONAL VA LAB CODE: AMIK<Enter>ACIN  Amikacin      81098.0000
Continue YES/<Enter>

AMPICLN      AMPICILLIN
NATIONAL VA LAB CODE: AMP<Enter>
  1  AMP CYCLIC                81029.0000
  2  AMPHETAMINE Amphetamine   81528.0000
  3  AMPHOTERICIN B Amphotericin B 81530.0000
  4  AMPICILLIN Ampicillin      81532.0000
CHOOSE 1-4: 4 Ampicillin
Continue YES// <Enter>

CLINDAM      CLINDAMYCIN
NATIONAL VA LAB CODE: CLINDAMYCIN  Clindamycin      81676.0000
Continue YES// <Enter>

CARBCLN      CARBENICILLIN
NATIONAL VA LAB CODE:
Continue YES// NO<Enter>
```

Delete Entry from Laboratory EPI Parameters Input Screen

Use the tab key to move the cursor. Highlight the entry that is to be deleted, select the “@” symbol, then press enter/return. You will then receive a deletion warning asking if you are sure.

Example: Deleting an entry from the Laboratory EPI Parameters Input Screen.

| | | |
|--|-------------|-----------------------|
| LABORATORY EPI PARAMETERS INPUT SCREEN | | Page 2 of 5 |
| NAME: CANDIDA | ACTIVE: YES | |
| <hr/> | | |
| Selected Etiology | | |
| CANDIDA PARAPSILOSIS <Tab> | | |
| CANDIDA PSEUDOTROPICALIS <Tab> | | |
| CANDIDA SKIN TEST ANTIGEN @ <Enter> | | |
| CANDIDA STELLATOIDEA | | |
| Antimicrobial Susceptibility | NLT Code | NLT Description |
| <Tab> | | |
| <hr/> | | |
| Exit | Save | Next Page Refresh |
| <hr/> | | |
| COMMAND: | | Press <PF1>H for help |
| WARNING: DELETIONS ARE DONE IMMEDIATELY! | | |
| (EXITING WITHOUT SAVING WILL NOT RESTORE DELETED RECORDS.) | | |
| Are you sure you want to delete this entire Subrecord (Y/N)? y <Ret> | | |

How to add an entry to the Laboratory EPI Parameters Input Screen

Use the tab key to move the cursor. Highlight a blank line where the entry is to be added.

Example: Adding entries via the Laboratory EPI Parameters Input Screen

| LABORATORY EPI PARAMETERS INPUT SCREEN | | Page 2 of 5 |
|--|------------------------|-----------------|
| NAME: CANDIDA | ACTIVE: YES | |
| <hr/> | | |
| Selected Etiology | | |
| CANDIDA | | |
| CANDIDA GUILLIERMONDII | | |
| CAN <Ret> | | |
| Antimicrobial Susceptibility | NLT Code | NLT Description |
| <Tab> | | |
| <hr/> | | |
| 1 | CAN CANDIDA ALBICANS | 4081 |
| 2 | CANARYPOX VIRUS | 3604 |
| 3 | CANDICIDIN | 7328 |
| 4 | CANDIDA, NOS | 4080 |
| 5 | CANDIDA GUILLIERMONDII | 4082 |
| Choose 1-5 or '^' to quit: 1 <Ret> | | |

| | | |
|---|-------------|-----------------|
| LABORATORY EPI PARAMETERS INPUT SCREEN | | Page 2 of 5 |
| NAME: CANDIDA | ACTIVE: YES | |
| <hr/> | | |
| Selected Etiology | | |
| CANDIDA GUILLIERMONDII | | |
| CANDIDA KRUSEI | | |
| CANDIDA ALBICANS | | |
| <- The entry will appear after answering yes to the adding a new ETIOLOGY prompt. | | |
| Antimicrobial Susceptibility | NLT Code | NLT Description |
| <Tab> | | |
| <hr/> | | |
| CAN CANDIDA ALBICANS | | |
| Are you adding 'CANDIDA ALBICANS' as a new ETIOLOGY? Y <Ret> | | |

Lab EPI Generate Local Report/Spreadsheet [LREPI GENERATE REPORT/SP] option
Field Definitions:

| SEGMENT | NUMBER | FIELD ELEMENT NAME | FIELD DESCRIPTION |
|---------|--------|-------------------------------|--|
| PID | 1 | Set ID | Patient ID Sequence Number The Set ID field is used to identify the number of repetitions of the PID segment by HL7. The first PID segment would have a Set ID value of 1, the next would have a value of 2, etc. |
| | 2 | Social Security Number | Patient's Social Security Number NNN-NN-NNNN |
| | 3 | VA Master Patient Index (MPI) | Patient's MPI |
| | 4 | Patient Name | Patient's Name Last, First M |
| | 5 | Date of Birth | Patient's Date of Birth |
| | 6 | Sex | Patient's Sex Refer to Table 0001. |
| | 7 | RACE | Patient's Race Refer to Table 0005. |
| | 8 | Homeless | If patient is homeless, then "Homeless" prints. |
| | 9 | State | Patient's State |
| | 10 | Zip Code | Patient's Zip Code |
| | 11 | County | Patient's County |
| | 12 | Ethnicity | Patient's Ethnicity Refer to table 0189. |
| | 13 | Period of Service | Military Status assigned to a veteran. Refer to Table VA011. |
| PV1 | 1 | Set ID - Patient VisitA | PV1 Sequence Number The Set ID field is used to identify the number of repetitions of the PV1 segment by HL7. The first PV1 segment would have a Set ID value of 1, the next would have a value of 2, etc. |
| | 2 | Patient Class | Inpatient or Outpatient |
| | 3 | Hospital Location | Assigned Patient Location-Treatment Location For inpatients only. WARD~ROOM~BED |
| | 4 | Discharge Disposition | Type of Disposition For Inpatients Only Source VA File PTF (#45) |

Lab EPI Generate Local Report/Spreadsheet [LREPI GENERATE REPORT/SP] option Field Definitions
continued.

| SEGMENT | NUMBER | FIELD ELEMENT NAME | FIELD DESCRIPTION |
|---------|--------|---|--|
| | 5 | Facility | Servicing Facility-Primary Facility |
| | 6 | Admit Date/Time | Inpatient-Admission Date/Time Outpatient- Accession Date |
| | 7 | Discharge Date/Time | Discharge Date/Time For Inpatients Only |
| DG1 | 1 | Set ID-Diagnosis (Sequence #) | DG1 Sequence Number The Set ID field is used to identify the number of repetitions of the DG1 segment by HL7. The first DG1 segment would have a Set ID value of 1, the next would have a value of 2, etc. |
| | 2 | Diagnosis Code (Code(id) ~Text (St.) ~ Name of coding system (st) | Diagnosis Code |
| | 3 | Diagnosis | Diagnosis |
| | 4 | Admission Date | Inpatient- Admission Date Outpatient- Accession Date |
| | 2 | DATE | Date |
| | 3 | RESOLVED TERM | Resolved Term |
| | 4 | TEXT | Text |
| | 5 | RESULT | Test result |
| | | SOURCE ID | Source ID |
| NTE | 1 | Set ID | Sequence Number The Set ID field is used to identify the number of repetitions of the NTE segment by HL7. The first NTE segment would have a Set ID value of 1, the next would have a value of 2, etc. |
| | 3 | Comment | Five formats exist for this segment: a. NTE manual/automatic indicator (Null for automatic, R for Manual)~REPORTING DATE FROM from date TO to date~message number~~software version number (blank for original system/V2 for new system(epi)~Negative Input Indicator (null if input is present, N if negative) b. NTE sequence number reference number from field .05 (reference number) in file 69.5 (LAB SEARCH/EXTRACT) |

Lab EPI Generate Local Report/Spreadsheet [LREPI GENERATE REPORT/SP] option Field Definitions
continued.

| SEGMENT | NUMBER | FIELD ELEMENT NAME | FIELD DESCRIPTION |
|---------|--------|------------------------------------|--|
| | | | <p>c. NTE Totals indicator (T if NTE describes totals for run)~National Lab Test Code~Test Name from files 60 (Lab Test) or file 61.2 (Etiology Field)~Total number of tests performed.</p> <p>d. NTE Totals indicator (T if NTE describes totals for run)~National Lab Test Code~"PATIENTS WITH "_Test Name from files 60 (Lab Test) or file 61.2 (Etiology Field)~Number of unique patients receiving this test</p> <p>e. NTE Totals indicator (T if NTE describes totals for run)~Hepatitis Assessment~Total number of Hepatitis C Assessments</p> |
| OBR | 1 | Set ID-Observation Request (Seq #) | <p>OBR Sequence Number</p> <p>The Set ID field is used to identify the number of repetitions of the OBR segment by HL7. The first OBR segment would have a Set ID value of 1, the next would have a value of 2, etc.</p> |
| | 2 | Test Name | The name of the lab test performed. |
| | 3 | Accession Date | Accession Date |
| | 4 | Specimen | Specimen |
| | 5 | Accession Number | Accession Number |
| OBX | 1 | Set Id-Observational | <p>OBX Sequence Number</p> <p>The Set ID field is used to identify the number of repetitions of the OBX segment by HL7. The first OBX segment would have a Set ID value of 1, the next would have a value of 2, etc.</p> |
| | 2 | Value Type | CE or ST |
| | 3 | Test Name | The name of the lab test performed. |
| | 4 | LOINC Code | LOINC Code |
| | 5 | LOINC Name | LOINC Name |
| | 6 | Test Result | Result of the test performed or the MIC value. |
| | 7 | Units | Units |
| | 8 | Abnormal Flags | Abnormal Flags |
| | 9 | Verified Date/Time | The date/time that the test was verified. |

APPENDIX-B HELPFUL HINTS

Appendix – B Helpful Hints

This section provides helpful hints, methods, and examples for maintaining and validating EPI data.

Preferred Methods for *Clostridium difficile* Data Capture

There are two preferred methods that will make it easy to capture data for *Clostridium difficile* criteria (i.e., as well as several other methods which sites may already employ).

NOTE: As long as the designated parameter results being tracked are in a retrievable field (i.e., **not** a “Free Text” or “Comment” field) the method the site chooses is an individual decision.

Preferred Method #1:

The first preferred method is to have the site define an etiology of “***Clostridium difficile* toxin positive**”. This allows a topography specimen of accession area “**feces/stool**” to be accessioned through the Microbiology accession area. Then, if the stool specimen were indeed positive for *Clostridium difficile* toxin, by any of the known methods of testing, the etiology would be “***Clostridium difficile* toxin positive**.” To accomplish this method would require sites to enter three new local etiologies:

- *Clostridium difficile* toxin positive
- *Clostridium difficile* toxin negative
- *Clostridium difficile* toxin in determinant

These would be different from a culture isolate being positive for *Clostridium difficile*, in that they actually are etiologies/results based on toxin testing. This leaves the etiology of *Clostridium difficile* for actual culture positive specimens for the organism *Clostridium difficile*. The Lab EPI Parameter Setup [LREPI PARAMETER SETUP] option, the site parameter by which the software will capture a patient diagnosed with proven *Clostridium difficile*-associated colitis, will be by placing “***Clostridium difficile* toxin positive**” etiology into the selected etiology entry screen. This has the advantage of being more consistent with other data entry practices in the Microbiology sections of most laboratories.

Preferred Method #2:

The second preferred method is having the data in retrievable form would be to enter/accession the specimen for *Clostridium difficile* toxin assay under the chemistry/serology format (regardless of where the test is physically done) with the results being a choice of “positive”, “negative”, or “indeterminate”. This would allow one to enter “*Clostridium difficile* toxin” assay as the test for the EPI software to search in the chemistry/serology format. The result would be retrievable for EPI under a chemistry/serology lab test of “*Clostridium difficile* toxin” with the indicator “contains” and the value of “pos”, as noted in the sample page. If your site does not routinely do *Clostridium difficile* toxin assay testing this way, a different method of accessioning the specimen to get it in chemistry/serology format would be needed.

However, the Chemistry/Serology format would give additional flexibility in placing interpretational guidelines for the test results in the “Comments” field. For the EPI, “positive” or “negative” results **cannot** be located in a “Free Text” or “Comments” field as these are **not** retrievable.

Some VAMCs accession the stool specimen for the *Clostridium difficile* toxin assay under the Microbiology format. An etiology is not given under the final culture result, but written into free text or comments section stating the *Clostridium difficile* toxin assay test result. This is not in a retrievable format and therefore not acceptable for the EPI criteria.

Some VAMCs still use cytotoxin assays of cell culture, which are again entered in a “Free Text” or “Comment” field. This again is not acceptable unless it is accessioned and recorded under the chemistry/serology format as a straightforward lab test result of “positive” or “negative” or “indeterminate”.

Some VAMCs choose to report *Clostridium difficile* toxin assay positivity under the Microbiology application. As an etiology/culture result of *Clostridium difficile* (even though culture, was not actually done) this is not a true measure of what is actually being tested (as most sites do not culture the organism but just run the toxin assay test). However, if your site uses this means to represent *Clostridium difficile* toxin assay positivity and there are no exceptions (such as the site reporting an actual positive culture of (*Clostridium difficile* which is toxin assay negative), then this would be acceptable though less desirable for EPI purposes.

Validating EPI Data Captures

The purpose of validating EPI data captures is **not** to require extra paperwork for QI monitors and long-term document files. The validation should be done at the initial implementation of the Laboratory EPI software to ensure accurate data capture. Thereafter, a review should be done once every 4-6 months to ensure that Lab EPI Parameter Setup [LREPI (EPI) PARAMETER UPDATE] option entries for the EPI criteria remain accurate. Parameter updates may be required when a new lab test/result is to be implemented for one of the Emerging Pathogens Initiative.

Once the predetermined emerging pathogens parameter descriptions are defined using the Lab EPI Parameter Setup [LREPI PARAMETER SETUP] option EPI data captures and monthly EPI HL7 format mailman messages transmissions can take place. EPI data captures are “automatically generated” monthly and sent to AITC, formerly AAC, on the 15th day of each month. Upon receipt of the EPI HL7 Format mailman messages transmission, AITC sends individual “EPI Confirmation Mailman Message” to the sending VHA sites EPI mail group members notifying them that the EPI mailman messages transmission has ONLY been received and NO EPI data has been processed.

The **new** ‘EPI Summary Verification Report of EPI Extracted Data from Site’ mailman messages **replaced** the original Emerging Pathogens Verification Report mailman messages. The **new** EPI Summary Verification Report mailman messages are “automatically generated” at each site on the 15th day of the month and sent to the EPI-REPORT mail group members (i.e., in a human readable format). The **new** report includes the VHA site’s station number and all predetermined emerging pathogens extracted data occurrences totals for the monthly processing reporting cycle. This **new** report may be used for quick previewing of the EPI data captures entries and totals.

The **new** Detailed Verification Report of EPI Extracted Data from Site’ **replaces** the original Emerging Pathogens Verification Report. The **new** report contains the VHA reporting site’s station number with Notes and Comment Segments (NTE) findings in human readable pages. VHA sites reporting NTE findings (i.e., 1, 2, 3 . . . 23) starts with a new page for each NTE findings.

The Microbiology Laboratory personnel, Laboratory Manager, TQI/QI/QA, or other personnel (i.e., as determined by the sites) may already have data of isolated “organisms of interest”. Several of the nationally defined emerging pathogens may well corresponds. Therefore, a quick comparison can be done using the **new** Verification Detail Report of EPI Extracted Data from Site mailman messages. This comparison also ensures that the Laboratory EPI software is appropriately capturing all EPI cases and numbers.

For tests such as Hepatitis A Antibody NEG, Hepatitis B Antibody NEG, Hepatitis C Antibody POS, and Hepatitis C Antibody NEG most LIMs should be able to generate reports (with patient names) that include “positive” tests results to use for comparison. Additionally, the Health Information Management Section at each site should be able to generate a report of ICD Diagnoses by date. This ICD Diagnoses by-date-report helps determine if the VACO Infectious Disease Program Office EPI and emerging pathogens data captures concurs with the defined EPI criterion (i.e., Cryptosporidium-007.8, Legionnaire’s disease--482.80, malaria--084, 084.0, 084.1, 084.2, 084.3, 084.4, 084.5, 084.6, 085.7, 084.8, 084.9, dengue-061, 065.4, Creutzfeldt-Jakob--046.1, and Leishmaniasis--085, 085.0, 085.1, 085.2, 085.3, 085.4, 085.5, 085.9).

Be aware that a number of these pathogens DO NOT occur at a high frequency. VHA sites with previously known cases of emerging pathogens, such as TB, should run the Lab EPI Manual Run [LREPI (EPI) MANUAL RUN] option for the entire month to verify that the TB culture was isolated and to see if it is captured. Additionally, “test patients” known to have these lab results can also be run.

Required EPI Mail Groups and Descriptions

The EPI Roll up Modification software release requires the following mail groups:

- EPI mail group
- EPI-REPORT mail group

NOTES:

It is highly recommended that the **Office of the Director** (00) at each VHA facility initially designate the member(s) responsible for overseeing the EPI mail group, and the EPI-REPORT mail group.. The Office of Director (00)-designated staff for EPI process implementation should be assigned to this mail group and kept current as personnel assume this responsibility. This/these staff member(s) is/are responsible for reviewing processing (error) reports and coordinating EPI data corrections (as necessary) due to the numerous files from which the data is obtained (e.g., PTF, PIMS, Health Information Management, Laboratory, etc.). Once the corrections are made, it is the responsibility of this designated staff to re-transmit the EPI data to the AITC using the Lab EPI Manual Run (Enhanced) option. Other personnel at the site who may be of assistance trouble-shooting errors may also elect to be member of this mail group.

It is highly recommended that a TQI/QI/QA staff, Laboratory Information Manager (LIM), Microbiology director or supervisor, Infection Control Practitioners, or Hospital Epidemiologist), or individual(s) with similar functions be a member(s) of one or more of these mail groups as previously noted.

EPI Mail Group Description

The EPI mail group is used by VHA facilities to transmit EPI HL7 format mailman messages **TO** the Austin Information Technology Center (AITC). This mail group is also used by AITC to transmit EPI Confirmation mailman messages **BACK** to the sending VHA facilities once the EPI HL7 format mailman messages data transmission has been received by AITC.

EPI-REPORT Mail Group Description

The EPI-Report mail group is use to receive the automatically generated **new** Verification Summary Report on the 15th day of each month. This mail group is also use to receive the **new** Verification Summary Report when manually generated using the Lab EPI Manual Run (Enhanced) [LREPI ENHANCE MANUAL RUN] option.

NOTE: Members of the EPI-Report mail group will assist with the EPI data validation and data correction process.

EPI Data Processing Cycles

Currently, twenty three predetermined emerging pathogens act as triggers for EPI data extraction (i.e., as defined by VACO) within the EPI software application. The software then retrieves relevant, predetermined, and patient-specific data.

EPI software builds a HL7 format mailman message transmission on the 15th day of each month containing specific EPI data extractions. **Note:** A local global build is used to automatically generate the **new** “Verification Summary Report and Verification Detailed Report of EPI Extracted Data From Site’ in a HL7 format mailman message.

EPI HL7 format mailman messages containing the EPI data extractions are transmitted to the Austin Automation Center via the Q-EPI.MED.VA.GOV domain on the 15th day of each month.

Austin Automation Center returns an EPI Confirmation mailman message upon receiving the sending facility EPI HL7 format mailman message. **Note:** The EPI Confirmation mailman message **ONLY** confirms that the EPI HL7 Format mailman messages have reached the Austin Automation Center queue, **NOT** necessarily accepted for processing.

On about the 25th day of the month Austin Automation Center processes the EPI data set and sends an EPI Processing (Error)Report mailman messages back to each sending facility via the EPI mail group. **Note:** The EPI Processing Report notifies the sending facility that the EPI data set has been processed by the Austin Automation Center, either with **NO** fatal errors indicating EPI data set acceptance **OR** that Fatal Error codes occurred constituting rejection of the entire EPI data set.

Once the EPI data set is accepted, the Austin Automation Center analyzes the EPI data set using the Statistical Analysis System (SAS) based statistical software. VACO Reports may then be generated for appropriate use and distribution at the national level.

EPI HL7 Format Mailman Message

The VistA Laboratory EPI software automatically searches, extracts, processes, and transmits EPI data using an HL7 format mailman message on the 15th of each month via the Q-EPI.MED.VA.GOV domain to the AITC for processing. The EPI software is **enhanced** to include LOINC, MIC values, MPI values, race, ethnic Groups, county codes, and assigned patient class for inpatient/outpatient data.

Example: New EPI HL7 Format Mailman Message

```
MailMan message for LABPROGRAMMER, ONE
Printed at TEST.CINCINNATI.MED.VA.GOV 01/15/04@11:31
Subj: HL7 Msg JAN 14,2004@23:03:31 from CINCINNATI [#53959] 01/14/04@23:03
588 lines
From: POSTMASTER (POSTMASTER In 'IN' basket. Page 1 *New*)
-----
MSH|^~\&|EPI-LAB|539|EPI-LAB|539|20040114230323-
0400||ORU~R01|53923600917|T|2.2
||NE|NE|USA

NTE||R~REPORTING DATE FROM 20030101 TO 20030131~1~~V3

PID|1|000-00-0035~~|122~2~M10~1004151421V503772~VAMPI||LABPATIENT3,
FIVE||193403
14|M|||~~~39^OHIO~45227~~~~89^PATIENT|||||000000035|||||||0

PV1|1|O|||||||||||||||||||||||||||539|||||20030116084420-0400

DG1|1||401.9~HYPERTENSION NOS~I9

DSP|1||20030116084420-0400~HEP C VIRUS ANTIBODY NEGATIVE~6~NEGATIVE~||0

NTE|1|15~HEPATITIS C ANTIBODY NEG

OBR|1|||81121.0000~CHEMISTRY TEST~VANLT|||20030116084420-
0400||||||SER~~SERUM
||RIA 03 637

OBX|1|ST|89070.0000~HEPATITIS C AB~VANLT~1486~HEP C
ANTIBODY~VA60~13955~HEPATIT
IS C VIRUS AB:ACNC:PT:S~LOINC||NEGATIVE||-|||||20030122144539-0400

PID|2|000-00-0036~~|140~4~M10~1004666645V068241~VAMPI||LABPATIENT3,
SIX||1947020
3|M|||~~~39^OHIO~45229~~~~89^PATIENT|||||000000036|||||||7

PID|3|000-00-0037~~|310~3~M10~1008185084V033776~VAMPI||LABPATIENT3,
SEVEN||19551019
|M|||~~~12^FLORIDA~33931~~~~39^LEE|||||000000037|||||||8
PV1|1|O|||||||||||||||||||||||||||539|||||200301080813-0400
OBR|1|||81121.0000~CHEMISTRY TEST~VANLT|||200301080813-
0400||||||SER~~SERUM|
|RIA 03 244
```

Example: New EPI HL7 Format Mailman Message *continued*

```

OBX|1|ST|89070.0000~HEPATITIS C AB~VANLT~1486~HEP C
ANTIBODY~VA60~13955~HEPATIT
IS C VIRUS AB:ACNC:PT:S~LOINC|NEGATIVE||-|||||20030114135036-0400

PID|4|000-00-0038~~|480~4~M10~1004671166V025205~VAMPI|LABPATIENT3, EIGHT|
|19230612|M|||~~~39^OHIO~45212~~~~89^PATIENT|||||282534399||||||2

PV1|1|I|6 NORTH~A611~2|||||||||||||||||||||||||||||7~DEATH WITHOUT
AUTOPSY~
VA45|||539|||||20021227043712-0400|20030126155036-0400

DG1|1||112.2~CANDIDIAS UROGENITAL NEC~I9|20021227043712-0400||

DG1|2||287.1~THROMBOCYTOPATHY~I9|20021227043712-0400||

NTE|1|4~CLOSTRIDIUM DIFFICILE

OBR|1|||87999.0000~MICRO CULTURE~VANLT|||200301061200-
0400|||||STL~~FECES|||
MICRO 03 34

OBX|1|CE|87993.0000~BACTERIOLOGY CULTURE~VANLT|1|~YEAST|||||||20030127

OBX|3|CE|87993.0000~BACTERIOLOGY CULTURE~VANLT|3|~STAPHYLOCOCCUS (COAGULASE

PID|5|000-00-0039~~|563~7~M10~1004677502V513322~VAMPI|LABPATIENT3,
NINE||19300
425|M||2076-8-SLF~NATIVE HAWAIIAN OR OTHER PACIFIC ISLANDER~0005~2076-8~NATIVE
HAWAIIAN OR OTHER PACIFIC
ISLANDER~CDC|~~~39^OHIO~45230~~~~89^PATIENT|||||000000039|||2186-5-SLF~NOT
HISPANIC OR LATINO~0189~2186-5||||0

PV1|1|I|6
SOUTH~A649~2|||||||||||||||||||||||||||||1~REGULAR~VA45|||539||||
|20030109175930-0400|20030121104552-0400

DG1|9||575.11~CHRONIC CHOLECYSTITIS~I9|20030109175930-0400||

DSP|1||20030110021103-0400~HEP C VIRUS ANTIBODY NEGATIVE~6~NEGATIVE~||0

OBX|1|ST|89070.0000~HEPATITIS C AB~VANLT~1486~HEP C
ANTIBODY~VA60~13955~HEPATIT
IS C VIRUS AB:ACNC:PT:S~LOINC|NEGATIVE||-|||||20030116134325-0400
NTE|2|16~HEPATITIS A ANTIBODY POS

OBR|1|||81121.0000~CHEMISTRY TEST~VANLT|||20030110021103-
0400|||||SER~~SERUM
||RIA 03 355

OBX|1|ST|89083.0000~HEPATITIS A IGM AB~VANLT~505~HEP A
ANTIBODY(IGM)~VA60~13950

```


EPI Confirmation Mailman Message

Upon AITC receipt of the VHA facilities EPI HL7 format mailman message monthly transmission (i.e., 15th of each month via the Q-EPI.MED.VA.GOV domain) individual EPI Confirmation mailman messages are sent by AITC to the originating VHA facilities via the EPI mail group. Members of this mail group are being notified that EPI HL7 format mailman message data transmission has been received by AITC for processing.

Examples: EPI Confirmation mailman message sent by AITC

```
Subj: DOY7352 EPI Confirmation [#11057401] 15 Feb 01 23:11 CST 2 lines
From: POSTMASTER@FOC-AUSTIN.VA.GOV In 'EPI' basket. Page 1
```

```
-----
Ref: Your EPI message #11057352 with Austin ID #130120489, is assigned
confirmation number 010462303783006.
```

```
Enter message action (in EPI basket): Ignore//
```

New EPI Summary Verification Report of EPI Extracted Data from Site' HL7 Mailman Message

The **new** EPI Verification Summary Report of EPI Extracted Data from Site HL7 format mailman message **replaced** the original Emerging Pathogens Verification Report HL7 format mailman message. This **new** EPI Summary Verification Report HL7 format mailman message is automatically generated at the VHA site on the 15th the month and sent to the EPI-REPORT mail group members via a HL7 format mailman messages (i.e., in a human readable format). The **new** EPI Verification Summary Report mailman messages contains the VHA site's station number and all predetermined emerging pathogens extracted data occurrences totals for the monthly processing reporting cycle. This **new** report may be used for quick previewing of the EPI data captures entries and totals.

NOTES:

The **new** EPI Summary Verification Report of EPI Extracted Data from Site can also be generated **manually** as often as necessary using the Lab EPI Manual Run (Enhanced) [LREPI ENHANCE MANUAL RUN] option. This option can be **manually** generated as often as necessary. After the report is generated data is automatically sent to EPI-REPORT mail group which may be use for EPI data validation.

Lab EPI extract data transmissions to AITC occur after 6:00 pm and are processed the next day.

DO NOT run the Lab EPI Manual Run (Enhanced) [LREPI ENHANCED MANUAL RUN] option to transmit EPI extract data on Wednesdays of PAY ROLL weeks. These transmissions may cause a delay in processing the PAY ROLL data.

Example: New EPI Summary Verification Report of EPI Extracted Data from Site' mailman message.

NOTE: The **new** EPI Summary Verification Report of EPI Extracted Data from Sites can be manually generated using the Lab EPI Manual Run (Enhanced) [LREPI ENHANCE MANUAL RUN] option. After the report is generated it is automatically sent to EPI-REPORT mail group which can be use for EPI data validation.

Subj: EPI Summary Verification Report [#19669319] 05/19/04@23:35

128 lines

From: POSTMASTER In 'IN' basket. Page 1 *New*

SUMMARY VERIFICATION REPORT OF EPI EXTRACTED DATA
FROM STATION 539 CINCINNATI

Processing Month PROCESSING PERIOD: 04-01-2004 through 04-30-2004

| | Number of Occurrences | Number of Persons Occurrence |
|---|--------------------------|------------------------------------|
| with Emerging Pathogen | | |
| NTE~1-Vancomycin-resistant Enterococcus | 4 | 4 |
| NTE~2-Hepatitis C antibody Positive | 24 | 22 |
| NTE~3-Penicillin-Resistant Streptococcus pneumoniae | 0 | 0 |
| NTE~4-Clostridium difficile | 4 | 4 |
| NTE~5-Tuberculosis | 0 | 0 |
| NTE~6-Streptococcus, Group A | 4 | 4 |
| NTE~7-Legionella/Legionaire's Disease | 0 | 0 |
| NTE~8-Candida bloodstream infections | 1 | 1 |

Subj: EPI Summary Verification Report [#19669319] Page 2

| | | |
|--|-----|-----|
| NTE~9-Cryptosporidium | 0 | 0 |
| NTE~10-Escherichia coli O157 | 0 | 0 |
| NTE~11-Malaria | 0 | 0 |
| NTE~12-Dengue | 0 | 0 |
| NTE~13-Creutzfeldt-Jakob Disease | 0 | 0 |
| NTE~14-Leishmaniasis | 0 | 0 |
| NTE~15-Hepatitis C antibody negative | 208 | 205 |
| NTE~16-Hepatitis A antibody positive | 24 | 22 |
| NTE~17-Hepatitis B positive | 65 | 42 |
| NTE~18-All Staphylococcus Aureus | 32 | 29 |
| NTE~19-Methicillin-Resistant Staphylococcus Aureus (Mrsa) | 22 | 20 |
| NTE~20-Vancomycin-Resistant Staphylococcus Aureus (Vrsa) | 0 | 0 |
| NTE~21-Vancomycin-Resistant Coagulase Negative Staphylococci/Staph EPI (Vrse) | 0 | 0 |
| NTE~22-All Streptococcus Pneumoniae | 5 | 4 |
| NTE~23-All Enterococci | 24 | 21 |

Example: New EPI Summary Verification Report of EPI Extracted Data from Site' mailman message
continued.

For definitions of case ascertainment for each category, please refer to documentation in Laboratory EPI Patch LR*5.2*281 Technical and User Guide in conjunction with your local parameter set-up of this process.

Subj: EPI Summary Verification Report [#19669319] Page 3

 If you feel that these numbers are in error, please verify with the local facility personnel responsible for setting the EPI Laboratory Search/Extract parameters. However, do not change these parameters if they are incorrect without fully reading the documentation; this will be crucial in order to avoid any misalignment with the concomitant Hepatitis C Extract patches (PXR*1.5*1, VA-National EPI DB Update, LR*5.2*260, PSJ*5*48, Hepatitis C Initiative, and PSO*7*45, Hepatitis C Initiative). In particular, the hepatitis C antibody positive, hepatitis C antibody negative, hepatitis A antibody positive and hepatitis B positive will be especially sensitive to changes, and concomitant changes of all of the patches may need to occur.

| Nationally rolled-up resolution term | Number of Persons with the Term and Transmitted For National Roll-up |
|---|---|
| Resolved term-1-Declined Assessment for Hepatitis C | 6 |
| Resolved term-2-No Risk Factors for Hepatitis C | 142 |
| Resolved term-3-Previously Assessed for Hepatitis C | 0 |
| Resolved term-4-Risk Factors for Hepatitis C | 88 |

Enter RETURN to continue or '^' to exit:

Subj: EPI Summary Verification Report [#19669319] Page 4

| | |
|--|-----|
| Resolved term-5-Positive Test for Hepatitis C antibody | 22 |
| Resolved term-6-Negative Test for Hepatitis C antibody | 205 |
| Resolved term-7-Hepatitis C diagnosis (ICD based) | 173 |

 Total Hepatitis C Risk Assessment Resolution 636

This table represents only those who had a once-lifetime resolution of the National Clinical Reminder for Risk Assessment for Hepatitis C. This resolution will only occur once during the care of a patient (unless actively changed by a point-of-care practitioner at a later date).

Processing Month: PROCESSING PERIOD: 04-01-2004 through 04-30-2004 for site # 539 CINCINNATI
 Site totals

Example: New EPI Summary Verification Report of EPI Extracted Data from Site' mailman message
continued.

| | |
|-------------------------------------|----|
| STAPHYLOCOCCUS AUREUS | 12 |
| PATIENTS WITH STAPHYLOCOCCUS AUREUS | 9 |
| CANDIDA ALBICANS | 36 |
| PATIENTS WITH CANDIDA ALBICANS | 20 |
| ENTEROCOCCUS | 20 |
| PATIENTS WITH ENTEROCOCCUS | 15 |

Subj: EPI Summary Verification Report [#19669319] Page 5

| | |
|--|----|
| STREPTOCOCCUS BETA HEMOLYTIC, GROUP A | 4 |
| PATIENTS WITH STREPTOCOCCUS BETA HEMOLYTIC, GROUP A | 4 |
| CANDIDA TROPICALIS | 1 |
| PATIENTS WITH CANDIDA TROPICALIS | 1 |
| CANDIDA (TORULOPSIS) GLABRATA | 4 |
| PATIENTS WITH CANDIDA (TORULOPSIS) GLABRATA | 4 |
| YEAST NOT CANDIDA ALBICANS | 8 |
| PATIENTS WITH YEAST NOT CANDIDA ALBICANS | 5 |
| STAPHYLOCOCCUS (COAGULASE NEGATIVE) | 38 |
| PATIENTS WITH STAPHYLOCOCCUS (COAGULASE NEGATIVE) | 29 |
| STREPTOCOCCUS PNEUMONIAE | 7 |
| PATIENTS WITH STREPTOCOCCUS PNEUMONIAE | 4 |
| STAPHYLOCOCCUS AUREUS (MRSA) | 28 |
| PATIENTS WITH STAPHYLOCOCCUS AUREUS (MRSA) | 20 |
| ENTEROCOCCUS FAECALIS | 6 |
| PATIENTS WITH ENTEROCOCCUS FAECALIS | 3 |
| ENTEROCOCCUS FAECIUM | 3 |
| PATIENTS WITH ENTEROCOCCUS FAECIUM | 3 |
| POSITIVE FOR CLOSTRIDIUM DIFFICILE TOXIN | 4 |
| PATIENTS WITH POSITIVE FOR CLOSTRIDIUM DIFFICILE TOXIN | 4 |

Subj: EPI Summary Verification Report [#19669319] Page 6

| | |
|---------------------------------------|-----|
| ENTEROCOCCUS GALLINARUM | 1 |
| PATIENTS WITH ENTEROCOCCUS GALLINARUM | 1 |
| HEP B SURFACE AG | 141 |
| PATIENTS WITH HEP B SURFACE AG | 136 |
| HEP A ANTIBODY(IGM) | 12 |
| PATIENTS WITH HEP A ANTIBODY(IGM) | 12 |
| HEP B SURFACE AB | 130 |
| PATIENTS WITH HEP B SURFACE AB | 127 |
| HEP B CORE AB(IGM) | 16 |
| PATIENTS WITH HEP B CORE AB(IGM) | 16 |
| HEP C ANTIBODY | 232 |
| PATIENTS WITH HEP C ANTIBODY | 227 |
| HEP A ANTIBODY-TOTAL | 42 |
| PATIENTS WITH HEP A ANTIBODY-TOTAL | 41 |

Example: New EPI Summary Verification Report of EPI Extracted Data from Site' mailman message *continued.*

1. For Microbiology Lab Package Organism results/isolates (e.g. Enterococcus, or Streptococcus pneumoniae), the number corresponding to the name represents the total number reported from your local microbiology package during the processing month. The number corresponding to the line 'Patients with...<Microbiology Lab Result/isolates> (e.g. Patients with Enterococcus or Patients with Streptococcus pneumoniae) represents the number of individual patients from whom the results were isolated.

Subj: EPI Summary Verification Report [#19669319] Page 7

2. For non-microbiology results (e.g. chemistry/serology results such as Hepatitis C antibody), the number corresponding to the name represents the TOTAL number of <named> tests done at your facility during the processing month. The number corresponding to the line <Patients with...<non-Microbiology test> (e.g. Hepatitis C antibody) represents the number of individuals on whom the test(s) was/were performed. This does not represent the number of persons who had a positive test result.

3. These results have been obtained based on specimen accession date and not results reported dating.

Enter message action (in IN basket): Ignore//

1. For Microbiology Lab Package Organism results/isolates (e.g. Enterococcus, or Streptococcus pneumoniae), the number corresponding to the name represents the total number reported from your local microbiology package during the processing month. The number corresponding to the line 'Patients with...<Microbiology Lab Result/isolates> (e.g. Patients with Enterococcus or Patients with Streptococcus pneumoniae) represents the number of individual patients from whom the results were isolated.

2. For non-microbiology results (e.g. chemistry/serology results such as Hepatitis C antibody), the number corresponding to the name represents the TOTAL number of <named> tests done at your facility during the processing month. The number corresponding to the line <Patients with...<non-Microbiology test> (e.g. Hepatitis C antibody) represents the number of individuals on whom the test(s) was/were performed. This does not represent the number of persons who had a positive test result.

3. These results have been obtained based on specimen accession date and not results reported dating.

New EPI Summary Verification Report for prior month - TB only

NOTE: This **new** EPI Summary Verification Report for prior month – TB only represents a second pass at acquiring data for the EPI from the prior month on Mycobacterium tuberculosis due to the extended period of time that may be expected with accessioning, growth, and finally reporting of results. Since this is designed to acquire only the remaining Mycobacterium tuberculosis data from the prior month, most of the numbers present for this report will be zero. The accompanying Summary Verification Report for the current month should contain more complete number counts on the other EPI pathogens and data items for this current month.

Example: New EPI Summary Verification Report for prior month - TB only

Subj: EPI Summary Verification Report for prior month -TB only

[#19669069] 05/19/04@22:18 97 lines

From: POSTMASTER In 'IN' basket. Page 1 *New*

This report represents a second pass at acquiring data for the EPI from the prior month on Mycobacterium tuberculosis due to the extended period of time that may be expected with accessioning, growth, and finally reporting of results. Since this is designed to acquire only the remaining Mycobacterium tuberculosis data from the prior month, most of the numbers present for this report will be zero. The accompanying Summary Verification Report for the current month should contain more complete number counts on the other EPI pathogens and data items for this current month.

SUMMARY VERIFICATION REPORT OF EPI EXTRACTED DATA
FROM STATION 539 CINCINNATI

Processing Month PROCESSING PERIOD: 03-01-2004 through 03-31-2004

| | Number of Occurrences | Number of Persons Occurrence |
|------------------------|--------------------------|------------------------------------|
| with Emerging Pathogen | | |

Subj: EPI Summary Verification Report for prior month -TB only

[#19669069] Page 2

| | | |
|---|---|---|
| NTE~1-Vancomycin-resistant Enterococcus | 0 | 0 |
| NTE~2-Hepatitis C antibody Positive | 0 | 0 |
| NTE~3-Penicillin-Resistant Streptococcus pneumoniae | 0 | 0 |

Example: New EPI Summary Verification Report for prior month - TB only *continued.*

| | | |
|---------------------------------------|---|---|
| NTE~4-Clostridium difficile | 0 | 0 |
| NTE~5-Tuberculosis | 0 | 0 |
| NTE~6-Streptococcus, Group A | 0 | 0 |
| NTE~7-Legionella/Legionaire's Disease | 0 | 0 |
| NTE~8-Candida bloodstream infections | 0 | 0 |
| NTE~9-Cryptosporidium | 0 | 0 |
| NTE~10-Escherichia coli O157 | 0 | 0 |
| NTE~11-Malaria | 0 | 0 |
| NTE~12-Dengue | 0 | 0 |
| NTE~13-Creutzfeldt-Jakob Disease | 0 | 0 |
| NTE~14-Leishmaniasis | 0 | 0 |
| NTE~15-Hepatitis C antibody negative | 0 | 0 |
| NTE~16-Hepatitis A antibody positive | 0 | 0 |
| NTE~17-Hepatitis B positive | 0 | 0 |
| NTE~18-All Staphylococcus Aureus | 0 | 0 |

Subj: EPI Summary Verification Report for prior month -TB only
 [#19669069] Page 3

| | | |
|--|---|---|
| NTE~19-Methicillin-Resistant Staphylococcus Aureus (Mrsa) | 0 | 0 |
| NTE~20-Vancomycin-Resistant Staphylococcus Aureus (Vrsa) | 0 | 0 |
| NTE~21-Vancomycin-Resistant Coagulase Negative Staphylococci/Staph EPI (Vrse) | 0 | 0 |
| NTE~22-All Streptococcus Pneumoniae | 0 | 0 |
| NTE~23-All Enterococci | 0 | 0 |

For definitions of case ascertainment for each category, please refer to documentation in Laboratory EPI Patch LR*5.2*281 Technical and User Guide in conjunction with your local parameter set-up of this process.

If you feel that these numbers are in error, please verify with the local facility personnel responsible for setting the EPI Laboratory Search/Extract parameters. However, do not change these parameters if they are incorrect without fully reading the documentation; this will be crucial in order to avoid any misalignment with the concomitant Hepatitis C Extract patches (PXR*1.5*1, VA-National EPI DB Update, LR*5.2*260, PSJ*5*48, Hepatitis C Initiative, and PSO*7*45, Hepatitis C Initiative). In particular, the hepatitis C antibody positive, hepatitis C antibody negative, hepatitis A antibody positive and hepatitis B positive will be especially sensitive to changes, and concomitant changes of all of the patches may need to occur.

Subj: EPI Summary Verification Report for prior month -TB only
 [#19669069] Page 4

| | |
|--------------------------------------|---|
| Nationally rolled-up resolution term | Number of Persons with the Term and Transmitted For National Roll-up |
|--------------------------------------|---|

Example: New EPI Summary Verification Report for prior month - TB only *continued.*

| | |
|--|---|
| Resolved term-1-Declined Assessment for Hepatitis C | 0 |
| Resolved term-2-No Risk Factors for Hepatitis C | 0 |
| Resolved term-3-Previously Assessed for Hepatitis C | 0 |
| Resolved term-4-Risk Factors for Hepatitis C | 0 |
| Resolved term-5-Positive Test for Hepatitis C antibody | 0 |
| Resolved term-6-Negative Test for Hepatitis C antibody | 0 |
| Resolved term-7-Hepatitis C diagnosis (ICD-9 based) | 0 |

Total Hepatitis C Risk Assessment Resolution 0

This table represents only those who had a once-lifetime resolution of the National Clinical Reminder for Risk Assessment for Hepatitis C. This resolution will only occur once during the care of a patient (unless actively changed by a point-of-care practitioner at a later date).

Enter RETURN to continue or '^' to exit:

Subj: EPI Summary Verification Report for prior month -TB only
[#19669069] Page 5

Processing Month: PROCESSING PERIOD: 03-01-2004 through 03-31-2004 for site #
539 CINCINNATI
Site totals

1. For Microbiology Lab Package Organism results/isolates (e.g. Enterococcus, or Streptococcus pneumoniae), the number corresponding to the name represents the total number reported from your local microbiology package during the processing month. The number corresponding to the line 'Patients with...<Microbiology Lab Result/isolates> (e.g. Patients with Enterococcus or Patients with Streptococcus pneumoniae) represents the number of individual patients from whom the results were isolated.

2. For non-microbiology results (e.g. chemistry/serology results such as Hepatitis C antibody), the number corresponding to the name represents the TOTAL number of <named> tests done at your facility during the processing month. The number corresponding to the line <Patients with...<non-Microbiology test> (e.g. Hepatitis C antibody) represents the number of individuals on whom the test(s) was/were performed. This does not represent the number of persons who had a positive test result.

Subj: EPI Summary Verification Report for prior month -TB only
[#19669069] Page 6

3. These results have been obtained based on specimen accession date and not results reported dating.

Enter message action (in IN basket): Ignore//<Enter>

IN Basket Message: 7842//<Enter>

New Detailed Verification Report of EPI Extracted Data from Site Mailman Message

The **new** Verification Detailed Report of EPI Extracted Data from Site' **replaces** the original Emerging Pathogens Verification Report. The **new** report contains the VHA reporting site's station number with Notes and Comment Segments (NTE) findings in a human readable format. VHA sites reporting NTE findings (i.e., 1, 2, 3 . . . 23) starts with a new page for each NTE findings. The report is automatically generated on the 15th of the month and can also be generated **manually** as often as necessary using the Lab EPI Manual Run (Enhanced) [LREPI ENHANCE MANUAL RUN] option. After the report is generated the data is automatically sent to EPI-REPORT mail group which may be use for EPI data validation. Use the **new** Print Detailed Verification Report [LREPI VERIFICATION REPORT] option to print the **new** Verification Detailed Report.

Example: New Detailed Verification Report of EPI Extracted Data from Site mailman messages.

PAGE 1

DETAILED VERIFICATION REPORT OF EPI EXTRACTED DATA
FROM STATION (Your station number and name is displayed here.)
PROCESSING PERIOD: 03-01-2003 through 03-31-2003

NTE~1-Report of Vancomycin-resistant Enterococcus

These data note persons at your facility during the month that had a positive result for Vancomycin-resistant Enterococcus. Identifying information, along with specimen and culture results has been provided.

| PATIENT NAME | LAST 4 | DOB | SEX | PERIOD OF SERVICE |
|--|--------|------------|-----|-------------------|
| LABPATIENT3, TEN | 0310 | 03-11-1925 | M | WORLD WAR II |
| Inpatient Admission Date: 03-08-2003@1717 | | | | |
| Discharge Date: --" Discharge Disposition: | | | | |

| | | | | | | |
|-----------------|------|----|------|------------|---------|----------------------|
| 03-18-2003@0700 | BACT | 03 | 2038 | MICRO | CULTURE | URINE |
| 2 | | | | 03-20-2003 | | ENTEROCOCCUS FAECIUM |

ORG # 2 03-18-2003@0700 ANTIBIOTIC MIC URINE

| | | |
|-----------------|-------|-------|
| PENICILLIN | R | R |
| VANCOMYCIN | R | R |
| NITROFURANTOIN | S | S |
| CIPROFLOXACIN | R | R |
| LEVOFLOXACIN | R | R |
| GENTAMICIN HP | SYN-S | SYN-S |
| STREPTOMYCIN HP | SYN-R | SYN-R |

Example: New Detailed Verification Report of EPI Extracted Data from Site mailman messages
continued.

PAGE 2

DETAILED VERIFICATION REPORT OF EPI EXTRACTED DATA
 FROM STATION (Your station number and name is displayed here.)
 PROCESSING PERIOD: 03-01-2003 through 03-31-2003

NTE~2 Report of Hepatitis C antibody positive

This represents a line listing of persons reported during the month that had a positive test for hepatitis C antibody (based on accession date and not results reported date). Definitions for data to be extracted are provided in the Technical and User Guide documentation for Laboratory EPI LR*5.2*281.

| Name | LAST | 4 | Accession Date | Test Name | Test Result |
|-------------------|------|-----------------|----------------|-----------|-------------|
| LABPATIENT4~ONE | 0041 | 03-26-2003@1240 | HEP C | ANTIBODY | STRONG |
| POSITIVE | | | | | |
| LABPATIENT4~TWO | 0042 | 03-27-2003@1614 | HEP C | ANTIBODY | STRONG |
| POSITIVE | | | | | |
| LABPATIENT4~THREE | 0043 | 03-13-2003@0700 | HEP C | ANTIBODY | STRONG |
| POSITIVE | | | | | |
| LABPATIENT4~FOUR | 0044 | 03-19-2003 | HEP C | ANTIBODY | STRONG |
| POSITIVE | | | | | |
| LABPATIENT4~FIVE | 0045 | 03-08-2003@0700 | HEP C | ANTIBODY | STRONG |
| POSITIVE | | | | | |
| LABPATIENT4~SIX | 0046 | 03-05-2003@0823 | HEP C | ANTIBODY | STRONG |
| POSITIVE | | | | | |
| LABPATIENT4~SEVEN | 0047 | 03-08-2003@0700 | HEP C | ANTIBODY | STRONG |
| POSITIVE | | | | | |
| LABPATIENT4~EIGHT | 0048 | 03-08-2003@0700 | HEP C | ANTIBODY | STRONG |
| POSITIVE | | | | | |
| LABPATIENT4~NINE | 0049 | 03-05-2003@1726 | HEP C | ANTIBODY | STRONG |
| POSITIVE | | | | | |
| LABPATIENT4~TEN | 0410 | 03-14-2003@1004 | HEP C | ANTIBODY | STRONG |
| POSITIVE | | | | | |
| LABPATIENT5~ONE | 0051 | 03-07-2003@1015 | HEP C | ANTIBODY | STRONG |
| POSITIVE | | | | | |
| LABPATIENT5~TWO | 0052 | 03-21-2003@0700 | HEP C | ANTIBODY | STRONG |
| POSITIVE | | | | | |
| LABPATIENT5~THREE | 0053 | 03-10-2003@0807 | HEP C | ANTIBODY | STRONG |
| POSITIVE | | | | | |
| LABPATIENT5~FOUR | 0054 | 03-18-2003 | HEP C | ANTIBODY | STRONG |
| POSITIVE | | | | | |

Example: New Detailed Verification Report of EPI Extracted Data from Site mailman messages
continued.

| | | | |
|-------------------------------|------|-----------------|-----------------------|
| LABPATIENT5~FIVE POSITIVE | 0055 | 03-11-2003@0916 | HEP C ANTIBODY STRONG |
| LABPATIENT5~SIX POSITIVE | 0056 | 03-27-2003@0700 | HEP C ANTIBODY STRONG |
| LABPATIENT5~SEVEN POSITIVE | 0057 | 03-06-2003@0700 | HEP C ANTIBODY STRONG |
| LABPATIENT5~EIGHT POSITIVE | 0058 | 03-21-2003@0700 | HEP C ANTIBODY STRONG |
| LABPATIENT5~NINE POSITIVE | 0059 | 03-12-2003@0911 | HEP C ANTIBODY STRONG |
| LABPATIENT5~TEN POSITIVE | 0510 | 03-25-2003@1443 | HEP C ANTIBODY STRONG |
| LABPATIENT6~ONE POSITIVE | 0061 | 03-04-2003@1019 | HEP C ANTIBODY STRONG |
| LABPATIENT6~TWO POSITIVE | 0062 | 03-13-2003@0700 | HEP C ANTIBODY STRONG |
| LABPATIENT6~THREE POSITIVE | 0063 | 03-13-2003@0700 | HEP C ANTIBODY STRONG |
| LABPATIENT6~FOUR POSITIVE | 0064 | 03-04-2003@1648 | HEP C ANTIBODY STRONG |
| LABPATIENT6~FIVE POSITIVE | 0065 | 03-08-2003@0700 | HEP C ANTIBODY STRONG |
| LABPATIENT6~SIX POSITIVE | 0066 | 03-27-2003@1141 | HEP C ANTIBODY STRONG |
| LABPATIENT6~SEVEN POSITIVE | 0067 | 03-03-2003@1503 | HEP C ANTIBODY STRONG |
| LABPATIENT6~EIGHT POSITIVE | 0068 | 03-27-2003@0700 | HEP C ANTIBODY STRONG |
| LABPATIENT6~NINE POSITIVE | 0069 | 03-13-2003@0700 | HEP C ANTIBODY STRONG |
| LABPATIENT6~TEN POSITIVE | 0610 | 03-28-2003@1356 | HEP C ANTIBODY STRONG |

PAGE 3

DETAILED VERIFICATION REPORT OF EPI EXTRACTED DATA
FROM STATION (Your station number and name is displayed here.)
PROCESSING PERIOD: 03-01-2003 through 03-31-2003

NTE~3-Report of Pencillin-resistant Streptococcus pneumoniae
These data note persons at your facility during the month that had a
positive result for Penicillin-resistant Streptococcus pneumoniae.
Identifying information, along with specimen and culture results has been
provided.

NO PATIENTS REPORTED FOR THE REPORT PERIOD.

Example: New Detailed Verification Report of EPI Extracted Data from Site mailman messages
continued.

PAGE 4

DETAILED VERIFICATION REPORT OF EPI EXTRACTED DATA
 FROM STATION (Your station number and name is displayed here.)
 PROCESSING PERIOD: 03-01-2003 through 03-31-2003

NTE~4-Report of Clostridium difficile

These data note persons at your facility during the month that had a positive result for Clostridium difficile. Identifying information, along with specimen and culture results has been provided.

| PATIENT NAME | LAST 4 | DOB | SEX | PERIOD OF SERVICE |
|--------------|--------|-----|-----|-------------------|
|--------------|--------|-----|-----|-------------------|

| | | | | |
|------------------|------|------------|---|--------------|
| LABPATIENT7, ONE | 0071 | 01-00-1925 | M | WORLD WAR II |
|------------------|------|------------|---|--------------|

Inpatient Admission Date: 02-21-2003@2147

Discharge Date: 03-10-2003@2354 Discharge Disposition: DEATH WITH AUTOPSY

03-04-2003 MICRO 03 286 MICRO CULTURE FECES

| | | |
|---|------------|--------------------------|
| 1 | 03-05-2003 | POSITIVE FOR CLOSTRIDIUM |
|---|------------|--------------------------|

DIFFICILE TOXIN

| PATIENT NAME | LAST 4 | DOB | SEX | PERIOD OF SERVICE |
|--------------|--------|-----|-----|-------------------|
|--------------|--------|-----|-----|-------------------|

| | | | | |
|------------------|------|------------|---|-------------|
| LABPATIENT7, TWO | 0072 | 09-11-1934 | M | VIETNAM ERA |
|------------------|------|------------|---|-------------|

Outpatient Accession Date: 03-04-2003

03-04-2003 MICRO 03 279 MICRO CULTURE FECES

| | | |
|---|------------|--------------------------|
| 1 | 03-05-2003 | POSITIVE FOR CLOSTRIDIUM |
|---|------------|--------------------------|

DIFFICILE TOXIN

| PATIENT NAME | LAST 4 | DOB | SEX | PERIOD OF SERVICE |
|--------------|--------|-----|-----|-------------------|
|--------------|--------|-----|-----|-------------------|

| | | | | |
|--------------------|------|------------|---|-------------|
| LABPATIENT7, THREE | 0073 | 10-20-1946 | M | VIETNAM ERA |
|--------------------|------|------------|---|-------------|

Inpatient Admission Date: 03-14-2003@1202

Discharge Date: 03-20-2003@0341 Discharge Disposition: DEATH WITHOUT AUTOPSY

03-17-2003 MICRO 03 383 MICRO CULTURE FECES

| | | |
|---|------------|--------------------------|
| 1 | 03-19-2003 | POSITIVE FOR CLOSTRIDIUM |
|---|------------|--------------------------|

DIFFICILE TOXIN

Example: New Detailed Verification Report of EPI Extracted Data from Site mailman messages
continued.

PAGE 5

DETAILED VERIFICATION REPORT OF EPI EXTRACTED DATA
 FROM STATION (Your station number will be displayed here.)
 PROCESSING PERIOD: 03-01-2003 through 03-31-2003

NTE~5-Report of Tuberculosis

These data note persons at your facility during the month that had a positive result for Mycobacterium tuberculosis. Identifying information, along with specimen and culture results has been provided.

| PATIENT NAME | LAST 4 | DOB | SEX | PERIOD OF SERVICE |
|---------------------------------------|--------|------------|-----|-------------------|
| LABPATIENT7, FOUR | 0074 | 06-07-1930 | F | VIETNAM ERA |
| Outpatient Accession Date: 03-12-2003 | | | | |

| | |
|---|--------------------------|
| 03-12-2003 TB 03 212 MICRO CULTURE SPUTUM | |
| 3 | 05-21-2003 MYCOBACTERIUM |
| TUBERCULOSIS COMPLEX | |
| Outpatient Accession Date: 03-22-2003 | |

| | |
|---|--------------------------------|
| 03-22-2003 TB 03 213 MICRO CULTURE SPUTUM | |
| 2 | --0 MYCOBACTERIUM TUBERCULOSIS |
| COMPLEX | |

Example: New Detailed Verification Report of EPI Extracted Data from Site mailman messages
continued.

PAGE 6

DETAILED VERIFICATION REPORT OF EPI EXTRACTED DATA
 FROM STATION (Your station number and name is displayed here.)
 PROCESSING PERIOD: 03-01-2003 through 03-31-2003

NTE~6-Report of Group A Streptococcus

These data note persons at your facility during the month that had a positive result for Group A Streptococcus. Identifying information, along with specimen and culture results has been provided.

| PATIENT NAME | LAST 4 | DOB | SEX | PERIOD OF SERVICE |
|--|--------|------------|-----|-------------------|
| LABPATIENT7, FIVE | 0075 | 08-14-1941 | M | VIETNAM ERA |
| Inpatient Admission Date: 03-13-2003@1229 | | | | |
| Discharge Date: 03-14-2003@1333 Discharge Disposition: REGULAR | | | | |

| | | |
|--|------------|--------------------|
| 03-14-2003 BACT 03 1941 MICRO CULTURE RECTUM | | |
| 1 | 03-17-2003 | STREPTOCOCCUS BETA |
| HEMOLYTIC, GROUP A | | |
| 2 | 03-17-2003 | ESCHERICHIA COLI |

ORG # 2 03-14-2003 ANTIBIOTIC MIC RECTUM

| | | |
|-------------------------------|---|---|
| GENTAMICIN | S | S |
| CEFAZOLIN | S | S |
| AMPICILLIN | S | S |
| POLYMYXIN B | S | S |
| TRIMETHOPRIM+SULFAMETHOXAZOLE | R | R |
| AMIKACIN | S | S |
| PIPERACILLIN | S | S |
| CEFOTAXIME | S | S |
| CIPROFLOXACIN | S | S |
| IMIPENEM | S | S |
| CEFTAZIDIME | S | S |
| AMPICILLIN+SULBACTAM | S | S |
| CEFOTETAN | S | S |
| LEVOFLOXACIN | S | S |
| CEFEPIME | S | S |
| PIPERACILLIN+TAZOBACTAM | S | S |

| PATIENT NAME | LAST 4 | DOB | SEX | PERIOD OF SERVICE |
|---------------------------------------|--------|------------|-----|-------------------|
| LABPATIENT7, SIX | 0076 | 02-13-1973 | M | OTHER OR NONE |
| Outpatient Accession Date: 03-04-2003 | | | | |

| | | |
|---|------------|--------------------|
| 03-04-2003 BACT 03 1655 MICRO CULTURE PHARYNX | | |
| 1 | 03-05-2003 | STREPTOCOCCUS BETA |
| HEMOLYTIC, GROUP A | | |

Example: New Detailed Verification Report of EPI Extracted Data from Site mailman messages
continued.

PAGE 7

DETAILED VERIFICATION REPORT OF EPI EXTRACTED DATA
 FROM STATION (Your station number and name is displayed here.)
 PROCESSING PERIOD: 03-01-2003 through 03-31-2003

NTE~7- Report of Legionella/Legionaire's

These data note persons at your facility during the month who had an EITHER an ICD-9 coded diagnosis for Legionella/Legionaire's disease OR a positive culture result. Identifying information, along with specimen and culture results has been provided.

NO PATIENTS REPORTED FOR THE REPORT PERIOD.

PAGE 8

DETAILED VERIFICATION REPORT OF EPI EXTRACTED DATA
 FROM STATION (Your station number and name is displayed here.)
 PROCESSING PERIOD: 03-01-2003 through 03-31-2003

NTE~8-Report of Candida bloodstream infections

These data note persons at your facility during the month that had a positive result for Candida (or other yeast) bloodstream infections. Identifying information, along with specimen and culture results has been provided.

| PATIENT NAME | LAST 4 | DOB | SEX | PERIOD OF SERVICE |
|--|--------|------------|-----|-------------------|
| LABPATIENT7, SEVEN | 0077 | 05-25-1943 | M | VIETNAM ERA |
| Update Admission Date: 12-19-2002@1605 | | | | |

| | | | | | |
|-----------------|-----|----|-----|---------------------|----------------------|
| 03-18-2003@2235 | BLD | 03 | 856 | MICRO CULTURE BLOOD | |
| 1 | | | | 03-25-2003 | YEAST |
| 1 | | | | 03-25-2003 | CANDIDA (TORULOPSIS) |
| GLABRATA | | | | | |

| | | | | | |
|-----------------|-----|----|-----|---------------------|----------------------|
| 03-16-2003@1600 | BLD | 03 | 837 | MICRO CULTURE BLOOD | |
| 1 | | | | 03-22-2003 | YEAST |
| 1 | | | | 03-23-2003 | CANDIDA (TORULOPSIS) |
| GLABRATA | | | | | |

| | | | | | |
|----------------------|-----|----|-----|---------------------|----------------------|
| 03-12-2003 | BLD | 03 | 793 | MICRO CULTURE BLOOD | |
| 1 | | | | 03-17-2003 | YEAST |
| 2 | | | | 03-17-2003 | STAPHYLOCOCCUS |
| (COAGULASE NEGATIVE) | | | | | |
| 1 | | | | 03-15-2003 | CANDIDA (TORULOPSIS) |
| GLABRATA | | | | | |

Example: New Detailed Verification Report of EPI Extracted Data from Site mailman messages
continued.

```
03-11-2003@0230 MYCOL 03 166 MICRO CULTURE BLOOD
      1                                03-17-2003  CANDIDA (TORULOPSIS)
GLABRATA
```

```
03-11-2003@0230 BLD 03 780 MICRO CULTURE BLOOD
      1                                03-17-2003  STAPHYLOCOCCUS
(COAGULASE NEGATIVE)
      2                                03-17-2003  YEAST
      1                                03-17-2003  CANDIDA (TORULOPSIS)
GLABRATA
```

```
03-08-2003@0915 BLD 03 757 MICRO CULTURE BLOOD
      1                                03-12-2003  YEAST
      1                                03-12-2003  CANDIDA (TORULOPSIS)
GLABRATA
```

PAGE 9

DETAILED VERIFICATION REPORT OF EPI EXTRACTED DATA
FROM STATION (Station name/number displayed here.)
PROCESSING PERIOD: 03-01-2003 through 03-31-2003

NTE~9-Report of Cryptosporidium

These data note persons at your facility during the month that had EITHER an ICD-9 coded diagnosis for Cryptosporidium OR a positive culture result. Identifying information, along with specimen and culture results has been provided.

NO PATIENTS REPORTED FOR THE REPORT PERIOD.

PAGE 10

DETAILED VERIFICATION REPORT OF EPI EXTRACTED DATA
FROM STATION (Station name/number displayed here.)
PROCESSING PERIOD: 03-01-2003 through 03-31-2003

NTE~10-Report of Escherichia coli O157

These data note persons at your facility during the month that had a positive result for Escherichia coli serotype O157. Identifying information, along with specimen and culture results has been provided.

NO PATIENTS REPORTED FOR THE REPORT PERIOD.

Example: New Detailed Verification Report of EPI Extracted Data from Site mailman messages
continued.

PAGE 11

DETAILED VERIFICATION REPORT OF EPI EXTRACTED DATA
 STATION (Your station your number is displayed here)
 PROCESSING PERIOD: 03-01-2003 through 03-31-2003

NTE~11-Report of Malaria
 These data note persons at your facility during the month that had an ICD-9 coded diagnosis for malaria. Identifying information has been provided.

NO PATIENTS REPORTED FOR THE REPORT PERIOD.

PAGE 12

DETAILED VERIFICATION REPORT OF EPI EXTRACTED DATA
 STATION (Your station your number is displayed here)
 PROCESSING PERIOD: 03-01-2003 through 03-31-2003

NTE~12-Report of Dengue
 These data note persons at your facility during the month that had an ICD-9 coded diagnosis for dengue. Identifying information has been provided.

NO PATIENTS REPORTED FOR THE REPORT PERIOD.

PAGE 13

DETAILED VERIFICATION REPORT OF EPI EXTRACTED DATA
 FROM STATION (Your station number and name is displayed here.)
 PROCESSING PERIOD: 03-01-2003 through 03-31-2003

NTE~13-Report of Creutzfeldt-Jakob Disease
 These data note persons at your facility during the month that had an ICD-9 coded diagnosis for Creutzfeldt-Jakob disease. Identifying information has been provided.

NO PATIENTS REPORTED FOR THE REPORT PERIOD.

PAGE 14

DETAILED VERIFICATION REPORT OF EPI EXTRACTED DATA
 FROM STATION (Your station number and name is displayed here.)
 PROCESSING PERIOD: 03-01-2003 through 03-31-2003

NTE~14-Report of Leishmaniasis
 These data note persons at your facility during the month that had an ICD-9 coded diagnosis for Leishmania. Identifying information has been provided.

NO PATIENTS REPORTED FOR THE REPORT PERIOD.

Example: New Detailed Verification Report of EPI Extracted Data from Site mailman messages
continued.

PAGE 15

DETAILED VERIFICATION REPORT OF EPI EXTRACTED DATA
 FROM STATION (Your station number and name is displayed here.)
 PROCESSING PERIOD: 03-01-2003 through 03-31-2003

NTE~15 Report of Hepatitis C antibody negative

This represents a line listing of persons reported during the month who had a negative test for hepatitis C antibody (based on accession date and not results reported date). Definitions for data to be extracted are provided in the Technical and User Guide documentation for Laboratory EPI LR*5.2*281.

| Name | LAST 4 | Accession Date | Test Name | Test Result |
|-------------------|--------|-----------------|----------------|-------------|
| LABPATIENT7~EIGHT | 0078 | 03-05-2003@0700 | HEP C ANTIBODY | NEGATIVE |
| LABPATIENT7~NINE | 0079 | 03-18-2003@0743 | HEP C ANTIBODY | NEGATIVE |
| LABPATIENT7~TEN | 0710 | 03-03-2003@0846 | HEP C ANTIBODY | NEGATIVE |
| LABPATIENT8~ONE | 0081 | 03-26-2003@1515 | HEP C ANTIBODY | NEGATIVE |
| LABPATIENT8~TWO | 0082 | 03-28-2003@1506 | HEP C ANTIBODY | NEGATIVE |
| LABPATIENT8~THREE | 0083 | 03-03-2003@0700 | HEP C ANTIBODY | NEGATIVE |
| LABPATIENT8~FOUR | 0084 | 03-25-2003@1039 | HEP C ANTIBODY | NEGATIVE |
| LABPATIENT8~FIVE | 0085 | 03-04-2003@1138 | HEP C ANTIBODY | NEGATIVE |
| LABPATIENT8~SIX | 0086 | 03-20-2003@0700 | HEP C ANTIBODY | NEGATIVE |
| LABPATIENT8~SEVEN | 0087 | 03-21-2003@0700 | HEP C ANTIBODY | NEGATIVE |
| LABPATIENT8~EIGHT | 0088 | 03-27-2003@0700 | HEP C ANTIBODY | NEGATIVE |
| LABPATIENT8~NINE | 0089 | 03-18-2003@1111 | HEP C ANTIBODY | NEGATIVE |
| LABPATIENT8~TEN | 0810 | 03-05-2003@0819 | HEP C ANTIBODY | NEGATIVE |
| LABPATIENT9~ONE | 0091 | 03-19-2003@1335 | HEP C ANTIBODY | NEGATIVE |
| LABPATIENT9~TWO | 0092 | 03-27-2003@1622 | HEP C ANTIBODY | NEGATIVE |
| LABPATIENT9~THREE | 0093 | 03-17-2003@1418 | HEP C ANTIBODY | NEGATIVE |
| LABPATIENT9~FOUR | 0094 | 03-28-2003@1439 | HEP C ANTIBODY | NEGATIVE |
| LABPATIENT9~FIVE | 0095 | 03-05-2003@0822 | HEP C ANTIBODY | NEGATIVE |
| LABPATIENT9~SIX | 0096 | 03-19-2003@1553 | HEP C ANTIBODY | NEGATIVE |
| LABPATIENT9~SEVEN | 0097 | 03-17-2003@1423 | HEP C ANTIBODY | NEGATIVE |
| LABPATIENT9~EIGHT | 0098 | 03-14-2003 | HEP C ANTIBODY | NEGATIVE |
| LABPATIENT9~NINE | 0099 | 03-21-2003@0939 | HEP C ANTIBODY | NEGATIVE |
| LABPATIENT9~TEN | 0910 | 03-06-2003@1007 | HEP C ANTIBODY | NEGATIVE |
| LABPATIENT10~ONE | 0101 | 03-21-2003@1210 | HEP C ANTIBODY | NEGATIVE |

Example: New Detailed Verification Report of EPI Extracted Data from Site mailman messages
continued.

PAGE 16

DETAILED VERIFICATION REPORT OF EPI EXTRACTED DATA
 FROM STATION (Your station number and name is displayed here.)
 PROCESSING PERIOD: 03-01-2003 through 03-31-2003

NTE~16 Report of Hepatitis A antibody positive

This represents a line listing of persons reported during the month who had a positive test for hepatitis A antibody (based on accession date and not results reported date). Definitions for data to be extracted are provided in the Technical and User Guide documentation for Laboratory EPI LR*5.2*281.

| Name | LAST 4 | Accession Date | Test Name | Test Result |
|--------------------|--------|-----------------|----------------------|-------------|
| LABPATIENT7~NINE | 0079 | 03-18-2003@0743 | HEP A ANTIBODY(IGM) | NEGATIVE |
| LABPATIENT8~THREE | 0083 | 03-03-2003@0700 | HEP A ANTIBODY(IGM) | NEGATIVE |
| LABPATIENT4~ONE | 0041 | 03-26-2003@1240 | HEP A ANTIBODY-TOTAL | |
| REACTIVE | | | | |
| LABPATIENT9~TWO | 0092 | 03-27-2003@1622 | HEP A ANTIBODY(IGM) | NEGATIVE |
| LABPATIENT4~FOUR | 0044 | 03-19-2003 | HEP A ANTIBODY-TOTAL | |
| REACTIVE | | | | |
| LABPATIENT9~FOUR | 0094 | 03-28-2003@1439 | HEP A ANTIBODY(IGM) | NEGATIVE |
| LABPATIENT9~SIX | 0096 | 03-19-2003@1553 | HEP A ANTIBODY-TOTAL | |
| REACTIVE | | | | |
| LABPATIENT10~TWO | 0102 | 03-17-2003@1117 | HEP A ANTIBODY-TOTAL | |
| REACTIVE | | | | |
| LABPATIENT4~EIGHT | 0048 | 03-08-2003@0700 | HEP A ANTIBODY-TOTAL | |
| REACTIVE | | | | |
| LABPATIENT10~THREE | 0103 | 03-27-2003@0950 | HEP A ANTIBODY(IGM) | NEGATIVE |
| LABPATIENT10~FOUR | 0104 | 03-28-2003@1025 | HEP A ANTIBODY-TOTAL | |
| REACTIVE | | | | |
| LABPATIENT10~FIVE | 0105 | 03-17-2003@1024 | HEP A ANTIBODY-TOTAL | |
| REACTIVE | | | | |
| LABPATIENT10~SIX | 0106 | 03-12-2003@1450 | HEP A ANTIBODY-TOTAL | |
| REACTIVE | | | | |
| LABPATIENT10~SEVEN | 0107 | 03-12-2003@1016 | HEP A ANTIBODY(IGM) | NEGATIVE |
| LABPATIENT5~ONE | 0051 | 03-07-2003@1015 | HEP A ANTIBODY-TOTAL | |
| REACTIVE | | | | |
| LABPATIENT10~EIGHT | 0108 | 03-10-2003@0943 | HEP A ANTIBODY-TOTAL | |
| REACTIVE | | | | |
| LABPATIENT10~NINE | 0109 | 03-06-2003@0920 | HEP A ANTIBODY(IGM) | NEGATIVE |

Example: New Detailed Verification Report of EPI Extracted Data from Site mailman messages
continued.

| LABPATIENT10~TEN | 1010 | 03-06-2003@0700 | HEP A ANTIBODY(IGM) NEGATIVE |
|---|--------|-----------------|------------------------------|
| LABPATIENT11~ONE | 0111 | 03-28-2003@0930 | HEP A ANTIBODY(IGM) NEGATIVE |
| LABPATIENT11~TWO | 0112 | 03-03-2003@1549 | HEP A ANTIBODY-TOTAL |
| REACTIVE | | | |
| LABPATIENT11~THREE | 0113 | 03-17-2003@1136 | HEP A ANTIBODY-TOTAL |
| REACTIVE | | | |
| LABPATIENT11~FOUR | 0114 | 03-29-2003@0700 | HEP A ANTIBODY-TOTAL |
| REACTIVE | | | |
| LABPATIENT11~FIVE | 0115 | 03-28-2003@1357 | HEP A ANTIBODY(IGM) NEGATIVE |
| LABPATIENT11~FIVE | 0115 | | HEP A ANTIBODY-TOTAL |
| REACTIVE | | | |
| PAGE 17 | | | |
| DETAILED VERIFICATION REPORT OF EPI EXTRACTED DATA | | | |
| FROM STATION (Your station number and name is displayed here.) | | | |
| PROCESSING PERIOD: 03-01-2003 through 03-31-2003 | | | |
| NTE~17 Report of Hepatitis B positive | | | |
| This represents a line listing of persons reported during the month who had | | | |
| a positive test for hepatitis B (based on accession date and not results | | | |
| reported date). Definitions for data to be extracted are provided in the | | | |
| Technical and User Guide documentation for Laboratory EPI LR*5.2*281. | | | |
| Name | LAST 4 | Accession Date | Test Name Test Result |
| LABPATIENT7~EIGHT | 0078 | 03-05-2003@0700 | HEP B SURFACE AG NEGATIVE |
| LABPATIENT7~EIGHT | 0078 | | HEP B SURFACE AB LOW TITER |
| POSITIVE | | | |
| LABPATIENT9~TWO | 0092 | 03-27-2003@1622 | HEP B SURFACE AG NEGATIVE |
| LABPATIENT9~TWO | 0092 | | HEP B SURFACE AB LOW TITER |
| POSITIVE | | | |
| LABPATIENT9~TWO | 0092 | | HEP B CORE AB(IGM) NEGATIVE |
| LABPATIENT11~SIX | 0116 | 03-22-2003@0700 | HEP B SURFACE AG NEGATIVE |
| LABPATIENT11~SIX | 0116 | | HEP B SURFACE AB ADEQUATE |
| TITER | | | |
| POSITIVE | | | |
| LABPATIENT11~SEVEN | 0117 | 03-25-2003@1610 | HEP B SURFACE AB ADEQUATE |
| TITER | | | |
| POSITIVE | | | |
| LABPATIENT11~EIGHT | 0118 | 03-06-2003@1025 | HEP B SURFACE AB LOW TITER |
| POSITIVE | | | |
| LABPATIENT4~TEN | 0410 | 03-14-2003@1004 | HEP B SURFACE AG NEGATIVE |
| LABPATIENT4~TEN | 0410 | | HEP B SURFACE AB ADEQUATE |
| TITER POSITIVE | | | |
| LABPATIENT11~NINE | 0119 | 03-28-2003@1530 | HEP B SURFACE AB LOW TITER |
| POSITIVE | | | |

Example: New Detailed Verification Report of EPI Extracted Data from Site mailman messages
continued.

| | | | |
|---|------------|---------------------|--|
| LABPATIENT11~TEN | 1110 | 03-13-2003@0700 | HEP B SURFACE AG POSITIVE |
| LABPATIENT11~TEN | 1110 | | HEP B SURFACE AB NEGATIVE |
| LABPATIENT12~ONE | 0121 | 03-19-2003@0700 | HEP B SURFACE AG NEGATIVE |
| LABPATIENT12~ONE | 0121 | | HEP B SURFACE AB LOW TITER POSITIVE |
| LABPATIENT12~ONE | 0121 | | HEP B CORE AB (IGM) NEGATIVE |
| WUDFES~JUHDFESXY~K | 6546 | 03-07-2003@1258 | HEP B SURFACE AB LOW TITER POSITIVE |
| LABPATIENT12~TWO | 0122 | 03-18-2003@1155 | HEP B SURFACE AG NEGATIVE |
| LABPATIENT12~TWO | 0122 | | HEP B SURFACE AB LOW TITER POSITIVE |
| LABPATIENT12~THREE | 0123 | 03-10-2003@1214 | HEP B SURFACE AG NEGATIVE |
| LABPATIENT12~THREE | 0123 | | HEP B SURFACE AB ADEQUATE TITER POSITIVE |
| LABPATIENT12~FOUR | 0124 | 03-19-2003@1520 | HEP B SURFACE AG NEGATIVE |
| LABPATIENT12~FOUR | 0124 | | HEP B SURFACE AB ADEQUATE TITER POSITIVE |
| PAGE 18 | | | |
| DETAILED VERIFICATION REPORT OF EPI EXTRACTED DATA FROM STATION (Your station number and name is displayed here.) PROCESSING PERIOD: 03-01-2003 through 03-31-2003 | | | |
| NTE~18-Report of All Staphylococcus aureus These data note persons at your facility during the month that had a positive result for all Staphylococcus aureus. Identifying information, along with specimen and culture results has been provided. | | | |
| PATIENT NAME | LAST 4 | DOB | SEX PERIOD OF SERVICE |
| LABPATIENT12, FIVE | 0125 | 04-25-1930 | M KOREAN |
| Inpatient Admission Date: 03-14-2003@2035 | | | |
| Discharge Date: 03-27-2003@1646 Discharge Disposition: REGULAR | | | |
| 03-16-2003@2120 | BLD 03 835 | MICRO CULTURE BLOOD | |
| 1 | | 03-23-2003 | STAPHYLOCOCCUS AUREUS |
| 03-16-2003@2100 | BLD 03 836 | MICRO CULTURE BLOOD | |
| 1 | | 03-23-2003 | STAPHYLOCOCCUS AUREUS |
| 03-15-2003@2222 | BLD 03 826 | MICRO CULTURE BLOOD | |
| 1 | | 03-18-2003 | STAPHYLOCOCCUS AUREUS |
| 03-15-2003@2222 | BLD 03 825 | MICRO CULTURE BLOOD | |
| 1 | | 03-18-2003 | STAPHYLOCOCCUS AUREUS |
| 03-14-2003@2213 | BLD 03 812 | MICRO CULTURE BLOOD | |
| 1 | | 03-20-2003 | STAPHYLOCOCCUS AUREUS |

Example: New Detailed Verification Report of EPI Extracted Data from Site mailman messages
continued.

ORG # 1 03-14-2003@2213 ANTIBIOTIC MIC BLOOD

| | | |
|-------------------------------|---|---|
| PENICILLIN | R | R |
| CLINDAMYCIN | S | S |
| VANCOMYCIN | S | S |
| GENTAMICIN | S | S |
| CEFAZOLIN | S | S |
| TETRACYCLINE | S | S |
| TRIMETHOPRIM+SULFAMETHOXAZOLE | S | S |
| ERYTHROMYCIN | S | S |
| NITROFURANTOIN | S | S |
| RIFAMPIN | S | S |
| OXACILLIN | S | S |
| CIPROFLOXACIN | S | S |
| AMPICILLIN+SULBACTAM | S | S |
| LEVOFLOXACIN | S | S |
| AMOXICILLIN CLAVULANIC ACID | S | S |

| PATIENT NAME | LAST 4 | DOB | SEX | PERIOD OF SERVICE |
|-------------------|--------|------------|-----|-------------------|
| LABPATIENT12, SIX | 0126 | 01-28-1934 | M | KOREAN |

Outpatient Accession Date: 03-04-2003

03-04-2003 BLD 03 726 MICRO CULTURE BLOOD
 1 03-07-2003 STAPHYLOCOCCUS AUREUS

ORG # 1 03-04-2003 ANTIBIOTIC MIC BLOOD

| | | |
|-------------------------------|---|---|
| PENICILLIN | R | R |
| CLINDAMYCIN | S | S |
| VANCOMYCIN | S | S |
| GENTAMICIN | S | S |
| CEFAZOLIN | S | S |
| TETRACYCLINE | S | S |
| TRIMETHOPRIM+SULFAMETHOXAZOLE | S | S |
| ERYTHROMYCIN | S | S |
| NITROFURANTOIN | S | S |
| RIFAMPIN | S | S |
| OXACILLIN | S | S |
| CIPROFLOXACIN | S | S |
| AMPICILLIN+SULBACTAM | S | S |
| LEVOFLOXACIN | S | S |
| AMOXICILLIN CLAVULANIC ACID | S | S |

Outpatient Accession Date: 03-05-2003@0000

03-05-2003@0000 BLD 03 730 MICRO CULTURE BLOOD
 1 03-07-2003 STAPHYLOCOCCUS AUREUS

Example: New Detailed Verification Report of EPI Extracted Data from Site mailman messages
continued.

```

Inpatient Admission Date: 03-05-2003@1520
Discharge Date: 03-31-2003@1447 Discharge Disposition: REGULAR

03-09-2003@0940 BLD 03 762 MICRO CULTURE BLOOD
      1                                03-14-2003    STAPHYLOCOCCUS AUREUS

ORG # 1 03-09-2003@0940 ANTIBIOTIC MIC BLOOD
      PENICILLIN                      R              R
      CLINDAMYCIN                     S              S
      VANCOMYCIN                      S              S
      GENTAMICIN                      S              S
      CEFAZOLIN                      S              S
      TETRACYCLINE                    S              S
      TRIMETHOPRIM+SULFAMETHOXAZOLE  S              S
      ERYTHROMYCIN                   S              S
      NITROFURANTOIN                 S              S
      RIFAMPIN                       S              S
      OXACILLIN                      S              S
      CIPROFLOXACIN                  S              S
      AMPICILLIN+SULBACTAM            S              S
      LEVOFLOXACIN                   S              S
      AMOXICILLIN CLAVULANIC ACID     S              S

03-05-2003 BLD 03 729 MICRO CULTURE BLOOD
      1                                03-07-2003    STAPHYLOCOCCUS AUREUS

PATIENT NAME                      LAST 4 DOB          SEX    PERIOD OF SERVICE
LABPATIENT12, SEVEN              0127    04-27-1953 M    VIETNAM ERA
HOMELESS Inpatient Admission Date: 03-16-2003@0035
Discharge Date: 03-31-2003@1459 Discharge Disposition: REGULAR

03-22-2003@0419 BLD 03 879 MICRO CULTURE BLOOD
      2                                03-24-2003    STAPHYLOCOCCUS AUREUS
(MRSA)

ORG # 2 03-22-2003@0419 ANTIBIOTIC MIC BLOOD
      PENICILLIN                      R              R
      CLINDAMYCIN                     S              S
      VANCOMYCIN                      S              S
      GENTAMICIN                      S              S
      CEFAZOLIN                      R              R
      TETRACYCLINE                    S              S
      TRIMETHOPRIM+SULFAMETHOXAZOLE  S              S
      ERYTHROMYCIN                   R              R
      NITROFURANTOIN                 S              S
      RIFAMPIN                       S              S
      OXACILLIN                      R              R
      CIPROFLOXACIN                  S              S

```


Example: New Detailed Verification Report of EPI Extracted Data from Site mailman messages
continued.

| | | |
|---|-----------------|------------------------------|
| AMPICILLIN+SULBACTAM | R | R |
| LEVOFLOXACIN | S | S |
| AMOXICILLIN CLAVULANIC ACID | R | R |
| 03-22-2003@0300 BLD 03 880 MICRO CULTURE BLOOD | | |
| 1 | 03-24-2003 | STAPHYLOCOCCUS AUREUS (MRSA) |
| 03-22-2003@0245 BLD 03 881 MICRO CULTURE BLOOD | | |
| 1 | 03-24-2003 | STAPHYLOCOCCUS AUREUS (MRSA) |
| PAGE 19 | | |
| DETAILED VERIFICATION REPORT OF EPI EXTRACTED DATA | | |
| FROM STATION 539 CINCINNATI VAMC | | |
| PROCESSING PERIOD: 03-01-2003 through 03-31-2003 | | |
| NTE~19-Report of methicillin-resistant Staphylococcus | | |
| These data note persons at your facility during the month that had a | | |
| positive result for methicillin-resistant Staphylococcus aureus. | | |
| Identifying information, along with specimen and culture results has been | | |
| provided. | | |
| PATIENT NAME | | |
| LABPATIENT12, SEVEN | LAST 4 DOB | SEX |
| HOMELESS | 0127 04-27-1953 | M |
| Inpatient Admission Date: 03-16-2003@0035 | | |
| Discharge Date: 03-31-2003@1459 Discharge Disposition: REGULAR | | |
| 03-22-2003@0419 BLD 03 879 MICRO CULTURE BLOOD | | |
| 2 | 03-24-2003 | STAPHYLOCOCCUS AUREUS |
| (MRSA) | | |
| ORG # 2 03-22-2003@0419 ANTIBIOTIC MIC BLOOD | | |
| PENICILLIN | R | R |
| CLINDAMYCIN | S | S |
| VANCOMYCIN | S | S |
| GENTAMICIN | S | S |
| CEFAZOLIN | R | R |
| TETRACYCLINE | S | S |
| TRIMETHOPRIM+SULFAMETHOXAZOLE | S | S |
| ERYTHROMYCIN | R | R |
| NITROFURANTOIN | S | S |
| RIFAMPIN | S | S |
| OXACILLIN | R | R |

Example: New Detailed Verification Report of EPI Extracted Data from Site mailman messages
continued.

| | | |
|--|-------------------|------------------------|
| CIPROFLOXACIN | S | S |
| AMPICILLIN+SULBACTAM | R | R |
| LEVOFLOXACIN | S | S |
| AMOXICILLIN CLAVULANIC ACID | R | R |
| PATIENT NAME LAST 4 DOB SEX PERIOD OF SERVICE | | |
| LABPATIENT12, EIGHT | 0128 08-26-1922 M | KOREAN |
| Inpatient Admission Date: 03-13-2003@2113 | | |
| Discharge Date: 04-03-2003@1216 Discharge Disposition: REGULAR | | |
| 03-23-2003@2130 BACT 03 2186 MICRO CULTURE SKIN | | |
| 1 | 03-27-2003 | STAPHYLOCOCCUS AUREUS |
| (MRSA) | | |
| ORG # 1 03-23-2003@2130 ANTIBIOTIC MIC SKIN | | |
| PENICILLIN | R | R |
| CLINDAMYCIN | R | R |
| VANCOMYCIN | S | S |
| GENTAMICIN | S | S |
| CEFAZOLIN | R | R |
| TETRACYCLINE | S | S |
| TRIMETHOPRIM+SULFAMETHOXAZOLE | S | S |
| ERYTHROMYCIN | R | R |
| NITROFURANTOIN | S | S |
| RIFAMPIN | S | S |
| OXACILLIN | R | R |
| CIPROFLOXACIN | R | R |
| AMPICILLIN+SULBACTAM | R | R |
| LEVOFLOXACIN | R | R |
| AMOXICILLIN CLAVULANIC ACID | R | R |
| 03-15-2003@0000 BACT 03 1984 MICRO CULTURE SPUTUM | | |
| 1 | 03-18-2003 | STAPHYLOCOCCUS AUREUS |
| (MRSA) | | |
| 2 | 03-18-2003 | PROTEUS MIRABILIS |
| 3 | 03-18-2003 | ACINETOBACTER BAUMANII |
| 4 | 03-18-2003 | CITROBACTER KOSERII |
| (DIVERSUS) | | |
| ORG # 1 03-15-2003@0000 ANTIBIOTIC MIC SPUTUM | | |
| PENICILLIN | R | R |
| CLINDAMYCIN | R | R |
| VANCOMYCIN | S | S |
| GENTAMICIN | S | S |
| CEFAZOLIN | R | R |
| TETRACYCLINE | S | S |

Example: New Detailed Verification Report of EPI Extracted Data from Site mailman messages
continued.

| | | |
|---|---|---|
| TRIMETHOPRIM+SULFAMETHOXAZOLE | S | S |
| ERYTHROMYCIN | R | R |
| NITROFURANTOIN | S | S |
| RIFAMPIN | S | S |
| OXACILLIN | R | R |
| CIPROFLOXACIN | R | R |
| AMPICILLIN+SULBACTAM | R | R |
| LEVOFLOXACIN | R | R |
| AMOXICILLIN CLAVULANIC ACID | R | R |
| ORG # 2 03-15-2003@0000 ANTIBIOTIC MIC SPUTUM | | |
| GENTAMICIN | S | S |
| CEFAZOLIN | S | S |
| AMPICILLIN | R | R |
| POLYMXIN B | S | S |
| TRIMETHOPRIM+SULFAMETHOXAZOLE | R | R |
| AMIKACIN | S | S |
| PIPERACILLIN | R | R |
| CEFOTAXIME | S | S |
| CIPROFLOXACIN | R | R |
| IMIPENEM | S | S |
| CEFTAZIDIME | S | S |
| AMPICILLIN+SULBACTAM | R | R |
| CEFOTETAN | S | S |
| LEVOFLOXACIN | R | R |
| CEFEPIME | S | S |
| PIPERACILLIN+TAZOBACTAM | S | S |
| ORG # 3 03-15-2003@0000 ANTIBIOTIC MIC SPUTUM | | |
| GENTAMICIN | S | S |
| CEFAZOLIN | R | R |
| AMPICILLIN | I | I |
| POLYMXIN B | S | S |
| TRIMETHOPRIM+SULFAMETHOXAZOLE | S | S |
| AMIKACIN | S | S |
| PIPERACILLIN | S | S |
| CEFOTAXIME | S | S |
| CIPROFLOXACIN | R | R |
| IMIPENEM | S | S |
| CEFTAZIDIME | S | S |
| AMPICILLIN+SULBACTAM | S | S |
| CEFOTETAN | R | R |
| LEVOFLOXACIN | R | R |
| CEFEPIME | S | S |
| PIPERACILLIN+TAZOBACTAM | S | S |

Example: New Detailed Verification Report of EPI Extracted Data from Site mailman messages
continued.

| | | |
|-------------------------------|----------------|--------|
| ORG # 4 03-15-2003@0000 | ANTIBIOTIC MIC | SPUTUM |
| GENTAMICIN | S | S |
| CEFAZOLIN | S | S |
| POLYMXIN B | S | S |
| TRIMETHOPRIM+SULFAMETHOXAZOLE | S | S |
| AMIKACIN | S | S |
| PIPERACILLIN | S | S |
| CEFOTAXIME | S | S |
| CIPROFLOXACIN | S | S |
| IMIPENEM | S | S |
| CEFTAZIDIME | S | S |
| CEFOTETAN | S | S |
| LEVOFLOXACIN | S | S |
| CEFEPIME | S | S |
| PIPERACILLIN+TAZOBACTAM | S | S |

PAGE 20

DETAILED VERIFICATION REPORT OF EPI EXTRACTED DATA
FROM STATION (Your station number and name is displayed here.)
PROCESSING PERIOD: 03-01-2003 through 03-31-2003

NTE~20-Vancomycin-resistant Staphylococcus aureus
These data note persons at your facility during the month that had a positive result for Vancomycin-resistant Staphylococcus aureus. Identifying information, along with specimen and culture results has been provided.

NO PATIENTS REPORTED FOR THE REPORT PERIOD.

PAGE 21

DETAILED VERIFICATION REPORT OF EPI EXTRACTED DATA
FROM STATION (Your station number and name is displayed here.)
PROCESSING PERIOD: 03-01-2003 through 03-31-2003

NTE~21-Vancomycin-resistant coagulase negative Staphylococcus
These data note persons at your facility during the month that had a positive result for Vancomycin-resistant coagulase negative staphylococcus. Identifying information, along with specimen and culture results has been provided.

NO PATIENTS REPORTED FOR THE REPORT PERIOD.

Example: New Detailed Verification Report of EPI Extracted Data from Site mailman messages
continued.

PAGE 22

DETAILED VERIFICATION REPORT OF EPI EXTRACTED DATA
 FROM STATION (Your station number and name is displayed here.)
 PROCESSING PERIOD: 03-01-2003 through 03-31-2003

NTE~22-All Streptococcus pneumoniae

These data note persons at your facility during the month that had a positive result for all Streptococcus pneumoniae. Identifying information, along with specimen and culture results has been provided.

| PATIENT NAME | LAST 4 | DOB | SEX | PERIOD OF SERVICE |
|--|--------|------------|-----|-------------------|
| LABPATIENT12, NINE | 0129 | 07-06-1922 | M | VIETNAM ERA |
| Inpatient Admission Date: 03-12-2003@1205 | | | | |
| Discharge Date: 03-20-2003@1320 Discharge Disposition: REGULAR | | | | |

| | | |
|-----------------|--------------|--------------------------|
| 03-12-2003@1420 | BACT 03 1894 | MICRO CULTURE SPUTUM |
| 1 | 03-15-2003 | STREPTOCOCCUS PNEUMONIAE |

| ORG # | 1 | 03-12-2003@1420 | ANTIBIOTIC MIC | SPUTUM |
|-------|-------------------------------|-----------------|----------------|--------|
| | PENICILLIN | | S | S |
| | CLINDAMYCIN | | S | S |
| | VANCOMYCIN | | S | S |
| | CHLORAMPHENICOL | | S | S |
| | TETRACYCLINE | | S | S |
| | TRIMETHOPRIM+SULFAMETHOXAZOLE | | S | S |
| | ERYTHROMYCIN | | S | S |
| | CEFOTAXIME | | S | S |
| | CEFTRIAXONE | | S | S |
| | LEVOFLOXACIN | | S | S |

| PATIENT NAME | LAST 4 | DOB | SEX | PERIOD OF SERVICE |
|--|--------|------------|-----|-------------------|
| LABPATIENT12, TEN | 1210 | 03-27-1924 | M | WORLD WAR II |
| Inpatient Admission Date: 03-21-2003@1657 | | | | |
| Discharge Date: --" Discharge Disposition: | | | | |

| | | |
|------------|--------------|--------------------------|
| 03-21-2003 | BACT 03 2154 | MICRO CULTURE SPUTUM |
| 1 | 03-25-2003 | STREPTOCOCCUS PNEUMONIAE |
| 2 | 03-25-2003 | HAEMOPHILUS INFLUENZAE |
| 3 | 03-25-2003 | CANDIDA ALBICANS |

Example: New Detailed Verification Report of EPI Extracted Data from Site mailman messages
continued.

| | | | |
|--|------------|--------------------------|-------------|
| ORG # 1 03-21-2003 ANTIBIOTIC MIC SPUTUM | | | |
| PENICILLIN | S | | S |
| CLINDAMYCIN | S | | S |
| VANCOMYCIN | S | | S |
| CHLORAMPHENICOL | S | | S |
| TETRACYCLINE | S | | S |
| AMPICILLIN | S | | S |
| TRIMETHOPRIM+SULFAMETHOXAZOLE | S | | S |
| ERYTHROMYCIN | S | | S |
| CEFOTAXIME | S | | S |
| CEFTRIAXONE | S | | S |
| LEVOFLOXACIN | S | | S |
| PATIENT NAME LAST 4 DOB SEX PERIOD OF SERVICE | | | |
| LABPATIENT13, ONE | 0131 | 12-13-1947 M | VIETNAM ERA |
| Outpatient Accession Date: 03-24-2003 | | | |
| 03-24-2003 BACT 03 2200 MICRO CULTURE BRONCHUS | | | |
| 1 | 03-27-2003 | STREPTOCOCCUS PNEUMONIAE | |
| ORG # 1 03-24-2003 ANTIBIOTIC MIC BRONCHUS | | | |
| PENICILLIN | S | | S |
| CLINDAMYCIN | S | | S |
| VANCOMYCIN | S | | S |
| CHLORAMPHENICOL | S | | S |
| TETRACYCLINE | S | | S |
| AMPICILLIN | S | | S |
| TRIMETHOPRIM+SULFAMETHOXAZOLE | S | | S |
| ERYTHROMYCIN | S | | S |
| CEFOTAXIME | S | | S |
| CEFTRIAXONE | S | | S |
| LEVOFLOXACIN | S | | S |
| PAGE 23 | | | |
| DETAILED VERIFICATION REPORT OF EPI EXTRACTED DATA | | | |
| FROM STATION (Your station number and name is displayed here.) | | | |
| PROCESSING PERIOD: 03-01-2003 through 03-31-2003 | | | |
| NTE~23- All Enterococci | | | |
| These data note persons at your facility during the month that had a | | | |
| positive result for all Enterococci. Identifying information, along with | | | |
| specimen and culture results has been provided. | | | |

Example: New Detailed Verification Report of EPI Extracted Data from Site mailman messages
continued.

| | | | | |
|--|--------|------------|-----|-----------------------|
| PATIENT NAME | LAST 4 | DOB | SEX | PERIOD OF SERVICE |
| LABPATIENT3, TEN | 0310 | 03-11-1925 | M | WORLD WAR II |
| Inpatient Admission Date: 03-08-2003@1717 | | | | |
| Discharge Date: --" Discharge Disposition: | | | | |
| 03-18-2003@0700 BACT 03 2038 MICRO CULTURE URINE | | | | |
| 2 | | 03-20-2003 | | ENTEROCOCCUS FAECIUM |
| ORG # 2 03-18-2003@0700 ANTIBIOTIC MIC URINE | | | | |
| PENICILLIN | | R | | R |
| VANCOMYCIN | | R | | R |
| NITROFURANTOIN | | S | | S |
| CIPROFLOXACIN | | R | | R |
| LEVOFLOXACIN | | R | | R |
| GENTAMICIN HP | | SYN-S | | SYN-S |
| STREPTOMYCIN HP | | SYN-R | | SYN-R |
| PATIENT NAME | | | | |
| LABPATIENT13, TWO | | | | |
| LAST 4 DOB | | | | |
| 0132 05-29-1928 M | | | | |
| SEX | | | | |
| PERIOD OF SERVICE | | | | |
| WORLD WAR II | | | | |
| Inpatient Admission Date: 02-27-2003@1650 | | | | |
| Discharge Date: 04-02-2003@1415 Discharge Disposition: REGULAR | | | | |
| 03-20-2003@1740 BLD 03 870 MICRO CULTURE BLOOD | | | | |
| 1 | | 03-24-2003 | | ENTEROCOCCUS FAECALIS |
| 2 | | 03-24-2003 | | STAPHYLOCOCCUS |
| (COAGULASE NEGATIVE) | | | | |
| ORG # 1 03-20-2003@1740 ANTIBIOTIC MIC BLOOD | | | | |
| PENICILLIN | | S | | S |
| VANCOMYCIN | | S | | S |
| TETRACYCLINE | | R | | R |
| NITROFURANTOIN | | S | | S |
| CIPROFLOXACIN | | S | | S |
| LEVOFLOXACIN | | S | | S |
| GENTAMICIN HP | | SYN-S | | SYN-S |
| STREPTOMYCIN HP | | SYN-R | | SYN-R |
| ORG # 2 03-20-2003@1740 ANTIBIOTIC MIC BLOOD | | | | |
| PENICILLIN | | R | | R |
| CLINDAMYCIN | | S | | S |
| VANCOMYCIN | | S | | S |
| GENTAMICIN | | S | | S |
| CEFAZOLIN | | R | | R |
| TRIMETHOPRIM+SULFAMETHOXAZOLE | | S | | S |
| ERYTHROMYCIN | | R | | R |
| NITROFURANTOIN | | S | | S |

Example: New Detailed Verification Report of EPI Extracted Data from Site mailman messages
continued.

| | | | |
|--|-------------------|-----------------|-----------------|
| RIFAMPIN | S | S | |
| OXACILLIN | R | R | |
| CIPROFLOXACIN | R | R | |
| AMPICILLIN+SULBACTAM | R | R | |
| LEVOFLOXACIN | I | I | |
| AMOXICILLIN CLAVULANIC ACID | R | R | |
| PATIENT NAME LAST 4 DOB SEX PERIOD OF SERVICE | | | |
| LABPATIENT13, FOUR | 0134 06-25-1939 M | POST-KOREAN | |
| Outpatient Accession Date: 03-10-2003 | | | |
| 03-10-2003 BACT 03 1816 MICRO CULTURE URINE | | | |
| 1 | 03-12-2003 | ENTEROCOCCUS | |
| 2 | 03-12-2003 | STAPHYLOCOCCUS | |
| (COAGULASE NEGATIVE) | | | |
| ORG # 1 03-10-2003 ANTIBIOTIC MIC URINE | | | |
| PENICILLIN | S | S | |
| VANCOMYCIN | S | S | |
| TETRACYCLINE | R | R | |
| NITROFURANTOIN | S | S | |
| CIPROFLOXACIN | R | R | |
| LEVOFLOXACIN | R | R | |
| GENTAMICIN HP | SYN-R | SYN-R | |
| STREPTOMYCIN HP | SYN-S | SYN-S | |
| PAGE 24 | | | |
| UPDATES | | | |
| This section presents patients who had a transmission of information during a month on an EPI defined topic that was incomplete. These patients have information that has been transmitted during the current processing month in order to complete the EPI files. This information usually contains inpatient information about discharge date; ICD coded diagnoses, and occasionally will contain laboratory based testing. This line listing of patient, SSN, and admission date and discharge date is provided to assist with analysis should a processing/error report occur with your monthly automated transmission of this data. | | | |
| Name | LAST 4 | Admission date | Discharge date |
| LABPATIENT13~FIVE | 0135 | 12-19-2002@1605 | 04-05-2003@1213 |
| LABPATIENT13~SIX | 0136 | 01-28-2003@1720 | 03-06-2003@1614 |
| LABPATIENT13~SEVEN | 0137 | 02-04-2003@1045 | 03-07-2003@1847 |

Example: New Detailed Verification Report of EPI Extracted Data from Site mailman messages
continued.

PAGE 25

Pharmacy-based data extracted for EPI data base.

INTERFERON BETA-1A (AVONEX) 30MCG

| | | | |
|------|--------------------|------------|------------|
| 0138 | LABPATIENT13~EIGHT | Outpatient | 03-12-2003 |
| 0139 | LABPATIENT13~NINE | Outpatient | 03-27-2003 |
| 1310 | LABPATIENT13~TEN | Outpatient | 03-19-2003 |
| 1310 | LABPATIENT13~TEN | Outpatient | 03-21-2003 |
| 1310 | LABPATIENT13~TEN | Outpatient | 03-28-2003 |
| 0141 | LABPATIENT14~ONE | Outpatient | 03-11-2003 |
| 0142 | LABPATIENT14~TWO | Outpatient | 03-20-2003 |
| 0143 | LABPATIENT14~THREE | Outpatient | 03-03-2003 |
| 0144 | LABPATIENT14~FOUR | Outpatient | 03-11-2003 |
| 0145 | LABPATIENT14~FIVE | Outpatient | 03-18-2003 |
| 0146 | LABPATIENT14~SIX | Outpatient | 03-28-2003 |
| 0147 | LABPATIENT14~SEVEN | Outpatient | 03-03-2003 |
| 0148 | LABPATIENT14~EIGHT | Outpatient | 03-24-2003 |
| 0149 | LABPATIENT14~NINE | Outpatient | 03-14-2003 |
| 1410 | LABPATIENT14~TEN | Outpatient | 03-10-2003 |
| 0151 | LABPATIENT15~ONE | Outpatient | 03-02-2003 |
| 0151 | LABPATIENT15~ONE | Outpatient | 03-21-2003 |
| 0152 | LABPATIENT15~TWO | Outpatient | 03-20-2003 |
| 0153 | LABPATIENT15~THREE | Outpatient | 03-20-2003 |
| 0154 | LABPATIENT15~FOUR | Outpatient | 03-14-2003 |
| 0155 | LABPATIENT15~FIVE | Outpatient | 03-14-2003 |
| 0156 | LABPATIENT15~SIX | Outpatient | 03-10-2003 |

 SUBCOUNT 22

INTERFERON BETA-1A 44MCG/SYR INJ (REBIF)

| | | | |
|------|---------------------|------------|------------|
| 0951 | FLUZHU~BHYYHSE U~TU | Outpatient | 03-06-2003 |
|------|---------------------|------------|------------|

 SUBCOUNT 1

INTERFERON BETA-1B 0.3MG (BETASERON)

| | | | |
|------|--------------------|------------|------------|
| 0157 | LABPATIENT15~SEVEN | Outpatient | 03-25-2003 |
| 0158 | LABPATIENT15~EIGHT | Outpatient | 03-26-2003 |
| 0159 | LABPATIENT15~NINE | Outpatient | 03-06-2003 |
| 0159 | LABPATIENT15~NINE | Outpatient | 03-26-2003 |
| 1510 | LABPATIENT15~TEN | Outpatient | 03-18-2003 |

 SUBCOUNT 5

Example: New Detailed Verification Report of EPI Extracted Data from Site mailman messages
continued.

PAGE 26

Detailed Listing of Hepatitis C Risk Assessment

These Health factors/Resolved terms for hepatitis C risk assessment are the national Health factors used for roll-up of risk assessment data. They may not reflect the terms actually utilized (seen) in the Clinical Reminder package at this facility. To determine which local/facility Clinical Reminder health factor(s) correspond(s) to the national term, please contact your facility Clinical Reminder application coordinator. Note that hepatitis C infection is based on a previously ICD coded diagnosis of hepatitis C at your site/facility.

DECLINED ASSESSMENT FOR HEPATITIS C

NO PATIENTS REPORTED FOR THE REPORT PERIOD

NO RISK FACTORS FOR HEPATITIS C

| | | | |
|------|--------------------|------------|-----------------|
| 0161 | LABPATIENT16~ONE | Outpatient | 03-24-2003@1140 |
| 0162 | LABPATIENT16~TWO | Outpatient | 03-20-2003@1300 |
| 0163 | LABPATIENT16~THREE | Outpatient | 03-03-2003@1500 |
| 0164 | LABPATIENT16~FOUR | Outpatient | 03-05-2003@1500 |
| 0165 | LABPATIENT16~FIVE | Outpatient | 03-18-2003@1000 |
| 0166 | LABPATIENT16~SIX | Outpatient | 03-17-2003@1500 |
| 0167 | LABPATIENT16~SEVEN | Outpatient | 03-24-2003@1515 |
| 0168 | LABPATIENT16~EIGHT | Outpatient | 03-05-2003@1000 |
| 0169 | LABPATIENT16~NINE | Outpatient | 03-10-2003@1500 |
| 1610 | LABPATIENT16~TEN | Outpatient | 03-31-2003@1400 |
| 0171 | LABPATIENT17~ONE | Outpatient | 03-05-2003@1000 |
| 0172 | LABPATIENT17~TWO | Outpatient | 03-18-2003@1500 |
| 0173 | LABPATIENT17~THREE | Outpatient | 03-04-2003@0815 |
| 0174 | LABPATIENT17~FOUR | Outpatient | 03-18-2003@1500 |
| 0175 | LABPATIENT17~FIVE | Outpatient | 03-12-2003@1300 |
| 0176 | LABPATIENT17~SIX | Outpatient | 03-24-2003@0900 |

SUBCOUNT 238

PREVIOUSLY ASSESSED FOR HEPATITIS C

| | | | |
|------|--------------------|-----------|------------|
| 0177 | LABPATIENT17~SEVEN | Inpatient | 03-15-2003 |
| 0178 | LABPATIENT17~EIGHT | Inpatient | 03-14-2003 |

SUBCOUNT 2

Example: New Detailed Verification Report of EPI Extracted Data from Site mailman messages
continued.

| RISK FACTORS FOR HEPATITIS C | | |
|--|--------------------|----------------------------|
| ----- | | |
| 0179 | LABPATIENT17~NINE | Outpatient 03-07-2003@1530 |
| 1710 | LABPATIENT17~TEN | Outpatient 03-26-2003@1300 |
| 0181 | LABPATIENT18~ONE | Outpatient 03-31-2003@1400 |
| 0182 | LABPATIENT18~TWO | Outpatient 03-27-2003@1530 |
| 0044 | LABPATIENT4~FOUR | Outpatient 03-19-2003@1300 |
| 0183 | LABPATIENT18~THREE | Outpatient 03-03-2003@1000 |
| 0184 | LABPATIENT18~FOUR | Outpatient 03-20-2003@1000 |
| 0185 | LABPATIENT18~FIVE | Inpatient 03-10-2003@1120 |
| 0186 | LABPATIENT18~SIX | Outpatient 03-26-2003@1000 |
| 0187 | LABPATIENT18~SEVEN | Outpatient 03-13-2003@1500 |
| 0068 | LABPATIENT6~EIGHT | Inpatient 03-25-2003@1203 |
| 0188 | LABPATIENT18~EIGHT | Inpatient 03-26-2003@1239 |
| ----- | | |
| SUBCOUNT 132 | | |
| POSITIVE TEST FOR HEPATITIS C ANTIBODY | | |
| ----- | | |
| 0041 | LABPATIENT4~ONE | Outpatient 03-26-2003@1240 |
| 0042 | LABPATIENT4~TWO | Outpatient 03-27-2003@1614 |
| 0043 | LABPATIENT4~THREE | Inpatient 03-13-2003@0700 |
| 0044 | LABPATIENT4~FOUR | Outpatient 03-19-2003 |
| 0045 | LABPATIENT4~FIVE | Inpatient 03-08-2003@0700 |
| 0046 | LABPATIENT4~SIX | Outpatient 03-05-2003@0823 |
| 0047 | LABPATIENT4~SEVEN | Inpatient 03-08-2003@0700 |
| 0048 | LABPATIENT4~EIGHT | Inpatient 03-08-2003@0700 |
| 0049 | LABPATIENT4~NINE | Outpatient 03-05-2003@1726 |
| 0410 | LABPATIENT4~TEN | Inpatient 03-14-2003@1004 |
| 0051 | LABPATIENT5~ONE | Outpatient 03-07-2003@1015 |
| 0052 | LABPATIENT5~TWO | Inpatient 03-21-2003@0700 |
| 0053 | LABPATIENT5~THREE | Outpatient 03-10-2003@0807 |
| 0054 | LABPATIENT5~FOUR | Outpatient 03-18-2003 |
| 0055 | LABPATIENT5~FIVE | Outpatient 03-11-2003@0916 |
| 0056 | LABPATIENT5~SIX | Inpatient 03-27-2003@0700 |
| 0057 | LABPATIENT5~SEVEN | Inpatient 03-06-2003@0700 |
| 0058 | LABPATIENT5~EIGHT | Inpatient 03-21-2003@0700 |
| 0189 | LABPATIENT18~NINE | Outpatient 03-31-2003@1057 |
| 0059 | LABPATIENT5~NINE | Outpatient 03-12-2003@0911 |
| 0510 | LABPATIENT5~TEN | Outpatient 03-25-2003@1443 |
| 0061 | LABPATIENT6~ONE | Outpatient 03-04-2003@1019 |
| 0062 | LABPATIENT6~TWO | Inpatient 03-13-2003@0700 |
| 0063 | LABPATIENT6~THREE | Inpatient 03-13-2003@0700 |
| 0064 | LABPATIENT6~FOUR | Outpatient 03-04-2003@1648 |
| 0065 | LABPATIENT6~FIVE | Inpatient 03-08-2003@0700 |
| 0066 | LABPATIENT6~SIX | Outpatient 03-27-2003@1141 |
| 0067 | LABPATIENT6~SEVEN | Outpatient 03-03-2003@1503 |
| 0068 | LABPATIENT6~EIGHT | Inpatient 03-27-2003@0700 |
| 0069 | LABPATIENT6~NINE | Inpatient 03-13-2003@0700 |
| 0610 | LABPATIENT6~TEN | Outpatient 03-28-2003@1356 |
| ----- | | |
| SUBCOUNT 31 | | |

Example: New Detailed Verification Report of EPI Extracted Data from Site mailman messages
continued.

| | | |
|--|---------------------|----------------------------|
| NEGATIVE TEST FOR HEPATITIS C ANTIBODY | | |
| ----- | | |
| 0078 | LABPATIENT7~EIGHT | Inpatient 03-05-2003@0700 |
| 0079 | LABPATIENT7~NINE | Outpatient 03-18-2003@0743 |
| 0710 | LABPATIENT7~TEN | Outpatient 03-03-2003@0846 |
| 0081 | LABPATEINT8~ONE | Outpatient 03-26-2003@1515 |
| 0082 | LABPATIENT8~TWO | Outpatient 03-28-2003@1506 |
| 0083 | LABPATIENT8~THREE | Inpatient 03-03-2003@0700 |
| 0084 | LABPATIENT8~FOUR | Outpatient 03-25-2003@1039 |
| 0085 | LABPATIENT8~FIVE | Outpatient 03-04-2003@1138 |
| 1810 | LABPATIENT18~TEN | Outpatient 03-24-2003@1700 |
| 0191 | LABPATIENT19~ONE | Outpatient 03-25-2003@1120 |
| 0188 | LABPATIENT18~EIGHT | Inpatient 03-27-2003@0700 |
| 0192 | LABPATIENT19~TWO | Outpatient 03-28-2003@1406 |
| ----- | | |
| SUBCOUNT | 212 | |
| HEPATITIS C DIAGNOSIS (ICD BASED) | | |
| ----- | | |
| 0193 | LABPATIENT19~THREE | Outpatient 03-17-2003@1330 |
| 0037 | LABPATIENT3~SEVEN | Outpatient 03-05-2003@1300 |
| 0194 | LABPATIENT19~FOUR | Outpatient 03-19-2003@1300 |
| 0195 | LABPATIENT19~FIVE | Outpatient 03-24-2003@0800 |
| 0196 | LABPATIENT19~SIX | Outpatient 03-18-2003 |
| 0197 | LABPATIENT19~SEVEN | Outpatient 03-26-2003@1430 |
| 0198 | LABPATIENT19, EIGHT | Outpatient 03-14-2003@1245 |
| 0064 | LABPATIENT6~FOUR | Outpatient 03-04-2003@1500 |
| 0199 | LABPATIENT19~NINE | Outpatient 03-18-2003 |
| 0069 | LABPATIENT6~NINE | Inpatient 03-26-2003@1007 |
| ----- | | |
| SUBCOUNT | 130 | |
| ----- | | |
| COUNT | 745 | |

New EPI Processing Error Report Mailman Message sent from Austin

The **new** EPI Processing/Error Report mailman message itemizes all transmissions received by AITC and document the records status as either being accepted or rejected (with the reason and reject code identified). This report is sent to the EPI mail group. (*Examples of “Tables of Rejects and Errors and/or Warning Codes” are located in the Appendix - B section of this manual.*)

Example: New EPI Processing Error Report Mailman Message

Subj: EPT/DOY #041381117683754 [#19644680] 17 May 04 11:18 CST 46 lines
From: <POSTMASTER@FOC-AUSTIN.VA.GOV> In 'IN' basket. Page 1

2EPI0003 DOY.

STATION 539 V3 EPI PROCESSING/ERROR REPORT REPORT DATE 2004/05/17
PAGE 01

| PROCESS DATE | SSN | ENCOUNTER DATE | MESSAGE | ERROR CODES |
|--------------|-----------|----------------|---------|-------------|
| 20040430 | 000001010 | 20040415114936 | 090 | 240 |
| 20040430 | 000001011 | 20040408101856 | 090 | 240 |
| 20040430 | 000001012 | 20040428 | 042 | W07 |
| 20040430 | 000001013 | 20040316145349 | 035 | W07 |
| 20040430 | 000001014 | 20040428194521 | 057 | W07 |
| 20040430 | 000001015 | 20040310110835 | 031 | W07 |
| 20040430 | 000001016 | 200404271400 | 071 | W05 |
| 20040430 | 000001017 | 19941104101210 | 026 | W05 |

THIS REPORT REPRESENTS DATA FROM APRIL 2004 FROM YOUR STATION

AS A GENERAL GUIDE FOR INTEPRETATION, THERE ARE 2 TYPES OF ERROR CODES.
ONE TYPE HAS 3 DIGITS (E.G., 240) AND THE OTHER TYPE HAS THE LETTER W
FOLLOWED BY 2 DIGITS (E.G., W05). A LISTING OF MEANINGS FOR THE ERRORS

Enter RETURN to continue or '^' to exit:

Example: EPI Processing Error Report Mailman Message *continued*

Subj: EPT/DOY #041381117683754 [#19644680] Page 2

IS PROVIDED BELOW. THE 3-DIGIT ERROR CODE INDICATES THAT A FATAL ERROR OCCURRED FOR THE LISTED PATIENT AND THE ENTIRE EPI MESSAGE FOR THE MONTH OF APRIL 2004 WAS NOT ACCEPTED INTO THE DATA REPOSITORY. YOUR SITE WILL NEED TO CORRECT A 3-DIGIT FATAL ERROR CODE FOR ALL PATIENTS HAVING IT PRESENT, AND THEN RE-TRANSMIT THE APRIL 2004 EPI MESSAGE USING THE MANUAL RUN OPTION--L AB EPI MANUAL RUN (ENHANCED). THIS MANUALLY RE-SUBMITTED MESSAGE WILL BE PROCESSED AT THE AUSTIN AUTOMATION CENTER. KEEP IN MIND THAT IF YOU DO RE-SUBMIT A TRANSMISSION, THE NORMAL EPI PROCESS WILL ALSO GENERATE AND SEND ITS NORMAL MONTHLY DATA AS SCHEDULED; THEREFORE, AT THE TIME OF RECEIPT OF PROESSING MESSAGES, YOU SHOULD RECEIVE REPORTS FOR MORE THAN ONE TRANSMISSION. A WARNING CODE DOES NOT CONSTITUTE A FATAL ERROR. THESE WARNING MESSAGES SHOULD BE CORRECTED IF ABLE, BUT DO NOT NEED FOR THE DATA TO BE RESUBMITTED. YOU SHOULD MONITOR THE WARNING MESSAGES OVER THE NEXT COUPLE OF TRANSMISSIONS TO BE ASSURED THAT THEY DO NOT PERSIST. IF YOUR PROCESSING MESSAGE CONTAINS ONLY WARNING ERROR CODES (I.E., THERE ARE NO FATAL ERROR CODES), MANUAL RE-TRANSMISSION DOES NOT NEED TO BE PERFORMED.

240 Period of Service was invalid.

W07 Specimen Source Code is blank.

Enter RETURN to continue or '^' to exit:

Subj: EPT/DOY #041381117683754 [#19644680] Page 3

W05 Patient Date of Birth is not in a valid date format.

END OF REPORT TOTAL PAGES: 01

Table of Reject and Errors and/or Warning Codes

The following Table of Rejects and Errors and/or Warning Codes definitions are used by the Austin Automation Center for the **new** EPI Error Processing Report mailman messages.

Examples: Tables of Rejects and Errors and/or Warning Codes.

| Tables of Rejects and Errors and/or Warning Codes | | | |
|---|------------------------|--|---|
| ERROR NUMBER | FIELD NAME | EDIT DESCRIPTION | ERROR MESSAGE |
| 000 Series | | | |
| <i>Miscellaneous</i> | | | |
| 001 | Message Control ID | Must not be blank | Message control ID was blank |
| 002 | Batch Sending Facility | Sending Station not valid. (Refer to table AA001) | Invalid Batch Sending Facility. |
| 003 | Segment Name | PID Segment missing. Do not edit for the existence of PID when NTE segments are present. | PID Segment missing. |
| 004 | Segment Name | PV1 Segment missing. Do not edit for the existence of PV1 when NTE segments are present. | PV1 Segment missing. |
| 005 | Segment Name | Invalid Segment Name. | Invalid HL7 Segment Name. |
| 006 | Message Creation Date | Must a valid date. | Message Creation Date is Invalid. |
| 007 | Message Creation Time | Must a valid time. | Message Creation Time is invalid. |
| 008 | Processing Period | Must a valid date. | Processing period in the NTE segment is invalid. |
| 009 | Processing Period | Historical processing for V2 of EPI (commonly known as HEP C) must be received in Austin sequentially from 1998 forward. | For V2 only - Processing into AITC must be sequential from 10/98 forward. |

Examples: Tables of Rejects and Errors and/or Warning Codes *continued*.

| Tables of Rejects and Errors and/or Warning Codes | | | |
|---|------------------------|---|---|
| ERROR NUMBER | FIELD NAME | EDIT DESCRIPTION | ERROR MESSAGE |
| 100 Series | | | |
| <i>NTE Totals Segment</i> | | | |
| 100 | Action Ind | Currently not being used. | Currently not being used. |
| 105 | Totals Total Count | Must be numeric, if Action Ind is 'T'. | NTE Totals Total Count was not numeric. |
| 110 | Negative Input Ind | Must be 'N', if Action Ind is not 'T'. | Negative Input Ind was not 'N'. |
| | | | |
| 200 Series | | | |
| <i>PID Segment</i> | | | |
| 200 | Patient Name | Required. Must be alpha numeric. Must not be all numeric. Must not be all blanks. | Patient Name is missing, or not alphanumeric, or all numeric, or all blanks. |
| 205 | Patient Date of Birth | Not required. Must be less than the processing year. | Date of Birth is after the Date of transmission. (Also see W03, W04, and W05) |
| 210 | Patient Sex | Not required. Must be blank or match table. (Refer to table T0001) | Sex code is not blank or a valid code. (Refer to table 0001) |
| 215 | Patient Race | Not required. Must be blank or a valid code. (Refer to table VA07) | Race code is not blank or a valid code. (Refer to table VA07) |
| 220 | Patient Address | Must be blank or 'H'. | Patient Address is not blank or 'H'. |
| 235 | Social Security Number | Required. Last byte must be 'P' or blank. | Pseudo SSN is not 'P' or blank. |
| 236 | Social Security Number | Required. Must be numeric. Must be greater than zeros. | Social Security Number is missing, or not numeric, or is equal to zeros. |
| 240 | Patient Veteran Status | Must be a valid code. (Refer to table VA11) | Period of Service was invalid. (Refer to table VA11). |

Examples: Tables of Rejects and Errors and/or Warning Codes *continued*.

| Tables of Rejects and Errors and/or Warning Codes | | | |
|---|-----------------------|---|---|
| ERROR NUMBER | FIELD NAME | EDIT DESCRIPTION | ERROR MESSAGE |
| 300 Series | | | |
| <i>OBR Segment</i> | | | |
| 300 | Universal Service ID | Must be a valid code. (Refer to table NLT) | Invalid Universal Service ID (Refer to table NLT) |
| 305 | Observation Date | Must be numeric date. Must be a valid date. Must be less than Processing date. | Observation Date is invalid date or after the date of transmission. |
| 307 | Observation Time | Not required. Must be blank or numeric. If numeric, must be a valid time. | Observation Time is invalid. |
| 310 | Specimen Source Code | Not required. If not blank, must be a valid code. (Refer to table SPC) | Invalid Specimen Source (Refer to table SPC) Code. (also see W07) |
| 315 | Parent Observation ID | Not required. Must be blank or a valid code. (Refer to table NLT) | Invalid Parent Observation ID (Refer to table NLT). |

Examples: Tables of Rejects and Errors and/or Warning Codes *continued*.

| Tables of Rejects and Errors and/or Warning Codes | | | |
|---|-------------------|--|---|
| ERROR NUMBER | FIELD NAME | EDIT DESCRIPTION | ERROR MESSAGE |
| 400 Series | | | |
| <i>PV1 Segment</i> | | | |
| 400 | Patient Class | Required. Must be 'T', 'O', or 'U'. | Patient Class is not 'T', 'O', or 'U'. |
| 410 | Discharge Date | Not required. Must be blank or a valid date. Must be less than or equal to processing date. | Discharge Date is invalid or after date of transmission. |
| 411 | Discharge Time | Not required. Time must be blank or a valid time. | Discharge Time is invalid |
| 420 | Admit Date/Time | Required. Must be numeric. Must be a valid date. Must be less than or equal to processing date. | Admit Date is invalid or after date of transmission. |
| 421 | Admit Date/Time | Required. Time must be numeric. Must be a valid time. | Admit Time is invalid. |
| | | | |
| 500 Series | | | |
| <i>DG1 Segment</i> | | | |
| 500 | Diagnosis Code | Required. Must be a valid code. (Refer to table AA010) | Invalid Diagnosis Code (Refer to table 0051) |
| | | | |
| 600 Series | | | |
| <i>OBX Segment</i> | | | |
| 605 | Final Result Date | Must be blank or a valid date. Must be numeric. Must be a less than or equal to the processing date. | Final Result Date is invalid or after the date of transmission. |

Examples: Tables of Rejects and Errors and/or Warning Codes *continued*.

| Tables of Rejects and Errors and/or Warning Codes | | | |
|---|-------------------------|--|---|
| ERROR NUMBER | FIELD NAME | EDIT DESCRIPTION | ERROR MESSAGE |
| W00 Series | | | |
| <i>Warnings</i> | | | |
| W03 | Patient Date of Birth | Must not be all spaces. | Patient Date of Birth is all spaces. (Also see 205) |
| W04 | Patient Date of Birth | Year must not be all zeros | Patient Date of Birth Year is all zeros. (See also 205) |
| W05 | Patient Date of Birth | Must be a valid date. | Patient Date of Birth is not in a valid date format. (Also see 205) |
| W07 | Specimen Source Code | Blanks in code. | Specimen Source code is blank. (See also 310) |
| W09 | Observation Nat Lab Num | Blanks in code. | Observation Nat Lab Num is blank. (Also see 600) |
| W10 | Date of Prescription | Must not be all spaces. | Date of Prescription is all Spaces. |
| W11 | Date of Prescription | Year must not be all zeros. | Date of Prescription is all Zeros. |
| W12 | Date of Prescription | Must be a valid date. | Date of Prescription is not in a valid date format. |
| W14 | Resolve Term | Must be numeric. | Resolve Term must be numeric. |
| W15 | Days Supply | Must be numeric or blank. | Days Supply not numeric or blank. |
| W16 | Release Date | Must be numeric date. Must be a valid date. Must be less than processing date. | Release Date is invalid date or after the date of transmission. |
| W17 | Fill Date | Must be numeric date. Must be a valid date. Must be less than processing date. | Fill Date is invalid date or after the date of transmission. |

Examples: Tables of Rejects and Errors and/or Warning Codes *continued*.

| Tables of Rejects and Errors and/or Warning Codes | | | |
|---|------------------------|---|--|
| ERROR NUMBER | FIELD NAME | EDIT DESCRIPTION | ERROR MESSAGE |
| W18 | Stop Date | Must be numeric date. Must be a valid date. Must be less than processing date. | Stop Date is invalid date or after the date of transmission. |
| W19 | Primary Indicator | One DG1 diagnostic code must be designated as the primary code - valid starting with version 2 of the software. | No diagnostic code designated as primary |
| W20 | Release Date/Fill Date | At least one of the two - release date or fill date - must be present. | Release Date and Fill Date are both blank. |
| W21 | DSP Nomenclature | Must not be all spaces. | DSP Nomenclature is all spaces. |
| W22 | Resolve Term | Must be 1, 2, 3, 4, 5, 6, 7, or 0. | Invalid Resolve Term. |
| W23 | Lab Result | Must be spaces if Resolve Term is 1, 2, 3, 4, or 7. | Lab Result is not insync with Resolve Term. |
| W24 | LOINC Code | Must be a valid code or blank. | LOINC Code is invalid. |

National Laboratory Test (NLT) List

The NLT WKLD Code Request Form is accessible via the following web sites:

VistA Laboratory Version 5.2 Home Page

<http://vista.med.va.gov/ClinicalSpecialties/lab/>

VistA Documentation Library (VDL)

<http://www.va.gov/vdl/>

| | | | | |
|------------------------------|--------------------------------|-------------------|--|--------|
| DEVICE: 0;80;9999 UCX/TELNET | | MAR 25,2004 15:04 | | PAGE 1 |
| VistA NLT List 3/25/2004 | | | | |
| WKLD CODE | PROCEDURE | | | |
| ----- | | | | |
| 80000.0000 | Analyte NOS | | | |
| 80079.0000 | RAJI Cell | | | |
| 81000.0000 | Urinalysis Chemical w micr Man | | | |
| 81001.0000 | Urinalysis Micros only | | | |
| 81002.0000 | Urinalysis Chemical w o micro | | | |
| 81003.0000 | Bilirubin Conjugated | | | |
| 81004.0000 | Urinalysis Components | | | |
| 81005.0000 | Sulfonamide Crystals Qual | | | |
| 81006.0000 | Urine Volume Measure | | | |
| 81007.0000 | Urinalysis Microscopic | | | |
| 81008.0000 | Bilirubin Unconjugated | | | |
| 81009.0000 | Cholesterol VLDL | | | |
| 81010.0000 | Triglycerides VLDL | | | |
| 81011.0000 | Amylase Fractionation | | | |
| 81012.0000 | Angiotensin Converting Enzyme | | | |
| 81013.0000 | Histamine | | | |
| 81014.0000 | Desmethyldiazepam | | | |
| 81015.0000 | Drug Screen Opiate | | | |
| 81016.0000 | Pepsinogen | | | |
| 81017.0000 | Thiothixene | | | |
| 81018.0000 | Phenobarbital | | | |
| 81019.0000 | Vitamin B1 | | | |
| 81020.0000 | Primidone | | | |
| 81021.0000 | Vitamin B2 | | | |
| 81022.0000 | Procainamide | | | |
| 81023.0000 | Vitamin B6 | | | |
| 81024.0000 | Propranolol | | | |
| 81025.0000 | Vitamin E | | | |
| 81026.0000 | Citrate | | | |
| 81027.0000 | Carnitine | | | |
| 81028.0000 | Chromogranin A | | | |
| 81029.0000 | Cyclic AMP | | | |
| 81030.0000 | DHEA | | | |
| 81031.0000 | DHEA S | | | |
| 81032.0000 | Encainide | | | |
| 81033.0000 | Hemoglobin Fetal Feces | | | |
| 81034.0000 | Erythropoietin | | | |
| 81035.0000 | Estrone | | | |
| 81036.0000 | Ethmozine | | | |

VistA Laboratory EPI

Rollup Modifications

Technical and User Manual

| | |
|------------|--------------------------------|
| 81037.0000 | Fiorinal |
| 81038.0000 | Fluoxetine |
| 81039.0000 | Fluphenazine |
| 81040.0000 | Free T3 (dialysis) |
| 81041.0000 | Gonadotrophins REL Hormone |
| 81042.0000 | Insulin Ab |
| 81043.0000 | Insulin Free |
| 81044.0000 | Insulin Immunoreactive |
| 81045.0000 | Ionize Calcium |
| 81046.0000 | Iron Liver Tissue |
| 81047.0000 | Ketones |
| 81048.0000 | Mepho Barbitol |
| 81049.0000 | Mesantoin |
| 81050.0000 | Methylmalonic Acid |
| 81051.0000 | Metopirone Response |
| 81052.0000 | Navane |
| 81053.0000 | Nitrogen Total |
| 81054.0000 | Pepsinogen I |
| 81055.0000 | Pepsinogen II |
| 81056.0000 | Phytanic Acid |
| 81057.0000 | Proinsulin |
| 81058.0000 | Pseudocholinesterase Total |
| 81059.0000 | PTH Related Protein |
| 81060.0000 | Sex Hormone Binding Globulin |
| 81061.0000 | Hemoglobin Unstable Isopropyl |
| 81062.0000 | Testosterone Free |
| 81063.0000 | Thyrotropin Bind Inhib Immuno |
| 81064.0000 | Thyroxine Free (Dialysis) |
| 81065.0000 | Tolmetin |
| 81066.0000 | Trazodone |
| 81067.0000 | Verapamil |
| 81068.0000 | Acetaminophen |
| 81069.0000 | Arylsulfatase a |
| 81070.0000 | Vitamin B12 Binding Capacity |
| 81071.0000 | Carbohydrate Ag |
| 81072.0000 | Ativan |
| 81073.0000 | Urinalysis Chemical w micro Au |
| 81074.0000 | Carisprodal |
| 81075.0000 | Beta Glucuronidase |
| 81076.0000 | Beta Hydroxybutyrate |
| 81077.0000 | C1 Esterase Inhibitor (Qual) |
| 81078.0000 | C1 Esterase Inhibitor (Quant) |
| 81079.0000 | Hemoglobin electrophoresis |
| 81080.0000 | Homocystine |
| 81081.0000 | Dibucaine number |
| 81082.0000 | IgG Subsets |
| 81083.0000 | Cotinine |
| 81084.0000 | Chylomicrons |
| 81085.0000 | Total iron binding capacity |
| 81086.0000 | Opiate group |
| 81087.0000 | Transthyretin |
| 81088.0000 | Protein electrophoresis |
| 81089.0000 | Free Hemoglobin, serum |
| 81090.0000 | Lactescence |
| 81091.0000 | T-UPTAKE |
| 81092.0000 | ALA Dehydratase |
| 81093.0000 | UPG Synthase |
| 81094.0000 | Clozaril |
| 81095.0000 | Myoglobin Serum |

VistA Laboratory EPI

Rollup Modifications

Technical and User Manual

| | |
|------------|--------------------------------|
| 81096.0000 | Misc Chem Test 1 |
| 81097.0000 | Misc Chem Test 2 |
| 81098.0000 | Amikacin |
| 81098.3035 | Amino Levulinic Acid Delta~DU |
| 81098.3103 | Amino Levulinic Acid Delta~EKT |
| 81098.8044 | Amino Levulinic Acid Delta~LAB |
| 81099.0000 | Misc Chem Test 3 |
| 81100.0000 | Misc Chem Test 4 |
| 81101.0000 | Misc Chem Test 5 |
| 81102.0000 | Misc Chem Test 6 |
| 81103.0000 | Misc Chem Test 7 |
| 81104.0000 | Misc Chem Test 8 |
| 81105.0000 | Misc Chem Test 9 |
| 81106.0000 | Misc Chem Test 10 |
| 81107.0000 | Instrument CH Setup |
| 81108.0000 | Auto Chem 1-2 test |
| 81109.0000 | Auto Chem 3 test |
| 81110.0000 | Auto Chem 4 test |
| 81111.0000 | Auto Chem 5 test |
| 81112.0000 | Amitriptyline |
| 81113.0000 | Auto Chem 6 test |
| 81114.0000 | Auto Chem 7 test |
| 81115.0000 | Auto Chem 8 test |
| 81116.0000 | Auto Chem 9 test |
| 81117.0000 | Auto Chem 10 test |
| 81118.0000 | Auto Chem 11 test |
| 81119.0000 | Auto Chem 12 test |
| 81120.0000 | Auto Chem 13-16 test |
| 81121.0000 | Auto Chem 17-18 test |
| 81122.0000 | Auto Chem >18 test |
| 81123.0000 | General Health Screen panel |
| 81124.0000 | Pre Marital Profile |
| 81125.0000 | Executive Profile |
| 81126.0000 | Obstetric Profile |
| 81127.0000 | Amenorrhea Profile |
| 81128.0000 | Male Infertility and/or Gyneco |
| 81129.0000 | Hepatic Function Panel |
| 81130.0000 | Hepatitis Panel |
| 81131.0000 | Hypertension Panel |
| 81132.0000 | Lipid Panel |
| 81133.0000 | Cardiac Evaluation Panel |
| 81134.0000 | Cardiac Injury Panel |
| 81135.0000 | Cardiac Injury Panel w CPK and |
| 81136.0000 | Metabolic Panel |
| 81137.0000 | Malabsorption Panel |
| 81138.0000 | Pulmonary Panel |
| 81139.0000 | Lung Maturity Profile |
| 81140.0000 | Thyroid Panel |
| 81141.0000 | Thyroid Panel w TRH |
| 81142.0000 | Arthritis Panel |
| 81143.0000 | Renal Panel |
| 81144.0000 | Parathyroid Panel |
| 81145.0000 | Prostatic Panel |
| 81146.0000 | Pancreatic Panel |
| 81147.0000 | Pituitary Panel |
| 81148.0000 | Microcytic Anemia Panel |
| 81149.0000 | Macrocytic Anemia Panel |
| 81150.0000 | Transition Panel |
| 81151.0000 | Muscle Panel |

VistA Laboratory EPI

Rollup Modifications

Technical and User Manual

| | |
|------------|--------------------------------|
| 81152.0000 | Antibody Panel |
| 81153.0000 | Unlisted Panel |
| 81154.0000 | Thyrotropin Releasing Hormone |
| 81155.0000 | Therapeutic Quantitative Drug |
| 81156.0000 | Serum Antimicrobial Level, Bio |
| 81157.0000 | Serum RIA Circulating Antibiot |
| 81158.0000 | Vitamin K |
| 81159.0000 | Folate, RBC |
| 81160.0000 | Microalbumin |
| 81161.0000 | Felbamate |
| 81162.0000 | Glucose 2hr |
| 81163.0000 | Glucose Tolerance 3hr |
| 81164.0000 | Glucose Tolerance 6hr |
| 81165.0000 | Xylose TT |
| 81166.0000 | Lactose |
| 81167.0000 | Lactose TT |
| 81168.0000 | D-Xylose |
| 81169.0000 | Creatinine Clearance |
| 81170.0000 | Amorphus Sediment |
| 81171.0000 | Ascorbic Acid Stick |
| 81172.0000 | RBC Urine |
| 81173.0000 | Bilirubin Crystals |
| 81174.0000 | Bilirubin Stick |
| 81175.0000 | Calcium Carbonate Crystal |
| 81176.0000 | Calcium Oxalate Crystal |
| 81177.0000 | Calcium Phosphate Crystal |
| 81178.0000 | Cystine Crystal |
| 81179.0000 | Epithelial Cast |
| 81180.0000 | Epithelial Cell |
| 81181.0000 | Fat Globule |
| 81182.0000 | Fatty Cast |
| 81183.0000 | Filamentous Bodies |
| 81184.0000 | Glucose Stick |
| 81185.0000 | Granular Cast |
| 81186.0000 | Gross Blood |
| 81187.0000 | Hemoglobin Stick |
| 81188.0000 | Hyaline Cast |
| 81189.0000 | Ketone Stick |
| 81190.0000 | Mucus Urine |
| 81191.0000 | Nitrate Stick |
| 81192.0000 | pH Stick |
| 81193.0000 | Protein Stick |
| 81194.0000 | Pyrophosphate Crystal |
| 81195.0000 | RBC Cast |
| 81196.0000 | Reducing Substance |
| 81197.0000 | Renal Epithelial Cell |
| 81198.0000 | Specific Gravity Urine |
| 81199.0000 | Sperm in Urine |
| 81200.0000 | Squamous Epithelial Cell |
| 81201.0000 | Trichomonas in Urine |
| 81202.0000 | Triple Phosphate Crystal |
| 81203.0000 | Unidentified Crystal |
| 81204.0000 | Uric Acid Crystal |
| 81205.0000 | Clarity Urine |
| 81206.0000 | Color Urine |
| 81207.0000 | Urobilinogen Stick |
| 81208.0000 | Waxy Cast |
| 81209.0000 | WBC Cast |
| 81210.0000 | WBC Esterase Stick |

VistA Laboratory EPI

Rollup Modifications

Technical and User Manual

| | |
|------------|-------------------------|
| 81211.0000 | WBC in Urine |
| 81212.0000 | Yeast in Urine |
| 81213.0000 | Anion Gap |
| 81214.0000 | Albumin/Creat Ratio |
| 81215.0000 | Amylase Pancreatic |
| 81216.0000 | Bicarbonate |
| 81217.0000 | BSA |
| 81218.0000 | BUN/Creat Ratio |
| 81219.0000 | Calcium Normalized |
| 81220.0000 | Deoxyhemoglobin |
| 81221.0000 | Fio2 |
| 81222.0000 | Hemolyzed Specimen |
| 81223.0000 | Icteric Specimen |
| 81224.0000 | Turbid Specimen |
| 81225.0000 | LDH Isoenzyme 1 |
| 81226.0000 | LDH Isoenzyme 2 |
| 81227.0000 | LDH Isoenzyme 3 |
| 81228.0000 | LDH Isoenzyme 4 |
| 81229.0000 | LDH Isoenzyme 5 |
| 81230.0000 | O2 Content |
| 81231.0000 | Oxyhemoglobin |
| 81232.0000 | Volume |
| 81233.0000 | MASS |
| 81234.0000 | GGTP |
| 81234.3000 | Ethanol~MANUAL |
| 81234.3035 | Ethanol~DU PONT ACA |
| 81235.0000 | Dilantin |
| 81236.0000 | Ethanol |
| 81237.0000 | N-Acetyl |
| 81238.0000 | Mysoline |
| 81239.0000 | Tegretol |
| 81240.0000 | Bence Jones Protein |
| 81241.0000 | Motility |
| 81242.0000 | Mesothelial Cell |
| 81243.0000 | O2Hb % |
| 81244.0000 | COHb % |
| 81245.0000 | MetHb % |
| 81246.0000 | Base Excess |
| 81247.0000 | Pt Temp |
| 81248.0000 | pH |
| 81249.0000 | pH Corrected |
| 81250.0000 | PCO2 Corrected |
| 81251.0000 | PO2 Corrected |
| 81252.0000 | pH Urine |
| 81253.0000 | WBC/HPF |
| 81254.0000 | RBC/HPF |
| 81255.0000 | Bacteria Urine |
| 81256.0000 | Urine Cast |
| 81257.0000 | Crystal Urine |
| 81258.0000 | Amorphus Urate |
| 81259.0000 | Amorphus Phosphate |
| 81260.0000 | Leucine Crystal |
| 81261.0000 | Tyrosine Crystal |
| 81262.0000 | Cholesterol Crystal |
| 81263.0000 | Calculus Urine |
| 81264.0000 | Addis Count |
| 81265.0000 | Transitional Epithelial |
| 81266.0000 | %O2 |
| 81267.0000 | %CO2 |

VistA Laboratory EPI

Rollup Modifications

Technical and User Manual

| | |
|------------|--------------------------------|
| 81268.0000 | Osmolality Calc |
| 81269.0000 | Leukocyte Esterase |
| 81270.0000 | Mononuclear Cell |
| 81271.0000 | TCO2 |
| 81272.0000 | Xanthochromic |
| 81273.0000 | Amiodarone |
| 81274.0000 | Ritalin |
| 81275.0000 | Methyl Tertiary Butyl Ether |
| 81276.0000 | Phenolphthalein |
| 81277.0000 | Phenelzine |
| 81278.0000 | Sertraline |
| 81279.0000 | Silver |
| 81280.0000 | Propafenone |
| 81281.0000 | T3 OK Ag |
| 81282.0000 | T3 OK Ab |
| 81283.0000 | Myelin Glycoprotein |
| 81284.0000 | Molybdenum |
| 81285.0000 | 3-Methoxy 4-hydroxyphenylglyco |
| 81286.0000 | Anafranil |
| 81287.0000 | Bile Salt Conc. |
| 81288.0000 | Bypivacaine |
| 81289.0000 | Diltiazam |
| 81290.0000 | Xanthine |
| 81291.0000 | Bupropion Hydrochloride |
| 81292.0000 | Levodopa |
| 81293.0000 | Midazolam |
| 81294.0000 | Molindone Hydrochloride |
| 81295.0000 | Hexosamidiase |
| 81296.0000 | Disulfiram |
| 81297.0000 | Vitamin C |
| 81298.0000 | Trimipramine |
| 81299.0000 | 2 Methylcitric Acid |
| 81300.0000 | Benzene |
| 81301.0000 | Beta Lactoglobulin |
| 81302.0000 | CPK BB |
| 81303.0000 | CPK MM |
| 81304.0000 | Cystathionine |
| 81305.0000 | DNA Analysis |
| 81306.0000 | Estradiol 17 B |
| 81307.0000 | Gentamicin |
| 81308.0000 | Estradiol E1 E2 |
| 81309.0000 | Fluconazole |
| 81310.0000 | Gabapentin |
| 81311.0000 | Homocysteine |
| 81312.0000 | Metharbital |
| 81313.0000 | Normethsuximide |
| 81314.0000 | Fatty Acid VLC |
| 81315.0000 | Arylsulfatase a Leukocyte |
| 81316.0000 | Catecholamines Fract |
| 81317.0000 | Imipramine & Desipramine |
| 81318.0000 | PTH C Terminal |
| 81319.0000 | PTH Intact |
| 81320.0000 | Folic Acid |
| 81321.0000 | Vasopressin |
| 81322.0000 | FK506 |
| 81323.0000 | Gen Chem Specimen |
| 81324.0000 | Sp Chem Specimen |
| 81325.0000 | Kanamycin |
| 81326.0000 | UA Specimen |

VistA Laboratory EPI

Rollup Modifications

Technical and User Manual

| | |
|------------|-------------------------------|
| 81327.0000 | UA Chem Specimen |
| 81328.0000 | Tox Specimen |
| 81329.0000 | TDM Specimen |
| 81330.0000 | STAT Lab Specimen |
| 81331.0000 | RIA Specimen |
| 81332.0000 | RIA Sp Specimen |
| 81333.0000 | Gen Specimen |
| 81334.0000 | IgG |
| 81335.0000 | Buspirone |
| 81336.0000 | Desethylaminodarone |
| 81337.0000 | Norverapamil |
| 81338.0000 | Tertiary Butyl Alcohol |
| 81339.0000 | Trichloroethanol |
| 81340.0000 | IgM |
| 81341.0000 | Meclofenamic Acid |
| 81342.0000 | IgD |
| 81343.0000 | Moricizine |
| 81344.0000 | Naproxen |
| 81345.0000 | Procardia |
| 81346.0000 | Pyridinium |
| 81347.0000 | Schlicter Test |
| 81348.0000 | Spironolactone |
| 81349.0000 | Tripamine |
| 81350.0000 | IgL |
| 81351.0000 | IgK |
| 81352.0000 | Glucose Fasting |
| 81353.0000 | Urine Dipstick Manual |
| 81354.0000 | Urine Dipstick Auto |
| 81355.0000 | Electrophoretic Fractionation |
| 81356.0000 | Methotrexate |
| 81357.0000 | Electrolytes |
| 81358.0000 | GLC Analysis |
| 81359.0000 | Immunoassay |
| 81360.0000 | Alpha Galactosidase |
| 81361.0000 | D-Lactate |
| 81362.0000 | Alpha1 Globulins |
| 81363.0000 | Alpha2 Globulins |
| 81364.0000 | Beta Globulins |
| 81365.0000 | Albumin Fraction |
| 81366.0000 | Relative Index |
| 81367.0000 | Excretion Rate |
| 81368.0000 | Iron Panel Chemistry |
| 81369.0000 | Adenosine Deaminase |
| 81370.0000 | Trichloracetia Acid |
| 81371.0000 | Acetoacetate |
| 81372.0000 | Augmentin |
| 81373.0000 | N-Telopeptide |
| 81374.0000 | 5 Hydroxyindoleacetic Acid |
| 81375.0000 | Adenosine Diphosphate |
| 81376.0000 | Timentin |
| 81377.0000 | Free Hemoglobin, Urine |
| 81378.0000 | Fecal Electrolytes |
| 81379.0000 | Mycophenolic Acid |
| 81380.0000 | Phenazopyridine |
| 81381.0000 | Phosphofructokinase |
| 81382.0000 | Antabuse |
| 81383.0000 | Bertylium |
| 81384.0000 | Phencyclidine Quant |
| 81385.0000 | Bromocriptine |

VistA Laboratory EPI

Rollup Modifications

Technical and User Manual

| | |
|------------|---------------------------|
| 81386.0000 | Captopril |
| 81387.0000 | Malathion |
| 81388.0000 | N-Telopeptide ELISA |
| 81389.0000 | Pimozide |
| 81390.0000 | Sotalol |
| 81391.0000 | Sulfonylurea |
| 81392.0000 | Toxic Analysis |
| 81393.0000 | Toxic substance Analysis |
| 81394.0000 | Venlafaxine |
| 81395.0000 | Vistaril |
| 81396.0000 | Osmolality Urine |
| 81397.0000 | Osmolality Stool |
| 81398.0000 | Ictotest |
| 81399.0000 | Protein UR Quant |
| 81400.0000 | ACTH Stimulation |
| 81401.0000 | Amiodarone & Metabolite |
| 81402.0000 | Grepafloxacin |
| 81403.0000 | Trovafloxacin |
| 81404.0000 | T3 RIA |
| 81405.0000 | Clofazimine |
| 81406.0000 | Arsenic Nail |
| 81407.0000 | Trazodone2 |
| 81408.0000 | Aldosterone Suppression |
| 81409.0000 | Hexacarboxypoprhyrin |
| 81410.0000 | Pentacarboxyporphyrin |
| 81411.0000 | Norchlordiazepoxide |
| 81412.0000 | Cathartic Laxative Panel |
| 81413.0000 | Orotic Acid |
| 81414.0000 | Clonidine |
| 81415.0000 | Microalbumin Point |
| 81416.0000 | Arsenic Hair |
| 81417.0000 | Electrocardiogram |
| 81418.0000 | Cardiac Stress |
| 81419.0000 | Sulfonylurea Hypoglycemic |
| 81420.0000 | Dexamethasone |
| 81421.0000 | Beta-lactamase |
| 81422.0000 | C-Peptide 30min |
| 81423.0000 | X*C-Peptide |
| 81424.0000 | C-Peptide 60min |
| 81425.0000 | C-Peptide 90Min |
| 81426.0000 | C-Peptide 120min |
| 81427.0000 | C-Peptide 180min |
| 81428.0000 | Insulin 30min |
| 81429.0000 | Insulin 60min |
| 81430.0000 | Insulin 90min |
| 81431.0000 | Insulin 120min |
| 81432.0000 | Insulin 180min |
| 81433.0000 | LH 30min |
| 81434.0000 | LH Stimulation Panel |
| 81435.0000 | LH 60min |
| 81436.0000 | LH 90min |
| 81437.0000 | LH 120MIN |
| 81438.0000 | FSH Stimulation Panel |
| 81439.0000 | FSH 30min |
| 81440.0000 | FSH 60min |
| 81441.0000 | FSH 90min |
| 81442.0000 | FSH 120min |
| 81443.0000 | ACTH 30min |
| 81444.0000 | ACTH 60min |

VistA Laboratory EPI

Rollup Modifications

Technical and User Manual

| | |
|------------|---------------------------------|
| 81445.0000 | Cortisol 30min |
| 81446.0000 | Cortisol 60min |
| 81447.0000 | TRH Stimulation |
| 81448.0000 | TRH 30min |
| 81449.0000 | TRH 60min |
| 81450.0000 | Prolactin Stimulation |
| 81451.0000 | Prolactin 30min |
| 81452.0000 | Prolactin 60min |
| 81453.0000 | TSH 30min |
| 81454.0000 | TSH 60min |
| 81455.0000 | TSH Receptor Ab |
| 81456.0000 | Nifedipine |
| 81457.0000 | Lipase Urine |
| 81458.0000 | Normetanephrine |
| 81459.0000 | Norclozaril |
| 81460.0000 | Heptacarboxyprophyrin |
| 81461.0000 | Tripramine |
| 81462.0000 | Prednisoline |
| 81463.0000 | Porphyrin Feces |
| 81464.0000 | Joint Fluid Panel |
| 81465.0000 | Steroid Anabolic |
| 81466.0000 | Alpha Subunits Pituitary |
| 81467.0000 | Bentiromide |
| 81468.0000 | Phosphatase Alkaline Bone |
| 81469.0000 | Baclofen |
| 81470.0000 | Glucose Qual |
| 81471.0000 | Albumin/Globulin Ratio |
| 81472.0000 | Serotonin Release Heparin Indu |
| 81473.0000 | Phenolsulfophthalein |
| 81474.0000 | Trimethadoine |
| 81475.0000 | Tobramycin |
| 81476.0000 | Benztropine |
| 81477.0000 | Porphobilinogen Deaminase |
| 81478.0000 | Trifluoperazine |
| 81479.0000 | Tricyclic Antidepressants |
| 81480.0000 | Cardiomyopathy Panel |
| 81481.0000 | Apolipoprotein E |
| 81482.0000 | Lipid Phenotype |
| 81483.0000 | Plasma Volume |
| 81484.0000 | Blood Volume |
| 81485.0000 | Vancomycin |
| 81486.0000 | B12/Folate Panel |
| 81487.0000 | Valproic Acid |
| 81487.3035 | Vanillylmandelic Acid~DU PONT A |
| 81488.0000 | Adenosine Triphosphate |
| 81489.0000 | Methyl Tetra Hydor Folate Redu |
| 81490.0000 | Oxypurinol |
| 81491.0000 | Free Valproic Acid |
| 81492.0000 | Hemoglobin Acid Prep |
| 81493.0000 | Allopurinol |
| 81494.0000 | Polychlorindate Biphenyl |
| 81495.0000 | Pyphylline |
| 81496.0000 | B-Human Chorionic Gonadotropin |
| 81497.0000 | Protein electrophoresis HR |
| 81498.0000 | Alpha-naphthyl acetate esteras |
| 81499.0000 | Lamotrigine |
| 81500.0000 | Acepromazine |
| 81501.0000 | Furosemide |
| 81502.0000 | Acetaldehyde |

VistA Laboratory EPI

Rollup Modifications

Technical and User Manual

| | |
|------------|--------------------------------|
| 81503.0000 | Free Thyroxine Index |
| 81504.0000 | Acetone |
| 81505.0000 | Cefuroxime-Sodium |
| 81506.0000 | Alcohol Ethyl |
| 81507.0000 | Epoxide |
| 81508.0000 | Alcohol Isopropyl |
| 81509.0000 | Cefuroxime-Axetil |
| 81510.0000 | Alcohol Methyl |
| 81511.0000 | Alprazolam |
| 81512.0000 | Aluminum |
| 81513.0000 | Dimenhydrinate |
| 81514.0000 | Amdinocillin |
| 81515.0000 | Cefipime |
| 81516.0000 | Aminosalicyclic Acid Para |
| 81517.0000 | Cyclobenzaprine HCL |
| 81518.0000 | X*Amiodarone |
| 81519.0000 | Antihistamine |
| 81520.0000 | Amobarbital |
| 81521.0000 | Albuterol |
| 81522.0000 | Amoxapine |
| 81523.0000 | Trihexyphenidyl HCL |
| 81524.0000 | Amoxicillin |
| 81525.0000 | Tin |
| 81526.0000 | Amoxicillin Clavulanic Acid |
| 81527.0000 | Thiamine |
| 81528.0000 | Amphetamine |
| 81529.0000 | Phenol |
| 81530.0000 | Amphotericin B |
| 81531.0000 | Paroxetine |
| 81532.0000 | Ampicillin |
| 81533.0000 | Long Acting Thyroid Hormone |
| 81534.0000 | Amrinone |
| 81535.0000 | Anticonvulsants |
| 81536.0000 | Antimony |
| 81537.0000 | Crystals |
| 81538.0000 | Arsenic |
| 81539.0000 | Crystals Id |
| 81540.0000 | Atropine |
| 81541.0000 | Atrial Natriuretic Polypeptide |
| 81542.0000 | Azlocillin |
| 81543.0000 | Sperm Count |
| 81544.0000 | Aztreonam |
| 81545.0000 | Fluvoxamine |
| 81546.0000 | Bacitracin |
| 81547.0000 | Clotest |
| 81548.0000 | Barbiturate Identification |
| 81549.0000 | Barbiturate NOS |
| 81550.0000 | Barbiturate Screen |
| 81551.0000 | +Amikacin Peak |
| 81552.0000 | Benzodiazepines Quant |
| 81553.0000 | Marijuana |
| 81554.0000 | Benzodiazepines Screen |
| 81555.0000 | Amikacin Trough |
| 81556.0000 | Benzoylecgonine |
| 81557.0000 | Vancomycin Peak |
| 81558.0000 | Beryllium |
| 81559.0000 | Vancomycin Trough |
| 81560.0000 | Bismuth |
| 81561.0000 | Gentamicin Peak |

VistA Laboratory EPI

Rollup Modifications

Technical and User Manual

| | |
|------------|-------------------------------|
| 81562.0000 | Borate |
| 81563.0000 | Gentamicin Trough |
| 81564.0000 | Bromide |
| 81565.0000 | Tobramycin Peak |
| 81566.0000 | Butabarbital |
| 81567.0000 | Tobramycin Trough |
| 81568.0000 | Butalbital |
| 81569.0000 | Butorphanol Tartrate |
| 81570.0000 | Cadmium |
| 81571.0000 | Saturation % |
| 81572.0000 | Caffeine |
| 81573.0000 | Cyclosporine |
| 81574.0000 | Cannabinoids Screen |
| 81575.0000 | Cyclosporine Metabolite |
| 81576.0000 | Cannabinol Tetrahydro |
| 81577.0000 | Albumin Fract Urine |
| 81578.0000 | Cannabinol Tetrahydro Car |
| 81579.0000 | Alpha Globulin Urine |
| 81580.0000 | Cannabinol Tetrahydro Hydro |
| 81581.0000 | Beta Globulin Urine |
| 81582.0000 | Capreomycin |
| 81583.0000 | Gamma Globulin Urine |
| 81584.0000 | Carbamazepine |
| 81585.0000 | Amphetamine Quant |
| 81586.0000 | Carbamazepine Free |
| 81587.0000 | Opiate |
| 81588.0000 | Carbenicillin |
| 81589.0000 | Opiate Quant |
| 81590.0000 | Carbinoxamine |
| 81591.0000 | Propoxyphene Quant |
| 81592.0000 | Carbon Monoxide |
| 81593.0000 | Insulin Like Growth Factor II |
| 81594.0000 | Carbon Tetrachloride |
| 81595.0000 | Iodine |
| 81596.0000 | Carboxyhemoglobin |
| 81597.0000 | Estriol Unconjugated |
| 81598.0000 | Cefacetrile |
| 81599.0000 | Bartonella henselae Ab IgG |
| 81600.0000 | Cefaclor |
| 81601.0000 | Bartonella Henselae Ab IgM |
| 81602.0000 | Cefadroxil |
| 81603.0000 | Bartonella quintana Ab IgG |
| 81604.0000 | Cefamandole |
| 81605.0000 | Transglutaminase Tissue |
| 81606.0000 | Cefatrizinc |
| 81607.0000 | OK T3 and T Cells Total |
| 81608.0000 | Cefazaflur |
| 81609.0000 | Olanzapine |
| 81610.0000 | Cefazolin |
| 81611.0000 | Urea Urine |
| 81612.0000 | Cefmenoxime |
| 81613.0000 | Albumin Urine |
| 81614.0000 | Cefmetazole |
| 81615.0000 | Albumin Urine 24h |
| 81616.0000 | Cefoperazone |
| 81617.0000 | Report Chemistry |
| 81618.0000 | Ceforanide |
| 81619.0000 | Thyroid Ab |
| 81620.0000 | Cefotaxime |

VistA Laboratory EPI

Rollup Modifications

Technical and User Manual

| | |
|------------|---------------------------------|
| 81621.0000 | Adrenaline |
| 81622.0000 | Adrenocorticotrophic Hormone |
| 81623.0000 | Adrenocorticotrophic Hormone St |
| 81624.0000 | Cefoxitin |
| 81625.0000 | Phosphate Urine 24h |
| 81626.0000 | Uric Acid Urine 24h |
| 81627.0000 | Iron Urine 24h |
| 81628.0000 | Cefradine |
| 81629.0000 | Glucose Tolerance 2hr |
| 81630.0000 | Ceftazidime |
| 81631.0000 | Glucose Tolerance 1hr |
| 81632.0000 | Glucose Tolerance 30min |
| 81633.0000 | Glucose Tolerance Fasting |
| 81634.0000 | Ceftizoxime |
| 81635.0000 | Lactose Tolerance Fasting |
| 81636.0000 | Ceftriaxone |
| 81637.0000 | Myeloperoxidase |
| 81638.0000 | Cefsulodin |
| 81639.0000 | Cystic Fibrosis F508 |
| 81640.0000 | Cefuroxime |
| 81641.0000 | Deoxyypyridinoline |
| 81642.0000 | Cephalexin |
| 81643.0000 | Oxalate 24Hr |
| 81644.0000 | Cephaloglycin |
| 81645.0000 | Corticosteroids |
| 81646.0000 | Cephaloridine |
| 81647.0000 | Creatinine 24Hr |
| 81648.0000 | Cephalothin |
| 81649.0000 | Cryoglobulin Panel |
| 81650.0000 | Cephapirin |
| 81651.0000 | Cryoglobulin Comp |
| 81652.0000 | Cepharadine |
| 81653.0000 | Cortisol 24Hr |
| 81654.0000 | Chloral Hydrate |
| 81655.0000 | Cortisol PM |
| 81656.0000 | Chloramphenicol |
| 81657.0000 | Cortisol AM |
| 81658.0000 | Chlordiazepoxide |
| 81659.0000 | Amitriptyline Panel |
| 81660.0000 | Chloroform |
| 81661.0000 | Amiodarone Panel |
| 81662.0000 | Chlorpheniramine |
| 81663.0000 | p-ANCA |
| 81664.0000 | Chlorphentermine |
| 81665.0000 | c-ANCA |
| 81666.0000 | Chlorpromazine |
| 81667.0000 | Alpha Amino Acid |
| 81668.0000 | Chlorpropamide |
| 81669.0000 | Alcohol Screen |
| 81670.0000 | Chromium |
| 81671.0000 | Isopropanol |
| 81672.0000 | Cimetidine |
| 81673.0000 | Naltrexone |
| 81674.0000 | Ciprofloxacin |
| 81675.0000 | Cocaine Qt |
| 81676.0000 | Clindamycin |
| 81677.0000 | Pyridinoline |
| 81678.0000 | Clonazepam |
| 81679.0000 | Clorazepate |

VistA Laboratory EPI

Rollup Modifications

Technical and User Manual

| | |
|------------|--------------------------------|
| 81680.0000 | Cloxacillin |
| 81681.0000 | Cocaine |
| 81682.0000 | Codeine |
| 81683.0000 | Colistin |
| 81684.0000 | Copper |
| 81685.0000 | Coumermycin |
| 81686.0000 | Cyanide |
| 81687.0000 | Methadone Qt |
| 81688.0000 | Cycloserine |
| 81689.0000 | Cyclosporin |
| 81690.0000 | Dapsone |
| 81691.0000 | Daunomycin |
| 81692.0000 | Desipramine |
| 81693.0000 | Dexchlorpheniramine |
| 81694.0000 | Diazepam |
| 81695.0000 | Dicloxacillin |
| 81696.0000 | Digitoxin |
| 81697.0000 | Digoxin |
| 81698.0000 | Diphenhydramine |
| 81699.0000 | Dipyridamole |
| 81700.0000 | Disopyramide |
| 81701.0000 | Doxepin |
| 81702.0000 | Doxycycline |
| 81703.0000 | Drug Screen Acid Neutral |
| 81704.0000 | Drug Screen Basic |
| 81705.0000 | Drug Screen for Mult Const |
| 81706.0000 | Drug Screen Hypnotic |
| 81707.0000 | Drug Screen NOS |
| 81708.0000 | Enoxacin |
| 81709.0000 | Ephedrine |
| 81710.0000 | Erythromycin |
| 81711.0000 | Ethambutol |
| 81712.0000 | Ethchlorvynol |
| 81713.0000 | Ethionamide |
| 81714.0000 | Ethosuximide |
| 81715.0000 | Ethylene Glycol |
| 81716.0000 | Flucytosine |
| 81717.0000 | Fluoride |
| 81718.0000 | Fluorocytosine5 |
| 81719.0000 | Flurazepam |
| 81720.0000 | Formic Acid Formaldehyde Expos |
| 81721.0000 | Epinephrine |
| 81722.0000 | Glutethimide |
| 81723.0000 | Flecainide |
| 81724.0000 | Gold |
| 81725.0000 | Hydrocarbons Halogenated |
| 81726.0000 | Alpha1 Microglobulin |
| 81727.0000 | Haloperidol |
| 81728.0000 | Alpha2 Macroglobin |
| 81729.0000 | Heavy Metal Screen Reinsch |
| 81730.0000 | Aluminin Urine |
| 81731.0000 | Hydrochlorothiazide |
| 81732.0000 | Hydrocodone |
| 81733.0000 | Hydromorphone |
| 81734.0000 | Hydroxyzine |
| 81735.0000 | Ibuprofen |
| 81736.0000 | Imipenum |
| 81737.0000 | Imipramine |
| 81738.0000 | Iodide |

VistA Laboratory EPI

Rollup Modifications

Technical and User Manual

| | |
|------------|--------------------------------|
| 81739.0000 | Isoniazid |
| 81740.0000 | Ketoconazole |
| 81741.0000 | Lead |
| 81742.0000 | Lidocaine |
| 81743.0000 | Fentanyl Citrate |
| 81744.0000 | Lithium |
| 81744.3103 | Lung Carcinoma Surface Ag~EKTA |
| 81745.0000 | Mitotane |
| 81746.0000 | Loxapine |
| 81747.0000 | Aprobarbital |
| 81748.0000 | Lysergic Acid Diethylamide |
| 81749.0000 | Amino Acids CSF |
| 81750.0000 | Manganese |
| 81751.0000 | Amino Acids Urine |
| 81752.0000 | Maprotiline |
| 81753.0000 | 5-Aminolevulinic Acid Urine |
| 81754.0000 | Meperidine |
| 81755.0000 | Amitriptyline and Nortriptylin |
| 81756.0000 | Mephentermine |
| 81757.0000 | Amylase/Creat Clearance |
| 81758.0000 | Mephenytoin |
| 81759.0000 | CPK MB/CPK Tot |
| 81760.0000 | Meprobamate |
| 81761.0000 | Synercid |
| 81762.0000 | Mercury |
| 81763.0000 | Insulin Fasting |
| 81764.0000 | Mescaline |
| 81765.0000 | Insulin Total |
| 81766.0000 | Mesoridazine |
| 81767.0000 | Alkaline Phosphatase Other |
| 81768.0000 | Methadone |
| 81769.0000 | Arsenic Urine |
| 81770.0000 | Methamphetamine |
| 81771.0000 | Mercury Urine |
| 81772.0000 | Methapyrilene |
| 81773.0000 | Immunoglobulin G CSF |
| 81774.0000 | Methaqualone Quant |
| 81775.0000 | Albumin CSF |
| 81776.0000 | Methaqualone Screen |
| 81777.0000 | Methemoglobin and Sulfhemo |
| 81778.0000 | Methicillin |
| 81779.0000 | Methemoglobin |
| 81780.0000 | Methocarbamol |
| 81781.0000 | Albumin Index |
| 81782.0000 | Methorphan Dextro |
| 81783.0000 | CSF IgG Synthesis |
| 81784.0000 | Methsuximide |
| 81785.0000 | IgG Index |
| 81786.0000 | Methylphenidate Hydrochl |
| 81787.0000 | Albumin/IgG Ratio |
| 81788.0000 | Methyprylon |
| 81789.0000 | Estrogen Fract |
| 81790.0000 | Metronidazole |
| 81791.0000 | Exposure Panel |
| 81792.0000 | Mexilitine |
| 81793.0000 | Lead Exposure Panel |
| 81794.0000 | Mezlocillin |
| 81795.0000 | CPK BB/CPK Tot |
| 81796.0000 | Miconazole |

VistA Laboratory EPI

Rollup Modifications

Technical and User Manual

| | |
|------------|------------------------------|
| 81797.0000 | Microglobulin Beta 2 |
| 81798.0000 | Minocycline |
| 81799.0000 | CPK MM/CPK Tot |
| 81800.0000 | Morphine |
| 81801.0000 | Arsenic 24H |
| 81802.0000 | Morphine Diacetyl (heroin) |
| 81803.0000 | Arsenic Panel |
| 81804.0000 | Morphine Glucuronide |
| 81805.0000 | Arsenic/Creatinine |
| 81806.0000 | Moxalactam |
| 81807.0000 | Muramidase (lysozyme) |
| 81808.0000 | Nafcillin |
| 81809.0000 | Nalbuphine Hydrochloride |
| 81810.0000 | Nalidixic Acid |
| 81811.0000 | Triglyceride |
| 81812.0000 | Neomycin |
| 81813.0000 | Barbiturate |
| 81814.0000 | Netilmicin |
| 81815.0000 | Lipoprotein Beta |
| 81816.0000 | Nickel |
| 81817.0000 | Lipoprotein Pre Beta |
| 81818.0000 | Nicotine |
| 81819.0000 | Lipoprotein Alpha |
| 81820.0000 | Nitrate |
| 81821.0000 | Iron Index |
| 81822.0000 | Nitrite |
| 81823.0000 | Microalbumin/Creatinine |
| 81824.0000 | Nitrofurantoin |
| 81825.0000 | Xylose Absorption |
| 81826.0000 | Nitrophenol Para |
| 81827.0000 | Amoxapine 8 Hydroxy |
| 81828.0000 | Nordiazepam |
| 81829.0000 | Creatine Kinase (CK MB) Mass |
| 81830.0000 | Norfloxacin |
| 81831.0000 | Color |
| 81832.0000 | Norpethidine |
| 81833.0000 | Norepinephrine |
| 81834.0000 | Norpropoxyphene |
| 81835.0000 | Tube Number |
| 81836.0000 | Nortriptyline |
| 81837.0000 | Desmethylsertraline |
| 81838.0000 | Novobiocin |
| 81839.0000 | Sirolimus |
| 81840.0000 | Nystatin |
| 81841.0000 | Organic Acids |
| 81842.0000 | Organophosphate NOS |
| 81843.0000 | Platelet Function |
| 81844.0000 | Oxacillin |
| 81845.0000 | Phosphorus Urine |
| 81846.0000 | Oxazepam |
| 81847.0000 | Phosphorus Timed |
| 81848.0000 | Oxycodone |
| 81849.0000 | Phosphorus Urine 24H |
| 81850.0000 | Paraldehyde |
| 81851.0000 | Procainamide N Acetyl(NAPA) |
| 81852.0000 | Penicillin |
| 81853.0000 | Comprehensive Met Panel |
| 81854.0000 | Pentazocine |
| 81855.0000 | Potassium Misc |

VistA Laboratory EPI

Rollup Modifications

Technical and User Manual

| | |
|------------|---------------------------|
| 81856.0000 | Pentobarbital |
| 81857.0000 | Sodium Misc |
| 81858.0000 | Percodan |
| 81859.0000 | Urea 24H |
| 81860.0000 | Perphenazine |
| 81861.0000 | Hemocystein |
| 81862.0000 | Pethidine |
| 81863.0000 | Homocystine Urine |
| 81864.0000 | Phenacetin |
| 81865.0000 | Liprotein Fractionation |
| 81866.0000 | Phencyclidine Screen |
| 81867.0000 | Zonisamide |
| 81868.0000 | Phenmetrazine |
| 81869.0000 | Carnitine Tot |
| 81870.0000 | Phenothiazine Quant |
| 81871.0000 | Carnitine Free |
| 81872.0000 | Phenothiazine Screen |
| 81873.0000 | Chloride Misc |
| 81874.0000 | Phensuximide |
| 81875.0000 | Phentermine |
| 81876.0000 | Phenylbutazone |
| 81877.0000 | Chlorine Esterase Inh |
| 81878.0000 | Phenylephrine |
| 81879.0000 | Glucose Misc |
| 81880.0000 | Phenylpropanolamine |
| 81881.0000 | Levitracetam |
| 81882.0000 | Phenytoin |
| 81883.0000 | Uranium |
| 81884.0000 | Phenytoin Free |
| 81885.0000 | Uranium Depleted |
| 81886.0000 | Piperacillin |
| 81887.0000 | Pesticide Exposure |
| 81888.0000 | Polymixin B |
| 81889.0000 | Prazepam |
| 81890.0000 | Primidone+Phenobarbital |
| 81891.0000 | Carnitine Esterified |
| 81892.0000 | Prochlorperazine |
| 81893.0000 | Alpha 1 Acid Glucoprotein |
| 81894.0000 | Promazine |
| 81895.0000 | Lipid Assoc Sialic Acid |
| 81896.0000 | Promethazine |
| 81897.0000 | Didanosine |
| 81898.0000 | Propoxyphene |
| 81899.0000 | Zalcitabine |
| 81900.0000 | Protriptyline |
| 81901.0000 | Stavudine |
| 81902.0000 | Pseudoephedrine |
| 81903.0000 | Lamivudine |
| 81904.0000 | Psilocybin |
| 81905.0000 | Abacavir |
| 81906.0000 | Pyrazinamide |
| 81907.0000 | Tenofovir |
| 81908.0000 | Pyrilamine |
| 81909.0000 | Nevirapine |
| 81910.0000 | Pyrimethamine Sulfadoxine |
| 81911.0000 | Delavirdine |
| 81912.0000 | Quadracyclic NOS |
| 81913.0000 | Efavirenz |
| 81914.0000 | Quinidine |

VistA Laboratory EPI

Rollup Modifications

Technical and User Manual

| | |
|------------|--------------------------------|
| 81915.0000 | Indinavir |
| 81916.0000 | Quinine |
| 81917.0000 | Ritonavir |
| 81918.0000 | Rifampin |
| 81919.0000 | Nelfinavir |
| 81920.0000 | Salicylamide |
| 81921.0000 | Amprenavir |
| 81922.0000 | Salicylates |
| 81923.0000 | Lopinavir |
| 81924.0000 | Secobarbital |
| 81925.0000 | Lopinavir Ritonavir |
| 81926.0000 | Selenium |
| 81927.0000 | Norfluoxetine |
| 81928.0000 | Silicon |
| 81929.0000 | Creatinine Urine |
| 81930.0000 | Sisomicin |
| 81931.0000 | Clozapine |
| 81932.0000 | Spectinomycin |
| 81933.0000 | Norclozapine |
| 81934.0000 | Spiramycin |
| 81935.0000 | Atenolol |
| 81936.0000 | Streptomycin |
| 81937.0000 | Calcium/Creatinine |
| 81938.0000 | Strychnine |
| 81939.0000 | Sulfhemoglobin |
| 81940.0000 | Sulfamethoxazole |
| 81941.0000 | Saquinavir |
| 81942.0000 | Sulfonamide NOS |
| 81943.0000 | Arachidonate |
| 81944.0000 | Teichoic Acid |
| 81945.0000 | Temazepam |
| 81946.0000 | Tetracycline NOS |
| 81947.0000 | Azathioprine |
| 81948.0000 | Thallium |
| 81949.0000 | Linoleate |
| 81950.0000 | Theophylline |
| 81951.0000 | Platinum |
| 81952.0000 | Thiazide |
| 81953.0000 | Procaine |
| 81954.0000 | Thiocyanate |
| 81955.0000 | Quetiapine |
| 81956.0000 | Thiopental |
| 81957.0000 | Magnesium RBC |
| 81958.0000 | Thioridazine |
| 81959.0000 | Tranlycypromine |
| 81960.0000 | Ticarcillin |
| 81961.0000 | Acteazolamidine |
| 81962.0000 | Ticarcillin Clavulanic Acid |
| 81963.0000 | Succinyl Acetone |
| 81964.0000 | Tocainide |
| 81965.0000 | Alpha-naphthyl Butyrate Estera |
| 81966.0000 | Tolazamide |
| 81967.0000 | Cortisol 90min |
| 81968.0000 | Tolbutamide |
| 81969.0000 | Metanephrine Total |
| 81970.0000 | Toluene |
| 81971.0000 | Triazolam |
| 81972.0000 | Trichloroethylene |
| 81973.0000 | Tiech Acid |

VistA Laboratory EPI

Rollup Modifications

Technical and User Manual

| | |
|------------|--------------------------------|
| 81974.0000 | Hexagonal Phospholipid Neut |
| 81975.0000 | Dioxin |
| 81976.0000 | Tricyclic Antidepressants Scr |
| 81977.0000 | Metanephrine 24H |
| 81978.0000 | Sulfapyridine |
| 81979.0000 | Sperm Non-Motile |
| 81980.0000 | Trimethoprim |
| 81981.0000 | Sperm Slow |
| 81982.0000 | Tripelennamine |
| 81983.0000 | Blood Occult Semen |
| 81984.0000 | Volatile Screen |
| 81985.0000 | Hemoglobinuria Paroxysmal Noct |
| 81986.0000 | Warfarin |
| 81987.0000 | Topiramate |
| 81988.0000 | Zinc |
| 81989.0000 | Thin Layer Chromatography |
| 81990.0000 | Progesterone Binding Receptor |
| 81991.0000 | Allylbarbital |
| 81992.0000 | Talbutal |
| 81993.0000 | Demoxepam |
| 81994.0000 | Desalkylflurazepam |
| 81995.0000 | N Desmethyldiazepam |
| 81996.0000 | Flunitrazepam |
| 81997.0000 | Lorazepam |
| 81998.0000 | Mecloqualone |
| 81999.0000 | Levorphanol |
| 82000.0000 | TCP |
| 82001.0000 | Mercury Urine 24h |
| 82002.0000 | Blood Occult NOS |
| 82003.0000 | Carbohydrate Deficient Transfe |
| 82004.0000 | BUN Urine 24h |
| 82005.0000 | Microalbumin Urine Rand |
| 82006.0000 | Desmethylclomipramine |
| 82007.0000 | Glutamic Acid Decarboxylase |
| 82008.0000 | Antenolol |
| 82009.0000 | Clonidine Suppression |
| 82010.0000 | Cytomegalovirus PCR |
| 82011.0000 | Fragile X Syndrome |
| 82012.0000 | Glycerol Lysis |
| 82013.0000 | Hepatitis B Core Ab & IgM |
| 82014.0000 | Herpes simplex PCR |
| 82015.0000 | Tiagabine Hydrochloride |
| 82016.0000 | Hepatitis C RNA Qual |
| 82017.0000 | Hepatitis C RNA Quant |
| 82018.0000 | RBC Agglutinated |
| 82019.0000 | HIV 1 Qual PCR |
| 82020.0000 | ACTH |
| 82021.0000 | Natriuretic Peptide Brain (B T |
| 82022.0000 | Ovarian Ab |
| 82023.0000 | Microalbumin Urine 24h |
| 82024.0000 | Luteinizing Hormone Beta |
| 82025.0000 | Serotonin Platelet |
| 82026.0000 | C Reactive Protein HS |
| 82027.0000 | Sulfonylurea Urine |
| 82028.0000 | Viscosity Blood |
| 82029.0000 | Thrombotic Risk |
| 82030.0000 | Adenosine 5 Monophosphate |
| 82031.0000 | Mycobacterium TB Complex DNA P |
| 82032.0000 | Toxoplasma PCR |

VistA Laboratory EPI

Rollup Modifications

Technical and User Manual

| | |
|------------|--------------------------------|
| 82033.0000 | Viscosity Plasma |
| 82034.0000 | Glutamic Acid Decarboxylase Ab |
| 82035.0000 | Adenosine 5 Triphosphate |
| 82036.0000 | Clonidine Hydrochloride |
| 82037.0000 | Cortisol Stimulation Panel |
| 82038.0000 | Immunofixation Electrophoresis |
| 82039.0000 | Immunofixation Electrophoresis |
| 82040.0000 | Albumin |
| 82041.0000 | WBC Clumps |
| 82042.0000 | Albumin Pre |
| 82043.0000 | Ammonium Biruate Crystal |
| 82044.0000 | Lead Urine 24h |
| 82045.0000 | Malanin |
| 82046.0000 | Lactose Tolerance 30min |
| 82047.0000 | Lactose Tolerance 1h |
| 82048.0000 | Lactose Tolerance 2h |
| 82049.0000 | Lactose Tolerance 3h |
| 82050.0000 | Glucose Urine 24h |
| 82051.0000 | Acid Quant Urine |
| 82052.0000 | Macroglobulin Alpha2 |
| 82053.0000 | Macroglobulins SIA |
| 82054.0000 | Saturation of Serum w Iron |
| 82055.0000 | Cholinesterase RBC |
| 82056.0000 | Potassium Urine 24h |
| 82057.0000 | Tetrahydroeoxycortisol |
| 82058.0000 | Heparin Cofactor II |
| 82059.0000 | Glutamic Acid |
| 82060.0000 | Transferrin |
| 82061.0000 | Extraction and Quant Chromato |
| 82062.0000 | Concentration of Specimen Dial |
| 82063.0000 | Extraction w Organic Solvent |
| 82064.0000 | Derivatization Compnd Chromat |
| 82065.0000 | Precipitation and Separation |
| 82066.0000 | Hemochromatosis Scr |
| 82067.0000 | Hemolysate Preparation |
| 82068.0000 | Kiniogen High MW |
| 82069.0000 | Cefotiam |
| 82070.0000 | Cephadrine |
| 82071.0000 | Concentration of Specimen Ultr |
| 82072.0000 | Concentration of Specimen Evap |
| 82073.0000 | Levofloxacin |
| 82074.0000 | Levofloxacin Quant |
| 82075.0000 | Entrofloxacin |
| 82076.0000 | Fosfomycin |
| 82077.0000 | Fusidic Acid |
| 82078.0000 | 3-Methoxy O Desmethylencaïnide |
| 82079.0000 | Dry Weight |
| 82080.0000 | Total Solids |
| 82081.0000 | Phosphatidyl Glycerol |
| 82082.0000 | Glucose Mean |
| 82083.0000 | Glucose Tolerance 1.5hr |
| 82084.0000 | Glycolic Acid |
| 82085.0000 | Procain+NAPA |
| 82086.0000 | Cloz+Norcloz |
| 82087.0000 | Oxcarbazepine |
| 82088.0000 | Amylase/Creat Ratio |
| 82089.0000 | Hydroxylysine |
| 82090.0000 | Aldolase |
| 82091.0000 | Niacin Vitamin |

VistA Laboratory EPI

Rollup Modifications

Technical and User Manual

| | |
|------------|--------------------------------|
| 82092.0000 | Niacinamide |
| 82093.0000 | Sarcosine |
| 82094.0000 | Aminobutyric 4 |
| 82095.0000 | Camosine |
| 82096.0000 | Anserine |
| 82097.0000 | Transferrin Receptor Soluble |
| 82098.0000 | Digoxin Free |
| 82099.0000 | Hydroxyitraconazole |
| 82101.0000 | Promonocytes Percent |
| 82102.0000 | Amylase Salivary |
| 82103.0000 | Citrate 24hr |
| 82104.0000 | WBC Clumps Urine |
| 82105.0000 | Amino Acids Nitrogen Total Ur |
| 82106.0000 | Opiate Synthetic |
| 82107.0000 | Prostatic Specific Ag Free Per |
| 82108.0000 | Busulfan |
| 82109.0000 | Amylase Macro |
| 82110.0000 | Phosphatase Alkaline Placental |
| 82111.0000 | Parathyroid Relate Protein |
| 82112.0000 | Tocopherol Alpha |
| 82113.0000 | Tocopherol Beta Gamma |
| 82114.0000 | Corticosteriod Binding Globuli |
| 82115.0000 | Glucose POC |
| 82116.0000 | Glucose Capillary |
| 82117.0000 | Glycohemoglobin HbA 1c Capilla |
| 82118.0000 | Comment |
| 82119.0000 | Acetylmethadol |
| 82120.0000 | Ketoglutarate Alpha |
| 82121.0000 | Creatine Kinase (BB) |
| 82122.0000 | Callagen Crosslink N Telopepti |
| 82123.0000 | O Desmethylencaïnide |
| 82124.0000 | Isoleucine |
| 82125.0000 | Lenght |
| 82126.0000 | Calculus |
| 82127.0000 | Length Calculus |
| 82128.0000 | Length NOS |
| 82129.0000 | Leucine |
| 82130.0000 | Amino Acids Quant |
| 82131.0000 | Leucine/Creatinine |
| 82132.0000 | Isoleucine+Leucine |
| 82133.0000 | Lysine |
| 82134.0000 | C1 Esterase Inhibitor Function |
| 82135.0000 | Creatinine eGFR |
| 82136.0000 | Atazanavir |
| 82137.0000 | Oxycodone,Rapid |
| 82138.0000 | Cytomegalovirus DNA |
| 82139.0000 | Cytomegalovirus DNA Probe |
| 82140.0000 | Ammonia |
| 82141.0000 | Epstein Barr PCR |
| 82142.0000 | Amniotic Fluid Scan |
| 82143.0000 | Lysozyme |
| 82144.0000 | Magnesium Stool |
| 82145.0000 | Methionine |
| 82146.0000 | Carbidoba and Levodopa |
| 82147.0000 | Liver Kidney Microsomal Ab |
| 82148.0000 | Hu Ab IFA |
| 82149.0000 | MTHFR DNA Mutation |
| 82150.0000 | Amylase |
| 82151.0000 | Carbidoba |

VistA Laboratory EPI

Rollup Modifications

Technical and User Manual

| | |
|------------|------------------------------|
| 82152.0000 | Methlmalonic Acid Urine |
| 82153.0000 | Calculus Appearance |
| 82154.0000 | Androstanediol Glucuronide |
| 82155.0000 | Norclomipramine |
| 82156.0000 | Stone |
| 82157.0000 | Calculus Analysis |
| 82158.0000 | Calculus Constituents |
| 82159.0000 | Ornithine |
| 82160.0000 | Androstenedione |
| 82161.0000 | Other NOS |
| 82162.0000 | Drug NOS |
| 82163.0000 | Angiotensin II Enzyme |
| 82164.0000 | Phosphoethanolimine |
| 82165.0000 | Phophoserine |
| 82166.0000 | Pidgeon Serum |
| 82167.0000 | Band |
| 82168.0000 | Band Predominant |
| 82169.0000 | Sperm Progression |
| 82170.0000 | Proline |
| 82171.0000 | Vitamin K Protein Induced |
| 82172.0000 | Pyruvate CSF |
| 82173.0000 | Risk factor |
| 82174.0000 | Risk Relative |
| 82175.0000 | Cholesterol/HDL Risk Factor |
| 82177.0000 | Serine |
| 82178.0000 | Steroid Screen |
| 82179.0000 | Steroid ID |
| 82180.0000 | Ascorbic Acid |
| 82181.0000 | Sodium Urine 24h |
| 82182.0000 | Sodium Urine |
| 82183.0000 | Phosphate Urine |
| 82184.0000 | Uric Acid Urine |
| 82185.0000 | Iron Urine |
| 82186.0000 | Glucose Urine |
| 82187.0000 | Potassium Urine |
| 82188.0000 | Magnesium Urine |
| 82189.0000 | Lead Urine |
| 82190.0000 | Threonine |
| 82191.0000 | Homocysteine Urine |
| 82192.0000 | Amylase Urine |
| 82193.0000 | Calcium Urine |
| 82194.0000 | Bismuth Urine |
| 82195.0000 | Nitrogen Urine |
| 82196.0000 | Chloride Urine |
| 82197.0000 | Carbon Dioxide Urine |
| 82198.0000 | Copper Urine |
| 82199.0000 | Calcium Urine 24h |
| 82200.0000 | Thiopurine Methyltransferase |
| 82201.0000 | Valine |
| 82202.0000 | Amylase Urine 24h |
| 82203.0000 | Chloride Urine 24h |
| 82204.0000 | Carbon Dioxide Urine 24h |
| 82205.0000 | Phospate Urine 24h |
| 82206.0000 | Sperm Viscosity |
| 82207.0000 | Zinc Urine |
| 82208.0000 | Sperm Volume |
| 82209.0000 | Zinc Urine 24h |
| 82210.0000 | Sperm WBC |
| 82211.0000 | Dopamine Urine |

VistA Laboratory EPI

Rollup Modifications

Technical and User Manual

| | |
|------------|--------------------------------|
| 82212.0000 | Protein/Creatinine Ratio Urine |
| 82213.0000 | Calculus Morphology |
| 82214.0000 | PaO2/PAO2 ratio |
| 82215.0000 | PAO2-PaO2 Difference |
| 82216.0000 | Doxepin and Nordoxepin Tot |
| 82217.0000 | Phosphatase Alkaline Intestine |
| 82218.0000 | Amitriptyline and Nortriptylin |
| 82219.0000 | Phosphatase Alkaline Liver |
| 82220.0000 | Amino Acids Qual |
| 82221.0000 | Epinephrine+Norepinephrine |
| 82222.0000 | Clomipramine + N Desmethly Clo |
| 82223.0000 | Hexosaminidase A |
| 82224.0000 | Hexosaminidase A Percent |
| 82225.0000 | Drug Screen 5 |
| 82226.0000 | Drug Screen 5+ |
| 82227.0000 | Drug Screen 6 |
| 82228.0000 | Misc Toxicology 1 |
| 82229.0000 | Misc Toxicology 2 |
| 82230.0000 | Hemoglobin A1 |
| 82231.0000 | Misc Toxicology 3 |
| 82232.0000 | Misc Toxicology 4 |
| 82233.0000 | Misc Toxicology 5 |
| 82234.0000 | Misc Toxicology 6 |
| 82235.0000 | Thiopurine Methyltransferase R |
| 82236.0000 | N Desmethyldoxepin |
| 82237.0000 | Nefazodone |
| 82239.0000 | Bile Acids Total |
| 82240.0000 | Bile Acids Triunsaturated |
| 82241.0000 | Cholyglycine |
| 82242.0000 | Normephenytoin |
| 82243.0000 | Organochloride |
| 82244.0000 | Operator |
| 82245.0000 | Serial Number |
| 82246.0000 | Trichomonas |
| 82247.0000 | Russell's Viper Venom Ratio |
| 82249.0000 | Bilirubin Direct |
| 82249.3000 | Bilirubin Total and Direct~MAN |
| 82249.3035 | Bilirubin Total and Direct~DU |
| 82250.0000 | Bilirubin Total |
| 82250.3000 | Bilirubin Qual Feces~MANUAL |
| 82250.3035 | Bilirubin Qual Feces~DU PONT A |
| 82251.0000 | Bilirubin Total and Direct |
| 82252.0000 | Bilirubin Qual Feces |
| 82253.0000 | Bilirubin Binding Capacity |
| 82254.0000 | Trichophyton Skin Test |
| 82255.0000 | Tuberculin Skin Test |
| 82256.0000 | PTT Aged Serum |
| 82257.0000 | PTT Incubated Mix |
| 82258.0000 | PTT Immediate Mix |
| 82259.0000 | Prophobilinogen |
| 82260.0000 | Stone Risk Profile |
| 82261.0000 | Sulfite |
| 82262.0000 | Sulfate |
| 82263.0000 | Histamine Plasma |
| 82264.0000 | Strontium |
| 82265.0000 | Cadmium Urine |
| 82266.0000 | 1 Methylhistidine |
| 82267.0000 | 2 Amino adipic Acid |
| 82268.0000 | 2 Aminobutyric Acid |

VistA Laboratory EPI

Rollup Modifications

Technical and User Manual

| | |
|------------|--------------------------------|
| 82269.0000 | 3-Methylhistidine |
| 82270.0000 | Blood Occult feces |
| 82271.0000 | Blood Occult feces spot test |
| 82272.0000 | Amino Acid Interpretation |
| 82273.0000 | Alanine |
| 82274.0000 | Asparagine |
| 82275.0000 | Aldosterone Urine |
| 82276.0000 | Aspartic Acid |
| 82277.0000 | Alanine Beta |
| 82278.0000 | Blood Qual Duodenal Gastric |
| 82279.0000 | Chenodoxycholic Acid |
| 82280.0000 | Cholic Acid |
| 82281.0000 | Citrulline |
| 82283.0000 | Deoxycholic Acid |
| 82284.0000 | Ethanolamine |
| 82285.0000 | Phenobarbital Free |
| 82286.0000 | Bradykinin |
| 82287.0000 | Glycine |
| 82288.0000 | Histidine |
| 82289.0000 | Diazepam+Nordiazepam |
| 82290.0000 | P50 |
| 82291.0000 | Coagulation Profile |
| 82293.0000 | Coagulation Profile Hyper |
| 82294.0000 | Thrombin Time Control |
| 82295.0000 | Trypsinogen 1 |
| 82296.0000 | Trypsinogen 1 Free |
| 82297.0000 | Vitamin K Dependent Coag Facto |
| 82298.0000 | Anti Nuclear Ab Screen |
| 82299.0000 | Anti Nuclear Ab Stain |
| 82300.0000 | Atypical ANCA |
| 82301.0000 | Lactose Tolerance 4h |
| 82302.0000 | Drainage Site |
| 82303.0000 | Sulfate Urine |
| 82304.0000 | FSH Beta Subunit |
| 82305.0000 | 2 4 Dichlorophenoxyacetate |
| 82306.0000 | Apolipoprotein A1/B |
| 82307.0000 | Apolipoprotein B/A1 |
| 82308.0000 | Carotene Alpha |
| 82309.0000 | Carotene Beta |
| 82310.0000 | Calcium |
| 82311.0000 | Transferrin Saturation |
| 82312.0000 | Color NOS |
| 82313.0000 | Mono,Eos,Baso Percent |
| 82314.0000 | Sperm Motility |
| 82315.0000 | Tissue Cell Percent |
| 82316.0000 | Pressure |
| 82317.0000 | Tidal Volume |
| 82318.0000 | Ventilation |
| 82319.0000 | Lactose Tolerance 15min |
| 82320.0000 | Lactose Tolerance 45min |
| 82321.0000 | Lactose Tolerance 1.5hr |
| 82322.0000 | Phosphatase Alkaline Heat Labi |
| 82323.0000 | Reticulocyte % |
| 82324.0000 | Prostatic Specific Ag Free/Tot |
| 82325.0000 | Log |
| 82326.0000 | HDW |
| 82327.0000 | Histocytes |
| 82328.0000 | Phosphatase Acid Tartrate Resi |
| 82329.0000 | Leukocyte Stick |

VistA Laboratory EPI

Rollup Modifications

Technical and User Manual

| | |
|------------|--------------------------------|
| 82330.0000 | Phosphate Alkaline MacroHepati |
| 82331.0000 | Calcium Infusion |
| 82332.0000 | Porphobilinogen |
| 82333.0000 | Testosterone Bioavailable |
| 82334.0000 | Reticulocyte Immature |
| 82335.0000 | Terbinafine |
| 82336.0000 | Brompheniramine |
| 82337.0000 | Conglutin Immune Complex |
| 82338.0000 | Amacair |
| 82339.0000 | Ammonium |
| 82340.0000 | Methoxsalen |
| 82341.0000 | Hereditary Neuropathy Heridita |
| 82342.0000 | Hemachromatosis |
| 82343.0000 | Fat Neutral |
| 82344.0000 | Quentiapine |
| 82345.0000 | Calcium 24 hour Excret Feces |
| 82346.0000 | TAU Protein |
| 82347.0000 | Uroporphyrinogen Decarboxylase |
| 82348.0000 | Propoxyphene+Norpropoxyphenen |
| 82349.0000 | Nucleoside RT Inhibitors |
| 82350.0000 | Calculation |
| 82351.0000 | Nucleoside-Non RT Inhibitors |
| 82352.0000 | Protease Inhibitors |
| 82353.0000 | Calculus Nidus |
| 82354.0000 | KI-67 |
| 82355.0000 | Calculus Analysis Chemical |
| 82356.0000 | BUN Blood |
| 82357.0000 | CSF Panel |
| 82358.0000 | Cytotoxic Rejection Percent |
| 82359.0000 | Mexlocillin |
| 82361.0000 | Norfentanyl |
| 82363.0000 | Spinocerebellar Ataxia 6 |
| 82364.0000 | Occult |
| 82365.0000 | Pristamic Acid |
| 82366.0000 | Protein C Activity |
| 82367.0000 | Collagen/Epinephrine Platelet |
| 82368.0000 | Collagen/ADP Induced Platelet |
| 82369.0000 | Cortisol Binding Globulin |
| 82370.0000 | Ferritin |
| 82371.0000 | Schillings Test |
| 82372.0000 | G6PD Screen |
| 82373.0000 | Carbon Dioxide Combine Power |
| 82374.0000 | Phosphoinostiol |
| 82375.0000 | Phosphoethanolami |
| 82376.0000 | Persenilin 1 |
| 82377.0000 | Colchicine |
| 82378.0000 | Citalopram |
| 82379.0000 | Insulin 240min |
| 82380.0000 | Carotene |
| 82381.0000 | Insulin 300min |
| 82382.0000 | Insulin 360min |
| 82383.0000 | Insulin Bovine |
| 82384.0000 | Insulin Porcine |
| 82385.0000 | Left Shift |
| 82386.0000 | Oxyphenisatin |
| 82387.0000 | Cathepsin-D |
| 82388.0000 | Biscodyl |
| 82389.0000 | Triiodothyronine Uptake |
| 82390.0000 | Ceruloplasmin (Copper O) |

VistA Laboratory EPI

Rollup Modifications

Technical and User Manual

| | |
|------------|--------------------------------|
| 82390.3035 | Checking Timer on Centrifuge~D |
| 82390.3103 | Checking Timer on Centrifuge~E |
| 82391.0000 | Neopterin |
| 82392.0000 | Renin Direct |
| 82393.0000 | Tigabine |
| 82394.0000 | Mercaptopurine |
| 82395.0000 | Biotin |
| 82396.0000 | Limulus Lystae |
| 82397.0000 | Chemiluminescent |
| 82398.0000 | Hydroxypregnenolone 17 |
| 82399.0000 | Pincerred RBC |
| 82400.0000 | Chemistry Analysis Profile |
| 82401.0000 | Blood Unit Release |
| 82402.0000 | Hydroxyrisperidone 9 |
| 82403.0000 | Hydroxyloxepine 8 |
| 82404.0000 | Arsenic (Inorganic) |
| 82405.0000 | Arsenic(Inorganic)/Creatinine |
| 82406.0000 | Cadmium/Creatinine Ratio |
| 82407.0000 | Lead/Creatinine |
| 82408.0000 | Copper, RBC |
| 82409.0000 | Copper, Plasma |
| 82410.0000 | Instrument Set Up |
| 82411.0000 | Western Equine Encephalitis Ig |
| 82412.0000 | Ritalinic Acid |
| 82413.0000 | Brodifacoum |
| 82414.0000 | Varicella Zoster PCR |
| 82415.0000 | La Crosse Virus PCR |
| 82416.0000 | Jamestown Canyon Virus PCR |
| 82417.0000 | Eastern Equine Encephalitis PC |
| 82418.0000 | Powassan Virus PCR |
| 82419.0000 | Cache Valley Virus PCR |
| 82420.0000 | Multiple Ion Analysis |
| 82421.0000 | St Louis Equine Encephalitis P |
| 82422.0000 | Western Equine Encaphalitis PC |
| 82423.0000 | Enterovirus PCR |
| 82424.0000 | California Encephalitis PCR |
| 82425.0000 | Viral PCR Panel |
| 82426.0000 | Interferon Neutralizing Ab |
| 82427.0000 | Myositis Assessment Profile |
| 82428.0000 | Inhibin A |
| 82429.0000 | Inhibin B |
| 82430.0000 | Charcoal Urine |
| 82431.0000 | Dichloromethane |
| 82432.0000 | Perchloroethylene |
| 82433.0000 | Barium |
| 82434.0000 | Tellurium |
| 82435.0000 | Chloride |
| 82436.0000 | Fat Stool Total Qual |
| 82437.0000 | Fat Neutral Stool Qual |
| 82438.0000 | Muscle Fibers Stool Qual |
| 82439.0000 | Fat/Fibers Stool Qual |
| 82440.0000 | Zolpidem |
| 82441.0000 | Chlorohydrocarbons |
| 82442.0000 | Volatile Panel 1 |
| 82443.0000 | Volatile Panel 2 |
| 82444.0000 | Volatile Panel 3 |
| 82445.0000 | Volatile Panel 4 |
| 82446.0000 | Volatile Panel 5 |
| 82447.0000 | Acetonitrile |

VistA Laboratory EPI

Rollup Modifications

Technical and User Manual

| | |
|------------|--------------------------------|
| 82449.0000 | Acrolein |
| 82450.0000 | Acrylonitrile |
| 82451.0000 | Allyl Alcohol |
| 82452.0000 | Amyl Acetate |
| 82453.0000 | Butane |
| 82454.0000 | Butanois |
| 82455.0000 | Butyl Acetates |
| 82456.0000 | Cumene |
| 82457.0000 | Cyclohexane |
| 82458.0000 | Cyclopentane |
| 82459.0000 | Cyclopropane |
| 82460.0000 | Dichloroethanes |
| 82461.0000 | Dichloroethylene |
| 82462.0000 | Diisobutyl Ketone |
| 82463.0000 | Enflurane |
| 82464.0000 | Epichlorhydrin |
| 82465.0000 | Ethyl Acetate |
| 82466.0000 | Cholesterol Total |
| 82466.3035 | Cholinesterase plus DN~DU PONT |
| 82467.0000 | Ethyl Benzenes |
| 82468.0000 | Ethyl Ether |
| 82469.0000 | Ethyl t-Butyl Ether |
| 82470.0000 | Ethylene Oxide |
| 82471.0000 | Freons |
| 82472.0000 | Halothane |
| 82473.0000 | Heptane |
| 82474.0000 | Hexane |
| 82475.0000 | Isoamyl Acetate |
| 82476.0000 | Isoamyl Alcohol |
| 82477.0000 | Iso-Butane |
| 82478.0000 | Isoflurane |
| 82480.0000 | Isopropyl Ether |
| 82481.0000 | Isovaleraldehyde |
| 82482.0000 | Mesityl Oxide |
| 82483.0000 | Methane |
| 82484.0000 | Methanol |
| 82485.0000 | Chondroitin Sulfate |
| 82486.0000 | Methoxyflurane |
| 82487.0000 | Methyl Ethyl Ketone |
| 82488.0000 | Methyl Isoamyl Ketone |
| 82489.0000 | Methyl Isobutyl Ketone |
| 82490.0000 | Chromogenic Substrate |
| 82491.0000 | Methyl Methacrylate |
| 82492.0000 | Methyl n-Amyl Ketone |
| 82493.0000 | Methyl n-Butyl Ketone |
| 82494.0000 | Methyl n-Propyl Ketone |
| 82495.0000 | Methyl t-Butyl Ether |
| 82496.0000 | Methyl Acrylate |
| 82497.0000 | Methylene Chloride |
| 82498.0000 | Methylpentanes |
| 82499.0000 | n-Amyl Alcohol |
| 82500.0000 | Nonane |
| 82501.0000 | Octane |
| 82502.0000 | Pentane |
| 82503.0000 | Propane |
| 82504.0000 | Propanol |
| 82505.0000 | Propyl Acetate |
| 82507.0000 | Drug 1 ID |
| 82508.0000 | Drug 2 ID |

VistA Laboratory EPI

Rollup Modifications

Technical and User Manual

| | |
|------------|--------------------------------|
| 82509.0000 | Drug 3 ID |
| 82510.0000 | Drug 4 ID |
| 82511.0000 | Drug 5 ID |
| 82512.0000 | Drug 6 ID |
| 82513.0000 | Drug 7 ID |
| 82514.0000 | Drug 8 ID |
| 82515.0000 | Drug 9 ID |
| 82516.0000 | Drug 10 ID |
| 82517.0000 | Drug 11 ID |
| 82518.0000 | Drug 12 ID |
| 82519.0000 | Drug 13 ID |
| 82520.0000 | Drug 14 ID |
| 82521.0000 | Drug 15 ID |
| 82522.0000 | Drug 16 ID |
| 82523.0000 | Collagen Ab |
| 82524.0000 | Drug 17 ID |
| 82525.0000 | Drug 18 ID |
| 82526.0000 | Drug 19 ID |
| 82527.0000 | Drug 20 ID |
| 82528.0000 | Gamma Hydroxybutyrateacnc |
| 82529.0000 | Amylase Pancreatic P1 |
| 82530.0000 | Amylase Pancreatic P2 |
| 82531.0000 | Amylase Pancreatic P3 |
| 82532.0000 | Amylase Salivary S1 |
| 82533.0000 | Amylase Salivary S2 |
| 82534.0000 | Amylase Salivary S3 |
| 82535.0000 | Porphyrin Copro |
| 82536.0000 | Amylase P1/Amylase Ratio |
| 82537.0000 | Porphyrin Proto |
| 82538.0000 | Amylase P2/Amylase Ratio |
| 82539.0000 | Amylase P3/Amylase Ratio |
| 82540.0000 | Creatine |
| 82541.0000 | Amylase S1 Amylase Ratio |
| 82542.0000 | Amylase S2/Amylase Ratio |
| 82543.0000 | Amylase S3/Amylase Ratio |
| 82544.0000 | Fentanyl/Norfentanyl |
| 82545.0000 | Fentanyl Total |
| 82546.0000 | Fentanyl |
| 82547.0000 | Pancreatic Elastase 1 Stool |
| 82550.0000 | Creatine Kinase (CK) |
| 82555.0000 | Creatine Kinase (CK MB) |
| 82562.0000 | Creatine Kinase Isoenz (CK MB) |
| 82563.0000 | Xylene Exposure Panel Quant Ur |
| 82564.0000 | Ion exchange Column Prep |
| 82565.0000 | Creatinine |
| 82565.3035 | Creatinine~DU PONT ACA |
| 82565.3103 | Creatinine~EKTACHEM 700 |
| 82566.0000 | Pyridine |
| 82567.0000 | Styrene |
| 82568.0000 | Tetrachloroethane |
| 82569.0000 | Tetrachloroethylene |
| 82570.0000 | Tetrahydrofuran |
| 82571.0000 | Xylenes |
| 82572.0000 | Acetone Urine |
| 82573.0000 | o-Cresol Urine |
| 82574.0000 | Ethanol Urine |
| 82575.0000 | Hippuric Acid Urine |
| 82576.0000 | Isopropanol Urine |
| 82577.0000 | Mandelic Acid Urine |

VistA Laboratory EPI

Rollup Modifications

Technical and User Manual

| | |
|------------|--------------------------------|
| 82578.0000 | Methanol Urine |
| 82579.0000 | Methyl Ethyl Ketone Urine |
| 82580.0000 | Methylhippuric Acid Urine |
| 82581.0000 | Methyl Isobutyl Ketone Urine |
| 82582.0000 | Phenol Urine |
| 82583.0000 | Phenylglyoxylic Acid Urine |
| 82584.0000 | Trichlororganic Metabolites Ur |
| 82585.0000 | Cryofibrinogen |
| 82586.0000 | Paraquat |
| 82587.0000 | Paraquat Urine |
| 82588.0000 | Osmium |
| 82589.0000 | Osmium Urine |
| 82590.0000 | Osmium 24Hr |
| 82591.0000 | Pentachlorophenol |
| 82592.0000 | Pentachlorophenol Urine |
| 82593.0000 | Pentachlorophenol 24Hr |
| 82594.0000 | Pentachlorophenol Exposure Sur |
| 82595.0000 | Cryoglobulin Qual Blood |
| 82596.0000 | Carbamate Pesticides |
| 82597.0000 | Bendiocarb |
| 82598.0000 | Carbaryl |
| 82599.0000 | Carbofuran |
| 82600.0000 | 1-Naphthol |
| 82601.0000 | Propoxur |
| 82602.0000 | Bendiocarb Urine |
| 82603.0000 | Carbaryl Urine |
| 82604.0000 | Carbofuran Urine |
| 82605.0000 | 1-Naphthol Urine |
| 82606.0000 | Propoxur Urine |
| 82607.0000 | Carbamate Pesticides Urine |
| 82608.0000 | Organochlorine Pesticides |
| 82609.0000 | DDE |
| 82610.0000 | Lindane |
| 82611.0000 | DDE Urine |
| 82612.0000 | Lindane Urine |
| 82613.0000 | Alpha-Chlordane |
| 82614.0000 | Alpha-Chlordane Urine |
| 82615.0000 | Cystine |
| 82616.0000 | Gamma-Chlordane |
| 82617.0000 | Gamma-Chlordane Urine |
| 82618.0000 | Trans-Nonachlor |
| 82619.0000 | Trans-Nonachlor Urine |
| 82620.0000 | Heptachlor |
| 82621.0000 | Heptachlor Urine |
| 82623.0000 | Heptachlorepoxyde |
| 82624.0000 | Heptachlorepoxyde Urine |
| 82625.0000 | DDT |
| 82626.0000 | DDT Urine |
| 82627.0000 | Hexachlorobenzene |
| 82628.0000 | Hexachlorobenzene Urine |
| 82629.0000 | Dieldrin Urine |
| 82630.0000 | Amino Levulinic Acid Delta |
| 82632.0000 | Dehydroepiandrosterone (DHEA) |
| 82633.0000 | Desoxycorticosterone |
| 82634.0000 | Dehydroepiandrosterone Sulfate |
| 82635.0000 | Deoxycortisol |
| 82636.0000 | Dieldrin |
| 82637.0000 | Methoxychlor Urine |
| 82638.0000 | Methoxychlor |

VistA Laboratory EPI

Rollup Modifications

Technical and User Manual

| | |
|------------|--------------------------------|
| 82639.0000 | DDD |
| 82640.0000 | DDD Urine |
| 82641.0000 | Organochlorine Pesticides Urin |
| 82642.0000 | Organophosphate Pesticides |
| 82643.0000 | Organophosphate Pesticides Uri |
| 82644.0000 | Methyl Parathion Urine |
| 82645.0000 | Methyl Parathion |
| 82646.0000 | Dihydrocodeinone |
| 82647.0000 | Vinyl Chloride Metabolite Qual |
| 82649.0000 | Dihydromorphinone |
| 82651.0000 | Dihydrotestosterone |
| 82654.0000 | Dimethadione |
| 82655.0000 | Mevinphos |
| 82656.0000 | Mevinphos Urine |
| 82657.0000 | P-Nitrophenol |
| 82658.0000 | P-Nitrophenol Urine |
| 82659.0000 | Parathion |
| 82660.0000 | Parathion Urine |
| 82661.0000 | Phorate |
| 82662.0000 | Phorate Urine |
| 82663.0000 | Terbufos |
| 82664.0000 | Terbufos Urine |
| 82665.0000 | Azinphos-Methyl |
| 82666.0000 | Epiandrosterone |
| 82670.0000 | Diphosphoglycerate 2 3 |
| 82671.0000 | Azinphos-Methyl Urine |
| 82672.0000 | Carbophenthion |
| 82673.0000 | Carbophenthion Urine |
| 82674.0000 | Chlorpyrifos |
| 82675.0000 | Chlorpyrifos Urine |
| 82676.0000 | Coumaphos |
| 82677.0000 | Coumaphos Urine |
| 82678.0000 | Diazinon |
| 82679.0000 | Diazinon Urine |
| 82680.0000 | Deoxycorticosterone |
| 82681.0000 | Dichlorvos |
| 82682.0000 | Dichlorvos Urine |
| 82683.0000 | Dimethoate |
| 82684.0000 | Dimethoate Urine |
| 82685.0000 | EPN |
| 82686.0000 | EPN Urine |
| 82687.0000 | Ethion |
| 82688.0000 | Ethion Urine |
| 82689.0000 | Fenchlorphos Urine |
| 82690.0000 | Fenchlorphos |
| 82691.0000 | Fenthion |
| 82692.0000 | Fenthion Urine |
| 82693.0000 | Fonofos |
| 82694.0000 | Fonofos Urine |
| 82696.0000 | Etiocholanolone |
| 82697.0000 | Malathion Urine |
| 82698.0000 | Metasystox |
| 82699.0000 | Metasystox Urine |
| 82700.0000 | Dopamine |
| 82701.0000 | Cadmium Exposure Survey Panel |
| 82702.0000 | Oxychlordan |
| 82703.0000 | Oxychlordan Urine |
| 82704.0000 | Paraoxon |
| 82705.0000 | Fat Qual |

VistA Laboratory EPI

Rollup Modifications

Technical and User Manual

| | |
|------------|-------------------------------|
| 82706.0000 | Heavy Metal Panel 5 |
| 82707.0000 | Heavy Metal Panel 6 |
| 82708.0000 | Heavy Metal Panel 7 |
| 82709.0000 | Heavy Metal Panel 8 |
| 82710.0000 | Fat Total Quant Feces |
| 82711.0000 | Paraoxon Urine |
| 82712.0000 | Barium Urine |
| 82713.0000 | Barium 24Hr |
| 82714.0000 | Tellurium Urine |
| 82715.0000 | Tellurium 24Hr |
| 82716.0000 | Heavy Metal Panel 1 |
| 82717.0000 | Heavy Metal Panel 2 |
| 82718.0000 | Heavy Metal Panel 3 |
| 82719.0000 | Heavy Metal Panel 4 |
| 82720.0000 | Fatty Acid Esters |
| 82721.0000 | Heavy Metal Panel 9 |
| 82722.0000 | Heavy Metal Panel 10 |
| 82723.0000 | Trichloroacetic Acid Urine |
| 82724.0000 | Trichloroacetic Acid 24Hr |
| 82725.0000 | Fatty Acids Free |
| 82726.0000 | Toluene Urine |
| 82727.0000 | Toluene 24Hr |
| 82728.0000 | Trichloroethylene Urine |
| 82729.0000 | Trichloroethylene 24Hr |
| 82730.0000 | Fibrin Degradation Products |
| 82731.0000 | Trichloroethane Urine |
| 82732.0000 | Trichloroethane 24Hr |
| 82733.0000 | Trichloroethane |
| 82745.0000 | Folate Bioassay |
| 82751.0000 | Folate |
| 82756.0000 | Fructosamine |
| 82758.0000 | Fructose |
| 82759.0000 | Galactokinase |
| 82760.0000 | Galactose |
| 82775.0000 | GAL 1 PHOS Uridyl Transferase |
| 82785.0000 | Gamma Globulin |
| 82790.0000 | Transpeptidase Gamma Glut |
| 82804.0000 | Entrance or Correction Pt Dem |
| 82805.0000 | pH Body Fluids |
| 82820.0000 | PCO2 Direct Reading |
| 82830.0000 | Carbon Dioxide Content |
| 82840.0000 | Carbon Dioxide Titrimetric |
| 82870.0000 | O2 Saturation |
| 82880.0000 | PO2 Direct Reading |
| 82883.0000 | Blood Gas Analysis |
| 82884.0000 | Blood Gas POC |
| 82885.0000 | Coagulation POC |
| 82925.0000 | Acid Free QNT DUOD |
| 82930.0000 | Acid TOT QNT DUOD |
| 82945.0000 | Gastric Analysis Tubeless |
| 82955.0000 | Glucose 6 Phos Dehydrogenase |
| 82963.0000 | Glucosidase |
| 82965.0000 | Glutamate Dehydrogenase |
| 82975.0000 | Glutamine |
| 82980.0000 | Glycoprotein Acid Alpha1 |
| 82985.0000 | Glycoprotein |
| 83001.0000 | Glucose Tolerance 4hr |
| 83002.0000 | Glucose Tolerance 5hr |
| 83003.0000 | LDL Cholesterol Direct |

VistA Laboratory EPI

Rollup Modifications

Technical and User Manual

| | |
|------------|------------------------------|
| 83008.0000 | Guanosine |
| 83011.0000 | Haptoglobin |
| 83012.0000 | LDL/HDL Ratio |
| 83013.0000 | Cholesterol HDL |
| 83017.0000 | Cholesterol LDL |
| 83020.0000 | Hemoglobin |
| 83030.0000 | Hemoglobin Fetal Chemical |
| 83031.0000 | Fetal Hemoglobin Detection K |
| 83032.0000 | Hemoglobin Plasma |
| 83052.0000 | Hemoglobin S Solubility |
| 83055.0000 | Hemoglobin Unstable Heat |
| 83057.0000 | Hemoglobin A(2) |
| 83070.0000 | Hemosiderin Urine |
| 83071.0000 | Urine WBC Cast |
| 83072.0000 | Urine RBC Cast |
| 83073.0000 | Urine Granular Cast |
| 83074.0000 | Urine Fatty Cast |
| 83075.0000 | Crystal Am Urate |
| 83076.0000 | Phosphate Am Crystal |
| 83077.0000 | Urine RBC Clumps |
| 83090.0000 | Homogentisic Acid |
| 83110.0000 | Aldosterone |
| 83118.0000 | Calcitonin |
| 83125.0000 | Catecholamines |
| 83132.0000 | Acetohexamide |
| 83133.0000 | Renin Stimulation |
| 83134.0000 | Tryptase |
| 83135.0000 | Glipizide |
| 83140.0000 | Vanillylmandelic Acid |
| 83141.0000 | Phosphorus |
| 83145.0000 | Metanephrines |
| 83146.0000 | Pregnenolone |
| 83148.0000 | Protein CSF |
| 83150.0000 | Homovanillic Acid |
| 83151.0000 | Prostaglandin |
| 83155.0000 | Chemotaxis |
| 83156.0000 | Sialic Acid |
| 83185.0000 | Troponin T |
| 83186.0000 | Troponin C |
| 83190.0000 | Cortisol Free |
| 83191.0000 | Troponin I |
| 83199.0000 | Cortisol |
| 83200.0000 | Trimethadione |
| 83201.0000 | Tropomyosin |
| 83210.0000 | Insulin Tolerance |
| 83224.0000 | Nocardia |
| 83230.0000 | Corticosterone |
| 83232.0000 | Estrogen Binding Receptor |
| 83233.0000 | Estradiol |
| 83234.0000 | Estriol |
| 83235.0000 | Tripolid |
| 83236.0000 | Terfenadine |
| 83245.0000 | Estrogens |
| 83248.0000 | Gastrin |
| 83249.0000 | Hydroxyproline Free |
| 83250.0000 | Glucagon |
| 83251.0000 | Hydroxyproline |
| 83252.0000 | Iodine Total Urine |
| 83253.0000 | Hydroxyprogesterone 17 |

VistA Laboratory EPI

Rollup Modifications

Technical and User Manual

| | |
|------------|--------------------------------|
| 83254.0000 | Insulin |
| 83255.0000 | Ketogenic Steroids |
| 83256.0000 | Ketosteroids 17 |
| 83257.0000 | Hydroxycorticosterone 18 |
| 83258.0000 | Amantadine |
| 83259.0000 | Cobalt |
| 83260.0000 | Gallium |
| 83261.0000 | Glyburide |
| 83262.0000 | Heavy Metal Screen |
| 83263.0000 | Palladium |
| 83264.0000 | Para-Amino Benzoic Acid |
| 83265.0000 | Protoporphyrin |
| 83266.0000 | Protoporphyrin Zinc |
| 83267.0000 | Risperidone |
| 83280.0000 | Ketosteroids 17 Neutral |
| 83290.0000 | Ketosteroids 17 Beta |
| 83305.0000 | Luteinizing Hormone |
| 83306.0000 | LH/FSH Panel |
| 83310.0000 | Follicle Stimulating Hormone |
| 83316.0000 | Placental Lactogen |
| 83319.0000 | RBC Transketolase |
| 83320.0000 | Pregnanediol |
| 83340.0000 | Pregnanetriol |
| 83350.0000 | Progesterone |
| 83351.0000 | Progesterone Receptor |
| 83355.0000 | Prolactin |
| 83355.3035 | Protein Bence Jones Heat~DU PO |
| 83355.3103 | Protein Bence Jones Heat~EKTAC |
| 83360.0000 | Renin |
| 83370.0000 | Angiotensin |
| 83380.0000 | Growth Hormone |
| 83395.0000 | Parathoromone |
| 83400.0000 | Deoxynucleotidyl Transferase |
| 83405.0000 | Testosterone |
| 83415.0000 | Testosterone + Dihydrotest |
| 83440.0000 | Triiodothyronine (T 3) Resin |
| 83445.0000 | Triiodothyronine (T 3) |
| 83446.0000 | Triiodothyronine (T 3) Rev |
| 83447.0000 | Triiodothyronine Free (FT3) |
| 83448.0000 | Alphal Antitrypsin |
| 83449.0000 | Alphal Antitrypsin Phenotype |
| 83450.0000 | Thyroxine (T 4) |
| 83455.0000 | Thyroxine Free (FT4) |
| 83457.0000 | Thyroxine Free (FT4) SA Ligand |
| 83480.0000 | Thyroid Stimulating Hormone |
| 83490.0000 | Thyroxine Binding Globulin |
| 83495.0000 | Hydroxybutyric Dehydrogenase |
| 83496.0000 | Hydroxycorticosteroids 17 |
| 83540.0000 | Iron Total |
| 83550.0000 | Iron Total and Combining |
| 83555.0000 | Iron Binding Capac Unsatur(UIB |
| 83575.0000 | Isocitric Dehydrogenase |
| 83600.0000 | Kynurenic Acid |
| 83605.0000 | Lactic Acid |
| 83620.0000 | Lactate Dehydrogenase |
| 83620.3000 | Lactic Acid~MANUAL |
| 83620.3035 | Lactic Acid~DU PONT ACA |
| 83625.0000 | Lactate Dehydrogenase Isoenz |
| 83642.0000 | Lactose Qual Urine |

VistA Laboratory EPI

Rollup Modifications

Technical and User Manual

| | |
|------------|--------------------------------|
| 83665.0000 | Lecithin Sphingomyelin Ratio |
| 83675.0000 | Leucine Amino Peptidase |
| 83690.0000 | Lipase Blood |
| 83700.0000 | Lipids Total |
| 83715.0000 | Lipoprotein |
| 83735.0000 | Magnesium |
| 83775.0000 | Malate Dehydrogenase |
| 83795.0000 | Melanin Qual Urine |
| 83857.0000 | Methemalbumin |
| 83865.0000 | Mucopolysaccharides |
| 83875.0000 | Myoglobin Urine |
| 83900.0000 | Biotinidase |
| 83915.0000 | Nucleotidase 5' |
| 83920.0000 | Ornithine Carb Transferase |
| 83925.0000 | Osmolality |
| 83930.0000 | Osmolarity |
| 83944.0000 | Alphal Acid Glycoprotein |
| 83945.0000 | Oxalate |
| 83946.0000 | Anticentromere |
| 83950.0000 | Oxytocinase |
| 83955.0000 | Hippuric Acid Paraamino |
| 83960.0000 | Apolipoprotein A1 |
| 83962.0000 | Apolipoprotein B |
| 83966.0000 | Antichymotrypsin Alpha1 |
| 83967.0000 | Antitrypsin Alpha1 |
| 83968.0000 | Endorphin Beta |
| 83969.0000 | Hemoglobin A |
| 83970.0000 | Hemoglobin S |
| 83971.0000 | Red Blood Cell Ag A |
| 83972.0000 | Red Blood Cell Ag B |
| 83973.0000 | Red Blood Cell Ag H |
| 83974.0000 | Gonadotropin Chorionic alpha |
| 83975.0000 | Gonadotropin Chorionic B Qual |
| 83976.0000 | Gonadotropin Chorionic B Quant |
| 83977.0000 | Melanocyte Stimulating Horm a |
| 83978.0000 | Melanocyte Stimulating Horm b |
| 83979.0000 | Secretin |
| 83980.0000 | Somatostatin |
| 83981.0000 | Substance P |
| 83982.0000 | Vasoactive Intestinal Polypep |
| 83983.0000 | Lipotropin |
| 83984.0000 | Vasopressin Arginine |
| 83985.0000 | Vasopressin Lysine |
| 83986.0000 | Oxytocin |
| 83987.0000 | Somatomedin C (IGF 1) |
| 83988.0000 | C-Peptide |
| 83989.0000 | Preinsulin |
| 83990.0000 | Pancreatic Polypeptide |
| 83991.0000 | Gastrin 17 |
| 83992.0000 | Gastrin 34 |
| 83993.0000 | Cholecystokinin |
| 83994.0000 | Parathyroid Hormone C Terminal |
| 83995.0000 | Parathyroid Hormone N Terminal |
| 83996.0000 | Protein Total Electro |
| 83997.0000 | Vitamin D 25 Hydroxy |
| 83998.0000 | Vitamin D 1 25 Dihydroxy |
| 83999.0000 | Osteocalcin (GLA protein) |
| 84000.0000 | Enkephalin Leucine |
| 84001.0000 | Enkephalin Methionine |

VistA Laboratory EPI

Rollup Modifications

Technical and User Manual

| | |
|------------|--------------------------------|
| 84002.0000 | Bombesin |
| 84003.0000 | Neurotensin |
| 84004.0000 | Corticotropin Releasing Hormon |
| 84005.0000 | Luteinizing Releasing Hormone |
| 84006.0000 | Cardioexcitatory Peptide |
| 84007.0000 | Choline Acetyltransferase |
| 84008.0000 | Butyric Acid gamma Amino |
| 84009.0000 | Serotonin |
| 84009.3035 | Silicon~DU PONT ACA |
| 84009.3103 | Silicon~EKTACHEM 700 |
| 84009.8044 | Silicon~LAB1 SENDOUT |
| 84010.0000 | SP 1 Chromagranin |
| 84011.0000 | Parathyroid Hormone Mid Molec |
| 84012.0000 | Parathyroid Hormone Intact |
| 84013.0000 | Chymopapain |
| 84014.0000 | PTH Panel |
| 84015.0000 | Tubular Reabsorption PO4 |
| 84016.0000 | Fractional Extraction NA |
| 84017.0000 | Fractional Extraction Nitrogen |
| 84018.0000 | Sandostatin |
| 84019.0000 | Cortisol Tolerance Test |
| 84020.0000 | Globulin Electro |
| 84021.0000 | Griseofulvin |
| 84022.0000 | Pimaricin |
| 84023.0000 | Clotrimazole |
| 84024.0000 | LDH Electrophoresis |
| 84025.0000 | CPK Electrophoresis |
| 84026.0000 | Protein Electro Urine |
| 84027.0000 | Protein Electro CSF |
| 84028.0000 | X*Glaidin Ab |
| 84029.0000 | Fat Stool |
| 84030.0000 | Phenylalanine |
| 84031.0000 | IgG Synthesis |
| 84032.0000 | Lymphocyte Absolute |
| 84033.0000 | LAP Score |
| 84034.0000 | Bleeding Time Surgicut |
| 84035.0000 | Mycoplasma Titer |
| 84036.0000 | HIV 1&2 |
| 84037.0000 | Retinyl palitate |
| 84038.0000 | Interpretation |
| 84039.0000 | Parathyroid HRP |
| 84040.0000 | Phenylketone Urine (PKU) |
| 84041.0000 | Mercury/Creatinine |
| 84042.0000 | Copper 24H |
| 84043.0000 | Copper/Creatinine |
| 84044.0000 | Citric Acid |
| 84045.0000 | Citric Acid Urine |
| 84046.0000 | Cholinesterase Panel |
| 84047.0000 | 6TG |
| 84048.0000 | 6TG Metabolite |
| 84049.0000 | 6MMP |
| 84050.0000 | 6MMP Metabolites |
| 84051.0000 | B-Human Chorionic Gonadotropin |
| 84060.0000 | Phosphatase Acid Total |
| 84061.0000 | Phosphatase Acid Non Prost |
| 84065.0000 | Phosphatase Acid Prost Tart |
| 84067.0000 | Phosphatase Acid Prostatic |
| 84075.0000 | Phosphatase Alkaline |
| 84075.3000 | Phosphatase Alkaline Leukocyte |

VistA Laboratory EPI

Rollup Modifications

Technical and User Manual

| | |
|------------|--------------------------------|
| 84075.3035 | Phosphatase Alkaline Leukocyte |
| 84080.0000 | Phosphatase Alkaline Isoenz |
| 84087.0000 | Phosphohexose |
| 84100.0000 | Phosphate Inorganic |
| 84100.3035 | Photochromogenicity Test~DU PO |
| 84101.0000 | Alkaloids Screen |
| 84103.0000 | Phospholipids |
| 84105.0000 | Phosphorus Elemental |
| 84110.0000 | Porphobilinogen Quant Urine |
| 84115.0000 | Porphobilinogen Qual Urine |
| 84120.0000 | Porphyrim Quant Fraction |
| 84123.0000 | Protoporphyrin Free Erythro |
| 84125.0000 | Porphyrim Qual Urine |
| 84140.0000 | Potassium |
| 84141.0000 | Fungal Ab |
| 84142.0000 | Mycotoxin Ab |
| 84155.0000 | Protein Total |
| 84156.0000 | Protein Total Urine Point |
| 84157.0000 | Protein Total Urine Timed |
| 84158.0000 | Protein/Creatinine Ratio |
| 84159.0000 | Beta 2 transferrin |
| 84160.0000 | Pt Temp Est |
| 84161.0000 | Pt Temp Obs |
| 84162.0000 | Pt Weight Est |
| 84163.0000 | Pt Weight Obs |
| 84164.0000 | Pt Height Est |
| 84165.0000 | Pt Height Obs |
| 84166.0000 | Date LMP |
| 84167.0000 | Specimen Weight |
| 84168.0000 | Specimen Volume |
| 84169.0000 | Specimen Volume Reported |
| 84171.0000 | Globulin |
| 84180.0000 | Protein Quant Urine Fluid |
| 84181.0000 | Southern Blot |
| 84185.0000 | Protein Bence Jones Heat |
| 84210.0000 | Pyruvate |
| 84220.0000 | Pyruvate Kinase |
| 84235.0000 | Endocrine Hormone |
| 84263.0000 | Hydroxyind Acet Acid 5 Screen |
| 84265.0000 | Hydroxyind Acet Acid 5 Quant |
| 84295.0000 | Sodium |
| 84305.0000 | Urobilinogen |
| 84310.0000 | Sorbitol Dehydrogenase |
| 84315.0000 | Specific Gravity Excl Urine |
| 84330.0000 | +Glucose Quant |
| 84400.0000 | Body Fluid Exam for Crystals |
| 84408.0000 | Charcot Marie Tooth Screen |
| 84409.0000 | Enterovirus Ab by PCR |
| 84410.0000 | Spirometry |
| 84411.0000 | Bronchospasm Eval |
| 84412.0000 | Pulse Oximetry |
| 84413.0000 | Fibrinogen Activity |
| 84455.0000 | Transferase Aspartate SGOT |
| 84455.3000 | Urinalysis Micros only~MANUAL |
| 84455.3035 | Urinalysis Micros only~DU PONT |
| 84456.0000 | LDH1/LDH2 Ratio |
| 84457.0000 | Creatinine Random |
| 84458.0000 | Creatinine Random UA |
| 84459.0000 | LDH Total ISO |

VistA Laboratory EPI

Rollup Modifications

Technical and User Manual

| | |
|------------|--------------------------------|
| 84465.0000 | Transferase Alanine Amino SGP |
| 84465.3000 | Transpeptidase Gamma Glut~MANU |
| 84465.3035 | Transpeptidase Gamma Glut~DU P |
| 84466.0000 | X*Drug Dependant |
| 84476.0000 | Itraconazole |
| 84480.0000 | Triglycerides w o extract |
| 84481.0000 | Desmethsuximide |
| 84483.0000 | Helicobacter Pylorii Breath |
| 84484.0000 | Tryptophan |
| 84485.0000 | Trypsin Qual Duod or Gastric |
| 84486.0000 | Ethotoin |
| 84487.0000 | Ethinamate |
| 84488.0000 | Trypsin Qual Feces |
| 84489.0000 | Fatty Acid |
| 84490.0000 | Trypsin |
| 84491.0000 | Phosphatase Alkaline Heat Stab |
| 84492.0000 | Temperature |
| 84494.0000 | Temperature Observed |
| 84495.0000 | Temperature Body |
| 84496.0000 | Temperature Corrected |
| 84497.0000 | Phencyclidine |
| 84498.0000 | HDL/Cholesterol Ratio |
| 84499.0000 | Urine Microscopic |
| 84500.0000 | Legionella pneumophilia Ab EIA |
| 84501.0000 | Cyclic Citrulline Peptide Ab I |
| 84502.0000 | Calcium VG Channel Ab, N-Type |
| 84503.0000 | Calcium VG Channel Ab, P/Q Typ |
| 84504.0000 | Neuronal Ab Type 1 IFA |
| 84505.0000 | Purkinje Cell Cytoplasmic Ab T |
| 84506.0000 | Amphiphysin Ab |
| 84507.0000 | Levetiracetam |
| 84508.0000 | Nickel Urine |
| 84509.0000 | Nickel Urine 24Hr |
| 84510.0000 | Tyrosine |
| 84511.0000 | Nickel/Creatinine Ratio |
| 84512.0000 | Aminolevulinic Acid Urine 24Hr |
| 84513.0000 | N-Telopeptide/Creatinine Ratio |
| 84514.0000 | Lysozyme Urine |
| 84515.0000 | Microglobulin Beta 2 Urine |
| 84520.0000 | Urea Nitrogen |
| 84550.0000 | Uric Acid |
| 84581.0000 | Uroporphyrins |
| 84582.0000 | Urobilinogen Quant Feces |
| 84583.0000 | Urobilinogen Semiquant Urine |
| 84584.0000 | Porphyrin Uro |
| 84586.0000 | Viscosity Fluid |
| 84588.0000 | Vitamin B12 |
| 84590.0000 | Vitamin A |
| 84591.0000 | Retinol Binding Protein |
| 84592.0000 | Retinoic Acid |
| 84612.0000 | PCA I |
| 84613.0000 | Glycophorin A |
| 84614.0000 | Glycophorin |
| 84615.0000 | Xanthurenic Acid |
| 84619.0000 | Xylose |
| 84686.0000 | Bromide Serum Quant VIS |
| 84719.0000 | Cholinesterase plus DN |
| 84720.0000 | Cholinesterase Pseudo Serum |
| 84775.0000 | Galactose Transferase |

VistA Laboratory EPI

Rollup Modifications

Technical and User Manual

| | |
|------------|--------------------------------|
| 84902.0000 | Heparin-Protamine Sulfate Tole |
| 84906.0000 | Parathion Urine Quant |
| 84930.0000 | Appearance |
| 84931.0000 | Urine Appearance |
| 84988.0000 | Misc Sendout 1 |
| 84989.0000 | Misc Sendout 2 |
| 84990.0000 | Misc Sendout 3 |
| 84991.0000 | Misc Sendout 4 |
| 84992.0000 | Misc Sendout 5 |
| 84993.0000 | Misc Sendout 6 |
| 84994.0000 | Misc Sendout 7 |
| 84995.0000 | Misc Sendout 8 |
| 84996.0000 | Misc Sendout 9 |
| 84997.0000 | Misc Sendout 10 |
| 84998.0000 | Misc Sendout 11 |
| 84999.0000 | Hemogram Manual |
| 85000.0000 | Bleeding Time Duke |
| 85001.0000 | Bleeding Time Template |
| 85002.0000 | Acquired Inhibitory Screen |
| 85003.0000 | Protein C |
| 85004.0000 | Autohemolysis Test |
| 85005.0000 | Antithrombin III Assay |
| 85006.0000 | Protein S |
| 85007.0000 | Coagulation Factor II Assay |
| 85008.0000 | Blood Film Examination |
| 85009.0000 | Russell's Viper Venom |
| 85010.0000 | Blood Smear(s) |
| 85011.0000 | Cytoplasmic Neutrophil Ab |
| 85012.0000 | D Dimer |
| 85013.0000 | Fibrin Monomers |
| 85014.0000 | Granulocyte Ab |
| 85015.0000 | Hemogram I |
| 85016.0000 | Hemogram II |
| 85017.0000 | Hemogram III |
| 85018.0000 | Hemogram IV |
| 85019.0000 | Hemogram V |
| 85020.0000 | Red Blood Cell Count |
| 85021.0000 | Heparin Aggregation |
| 85022.0000 | Platelet Ab |
| 85023.0000 | Platelet AB (Drug) |
| 85024.0000 | Platelet MAO Inhibition |
| 85025.0000 | Protein A Ag |
| 85026.0000 | Osmotic fragility |
| 85027.0000 | Glycosylated HGB, total |
| 85028.0000 | Factor VIII Related Ag |
| 85029.0000 | Ristocetin cofactor |
| 85030.0000 | White Blood Cell Count |
| 85031.0000 | Misc Hem Test 1 |
| 85032.0000 | Misc Hem Test 2 |
| 85033.0000 | Misc Hem Test 3 |
| 85034.0000 | Misc Hem Test 4 |
| 85035.0000 | Misc Hem Test 5 |
| 85036.0000 | Instrument HE Setup |
| 85037.0000 | DIC Panel |
| 85038.0000 | Alpha2 Antiplasmin |
| 85039.0000 | Antithrombin 3 Ag |
| 85040.0000 | Beta Thromboglobulin |
| 85041.0000 | Factor 8 Inhibitor - QN |
| 85042.0000 | Factor 8 Related Ag |

VistA Laboratory EPI

Rollup Modifications

Technical and User Manual

| | |
|------------|--------------------------------|
| 85043.0000 | Lupus Inhibitor (PNP) |
| 85044.0000 | Lupus Inhibitor (TTI) |
| 85045.0000 | Platelet Neutralization Proced |
| 85046.0000 | Tissue Thromboplastin Inhibiti |
| 85047.0000 | Plasminogen Activator |
| 85048.0000 | Plasminogen Ag |
| 85049.0000 | Prekallikrein (Fletcher) Assay |
| 85050.0000 | Hemoglobin RBC |
| 85051.0000 | Glycohemoglobin Fast Fraction |
| 85052.0000 | Glycohemoglobin A(1) C |
| 85053.0000 | Glycohemoglobin HbA 1c |
| 85054.0000 | Buffy Coat (prep smear&count) |
| 85055.0000 | Hematocrit Macro or Micro |
| 85056.0000 | Protamine Sulfate |
| 85057.0000 | Von Willebrand's Profile |
| 85058.0000 | Protein C Cofactor |
| 85059.0000 | Activated Clotting Time |
| 85060.0000 | Indices Hematologic |
| 85061.0000 | Acanthocyte |
| 85062.0000 | Anisochromic |
| 85063.0000 | Anisocytosis |
| 85064.0000 | Atypical Lymphocyte |
| 85065.0000 | Auer Rods |
| 85066.0000 | Band Neutrophil |
| 85067.0000 | Basophilic Stippling |
| 85068.0000 | Basophil |
| 85069.0000 | Basophil % |
| 85070.0000 | Blast |
| 85071.0000 | Burr Cells |
| 85072.0000 | Corrected WBC |
| 85073.0000 | Crenated RBC |
| 85074.0000 | Dohle Bodies |
| 85075.0000 | Elliptocyte |
| 85076.0000 | Eosinophil % |
| 85077.0000 | Granulocyte |
| 85078.0000 | Granulocyte % |
| 85079.0000 | Helmet Cell |
| 85080.0000 | Howell Jolly Bodies |
| 85081.0000 | Hypersegmented Neutrophil |
| 85082.0000 | Hypochromia |
| 85083.0000 | INR |
| 85084.0000 | Lymphocyte |
| 85085.0000 | Lymphocyte % |
| 85086.0000 | Macrocytes |
| 85087.0000 | MCD |
| 85088.0000 | MCH |
| 85089.0000 | MCHC |
| 85090.0000 | MCV |
| 85091.0000 | Megakaryocytes |
| 85092.0000 | Microcytes |
| 85093.0000 | Monocyte |
| 85094.0000 | Monocyte % |
| 85095.0000 | MPD |
| 85096.0000 | MPV |
| 85097.0000 | Myelocyte |
| 85098.0000 | Neutrophil |
| 85099.0000 | Neutrophil % |
| 85100.0000 | Nucleated RBC |
| 85101.0000 | Other Leukocytes |

VistA Laboratory EPI

Rollup Modifications

Technical and User Manual

| | |
|------------|------------------------------|
| 85102.0000 | Ovalocytes |
| 85103.0000 | Pappenheimer |
| 85104.0000 | Pelger Huet |
| 85105.0000 | Bone Marrow Diff Count |
| 85106.0000 | Plasma Cell |
| 85107.0000 | Bone Marrow Film Prep |
| 85108.0000 | Bone Marrow Stain Romanowski |
| 85109.0000 | Platelet Estimate |
| 85110.0000 | Bone Marrow Aspiration |
| 85111.0000 | Poikilocytosis |
| 85112.0000 | Polychromasia |
| 85113.0000 | Promyelocyte |
| 85114.0000 | RDW |
| 85115.0000 | RDW-CV |
| 85116.0000 | RDW-SD |
| 85117.0000 | Reactive Lymphocyte |
| 85118.0000 | Red Blood Cell |
| 85119.0000 | Rouleaux |
| 85120.0000 | Schistocytes |
| 85121.0000 | Sickle Cell |
| 85122.0000 | Neutrophil Segmented |
| 85123.0000 | Siderocyte |
| 85124.0000 | Smudge Cell |
| 85125.0000 | Stomatocyte |
| 85126.0000 | Target Cell |
| 85127.0000 | Teardrop Cell |
| 85128.0000 | Toxic Granulation |
| 85129.0000 | Spherocyte |
| 85130.0000 | Malaria Forms |
| 85131.0000 | Malaria Smear |
| 85132.0000 | Factor V Leiden-DNA |
| 85133.0000 | Prothrombin Fragment |
| 85134.0000 | Eosinophil Smear |
| 85135.0000 | Erythroblast |
| 85136.0000 | Eosinophil Urine |
| 85137.0000 | Eosinophil Sputum Smear |
| 85138.0000 | Eosinophil Urine Smear |
| 85139.0000 | Porcine FVIII C Inhibitor |
| 85140.0000 | Hemoglobin & Hematocrit |
| 85141.0000 | Hem Specimen |
| 85142.0000 | Chronic Lymphoid Leukemia |
| 85143.0000 | Huntington's Disease |
| 85144.0000 | Vaginal Discharge Panel |
| 85145.0000 | Thalassemia Panel |
| 85146.0000 | Plasma Mix 1:1 |
| 85147.0000 | PT 1:1 Mix |
| 85148.0000 | Hemogram+Platelet |
| 85149.0000 | Hemogram+PLT+Diff |
| 85150.0000 | Misc Sendout 12 |
| 85151.0000 | Misc Sendout 13 |
| 85152.0000 | Misc Sendout 14 |
| 85153.0000 | Misc Sendout 15 |
| 85154.0000 | Misc Sendout 16 |
| 85155.0000 | Misc Sendout 17 |
| 85156.0000 | Misc Sendout 18 |
| 85157.0000 | Misc Sendout 19 |
| 85158.0000 | Misc Sendout 20 |
| 85159.0000 | Misc Stain 1 |
| 85160.0000 | Misc Stain 2 |

VistA Laboratory EPI

Rollup Modifications

Technical and User Manual

| | |
|------------|--------------------------------|
| 85161.0000 | Misc Stain 3 |
| 85162.0000 | HLA B8 |
| 85163.0000 | Eosinophil |
| 85164.0000 | Cells Other |
| 85165.0000 | Capillary Fragility |
| 85166.0000 | Chloroacetate Esterase Stain |
| 85167.0000 | Neutrophil Seg Fluid |
| 85168.0000 | Lymphocyte Fluid |
| 85169.0000 | Macrophage |
| 85170.0000 | Clot Retraction Qual |
| 85171.0000 | RBC Morphology |
| 85172.0000 | Euglobulin Lysis Time |
| 85173.0000 | Elapsed Time |
| 85174.0000 | PT w INR |
| 85175.0000 | Clot Lysis Time Whole Blood |
| 85176.0000 | von Willebrand's Factor Ag |
| 85177.0000 | Ristocetin Platelet Aggl |
| 85178.0000 | Plasma multimers |
| 85179.0000 | Plasminogen Activator Inhib |
| 85180.0000 | Report Hematology |
| 85181.0000 | Report Blood Bank |
| 85182.0000 | Kaolin Clotting Time |
| 85183.0000 | PT Mixing Study |
| 85184.0000 | PTT Mixing Study |
| 85185.0000 | Platelet Ag 1 |
| 85186.0000 | Tumor Cells |
| 85187.0000 | Platelet Ag 2 |
| 85188.0000 | Platelet Associated IgA Direct |
| 85189.0000 | Platelet Associated IgA Indire |
| 85190.0000 | Platelet Associated IgG Direct |
| 85191.0000 | Platelet Associated IgG Indire |
| 85192.0000 | Platelet Associated IgM Direct |
| 85193.0000 | Platelet Associated IgM Indire |
| 85194.0000 | Platelet Morphology |
| 85195.0000 | D Dimer Quant |
| 85196.0000 | MuSK Antibody |
| 85201.0000 | Biopsy |
| 85202.0000 | Bone Marrow, Flow Cyto, each m |
| 85203.0000 | Bone Marrow Aspirate Smear Int |
| 85204.0000 | Bone Marrow Core Touch Exam |
| 85205.0000 | Cytopath Flds,Brush,Wash w/out |
| 85206.0000 | Cytopath Fls,Wash,Brush w/out |
| 85210.0000 | Prothrombin Assay |
| 85220.0000 | Coagulation Factor V Assay |
| 85223.0000 | Mucin Clot |
| 85230.0000 | Coagulation Factor VII Assay |
| 85240.0000 | Coagulation Factor VIII Assay |
| 85249.0000 | Differential Count WBC |
| 85250.0000 | Coagulation Factor IX Assay |
| 85251.0000 | Factor IX Activity |
| 85252.0000 | Factor XI Activity |
| 85260.0000 | Coagulation Factor X Assay |
| 85270.0000 | Coagulation Factor XI Assay |
| 85280.0000 | Coagulation Factor XII Assay |
| 85290.0000 | Coagulation Factor XIII Assay |
| 85299.0000 | Fibrinogen Ag/Fibrinogen Ratio |
| 85300.0000 | Coagulation Factor VIII Inhib |
| 85301.0000 | Fibrinogen Ag |
| 85302.0000 | Fibrinogen Ab |

VistA Laboratory EPI

Rollup Modifications

Technical and User Manual

| | |
|------------|--------------------------------|
| 85303.0000 | Protein C Ag |
| 85304.0000 | Protein C Ab |
| 85305.0000 | Anticoagulant Circulating Scre |
| 85306.0000 | Bethesda Inhibitor |
| 85307.0000 | Wintrobe ESR |
| 85308.0000 | Anticoagulant Circulating Titr |
| 85309.0000 | Liquification |
| 85310.0000 | Reticulocyte |
| 85311.0000 | Viscosity |
| 85312.0000 | Methylenetetrahydrofolate Redu |
| 85313.0000 | PT Control |
| 85314.0000 | PTT Control |
| 85315.0000 | Prothrombin (20210) Gene Mut |
| 85316.0000 | Reticulin IgA Ab |
| 85317.0000 | Reticulin IgG Ab |
| 85320.0000 | Thrombin III Ab |
| 85321.0000 | Osmotic Fragility,0.50 g/dL Na |
| 85322.0000 | Osmotic Fragility,0.60 g/dL Na |
| 85323.0000 | Osmotic Fragility,0.65 g/dL Na |
| 85324.0000 | Osmotic Fragility,0.75 g/dL Na |
| 85336.0000 | Eosinophil # |
| 85345.0000 | Clotting Time Lee White |
| 85346.0000 | Coagulation Factor Assay Panel |
| 85350.0000 | Eosinophil Count |
| 85351.0000 | Eosinophil Nasal Smear |
| 85355.0000 | Ethanol Gel Test |
| 85370.0000 | Fibrinogen Screening Test |
| 85371.0000 | Fibrin Degradation Prod Kit |
| 85375.0000 | Fibrinogen Chem Quant |
| 85378.0000 | Fibrinogen Semiquant |
| 85379.0000 | Zetacrit |
| 85390.0000 | Fibrinolysis Whole Clot |
| 85394.0000 | Von Willebrand Multimer |
| 85395.0000 | Fibrinolysis DIL or Plate |
| 85397.0000 | Plasmin |
| 85490.0000 | Heinz Bodies Smear for |
| 85500.0000 | Heinz Bodies Induction Test |
| 85520.0000 | Heparin Assay |
| 85532.0000 | Iron Stain for Siderocytes |
| 85555.0000 | Phosphatase Acid Leukocyte |
| 85560.0000 | Platelet Aggregation Substrate |
| 85569.0000 | Leukocyte Count |
| 85570.0000 | Platelet Count Whole Blood |
| 85571.0000 | Platelet Count Plasma |
| 85572.0000 | Platelet Count (Phase) |
| 85573.0000 | Factor VIII Activity |
| 85574.0000 | Factor VII |
| 85576.0000 | Factor VII Ab |
| 85577.0000 | Factor VII Ag |
| 85581.0000 | Blood Film Screen |
| 85582.0000 | Beta Galactosidase |
| 85586.0000 | Plate Factor III PF III |
| 85587.0000 | Reptilase R Test |
| 85588.0000 | Hemolysin Acid |
| 85590.0000 | Plasminogen |
| 85595.0000 | LE Cell Preparation |
| 85596.0000 | Activated Protein C Resis |
| 85600.0000 | Platelet Adhesivity Salzman |
| 85610.0000 | Prothrombin Time |

VistA Laboratory EPI

Rollup Modifications

Technical and User Manual

| | |
|------------|--------------------------------|
| 85613.0000 | Prothrombin Time+PTT |
| 85615.0000 | Prothrombin Consumption |
| 85620.0000 | Red Blood Cell Fragility Qual |
| 85621.0000 | Platelet Aggreg Spon |
| 85622.0000 | Platelet Aggreg ADP 1:8 |
| 85623.0000 | Platelet Aggreg ADP 1:4 |
| 85624.0000 | Platelet Aggreg Rist |
| 85625.0000 | Platelet Aggreg Epinep |
| 85626.0000 | Platelet Aggreg Collagen |
| 85627.0000 | Platelet Aggreg Arach |
| 85632.0000 | Phosphatase Alkaline Leukocyte |
| 85634.0000 | Red Blood Cell Fragility Mech |
| 85636.0000 | Red Blood Cell Fragility Quant |
| 85637.0000 | Metamyelocyte |
| 85638.0000 | Normocytic |
| 85639.0000 | Normochromic |
| 85640.0000 | Aniocyctosis |
| 85641.0000 | Microcytosis |
| 85642.0000 | Cryocrit |
| 85643.0000 | Aspartate Erythrocyte |
| 85644.0000 | Iron Panel Hem |
| 85645.0000 | Reticulocyte Count |
| 85646.0000 | Natural Killer Cell |
| 85647.0000 | Foscarnet |
| 85648.0000 | LSA Lymph Subset |
| 85649.0000 | Fibrinogen |
| 85650.0000 | Reticulocyte Absolute |
| 85651.0000 | Fibrinogen Fragments |
| 85652.0000 | Polymorphonuclear Neutrophil |
| 85653.0000 | Ivy Bleeding Time |
| 85654.0000 | Hemoglobin E |
| 85655.0000 | Sedimentation Rate |
| 85656.0000 | Protein C&S Panel |
| 85657.0000 | Hemoglobin NOS |
| 85658.0000 | Reticulocyte Index |
| 85659.0000 | Kennedy Disease |
| 85660.0000 | Sickle Cell Identification |
| 85661.0000 | Snovial Cell |
| 85662.0000 | Sucrose Water Test |
| 85663.0000 | Sezary Cell |
| 85664.0000 | Malignant Cell |
| 85665.0000 | Sudan Black B Leucocyte |
| 85666.0000 | Epstein Barr Ab |
| 85667.0000 | Hgb Phenotype |
| 85668.0000 | Lining Cell |
| 85669.0000 | Epithelial NOS |
| 85670.0000 | Thrombin Time |
| 85671.0000 | PT-PTT Factor Assay |
| 85672.0000 | Hemoglobin C |
| 85674.0000 | PT Substitution |
| 85675.0000 | Thrombin Titer |
| 85676.0000 | Hemoglobin Phenotype |
| 85678.0000 | Ventricular Lining Cell |
| 85679.0000 | Columnar Epithelial Cell |
| 85680.0000 | Specimen Count |
| 85681.0000 | Mast Cell |
| 85682.0000 | Sperm Morphology |
| 85683.0000 | Ma Auto Ab |
| 85684.0000 | Ta Auto Ab |

VistA Laboratory EPI

Rollup Modifications

Technical and User Manual

| | |
|------------|--------------------------------|
| 85685.0000 | Metamyelocytes Absolute |
| 85686.0000 | Myelocyte Absolute |
| 85687.0000 | Promyelocyte Absolute |
| 85688.0000 | Plasma Cell Absolute |
| 85689.0000 | Red Blood Cells Nucleated Abso |
| 85690.0000 | PTT 1:1 MIX |
| 85691.0000 | PTT Mix 1Hr Incubation |
| 85692.0000 | PT Ratio |
| 85693.0000 | Prolymphocytes |
| 85694.0000 | PTT-Adsorbed |
| 85695.0000 | Prolymphocytes Percent |
| 85696.0000 | Promonocytes |
| 85700.0000 | Thromboplastin Screening H P |
| 85725.0000 | Thromboplastin Gen Defect ID |
| 85730.0000 | Thromboplastin Time Partial |
| 85731.0000 | Thromboplastin Time w Sub |
| 86000.0000 | HLA B27 |
| 86001.0000 | B and T Cell Quant Ros |
| 86002.0000 | Misc BB Test 1 |
| 86003.0000 | Misc BB Test 2 |
| 86004.0000 | Misc BB Test 3 |
| 86005.0000 | Misc BB Test 4 |
| 86006.0000 | Misc BB Test 5 |
| 86007.0000 | Instrument BB Setup |
| 86011.0000 | Phagocytic Bactericidal Assay |
| 86045.0000 | HLA Tissue Typing |
| 86046.0000 | HLA Tissue Typing A,B |
| 86047.0000 | HLA Class I II |
| 86048.0000 | Homocystein Genetic |
| 86049.0000 | 4:1 Plasma Mix |
| 86050.0000 | Chlamydia Diff |
| 86051.0000 | Chlamydia Probe |
| 86052.0000 | Factor II |
| 86053.0000 | Factor II Ag |
| 86054.0000 | Factor II Activity |
| 86055.0000 | Factor II Mutation |
| 86056.0000 | Factor IX Ag |
| 86057.0000 | Factor IX Inh |
| 86058.0000 | Factor XI Inh |
| 86059.0000 | Factor XIII |
| 86060.0000 | Factor XIII Urea |
| 86061.0000 | Hepatitis A IgG/IgM |
| 86062.0000 | Hepatitis E Ab IgG |
| 86063.0000 | Hepatitis E Ab IgM |
| 86064.0000 | Neutrophil Cytoplasm Ab |
| 86065.0000 | Coccidioides IgM |
| 86066.0000 | Cell Marker Panel |
| 86067.0000 | Triple Marker Panel |
| 86069.0000 | HIV 1 P24 |
| 86070.0000 | HIV 1 P18 |
| 86071.0000 | HIV 1 P55 |
| 86072.0000 | Transglutaminase Tissue Ab |
| 86073.0000 | Charcot Marie Tooth |
| 86074.0000 | Parvovirus B19 IgG |
| 86076.0000 | Parvovirus B19 IgM |
| 86077.0000 | Phytohemagglutinin |
| 86078.0000 | Protease Gene Mutation |
| 86079.0000 | Coxsackie A 10 |
| 86080.0000 | ABO Cell and Serum Typing |

VistA Laboratory EPI

Rollup Modifications

Technical and User Manual

| | |
|------------|--------------------------------|
| 86081.0000 | ABO Cell and Rh(D) Typing |
| 86082.0000 | ABO Cell Serum and Rh(D) |
| 86083.0000 | ABO Hemolysin Test |
| 86084.0000 | ABO Cell Typing Slide or Tube |
| 86085.0000 | ABO Cell,Serum & Rh Typing on |
| 86086.0000 | ABO Serum Typing Tube |
| 86087.0000 | ABO Cell & Rh Typing Unit |
| 86088.0000 | Rh(D) Typing |
| 86089.0000 | Coxsackie A 16 |
| 86090.0000 | Coxsackie A 2 |
| 86091.0000 | Coxsackie A 4 |
| 86092.0000 | Coxsackie A 7 |
| 86093.0000 | Coxsackie A 9 |
| 86094.0000 | Coxsackie B 1 |
| 86095.0000 | Coxsackie B 2 |
| 86097.0000 | Coxsackie B 3 |
| 86098.0000 | Coxsackie B 4 |
| 86099.0000 | Coxsackie B 5 |
| 86100.0000 | Rh(D) Typing Slide or Tube |
| 86101.0000 | Coxsackie B 6 |
| 86103.0000 | Neutrophil Cytoplasmic Ab IgA |
| 86104.0000 | Neutrophil Cytoplasmic Ab IgM |
| 86105.0000 | Beryllium Lymphocyte Prolifera |
| 86120.0000 | Ag Blood Type |
| 86121.0000 | Red Cell Mass |
| 86125.0000 | Ag Blood Type w Antihuman |
| 86129.0000 | Blood Unit Labeling |
| 86131.0000 | Blood Component or Derivative |
| 86132.0000 | Blood Compon Deriv Exter Reloc |
| 86133.0000 | Donor Blood Collection |
| 86134.0000 | Blood Compon Deriv Inter Reloc |
| 86135.0000 | Ab Absorption Blood Bank |
| 86136.0000 | Donor Autologous Schedul 1st |
| 86137.0000 | Warm Autoadsorption ZZAP |
| 86138.0000 | Donor Autologous 1 Unit |
| 86139.0000 | Ab Detection w Antihuman (1 st |
| 86140.0000 | Ab Detect w o antihuman (1 sta |
| 86141.0000 | Donor Autologou Sched Add |
| 86142.0000 | Ab Detect w o Antihuman (2 sta |
| 86143.0000 | Ab Detection w AHG Donor |
| 86144.0000 | Ab Detect Antihuman (2 stage) |
| 86145.0000 | Ab Detection w/o AHG Donor |
| 86148.0000 | Ab Detect Capillary Test |
| 86150.0000 | Ab Elution |
| 86152.0000 | Ab ID w Antihuman |
| 86153.0000 | Ab Identification w AHG Donor |
| 86154.0000 | Ab Ident w o Antihuman |
| 86155.0000 | Ab Identification w/o Donor |
| 86156.0000 | Ab ID Capillary Testing |
| 86158.0000 | Ab ID w o Antihuman |
| 86160.0000 | Ab ID Antihuman globulin |
| 86161.0000 | Ab Titration |
| 86162.0000 | HLA B7 |
| 86164.0000 | Compatibility Crossmatch Salin |
| 86165.0000 | HLA Phenotype A B |
| 86166.0000 | Compatibility Test Crossmatch |
| 86167.0000 | Ab Detection Type & Scr |
| 86168.0000 | Ab Detect crossmatch |
| 86169.0000 | HBcAb Blood Donor EIA |

VistA Laboratory EPI

Rollup Modifications

Technical and User Manual

| | |
|------------|--------------------------------|
| 86170.0000 | HIV Ab Blood Donor |
| 86171.0000 | HBsAg Blood Donor RIA batch |
| 86172.0000 | HBsAg Blood Donor RIA |
| 86173.0000 | HBsAg Blood Donor RPHA |
| 86174.0000 | HLA B14 |
| 86175.0000 | HBsAg Blood Donor ELISA batch |
| 86176.0000 | HCV Blood Donor EIA batch |
| 86177.0000 | HLA Ab Screen |
| 86178.0000 | HLA Single Ag Screening |
| 86179.0000 | HLA Compatibility Testing |
| 86180.0000 | Leukoagglutinin Compatibility |
| 86181.0000 | HLA Phenotype A B C Complete |
| 86182.0000 | HLA Phenotype A B C initial |
| 86183.0000 | Irradiation of Blood Component |
| 86184.0000 | Lymphocyte Separation T&B |
| 86185.0000 | HLA Typing Tray Production |
| 86186.0000 | Lymphocyte Separation fr Blood |
| 86187.0000 | Leukoagglutinin Screen |
| 86188.0000 | HLA Phenotype Dr (initial) |
| 86189.0000 | HLA Phenotype Dr by Lympho |
| 86190.0000 | Calibrating Centrifuge |
| 86191.0000 | HLA Phenotype A |
| 86192.0000 | Checking Centrifuge |
| 86193.0000 | HLA Phenotyping Donor |
| 86194.0000 | Checking Timer on Centrifuge |
| 86195.0000 | Lymphocyte Thawing |
| 86196.0000 | Alarm Activation Blood Storage |
| 86197.0000 | HLA Lymphocyte Cell Count |
| 86198.0000 | Blood Storage Recording Daily |
| 86199.0000 | Instrument Thermometer Reading |
| 86200.0000 | Blood Storage Chart Change |
| 86201.0000 | Reagent RBC Freeze Glycerol |
| 86202.0000 | HLA Lymphocyte Cell Ct & Adj |
| 86203.0000 | HLA Lymphocyte Viability |
| 86204.0000 | Reagent RBC Freeze Liq Nitro |
| 86205.0000 | HLA Phenotype B |
| 86206.0000 | Hemoglobin Fetal |
| 86207.0000 | Reagent RBC Thawing |
| 86208.0000 | MaTa Auto Ab |
| 86209.0000 | CD3/CD7 |
| 86210.0000 | DNA Mutation Analysis |
| 86211.0000 | Reagent RBC Prep A B O |
| 86212.0000 | Myotonic Dystrophy |
| 86213.0000 | Reagent RBC Prep Antihuman |
| 86214.0000 | Myotonic Dystrophy, DNA Mutati |
| 86215.0000 | T Cell Lymphocyte |
| 86216.0000 | Reagent RBC Prep Enzyme |
| 86217.0000 | Monocyte % Lymphocyte |
| 86219.0000 | Coagulation Concentrate Lyo |
| 86220.0000 | HTLV I Blood Donor |
| 86221.0000 | HLA DQW1 |
| 86222.0000 | HLA DR(Ia) |
| 86225.0000 | DNA Ab |
| 86226.0000 | DNA Single Strand Ab |
| 86227.0000 | DNA Ab Native |
| 86237.0000 | JO-1 Ab |
| 86250.0000 | Antihuman Globulin Test |
| 86252.0000 | Autologous Unit Invent Blood o |
| 86254.0000 | Directed Unit Invent Blood or |

VistA Laboratory EPI

Rollup Modifications

Technical and User Manual

| | |
|------------|--------------------------------|
| 86269.0000 | Cryoprecipitate Prep (4+) |
| 86270.0000 | Platelet Administration |
| 86271.0000 | Cryoprecipitate Preparation |
| 86272.0000 | Cryoprecipitate Thawing |
| 86273.0000 | Blood Products Administration |
| 86275.0000 | Frozen Blood Preparation |
| 86276.0000 | Frozen Blood Thaw & Deglyc |
| 86277.0000 | Rejuvenation of Red Cells |
| 86291.0000 | Cardiolipin Ag Prep |
| 86292.0000 | Washed RBC for CF HA HAI |
| 86293.0000 | Sensitize RBC for CF |
| 86294.0000 | Complement Titration |
| 86297.0000 | Preparation of Gelatin Water |
| 86299.0000 | Hemolysin Titration |
| 86380.0000 | Factor V Leiden PCR |
| 86381.0000 | Campylobacter Ab |
| 86382.0000 | Leukocyte Poor Blood Prep |
| 86383.0000 | Leukapheresis Donor |
| 86384.0000 | Lymphocyte Storage Liq Nitroge |
| 86385.0000 | Plasma Exchange Therapeutic |
| 86386.0000 | Thrombocytapheresis |
| 86387.0000 | Plasmapheresis First Unit |
| 86388.0000 | Platelet Agglutinins |
| 86389.0000 | Plasmapheresis add Units |
| 86390.0000 | Platelet Concentrate Prep 4+ |
| 86391.0000 | Platelet Rich Plasma Prep |
| 86392.0000 | Platelet Concentrate Prep |
| 86393.0000 | Platelet Concentrate Pool |
| 86394.0000 | Thrombocyte Leukapheresis Dono |
| 86395.0000 | Platelet Freezing DMSO |
| 86396.0000 | Platelet Thawing and DE DMSO |
| 86397.0000 | Red Cell Exchange |
| 86398.0000 | Dithiothreitol Destruction |
| 86399.0000 | Prewarm Technique |
| 86400.0000 | Thrombocytapheresis Therap |
| 86401.0000 | Leukapheresis Therapeutic |
| 86402.0000 | Separation of Red Cell Mix |
| 86403.0000 | Decontamination of Lymphocyte |
| 86404.0000 | Mixed Lymphocyte Culture Setup |
| 86405.0000 | Mixed Lymphocyte Culture Pulse |
| 86406.0000 | Mitogen Assay Setup |
| 86407.0000 | Mitogen Assay Pulse Harvest |
| 86408.0000 | Transfusion Outpatient Setup |
| 86409.0000 | Lymphocyte Separation fr Sol |
| 86410.0000 | Transferase Alanine Amino BLD |
| 86411.0000 | Transfusion Outpatient Each |
| 86412.0000 | Transfusion Reaction Clerical |
| 86413.0000 | BB Specimen |
| 86414.0000 | Donor Specimen |
| 86415.0000 | Crossmatch Specimen |
| 86416.0000 | Sp BB Specimen |
| 86430.0000 | Blood Administration |
| 86432.0000 | Blood Products Admin Other |
| 86472.0000 | Influenza B Victoria Ab |
| 86473.0000 | Influenza B Panama Ab |
| 86474.0000 | Influenza Profile |
| 86475.0000 | Lymphocyte Stimulation NOS |
| 86476.0000 | Lymphocyte Stimulation Candida |
| 86477.0000 | Nitroblue Tetrazolium Dye |

VistA Laboratory EPI

Rollup Modifications

Technical and User Manual

| | |
|------------|-------------------------------|
| 86478.0000 | Chemotactic Study |
| 86479.0000 | Lymphocyte Stimulation Concan |
| 86480.0000 | Lymphocyte Stimulation Phyto |
| 86481.0000 | Lymphocyte Stimulation Poke |
| 86482.0000 | Surface Marker Alpha Chain |
| 86483.0000 | Surface Marker Gamma Chain |
| 86484.0000 | Surface Marker B1 |
| 86485.0000 | Surface Marker B2 |
| 86486.0000 | Surface Marker BA 1 |
| 86489.0000 | Surface Marker Delta Chain |
| 86490.0000 | Surface Marker Epsilon Chain |
| 86491.0000 | Surface Marker Ia |
| 86492.0000 | Surface Marker J5 (CALLA) |
| 86493.0000 | Surface Marker Kappa Chain |
| 86494.0000 | Surface Marker Lambda Chain |
| 86495.0000 | Surface Marker Mu Chain |
| 86496.0000 | Surface Marker Leu Chain |
| 86497.0000 | Surface Marker Mo Chain |
| 86498.0000 | Surface Marker My Chain |
| 86499.0000 | Surface Marker T3 |
| 86500.0000 | Surface Marker T4 Leu 3 |
| 86501.0000 | Surface Marker T4 T8 Ratio |
| 86502.0000 | Surface Marker T6 |
| 86503.0000 | Surface Marker T8 Leu 2 |
| 86504.0000 | Surface Marker T10 |
| 86505.0000 | Surface Marker T11 |
| 86506.0000 | Surface Marker Tac |
| 86507.0000 | Surface Marker Leu 7 |
| 86508.0000 | Surface Marker Leu 11 |
| 86509.0000 | Surface Marker Leu 15 |
| 86510.0000 | Surface Marker Mo 1 |
| 86511.0000 | Surface Marker Mo 2 |
| 86512.0000 | Surface Marker My 4 |
| 86513.0000 | Surface Marker My 7 |
| 86514.0000 | Surface Marker My 8 |
| 86515.0000 | Surface Marker My 9 |
| 86516.0000 | Platelet Associated IgG |
| 86517.0000 | Neuronal Nuclear Ab |
| 86518.0000 | Neuronal Nuclear Ab Panel |
| 86519.0000 | Ri Ab IFA |
| 86520.0000 | Hu Ab |
| 86521.0000 | CD1a |
| 86522.0000 | CD1b |
| 86523.0000 | CD1c |
| 86524.0000 | CD2 |
| 86525.0000 | CD2R |
| 86526.0000 | CD3 |
| 86527.0000 | CD4 |
| 86528.0000 | CD5 |
| 86529.0000 | CD6 |
| 86530.0000 | CD7 |
| 86531.0000 | CD8 |
| 86532.0000 | CD8beta |
| 86533.0000 | CD9 |
| 86534.0000 | CD10 |
| 86535.0000 | CD11a |
| 86536.0000 | CD11b |
| 86537.0000 | CD11c |
| 86538.0000 | CDw12 |

VistA Laboratory EPI

Rollup Modifications

Technical and User Manual

| | |
|------------|--------|
| 86539.0000 | CD13 |
| 86540.0000 | CD14 |
| 86541.0000 | CD15 |
| 86542.0000 | CD15s |
| 86543.0000 | CD16 |
| 86544.0000 | CD16b |
| 86545.0000 | CDw17 |
| 86546.0000 | CD18 |
| 86547.0000 | CD19 |
| 86548.0000 | CD20 |
| 86549.0000 | CD21 |
| 86550.0000 | CD22 |
| 86551.0000 | CD23 |
| 86552.0000 | CD24 |
| 86553.0000 | CD25 |
| 86554.0000 | CD26 |
| 86555.0000 | CD27 |
| 86556.0000 | CD28 |
| 86557.0000 | CD29 |
| 86558.0000 | CD30 |
| 86559.0000 | CD31 |
| 86560.0000 | CD32 |
| 86561.0000 | CD33 |
| 86562.0000 | CD34 |
| 86563.0000 | CD35 |
| 86564.0000 | CD36 |
| 86565.0000 | CD37 |
| 86566.0000 | CD38 |
| 86567.0000 | CD39 |
| 86568.0000 | CD40 |
| 86569.0000 | CD40L |
| 86570.0000 | CD41 |
| 86571.0000 | CD42a |
| 86572.0000 | CD42b |
| 86573.0000 | CD42c |
| 86574.0000 | CD43 |
| 86575.0000 | CD44 |
| 86576.0000 | CD45 |
| 86577.0000 | CD45R0 |
| 86578.0000 | CD45RA |
| 86579.0000 | CD45RB |
| 86580.0000 | CD46 |
| 86581.0000 | CD47 |
| 86582.0000 | CD48 |
| 86583.0000 | CD49a |
| 86584.0000 | CD49b |
| 86585.0000 | CD49c |
| 86586.0000 | CD49d |
| 86587.0000 | CD49e |
| 86588.0000 | CD49f |
| 86589.0000 | CD50 |
| 86590.0000 | CD51 |
| 86591.0000 | CD52 |
| 86592.0000 | CD54 |
| 86593.0000 | CD55 |
| 86594.0000 | CD56 |
| 86595.0000 | CD57 |
| 86596.0000 | CD58 |
| 86597.0000 | CD59 |

| | |
|------------|----------------------------|
| 86598.0000 | CDw60 |
| 86599.0000 | CD61 |
| 86600.0000 | CD62E |
| 86601.0000 | Cell Suspension from Solid |
| 86602.0000 | CD62P |
| 86603.0000 | CD63 |
| 86604.0000 | CD64 |
| 86605.0000 | CDw65 |
| 86606.0000 | CD66a |
| 86607.0000 | CD66abce |
| 86608.0000 | CD66acd |
| 86609.0000 | CD66acde |
| 86610.0000 | CD66ace |
| 86611.0000 | CD66ae |
| 86612.0000 | CD66b |
| 86613.0000 | CD66be |
| 86614.0000 | CD66c |
| 86615.0000 | CDce |
| 86616.0000 | CD66d |
| 86617.0000 | CD66de |
| 86618.0000 | CD68 |
| 86619.0000 | CD69 |
| 86620.0000 | CD70 |
| 86621.0000 | CD71 |
| 86622.0000 | CD72 |
| 86623.0000 | CD73 |
| 86624.0000 | CD74 |
| 86625.0000 | CDw75 |
| 86626.0000 | CDw76 |
| 86627.0000 | CD77 |
| 86628.0000 | CDw78 |
| 86629.0000 | CD79a |
| 86630.0000 | CD79b |
| 86631.0000 | CD80 |
| 86632.0000 | CD81 |
| 86633.0000 | CD82 |
| 86634.0000 | CD83 |
| 86635.0000 | CDw84 |
| 86636.0000 | CD85 |
| 86637.0000 | CD86 |
| 86638.0000 | CD87 |
| 86639.0000 | CD88 |
| 86640.0000 | CD89 |
| 86641.0000 | CDw90 |
| 86642.0000 | CD91 |
| 86643.0000 | CDw92 |
| 86644.0000 | CD93 |
| 86645.0000 | CD94 |
| 86646.0000 | CD95 |
| 86647.0000 | CD96 |
| 86648.0000 | CD97 |
| 86649.0000 | CD99 |
| 86650.0000 | CD99R |
| 86651.0000 | CD100 |
| 86652.0000 | CDw101 |
| 86653.0000 | CD102 |
| 86654.0000 | CD103 |
| 86655.0000 | CD104 |
| 86656.0000 | CD106 |

| | |
|------------|------------------------------|
| 86657.0000 | CD107a |
| 86658.0000 | CD107b |
| 86659.0000 | CDw108 |
| 86660.0000 | CDw109 |
| 86661.0000 | CD115 |
| 86662.0000 | CDw116 |
| 86663.0000 | CD117 |
| 86664.0000 | CDw119 |
| 86665.0000 | CD120a |
| 86666.0000 | CD120b |
| 86667.0000 | CDw121a |
| 86668.0000 | CDw121b |
| 86669.0000 | CDw122 |
| 86670.0000 | Washed RBCs for Transfusion |
| 86671.0000 | CD126 |
| 86672.0000 | CDw127 |
| 86673.0000 | CDw128 |
| 86674.0000 | CDw130 |
| 86675.0000 | Leukocyte Agglutinins |
| 86676.0000 | Factor V Mutation |
| 86677.0000 | CD8 Percent |
| 86678.0000 | CD4/CD8 |
| 86679.0000 | CD4 Absolute |
| 86680.0000 | Leukocyte Common Ag |
| 86681.0000 | CD8 Absolute |
| 86682.0000 | CD62L |
| 86683.0000 | CDw124 |
| 86684.0000 | Strongyloides Ab |
| 86685.0000 | CD19 Percent |
| 86686.0000 | CD55/CD59 |
| 86687.0000 | Ri Ab |
| 86705.0000 | Therapeutic Phlebotomy |
| 86706.0000 | Isohemagglutin Titer |
| 86707.0000 | Blood Salvage |
| 86708.0000 | Fetal Screen |
| 86709.0000 | Bone Marrow Freezing |
| 86710.0000 | Bone Marrow Conc. |
| 86711.0000 | Bone Marrow Modification |
| 86712.0000 | Rh Typing |
| 86713.0000 | Apheresis |
| 86714.0000 | Rh Recheck |
| 86715.0000 | Immediate Spin Crossmatch |
| 86716.0000 | DAT |
| 86717.0000 | Splitting of Blood Products |
| 86718.0000 | Leukodeplete in Lab |
| 86719.0000 | Concentrate |
| 86720.0000 | Prepare Frozen Blood |
| 86721.0000 | Thawing Frozen Blood |
| 86722.0000 | Freezing and Thawing Blood |
| 86723.0000 | Enzyme Treated Panel |
| 86724.0000 | Antibody Titer |
| 86725.0000 | Chloroquine Dissociation |
| 86726.0000 | Cold Autoabsorption |
| 86727.0000 | Complete Crossmatch Incub |
| 86728.0000 | Complete Crossmatch Antiglob |
| 86729.0000 | Density Gradient Sep |
| 86730.0000 | Dithiothreitol Diff |
| 86731.0000 | Neutralization |
| 86732.0000 | Mucormycosis |

VistA Laboratory EPI

Rollup Modifications

Technical and User Manual

| | |
|------------|--------------------------------|
| 86733.0000 | RBC Antigen Type Other |
| 86734.0000 | Rh Phenotype |
| 86735.0000 | Serum Dilution |
| 86736.0000 | Unit Phenotype/Screen |
| 86737.0000 | ZZAP Autoabsorption |
| 86738.0000 | Mycoplasma |
| 86739.0000 | Plateletpheresis |
| 86740.0000 | Insulin Like Growth Factor |
| 86741.0000 | Protein S AB |
| 86742.0000 | Acetylcholine Receptor Ab Pane |
| 86743.0000 | Acetylcholine Receptor Binding |
| 86744.0000 | Acetylcholinesterase |
| 86745.0000 | Protein S Ag |
| 86746.0000 | HLA Bw Phenotype |
| 86747.0000 | HLA Cw Phenotype |
| 86748.0000 | HLA DR Phenotype |
| 86749.0000 | HLA DQ Phenotype |
| 86750.0000 | HLA A Phenotype |
| 86751.0000 | HLA B Phenotype |
| 86765.0000 | Enterovirus Ab |
| 86790.0000 | Packed Red Blood Sediment |
| 86795.0000 | Packed Red Blood Cells |
| 86796.0000 | Packed Red Blood (4 or more) |
| 86798.0000 | Fetal Hemoglobin Detection F |
| 86799.0000 | Red Blood Cells Unit |
| 86800.0000 | Fresh Frozen Plasma Prep |
| 86801.0000 | Fresh Frozen Plasma (4+) |
| 86802.0000 | Red Blood Cells Leukocytes Red |
| 86803.0000 | Red Blood Cells Deglycerolized |
| 86804.0000 | Platelet Pack Unit |
| 86805.0000 | Fresh Frozen Plasma Thawing |
| 86806.0000 | Platelets Leukocytes Reduced |
| 86807.0000 | Platelet Pheresis Leukocytes R |
| 86808.0000 | Granulocyte Pheresis Irradiate |
| 86809.0000 | Fresh Frozen Plasma |
| 86810.0000 | Separation of Blood Unit |
| 86811.0000 | Fresh Frozen 24Hr |
| 86812.0000 | Cryoprecipitate Reduced Plasma |
| 86813.0000 | Plasma Solvent Detergent Treat |
| 86814.0000 | Cryoprecipitate AHF |
| 86815.0000 | HLA Typed Blood Product |
| 86816.0000 | Platelet Ag 1 Negative Product |
| 86818.0000 | Donor Recruitment In Hospital |
| 86819.0000 | Donor Recruitment In Comm |
| 86820.0000 | Blood Unit Credit Function |
| 86821.0000 | Compatibility Crossmatch Plate |
| 86822.0000 | Type + Screen Platelets |
| 86823.0000 | Neutrophil Ab |
| 86824.0000 | Leukocyte Ab |
| 86825.0000 | Donor Rejected |
| 86826.0000 | CMV Ab Negative Product |
| 86827.0000 | Pooling Products |
| 86828.0000 | Compatibility non RBC Crossmat |
| 86829.0000 | Washing Blood Products |
| 86830.0000 | Volume Reduction |
| 86831.0000 | Directed Donation |
| 86832.0000 | Transfusion |
| 86833.0000 | Transfusion Blood Products |
| 86834.0000 | Transfusion Leukocytes |

VistA Laboratory EPI

Rollup Modifications

Technical and User Manual

| | |
|------------|--------------------------------|
| 86835.0000 | Transfusion Procedure NOS |
| 86836.0000 | CD3+HLA-DR+ Percent |
| 86837.0000 | CD3+HLA-DR+ Absolute |
| 86838.0000 | CD 2 Absolute |
| 86839.0000 | CD20 Absolute |
| 86840.0000 | Phlebotomy Therapeutic |
| 86841.0000 | T3 OK Percent |
| 86842.0000 | T3 OK Absolute |
| 86843.0000 | Cytoplasmic Neutrophil Atypica |
| 86844.0000 | Richettsia Panel |
| 86845.0000 | Phlebotomy Therapeutic Bedside |
| 86846.0000 | Norwalk Agent Ab |
| 86847.0000 | Inhibition Neutralization |
| 86848.0000 | Microplate Hemagglutination |
| 86849.0000 | Microplate Hemagg Tech Serum |
| 86850.0000 | Inventory(1) |
| 86851.0000 | Red Blood Cells ACD-A |
| 86852.0000 | Red Blood Cells Div Unit ACD-A |
| 86853.0000 | Red Blood Cells, Irrad ACD-A |
| 86854.0000 | Red Blood Cells Leuko Dep ACA- |
| 86855.0000 | Whole Blood ACD-A |
| 86856.0000 | Red Blood Cells CPD |
| 86857.0000 | Red Blood Cells Div Unit CPD |
| 86858.0000 | Red Blood Cell Irrad CPD |
| 86859.0000 | Red Blood Cell Leuko Dep CDP |
| 86860.0000 | Rh Immune Globulin |
| 86861.0000 | Squamous Cell CA Ag |
| 86862.0000 | C3 Nephritic Factor |
| 86863.0000 | BCR/ABL Gene |
| 86864.0000 | AutoImmune Ab Panel |
| 86865.0000 | Aspergillus Fumigatus Type 1 A |
| 86866.0000 | Aspergillus Fumigatus Type 2 A |
| 86867.0000 | Cytotoxic Ab Screen |
| 86868.0000 | HGE IgG Ab |
| 86869.0000 | Quinine Induced Ab |
| 86870.0000 | Toxocara Ab |
| 86871.0000 | Nabferon |
| 86872.0000 | CD138 |
| 86873.0000 | CD125 |
| 86874.0000 | CD NOS |
| 86875.0000 | IgG Subsets 1 |
| 86877.0000 | IgG Subsets 4 |
| 86878.0000 | Human Monocytic Ehrlichiosis A |
| 86879.0000 | Human Monocytic Ehrlichiosis A |
| 86880.0000 | Burkholderia pseudomallei Ab I |
| 86881.0000 | Burkholderia pseudomallei Ab I |
| 86885.0000 | Coombs Test |
| 86886.0000 | Coombs Test Indirect |
| 86903.0000 | Type + Screen Blood |
| 86910.0000 | Paternity Blood Typing |
| 86960.0000 | Hemochromatosis |
| 86961.0000 | Heparin Anti Xa Unfract |
| 86994.0000 | BKV ViActive qPCR |
| 86995.0000 | Adenovirus Ag,IF |
| 86996.0000 | Influenza A Ag,IF |
| 86997.0000 | Influenza B Ag,IF |
| 86998.0000 | Respiratory Syncytial Ag,IF |
| 86999.0000 | Rapid Respiratory Viral Panel |
| 87000.0000 | Bacteria Ab Coated |

VistA Laboratory EPI

Rollup Modifications

Technical and User Manual

| | |
|------------|-------------------------------|
| 87001.0000 | Fecal Leukocytes |
| 87002.0000 | Bacterium NOS |
| 87003.0000 | Legionella Culture |
| 87004.0000 | Bacteroides species |
| 87005.0000 | Bartonella species NOS |
| 87006.0000 | Bordatella Parapertussis |
| 87007.0000 | Bordetella Pertussis |
| 87008.0000 | Brucella species |
| 87009.0000 | Legionella DFA |
| 87010.0000 | Clostridium Difficile Toxin |
| 87011.0000 | Rapid Viral Smear |
| 87012.0000 | Clostridium Tetani Toxin |
| 87013.0000 | Corynebacterium species NOS |
| 87014.0000 | Corynebacterium Diphtheriae |
| 87015.0000 | Blood Culture Conventional |
| 87016.0000 | Escherichia coli Each Sero |
| 87017.0000 | Francisella tularensis |
| 87018.0000 | Haemophilus Influenzae |
| 87019.0000 | Feces Macroscopic Exam |
| 87020.0000 | Haemophilus influenzae Type A |
| 87021.0000 | Feces Microscopic Exam |
| 87022.0000 | Haemophilus Influenzae type B |
| 87023.0000 | Feces Pin Worm Examination |
| 87024.0000 | Legionella species NOS |
| 87025.0000 | Sodium Hydroxide Procedure |
| 87026.0000 | Legionella pneumophilia |
| 87027.0000 | Strep Grp A Coagglut |
| 87028.0000 | Listeria species |
| 87029.0000 | Neisseria species NOS |
| 87030.0000 | Neisseria Gonorrhoeae |
| 87031.0000 | Neisseria Meningitidis |
| 87032.0000 | Neisseria Meningitidis Typing |
| 87033.0000 | Norcardia species NOS |
| 87034.0000 | Proteus OX 2 |
| 87035.0000 | Strep Grp A Enzyme Immun |
| 87036.0000 | Proteus OX 19 |
| 87037.0000 | Strep Grp A Latex Agglut |
| 87038.0000 | Proteus OX K |
| 87039.0000 | Wet Prep for Trichomonas |
| 87040.0000 | Pseudomonas Pseudomallei |
| 87041.0000 | Escherichia Coli 0157 |
| 87042.0000 | Salmonella Each Grouping |
| 87043.0000 | Ziehl Neelsen Stain |
| 87044.0000 | Salmonella Paratyphi A |
| 87045.0000 | Zinc Sulfate Flotation |
| 87046.0000 | Salmonella Paratyphi B |
| 87047.0000 | Fluorochrome Type Stains |
| 87048.0000 | Salmonella Typhi H |
| 87049.0000 | Formalin Ether or Ethyl |
| 87050.0000 | Salmonella Typhi O |
| 87051.0000 | Iron Hematoxylin Stain |
| 87052.0000 | Salmonella Typhi Vi |
| 87053.0000 | Kinyoun's Acid Fast Stain |
| 87054.0000 | Salmonella Each Typing |
| 87055.0000 | Merthiolate Iodine Formalin |
| 87056.0000 | Shigella Each Grouping |
| 87057.0000 | NALC Procedure |
| 87058.0000 | Shigella Each Typing |
| 87059.0000 | Staphylococcus species NOS |

VistA Laboratory EPI

Rollup Modifications

Technical and User Manual

| | |
|------------|--------------------------------|
| 87060.0000 | Streptobacillus species |
| 87061.0000 | Trichrome Stain |
| 87062.0000 | Streptococcus Group A |
| 87063.0000 | Zephiran Trisodium Phosphate |
| 87064.0000 | Streptococcus Group B |
| 87065.0000 | Viral serology |
| 87066.0000 | Streptococcus Group C |
| 87067.0000 | India Ink prep |
| 87068.0000 | Streptococcus Group D |
| 87069.0000 | KOH prep, fungal |
| 87070.0000 | Streptococcus Group G |
| 87071.0000 | Haemophilus influenza Type B b |
| 87072.0000 | Streptococcus Group MG |
| 87073.0000 | Neisseria meningitidis by Late |
| 87074.0000 | Streptococcus Pneumoniae |
| 87075.0000 | Streptococcus species NOS |
| 87076.0000 | Vibrio Cholera |
| 87077.0000 | Histoplasmosis Ab yeast/mycel |
| 87078.0000 | Yersinia Enterocolitica |
| 87079.0000 | Chlamydia culture |
| 87080.0000 | Yersinia Pestis |
| 87081.0000 | Misc Micro Test 1 |
| 87082.0000 | Yersinia Pseudotuberculosis |
| 87083.0000 | Yersinia species NOS |
| 87084.0000 | Misc Micro Test 2 |
| 87085.0000 | Misc Micro Test 3 |
| 87086.0000 | Misc Micro Test 4 |
| 87087.0000 | Misc Micro Test 5 |
| 87088.0000 | Herpes Simplex Encephalitis |
| 87089.0000 | Culture GC |
| 87090.0000 | Coccidioides Precipitin |
| 87091.0000 | Enteroviral Ab |
| 87092.0000 | Chlamydia/GC Panel |
| 87093.0000 | API Etiology Rapid |
| 87094.0000 | Misc Culture 1 |
| 87095.0000 | Misc Culture 2 |
| 87096.0000 | Misc Culture 3 |
| 87097.0000 | Misc Culture 4 |
| 87098.0000 | Misc Culture 5 |
| 87099.0000 | Misc Culture 6 |
| 87100.0000 | Misc Culture 7 |
| 87101.0000 | InHouse or Send Out Test |
| 87102.0000 | Etiology |
| 87103.0000 | Specimen Source |
| 87104.0000 | Instrument MI Setup |
| 87105.0000 | Acyclovir |
| 87106.0000 | Almecillin |
| 87107.0000 | Anantadine |
| 87108.0000 | Amoxicillin+Clavulanate |
| 87109.0000 | Ampicillin+Sulbactam |
| 87110.0000 | Betalactase |
| 87111.0000 | Azithromycin |
| 87112.0000 | Bacampicillin |
| 87113.0000 | Betalactase ext Spectrum |
| 87114.0000 | Butirosin |
| 87115.0000 | Cefatrizine |
| 87116.0000 | Cefepime |
| 87117.0000 | Cefixime |
| 87118.0000 | Cefemetazole |

VistA Laboratory EPI

Rollup Modifications

Technical and User Manual

| | |
|------------|-------------------------------|
| 87119.0000 | Cefodizime |
| 87120.0000 | Cefonicid |
| 87121.0000 | Cefotetan |
| 87122.0000 | Cefpirome |
| 87123.0000 | Cefpodoxime |
| 87124.0000 | Cefprozil |
| 87125.0000 | Ceftazindime |
| 87126.0000 | Ceftibuten |
| 87127.0000 | Chlortetracycline |
| 87128.0000 | Cinoxacin |
| 87129.0000 | Clarithromycin |
| 87130.0000 | Colistimethate |
| 87131.0000 | Colistin |
| 87132.0000 | Cyclacillin |
| 87133.0000 | Demeclocycline |
| 87134.0000 | Dirithromycin |
| 87135.0000 | Erythromycin+Sulfisoxazole |
| 87136.0000 | Fleroxacin |
| 87137.0000 | Floxacillin |
| 87138.0000 | FP-Amycetin |
| 87139.0000 | Fusidate |
| 87140.0000 | Ganciclovir |
| 87141.0000 | Gentamicin HP |
| 87142.0000 | Gramicidind |
| 87143.0000 | Hetacillin |
| 87144.0000 | Imipenem+Cilastatin |
| 87145.0000 | Kanamycin HP |
| 87146.0000 | Lincomycin |
| 87147.0000 | Lomefloxacin |
| 87148.0000 | Loracarbef |
| 87149.0000 | Lymecycline |
| 87150.0000 | Skin Test |
| 87151.0000 | Borrelia Burgdorferi |
| 87152.0000 | Meropenem |
| 87153.0000 | Borrelia Vincentii |
| 87154.0000 | TB Tine |
| 87155.0000 | Treponema carateum (pinta) |
| 87156.0000 | Tazobactam |
| 87157.0000 | Treponema pallidum (syphilis) |
| 87158.0000 | Neurogenic Viral Panel |
| 87159.0000 | Treponema pertenue (yaws) |
| 87160.0000 | Piperacillin+Tazobactam |
| 87161.0000 | Leptospira species NOS |
| 87162.0000 | Trichinella Ab |
| 87163.0000 | Spirochete NOS |
| 87164.0000 | Echinococcus Ab |
| 87165.0000 | Methacycline |
| 87166.0000 | Miocamycin |
| 87167.0000 | Mupirocin |
| 87168.0000 | Coccidiodes Ab |
| 87169.0000 | Coccidiodes Ag |
| 87170.0000 | Nalidixate |
| 87171.0000 | Ofloxacin |
| 87172.0000 | Oleandomycin |
| 87173.0000 | Mycoplasma Ab |
| 87174.0000 | Oxytetracycline |
| 87175.0000 | Chlamydia Pneumoniae |
| 87176.0000 | Endotoxin |
| 87177.0000 | Chlamydia Psittaci |

VistA Laboratory EPI

Rollup Modifications

Technical and User Manual

| | |
|------------|-------------------------------|
| 87178.0000 | Pefloxacin |
| 87179.0000 | Penicillin G |
| 87180.0000 | Penicillin V |
| 87181.0000 | Phenethicillin |
| 87182.0000 | Chlamydia Trachomatis |
| 87183.0000 | Pepemidate |
| 87184.0000 | Pepercil+Tazobactam |
| 87185.0000 | Pivampicillin |
| 87186.0000 | Ristocetin |
| 87187.0000 | Chlamydia NOS |
| 87188.0000 | Rolitetracycline |
| 87189.0000 | Rosoxacin |
| 87190.0000 | Roxithromycin |
| 87191.0000 | Sparfloxacin |
| 87192.0000 | Lymphogranuloma venereum |
| 87193.0000 | Streptomycin HP |
| 87194.0000 | Sulfadiazine |
| 87195.0000 | Sulfisoxazole |
| 87196.0000 | Ataxia Profile |
| 87197.0000 | Mycoplasma NOS |
| 87198.0000 | Talampicillin |
| 87199.0000 | Mycoplasma pneumoniae |
| 87200.0000 | Teicoplanin |
| 87201.0000 | Misc Culture 8 |
| 87202.0000 | Actinomyces species |
| 87203.0000 | Temafloxacin |
| 87204.0000 | Temocillin |
| 87205.0000 | Tetracycline |
| 87206.0000 | Ticarcillin+Cavulanate |
| 87207.0000 | Aspergillus species NOS |
| 87208.0000 | Helicobacter Pylori |
| 87209.0000 | Trimethoprim+Sulfamethoxazole |
| 87210.0000 | Troleandomycin |
| 87211.0000 | Viomycin |
| 87212.0000 | Aspergillus Fumigatus |
| 87213.0000 | Zidovudine |
| 87214.0000 | Giardia Ag |
| 87215.0000 | Giardia Ab |
| 87216.0000 | Giardia Ag EIA |
| 87217.0000 | Blastomyces Dermatitidis |
| 87218.0000 | Misc Culture 9 |
| 87219.0000 | Misc Culture 10 |
| 87220.0000 | Misc Immuno Test 6 |
| 87221.0000 | Misc Immuno Test 7 |
| 87222.0000 | Candida Albicans |
| 87223.0000 | Misc Immuno Test 8 |
| 87224.0000 | Misc Immuno Test 9 |
| 87225.0000 | Misc Immuno Test 10 |
| 87226.0000 | Streptomycin Synergy Scr |
| 87227.0000 | Candida species NOS |
| 87228.0000 | IgA Quant Cardiolipin |
| 87229.0000 | Congo Red Stain |
| 87230.0000 | Acanthamoeba Culture |
| 87231.0000 | IgG Quant Cardiolipin |
| 87232.0000 | Coccidioides Immittis |
| 87233.0000 | IgG Qual Cardiolipin |
| 87234.0000 | Adenovirus Ab |
| 87235.0000 | Adrenal Ab |
| 87236.0000 | Acid Fast Org ID |

VistA Laboratory EPI

Rollup Modifications

Technical and User Manual

| | |
|------------|----------------------------------|
| 87237.0000 | Cryptococcus Neoformans |
| 87238.0000 | Fontana Masson Stain |
| 87239.0000 | Brown Hopp Stain |
| 87240.0000 | Leptospira Ab |
| 87241.0000 | Leptospira Ag |
| 87242.0000 | Fungus NOS |
| 87243.0000 | Dengue Virus Ab |
| 87244.0000 | Voriconazole |
| 87245.0000 | Sjorgren Syndrome A |
| 87246.0000 | Sjorgren Syndrome B |
| 87247.0000 | Histoplasma capsulatum Mycelia |
| 87248.0000 | Cytomegalovirus Ag |
| 87249.0000 | Chlamydia Trachomatis DNA |
| 87250.0000 | Cardiolipin Ab Panel |
| 87251.0000 | Cardiolipin Ab |
| 87252.0000 | Histoplasma capsulatum Yeast |
| 87253.0000 | IgM Quant Cardiolipin |
| 87254.0000 | Hepatitis C EIA |
| 87255.0000 | IgM Qual Cardiolipin |
| 87256.0000 | IgA Qual Cardiolipin |
| 87257.0000 | Micropolyspora faeni |
| 87258.0000 | Herpes I&II |
| 87259.0000 | Sjorgren Syndrome A Quant |
| 87260.0000 | Sjorgren Syndrome B Quant |
| 87261.0000 | Influenza A&B |
| 87262.0000 | Paracoccidioides Braziliensis |
| 87263.0000 | Axonal HMSN Eval |
| 87264.0000 | Platelet Associated Ab Dir |
| 87265.0000 | Platelet Associated Ab Ind |
| 87266.0000 | Herpesvirus-8 IgG |
| 87267.0000 | Saccharomonospora Viridis |
| 87268.0000 | Skin Dermal Epidermal Ab |
| 87269.0000 | Skin Intercellular Ab |
| 87270.0000 | Oxidase |
| 87271.0000 | Pipemidic Acid |
| 87272.0000 | Sporotrichum species |
| 87273.0000 | Pritstinamycin |
| 87274.0000 | Antibiotic NOS |
| 87275.0000 | Culture Clostridium Difficile |
| 87276.0000 | Cyclospora |
| 87277.0000 | Thermoactinomyces Candidus |
| 87278.0000 | Thermoactinomyces Candidus Ab |
| 87279.0000 | Mycobacterium Gordonea DNA |
| 87280.0000 | Mycobacterium Avium DNA |
| 87281.0000 | Neisseria Meningitidis A |
| 87282.0000 | Thermoactinomyces Vulgaris |
| 87283.0000 | Misc Flow Test 1 |
| 87284.0000 | Misc Flow Test 2 |
| 87285.0000 | Misc Flow Test 3 |
| 87286.0000 | Misc Flow Test 4 |
| 87287.0000 | Misc Flow Test 5 |
| 87288.0000 | Misc Flow Test 6 |
| 87289.0000 | Misc Flow Test 7 |
| 87290.0000 | Misc Flow Test 8 |
| 87291.0000 | Misc Flow Test 9 |
| 87292.0000 | Misc Flow Test 10 |
| 87293.0000 | Staphylococcus Aureus Meth Resis |
| 87294.0000 | Streptococcus Group A Scr |
| 87295.0000 | Sarcoptes Scabiei |

VistA Laboratory EPI

Rollup Modifications

Technical and User Manual

| | |
|------------|--------------------------------|
| 87296.0000 | Culture Vibrio |
| 87297.0000 | Viral Smear |
| 87298.0000 | CH100 |
| 87299.0000 | Friedreich Ataxia Mutation |
| 87300.0000 | Parvovirus AB IgM |
| 87301.0000 | Varicella Zoster AB IgM |
| 87302.0000 | Amoeba NOS |
| 87303.0000 | Cryptosporidium |
| 87304.0000 | Extractable Nuclear Ab |
| 87305.0000 | Fluoxetine+Norfluoxetine |
| 87306.0000 | Diasialyl Ganglioside Ab IgG |
| 87307.0000 | Tetrasialyl Ganglioside Ab IgG |
| 87308.0000 | Cysticercus |
| 87309.0000 | Hepatitis C Superoxidase Eis A |
| 87310.0000 | Myelin Associated Glycoprotein |
| 87311.0000 | Neural Thread Protein |
| 87312.0000 | Hepatitis C NS5 Ab |
| 87313.0000 | Echinococcus species |
| 87314.0000 | Linezolid |
| 87315.0000 | Parainfluenza 2 Ab |
| 87316.0000 | Parainfluenza 3 Ab |
| 87317.0000 | Entamoeba species NOS |
| 87318.0000 | Entamoeba Histolytica |
| 87319.0000 | Neisseria Gonorrhoeae DNA |
| 87320.0000 | Trypsinogen |
| 87321.0000 | Leishmania Braziliensis |
| 87322.0000 | Leishmania Braziliensis IgG |
| 87323.0000 | Filaria species |
| 87324.0000 | Leishmania Braziliensis IgM |
| 87325.0000 | Leishmania Donovan |
| 87326.0000 | Leishmania Donovan IgG |
| 87327.0000 | Leishmania Donovan IgM |
| 87328.0000 | Microfilarial Ag |
| 87329.0000 | Leishmania Mexicana |
| 87330.0000 | Leishmania Mexicana IgG |
| 87331.0000 | Leishmania Mexicana IgM |
| 87332.0000 | Leishmania Tropicalis |
| 87333.0000 | Leishmania species NOS |
| 87334.0000 | Leishmania Tropicalis IgG |
| 87335.0000 | Leishmania Tropicalis IgM |
| 87336.0000 | Basement Membrane Ab Titer |
| 87337.0000 | Basement Membrane Zone |
| 87338.0000 | Parasite NOS |
| 87339.0000 | BCL 2 |
| 87340.0000 | Intercellular Structure |
| 87341.0000 | Intercellular Structure Ab |
| 87342.0000 | Intercellular Structure Titer |
| 87343.0000 | Plasmodium species (malaria) |
| 87344.0000 | Hevea Brazil |
| 87345.0000 | Melas MT DNA Mutation |
| 87346.0000 | Hereditary Familial Hemochroma |
| 87347.0000 | HEF CYS 282 TRY Mutation |
| 87348.0000 | Schistosoma species |
| 87349.0000 | HEF HIS 63 ASP Mutation |
| 87350.0000 | PR Gene Mutation |
| 87351.0000 | Puumala Virus IgG |
| 87352.0000 | Puumala Virus IgM |
| 87353.0000 | Toxocara species |
| 87354.0000 | Prostrate Cancer Risk |

VistA Laboratory EPI

Rollup Modifications

Technical and User Manual

| | |
|------------|--------------------------------|
| 87355.0000 | Toxoplasma Gondii |
| 87356.0000 | RT Gene Mutation |
| 87357.0000 | Celiac Antibody Panel |
| 87358.0000 | Trichinella species NOS |
| 87359.0000 | Sulfatide ELISA IgM |
| 87360.0000 | Trypanosoma Cruzi |
| 87361.0000 | Sulfatide ELISA IgG |
| 87362.0000 | Trypanosoma Rhodesiensis |
| 87363.0000 | X25 |
| 87364.0000 | Trypanosoma Gambiense |
| 87365.0000 | X25 Allele1 |
| 87366.0000 | Visceral Larval Migrants |
| 87367.0000 | X25 Allele2 |
| 87368.0000 | Thyroid Stimulating Hormone Ab |
| 87369.0000 | Islet Cell Ag |
| 87370.0000 | Islet Cell Ab |
| 87371.0000 | Acanthamoeba Stain |
| 87372.0000 | Strongyloides Ab IgG |
| 87373.0000 | Cystic Fibrosis |
| 87374.0000 | Reticulin Ab |
| 87375.0000 | Smooth Muscle Ab |
| 87376.0000 | Arbovirus |
| 87377.0000 | Culture Varicella Zoster |
| 87378.0000 | Coxiella Burnetti |
| 87379.0000 | Herpes Virus VI |
| 87380.0000 | Rickettsia Akari |
| 87381.0000 | Influenza B Guangdong |
| 87382.0000 | Rickettsia NOS |
| 87383.0000 | Influenza A Taiwan |
| 87384.0000 | Rickettsia Rickettsii |
| 87385.0000 | Influenza B Beijing |
| 87386.0000 | Rickettsia typhi (mooseri) |
| 87387.0000 | Intrinsic Factor Ag |
| 87388.0000 | Rickettsia prowazekii |
| 87389.0000 | Pneumocystis |
| 87390.0000 | Rickettsia tsutsugamushi |
| 87391.0000 | Precipitating Ab |
| 87392.0000 | Salmonella C H |
| 87393.0000 | Salmonella C O |
| 87394.0000 | Salmonella D O |
| 87395.0000 | Stain |
| 87396.0000 | Paraneoplastic Neuronal Ab |
| 87397.0000 | Hepatitis B e Ag |
| 87398.0000 | Hepatitis B e Ab |
| 87399.0000 | Endocrine Neoplasia Type 2 Mul |
| 87400.0000 | Cryptococcus Ag |
| 87401.0000 | Cryptococcus Ab |
| 87402.0000 | Adenovirus |
| 87403.0000 | Pregnancy Test |
| 87404.0000 | California Encephalitis |
| 87405.0000 | Hepatitis C Neutral |
| 87406.0000 | Colorado Tick Fever Virus |
| 87407.0000 | Viro Specimen |
| 87408.0000 | Corona Virus |
| 87409.0000 | Myco Specimen |
| 87410.0000 | Coxsackie A |
| 87411.0000 | Parasite Specimen |
| 87412.0000 | Coxsackie B |
| 87413.0000 | Rubeola Ab |

VistA Laboratory EPI

Rollup Modifications

Technical and User Manual

| | |
|------------|------------------------------|
| 87414.0000 | Cytomegalovirus |
| 87415.0000 | Rubeola Ag |
| 87416.0000 | Dengue Fever Virus |
| 87417.0000 | Rubeola Ab Quant |
| 87418.0000 | Eastern Equine Encephalitis |
| 87419.0000 | X*Hepatitis C RNA |
| 87420.0000 | Echovirus |
| 87421.0000 | Viral Load |
| 87422.0000 | Epstein Barr Capsid Ag |
| 87423.0000 | HIV Viral Load Ultra |
| 87424.0000 | Epstein Barr Early Ag |
| 87425.0000 | VRE Culture |
| 87426.0000 | Epstein Barr Nuclear Ag |
| 87427.0000 | Epstein Barr |
| 87428.0000 | Hepatitis A |
| 87429.0000 | Epstein Barr Ag |
| 87430.0000 | Hepatitis B Core |
| 87431.0000 | Diasialyl Ganglioside Ab |
| 87432.0000 | Hepatitis B Delta |
| 87433.0000 | Diasialyl Ganglioside Ag |
| 87434.0000 | Hepatitis B e |
| 87435.0000 | Myeloperoxidase Ab |
| 87436.0000 | Hepatitis B Surface |
| 87437.0000 | Hepatitis C |
| 87438.0000 | Herpes simplex I |
| 87439.0000 | Hepatitis C Ag |
| 87440.0000 | Herpes simplex II |
| 87441.0000 | Myeloperoxidase Ag |
| 87442.0000 | Herpes zoster |
| 87443.0000 | Herpesvirus NOS |
| 87444.0000 | HTLV I |
| 87445.0000 | Chancroid Culture |
| 87446.0000 | HTLV II |
| 87447.0000 | Parvovirus B19 Ag |
| 87448.0000 | HIV |
| 87449.0000 | Phosphatidylserine Ab |
| 87450.0000 | Influenza A |
| 87451.0000 | Phosphatidylserine Ag |
| 87452.0000 | Influenza B |
| 87453.0000 | HEp 2 Cells ANA |
| 87454.0000 | Influenza C |
| 87455.0000 | Parvovirus B19 Ab |
| 87456.0000 | Japanese B Encephalitis |
| 87457.0000 | Mouse Kidney ANA |
| 87458.0000 | Lymphocytic Choriomeningitis |
| 87459.0000 | Mysoline Ab |
| 87460.0000 | Mumps Soluble |
| 87461.0000 | Mysoline Ag |
| 87462.0000 | Mumps Viral |
| 87463.0000 | Sarcolemma Ab |
| 87464.0000 | Papillomavirus |
| 87465.0000 | Sarcolemma Ag |
| 87466.0000 | Parainfluenza |
| 87467.0000 | Skeletal Muscle Ab |
| 87468.0000 | Poliomyelitis |
| 87469.0000 | Skeletal Muscle Ag |
| 87470.0000 | Q Fever Group |
| 87471.0000 | Arbovirus CALIF Titer |
| 87472.0000 | Reovirus |

VistA Laboratory EPI

Rollup Modifications

Technical and User Manual

| | |
|------------|--------------------------------|
| 87473.0000 | Arbovirus EEE Titer |
| 87474.0000 | Respiratory Syncytial Virus |
| 87475.0000 | Arbovirus SLE Titer |
| 87476.0000 | Rhinovirus |
| 87477.0000 | Arbovirus WEE Titer |
| 87478.0000 | Rotavirus |
| 87479.0000 | Clostridium Difficile Ag |
| 87480.0000 | Rubella |
| 87481.0000 | Clostridium Difficile Ab |
| 87482.0000 | Rubeola |
| 87483.0000 | Candida Complement Titer |
| 87484.0000 | St Louis Equine Encephalitis |
| 87485.0000 | Parvovirus Ab |
| 87486.0000 | Vaccinia |
| 87487.0000 | Histoplasmin Ag |
| 87488.0000 | Varicella Zoster |
| 87489.0000 | Histoplasmin Ab |
| 87490.0000 | Venezuelan Equine Encephalitis |
| 87491.0000 | Histoplasmin Titer |
| 87492.0000 | Virus NOS |
| 87493.0000 | HLA PRA |
| 87494.0000 | Yellow Fever |
| 87495.0000 | Influenza A Bangkok |
| 87496.0000 | Western Equine Encephalitis |
| 87497.0000 | Influenza A England |
| 87498.0000 | Influenza A Phillipine |
| 87499.0000 | Influenza A Singapore |
| 87500.0000 | Intrinsic Factor Ab |
| 87501.0000 | Bacteriology |
| 87502.0000 | Mycobacteriology |
| 87503.0000 | Mycology |
| 87504.0000 | Virology |
| 87505.0000 | Parasitology |
| 87506.0000 | Micro Misc |
| 87507.0000 | Thyperoxidase Ab |
| 87508.0000 | Aerobic Culture |
| 87509.0000 | Culture Fungus |
| 87510.0000 | Culture Chlamydia/GC |
| 87511.0000 | Blood Culture Manual |
| 87512.0000 | Blood Culture Automated |
| 87513.0000 | Gram Stain Blood Culture |
| 87514.0000 | Organism Identification Auto |
| 87515.0000 | Biochemical Test Automated |
| 87516.0000 | Organism ID MIC Automated |
| 87517.0000 | Body Fluid Culture Automated |
| 87518.0000 | Susceptibility MIC Automated |
| 87519.0000 | Brucella Abortus |
| 87520.0000 | Urine Bacterial Screen Automat |
| 87521.0000 | Org ID & Susceptibility Auto |
| 87522.0000 | Yeast ID Automated |
| 87523.0000 | Salmonella E |
| 87524.0000 | Bacteria Ag |
| 87525.0000 | Culture Mycobacteria |
| 87526.0000 | Culture Virus |
| 87527.0000 | Shell Vial (Spin) |
| 87528.0000 | Culture Aerobic&Anerobic |
| 87529.0000 | Culture Aerobic Routine |
| 87530.0000 | Accession Specimen Bac Cul |
| 87531.0000 | Planting 1 Pc Media Bact |

VistA Laboratory EPI

Rollup Modifications

Technical and User Manual

| | |
|------------|--------------------------------|
| 87532.0000 | Planting 2 Pc Media Bact |
| 87533.0000 | Planting 3 Pc Media Bact |
| 87534.0000 | Planting 4 Pc Media Bact |
| 87535.0000 | Planting 5 Pc Media Bact |
| 87536.0000 | Planting 6 Pc Media Bact |
| 87537.0000 | Planting 7 Pc Media Bact |
| 87538.0000 | Planting 8 Pc Media Bact |
| 87539.0000 | Culture Campylobacter |
| 87540.0000 | Planting each add Pc Bact |
| 87541.0000 | Culture Verotoxin E. Coli |
| 87542.0000 | Reading Bact Culture Sterile |
| 87543.0000 | Culture Yersinia |
| 87544.0000 | Reading Bact Cult Non sterile |
| 87545.0000 | Culture Group B Strep |
| 87546.0000 | Reading Bact Culture Any Spec |
| 87547.0000 | Specimen Preparation |
| 87548.0000 | Reading Bact Culture 2+ Org |
| 87548.7038 | Reading Bact Culture Sterile~M |
| 87549.0000 | Amebiasis |
| 87550.0000 | Recording & Reporting Bact |
| 87551.0000 | Ehrlichia Chaffeensi |
| 87552.0000 | Babesia Microti |
| 87553.0000 | Urine Culture |
| 87554.0000 | CSF Culture |
| 87555.0000 | Blood Culture |
| 87556.0000 | Wound Culture |
| 87557.0000 | Stool Culture |
| 87558.0000 | Nose/Throat Culture |
| 87559.0000 | Misc Culture |
| 87560.0000 | Environmental Culture |
| 87561.0000 | Pertussis Culture |
| 87562.0000 | Thermoactinomyces Viridis Ab |
| 87563.0000 | Q Fever Phase 1 Ab |
| 87564.0000 | Q Fever Phase 2 Ab |
| 87565.0000 | Bacteriology Susc |
| 87566.0000 | Culture HIV 1 Qual |
| 87567.0000 | Cefdinir |
| 87568.0000 | Mycobacterium Susc |
| 87569.0000 | Coccidioides IgG |
| 87570.0000 | Bacteriology Organism |
| 87571.0000 | HIV Genotype PCR |
| 87572.0000 | Hepatitis C Genotype PCR |
| 87573.0000 | Niemann Pick Type C |
| 87574.0000 | Tay Sach Dis Mutation |
| 87575.0000 | JC Virus |
| 87576.0000 | Parasite Organism |
| 87577.0000 | JC Virus Ab |
| 87578.0000 | Fungal Organism |
| 87579.0000 | Neural Tube Defect |
| 87580.0000 | Down Syndrome |
| 87581.0000 | Trisomy |
| 87582.0000 | Trisomy 18 |
| 87583.0000 | Acid Fast Quantity |
| 87584.0000 | Bartonella quintana Ab IgM |
| 87585.0000 | Platelet Associated IgM |
| 87586.0000 | Lymphoma Phenotype |
| 87587.0000 | Fetoprotein Alpha Maternal |
| 87588.0000 | Acetylcholine Modulating Ab |
| 87589.0000 | Mycobacterium Organism |

VistA Laboratory EPI

Rollup Modifications

Technical and User Manual

| | |
|------------|--------------------------------|
| 87590.0000 | Viral Agent |
| 87591.0000 | Myocardium Ab |
| 87592.0000 | Neutrophil Oxidative Burst |
| 87593.0000 | Salmonella O |
| 87594.0000 | Culture Skin |
| 87595.0000 | Salmonella O Grp D |
| 87596.0000 | Salmonella Flg d |
| 87597.0000 | Salmonella Flg a |
| 87598.0000 | Salmonella Flg b |
| 87599.0000 | Salmonella O Grp A |
| 87600.0000 | Inoculation Blood culture |
| 87601.0000 | Salmonella O Grp B |
| 87602.0000 | Histoplasma Ag |
| 87603.0000 | Weil Felix Ag |
| 87604.0000 | Subculture Blood Culture |
| 87605.0000 | AFB Smear |
| 87606.0000 | HIV 1 Genotype (PRI) |
| 87607.0000 | HIV 1 Genotype (RTI) |
| 87608.0000 | Calcium VG Channel Ab |
| 87609.0000 | West Nile IgG |
| 87610.0000 | West Nile IgM |
| 87611.0000 | Culture HS Virus |
| 87612.0000 | Autologous Collection |
| 87613.0000 | SGPG Ag |
| 87614.0000 | West Nile Ab |
| 87615.0000 | ECHO 11 |
| 87616.0000 | ECHO 30 |
| 87617.0000 | ECHO 4 |
| 87618.0000 | ECHO 6 |
| 87619.0000 | ECHO 7 |
| 87620.0000 | ECHO 9 |
| 87621.0000 | Chlamydia Pneumoniae IgG |
| 87622.0000 | Chlamydia Pneumoniae IgA |
| 87623.0000 | Chlamydia Pneumoniae IgM |
| 87624.0000 | Chlamydia Trachomatis IgG |
| 87625.0000 | Chlamydia Trachomatis IgA |
| 87626.0000 | Chlamydia Trachomatis IgM |
| 87627.0000 | Chlamydia Psittaci IgG |
| 87628.0000 | Chlamydia Psittaci IgA |
| 87629.0000 | Chlamydia Psittaci IgM |
| 87630.0000 | HU Ab |
| 87631.0000 | HU Ab Western Blot |
| 87632.0000 | Aspergillus Niger |
| 87633.0000 | Aspergillus Flavus |
| 87634.0000 | Neisseria Meningitis B |
| 87635.0000 | Neisseria Meningitis C |
| 87636.0000 | Neisseria Meningitis Y |
| 87637.0000 | Neisseria Meningitis W135 |
| 87638.0000 | Coxiella Burnetti 1 IgG |
| 87639.0000 | CD3-CD19+ Percent |
| 87640.0000 | Aspergillus Flavus Ab |
| 87641.0000 | Aspergillus Fumigatus Type 6 A |
| 87642.0000 | Thermoactinomyces Sacchri Ab |
| 87643.0000 | Human Papillomavirus |
| 87644.0000 | Diasialyl Ganglioside Ab IgM |
| 87645.0000 | Aspergillus Ab IgA |
| 87646.0000 | Aspergillus Ab IgG |
| 87647.0000 | Aspergillus Ab IgM |
| 87648.0000 | Brucella Brugneri |

VistA Laboratory EPI

Rollup Modifications

Technical and User Manual

| | |
|------------|---------------------------------|
| 87649.0000 | Brucella Interpretation |
| 87650.0000 | Organism Identification ID Kit |
| 87651.0000 | Brucella Canis |
| 87652.0000 | Burcella Pertussis |
| 87653.0000 | Candida Species Ag |
| 87654.0000 | CAR Associated Retinopathy Ab |
| 87655.0000 | Endomysial Ab IgA |
| 87656.0000 | Cysticerus Ab |
| 87657.0000 | Interferon Beta Ab IgG |
| 87658.0000 | PMP22 Gene Mutation |
| 87659.0000 | Sporotrichosis |
| 87660.0000 | Sporotrichosis Ab |
| 87661.0000 | Staphylococcus Aureus Toxin Ab |
| 87662.0000 | Staphylococcus Aureus Toxin 1 A |
| 87663.0000 | TSH Immunoglobulin Panel |
| 87664.0000 | TSH Immunoglobulin Index |
| 87665.0000 | Cytoplasmic Neutrophil Pattern |
| 87666.0000 | Culture Skin,Hair,Nails |
| 87667.0000 | Fungal Identification |
| 87668.0000 | Fungal ID Mold |
| 87669.0000 | Fungal ID Yeast |
| 87670.0000 | Bacteriology Organism ID |
| 87671.0000 | Bacteriology Organism Aerobic |
| 87672.0000 | Bacteriology Organism Anaerobi |
| 87673.0000 | DNA Probe Culture ID |
| 87674.0000 | Clostridium Difficile |
| 87675.0000 | Concentration Infectious Agent |
| 87676.0000 | Gatifloxacin |
| 87677.0000 | Moxifloxacin |
| 87678.0000 | Saccharomyces cerevisiae Ab Ig |
| 87679.0000 | Saccharomyces cerevisiae Ab Ig |
| 87680.0000 | Babesia Ab, Total |
| 87681.0000 | Babesia microti IgG |
| 87682.0000 | Babesia microti IgM |
| 87683.0000 | Babesia microti DNA PCR |
| 87684.0000 | SCA 7 Allele 1 |
| 87685.0000 | SCA 7 Allele 2 |
| 87686.0000 | HIV 1 Ab GP160 |
| 87687.0000 | HIV 1 Ab GP120 |
| 87688.0000 | HIV 1 Ab P66 |
| 87689.0000 | HIV 1 Ab P65 |
| 87690.0000 | HIV 1 Ab P51 |
| 87691.0000 | HIV 1 Ab GP41 |
| 87692.0000 | HIV 1 Ab P40 |
| 87693.0000 | HIV 1 Ab P31 |
| 87694.0000 | HIV 1 Ab P17 |
| 87695.0000 | Arthropod Identification |
| 87696.0000 | Tick Identification |
| 87697.0000 | Cockroach Identification |
| 87698.0000 | Epstein Barr Nuclear Ab |
| 87700.0000 | Acridine Orange Stain |
| 87701.0000 | Digestion Decontam of Spec |
| 87702.0000 | Agglutination Slide |
| 87703.0000 | Anaerobic Jar Flushing |
| 87704.0000 | Autoclave Control Attest |
| 87705.0000 | Bactigen for Group B Strep |
| 87706.0000 | Biochemical Test Rapid |
| 87707.0000 | Bactigen Meningitis Panel |
| 87708.0000 | Conventional Micro Tube Test |

VistA Laboratory EPI

Rollup Modifications

Technical and User Manual

| | |
|------------|--------------------------------|
| 87710.0000 | Dark field Examination |
| 87711.0000 | Direct FA |
| 87712.0000 | Direct Fluorescent Ab |
| 87713.0000 | Disposal of Contaminated Matrl |
| 87714.0000 | Freezing Organisms |
| 87715.0000 | Gas Chromatography 1st inject |
| 87716.0000 | Gas Chromatography subs inj |
| 87717.0000 | Gas Pak or Biobag |
| 87718.0000 | Gram Stain Direct from Spec |
| 87719.0000 | Colony Count |
| 87720.0000 | Gram Stain Organism |
| 87721.0000 | Calcofluor White Stain |
| 87722.0000 | Autoclave Control Killet |
| 87723.0000 | Colony Count Fungal |
| 87724.0000 | Media Preparation |
| 87725.0000 | Monitoring Incubator CO2 |
| 87726.0000 | Phadebac |
| 87728.0000 | Phenylalanine Blood Guthrie |
| 87730.0000 | Single Disc for Identification |
| 87732.0000 | Autoclave Control Spordex |
| 87734.0000 | Streptex |
| 87736.0000 | Subculture PBT |
| 87737.0000 | Strep Grp B Latex Agglut |
| 87738.0000 | Strep Grp B Enzyme Immun |
| 87740.0000 | Giardia Lamblia |
| 87741.0000 | Strongyloides |
| 87742.0000 | XV Strips for Haemophilus |
| 87744.0000 | Washing Bench Top |
| 87745.0000 | Biochemical ID |
| 87746.0000 | Abbreviated ID |
| 87747.0000 | Species ID |
| 87748.0000 | Species Typing |
| 87749.0000 | Biochemical ID + Sero |
| 87750.0000 | Organism ID MIC Combo Manual |
| 87751.0000 | Cellophane Tape Prep |
| 87752.0000 | Probe Test |
| 87753.0000 | Non-Immunologic ID |
| 87754.0000 | Gram Stain |
| 87755.0000 | Calcofluor Prep |
| 87756.0000 | Acid Fast Stain |
| 87757.0000 | Tzanck Prep |
| 87758.0000 | Giemsa Stain |
| 87759.0000 | Wet Prep w/o Iodine |
| 87760.0000 | Nucleic Acid Probe |
| 87761.0000 | Nucleic Acid Amplification |
| 87762.0000 | Darkfield |
| 87763.0000 | Agar Dilution |
| 87764.0000 | Diffusion Test |
| 87765.0000 | Disk Diffusion |
| 87766.0000 | Microtiter |
| 87767.0000 | Macrotube |
| 87768.0000 | Microtiter MBC |
| 87769.0000 | Macrotube MBC |
| 87770.0000 | Bactericidal Serum |
| 87771.0000 | Nuclear Molecular Diag |
| 87772.0000 | Enzymatic Digestion |
| 87773.0000 | Interpretation and Report |
| 87799.0000 | DNA Probe |
| 87800.0000 | Accession Specimen Mycol Cult |

VistA Laboratory EPI

Rollup Modifications

Technical and User Manual

| | |
|------------|--------------------------------|
| 87801.0000 | Planting 1 Pc Media Mycol |
| 87802.0000 | Planting 2 Pc Media Mycol |
| 87803.0000 | Planting 3 Pc Media Mycol |
| 87804.0000 | Planting 4 Pc Media Mycol |
| 87805.0000 | Planting each add Pc Mycol |
| 87806.0000 | Culture Urea Plasma |
| 87810.0000 | Reading Mycology Culture |
| 87820.0000 | Recording & Reporting Mycol |
| 87830.0000 | Germ Tube |
| 87832.0000 | Mycology Slide Test |
| 87834.0000 | Yeast Carbohydrate Assimil |
| 87836.0000 | Yeast Morphology Agar |
| 87850.0000 | Accession Specimen Mycob |
| 87851.0000 | Planting 1 Pc Media Mycobact |
| 87852.0000 | Planting 2 Pc Media Myco |
| 87853.0000 | Planting 3 Pc Media Myco |
| 87854.0000 | Planting 4 Pc Media Myco |
| 87856.0000 | Planting each add Pc Myco |
| 87860.0000 | Reading Mycobact Culture |
| 87870.0000 | Recording & Reporting Mycobac |
| 87885.0000 | Mycobacteriology Stains |
| 87886.0000 | Cryptosporidium Spec Stain |
| 87888.0000 | Arylsulfatase 3 Day |
| 87889.0000 | TCH Sensitivity for Microact |
| 87890.0000 | Blastomyces Ab |
| 87891.0000 | Catalase |
| 87892.0000 | Sodium Chloride Tolerance |
| 87893.0000 | Niacin Test |
| 87894.0000 | Nitrate Reduction |
| 87895.0000 | Photochromogenicity Test |
| 87896.0000 | Growth on MacConkey Agar |
| 87897.0000 | Tellurite Reduction |
| 87898.0000 | Tween Hydrolysis |
| 87899.0000 | Susceptibility Test Mycobact |
| 87900.0000 | Accession Specimen Parasitic E |
| 87901.0000 | Candida Species Ab |
| 87902.0000 | Fetoprotein Alpha Tumor |
| 87903.0000 | Micorsporidia Spore |
| 87904.0000 | GM1 IgA |
| 87905.0000 | Myelin Ab |
| 87906.0000 | Sulfatide Ab |
| 87907.0000 | p53 Tumor Suppressor Gene |
| 87910.0000 | Recording & Reporting Parasit |
| 87920.0000 | Concentration of Specimen Para |
| 87925.0000 | Parasitology Examination |
| 87930.0000 | Parasitology Stain |
| 87942.0000 | Extraction of Organism Ag |
| 87943.0000 | TB Specimen |
| 87944.0000 | Heat inactivation |
| 87945.0000 | Sputum Liquification |
| 87946.0000 | Tissue Grinding |
| 87947.0000 | Culture Herpes |
| 87948.0000 | Anaerobe Suscept Test Disk Elu |
| 87949.0000 | Culture Mycoplasma Pneumoniae |
| 87950.0000 | Antimicrobial Assay |
| 87951.0000 | Antimicrobial Assay tube |
| 87952.0000 | Bactericidal Activity |
| 87953.0000 | Hepatitis C Genotyping |
| 87954.0000 | Sensitivity Testing or MIC |

VistA Laboratory EPI

Rollup Modifications

Technical and User Manual

| | |
|------------|--------------------------------|
| 87956.0000 | Sensitivity Testing Broth |
| 87958.0000 | Sensitivity Testing Kirby |
| 87960.0000 | Accession Specimen for Viral C |
| 87964.0000 | Parvovirus B19 |
| 87965.0000 | Recording & Reporting Viral Cu |
| 87966.0000 | Media Prep Basal Medium |
| 87967.0000 | Media Prep Each Additive |
| 87968.0000 | Media Prep Basal Medium (500m |
| 87969.0000 | Virus Specimen Collection |
| 87970.0000 | Tzanck Test Viral Inclusions |
| 87971.0000 | Shell Vial Technique |
| 87972.0000 | Decontamination of Specimen |
| 87973.0000 | Viral Neutralization |
| 87974.0000 | Tissue Culture Feeding |
| 87975.0000 | Cytomegalovirus Culture |
| 87976.0000 | Tissue Culture Passage |
| 87978.0000 | Tissue Culture Reading |
| 87980.0000 | Tissue Culture Specimen |
| 87982.0000 | Tissue Culture Viral |
| 87984.0000 | Clostridium Difficile Toxin A |
| 87985.0000 | Report Microbiology |
| 87986.0000 | Fluconazole MIC |
| 87987.0000 | Thermocatinomyces Sacchari |
| 87988.0000 | Chlamydia T + Neisseria G DNA |
| 87989.0000 | Thermoactinomyces Vulgaris Ab |
| 87990.0000 | Anerobe Identification |
| 87991.0000 | Micro Smear Prep |
| 87992.0000 | Micro Serology |
| 87993.0000 | Micro Bacteriology Culture |
| 87994.0000 | Micro Mycology Culture |
| 87995.0000 | Micro Mycobacterium Culture |
| 87996.0000 | Micro Virology Culture |
| 87997.0000 | Micro Non Billable |
| 87998.0000 | Micro Anerobic Culture |
| 87999.0000 | Micro Misc Culture |
| 88000.0000 | SP Specimen |
| 88001.0000 | Alcoholic Hyaline Stain G3 |
| 88002.0000 | Amido Black Hemoglobin Stain |
| 88003.0000 | Amyloid Stain Group1 |
| 88004.0000 | Argentaffin Stain |
| 88005.0000 | Bielschowsky Stain Group 6 |
| 88006.0000 | Bile Stain or Gmelin Stain |
| 88007.0000 | Bodian Stain Group2 |
| 88008.0000 | Bowie Juxt Glom Stain |
| 88009.0000 | Calcium Stain Group1 |
| 88010.0000 | Cone and Penfield Stain |
| 88011.0000 | Connective Tissue Masson |
| 88012.0000 | Crystal Violet Stain |
| 88013.0000 | DNA Feulgin Stain |
| 88014.0000 | Elastic Tissue Verhoeff Stain |
| 88015.0000 | Enzymes Stain Group3 |
| 88016.0000 | Fat Neutral Nile Blue |
| 88017.0000 | Fatty Acid Fischler Stain |
| 88018.0000 | Acid Fast Incl Auromine O |
| 88019.0000 | Acridine Orange Fungus Stain |
| 88020.0000 | Fungus Gridley Stain |
| 88021.0000 | Fungus Silver Stain Group3 |
| 88022.0000 | Giemsa Stain Group1 |
| 88023.0000 | Glees and Marsland Stain |

VistA Laboratory EPI

Rollup Modifications

Technical and User Manual

| | |
|------------|--------------------------------|
| 88024.0000 | Glycogen Stain Group2 |
| 88025.0000 | Gram Stain Group2 |
| 88026.0000 | Halls Stain Group1 Anat |
| 88027.0000 | Hemosiderin Stain Group1 |
| 88028.0000 | Holmes Stain Group4 |
| 88029.0000 | Holzer Stain Group4 |
| 88030.0000 | Mucin Mucicrum PAS or Alcian |
| 88031.0000 | Russell MOVAT Mod |
| 88032.0000 | Lendrums Phloxrin Tartrazine S |
| 88033.0000 | Lipofuscin Stain Group2 |
| 88034.0000 | Manns Stain Group2 |
| 88035.0000 | Masson Trichrome Stain |
| 88036.0000 | Mast Cells Stain Group1 |
| 88037.0000 | Melanin Stain Group |
| 88038.0000 | PAS ALCIAN BLUE |
| 88039.0000 | Myelin Heidenhain Stain |
| 88040.0000 | Autopsy Attendant |
| 88041.0000 | Myelin Luxol Fast Blue Stain |
| 88042.0000 | Myelin Marchi Stain |
| 88043.0000 | PTAH Stain Group1 |
| 88044.0000 | PAS STAIN |
| 88045.0000 | Initial Handling Clerical Aut |
| 88046.0000 | Oil Red O Stain Group2 |
| 88047.0000 | Orcein Giemsa Stain Group3 |
| 88048.0000 | Spirochete Silver Stain |
| 88049.0000 | PTAH Neuropath Stain Group2 |
| 88050.0000 | Sections Paraffin Aut compl |
| 88051.0000 | Reticulin Stain Group3 |
| 88052.0000 | Romanes Stain Group3 |
| 88053.0000 | Saffron Stain Group2 |
| 88054.0000 | Unna Pappenheim Stain Group1 |
| 88055.0000 | Sections Paraffin Aut Slide |
| 88056.0000 | CY Specimen |
| 88057.0000 | EM Specimen |
| 88058.0000 | Immunoperoxidase Stain |
| 88059.0000 | Immunofluorescence Stain |
| 88060.0000 | Sections Paraffin Aut (Cut) |
| 88061.0000 | Misc AP Test 1 |
| 88062.0000 | Misc AP Test 2 |
| 88063.0000 | Misc AP Test 3 |
| 88064.0000 | Misc AP Test 4 |
| 88065.0000 | Misc AP Test 5 |
| 88066.0000 | Instrument AP Setup |
| 88067.0000 | Unstained Slide |
| 88068.0000 | Calreticulin |
| 88069.0000 | Cytokeratin 2D |
| 88070.0000 | Tissue Culture |
| 88071.0000 | Consultation and Report |
| 88072.0000 | Picornavirus |
| 88073.0000 | Filarial Ab |
| 88074.0000 | Leishmania Donovan Ab |
| 88075.0000 | Phosphoserine |
| 88076.0000 | Smith Ab |
| 88077.0000 | HLA A3 |
| 88078.0000 | English Plantain |
| 88079.0000 | English Plantain IgE |
| 88080.0000 | Agar Dilution E Test |
| 88081.0000 | HFE C282Y |
| 88082.0000 | HFE H63D |

VistA Laboratory EPI

Rollup Modifications

Technical and User Manual

| | |
|------------|--------------------------------|
| 88083.0000 | Ribonucleoprotein Ab |
| 88084.0000 | Polio Type 1 Ab |
| 88085.0000 | Polio Type 1 Ag |
| 88086.0000 | Polio Type 2 Ag |
| 88087.0000 | Polio Type 2 Ab |
| 88088.0000 | Polio Type 3 Ab |
| 88089.0000 | Polio Type 3 Ag |
| 88090.0000 | Latex IgE |
| 88125.0000 | Forensic Cytopathology |
| 88150.0000 | PAP Smear |
| 88151.0000 | PAP Thin Prep Cyto Interp |
| 88152.0000 | PAP Thin Prep Phy Interp |
| 88160.0000 | Hormonal Evaluation Cytology |
| 88161.0000 | Sperm Isolation |
| 88190.0000 | Slides Cytology Preparation |
| 88191.0000 | Smear Cyto Prep Pick&Smear |
| 88192.0000 | Smear and or Cell Block Cytol |
| 88200.0000 | Electron Micro Preparation |
| 88202.0000 | Electron Micro Embedding |
| 88204.0000 | Electron Micro Scan and Photo |
| 88206.0000 | Electron Micro Thick Section |
| 88208.0000 | Electron Micro Thin Section |
| 88230.0000 | Chromosome Karyotype Amni Comp |
| 88231.0000 | Chromosome Karyotype Amniot |
| 88232.0000 | Chromosome Karyotype Per Blood |
| 88233.0000 | Chromosome Karyotype Peri Bl |
| 88234.0000 | Chromosome Karyotype BM Leuk |
| 88235.0000 | Chromosome Karyotype Bone Mar |
| 88236.0000 | Chromosome Karyotype Tiss 1st |
| 88237.0000 | Chromosome Karyotype Tissue |
| 88238.0000 | Chromosome Karyotype Tiss Com |
| 88239.0000 | Chromosome Karyotype AST |
| 88240.0000 | Fine Needle Aspirate |
| 88241.0000 | Chromosome Karyotype |
| 88244.0000 | PAI Genetics |
| 88245.0000 | Sex Chromatin Smears |
| 88257.0000 | Autoradiography |
| 88282.0000 | Cystine Urine |
| 88300.0000 | Stain Group1 |
| 88305.0000 | Stain Group2 |
| 88306.0000 | Brown & Brenin Stain |
| 88307.0000 | C Schenk Stain |
| 88308.0000 | Iron Stain Colloidal |
| 88309.0000 | Fite Stain |
| 88310.0000 | Stain Group3 |
| 88311.0000 | Mallory Heidenhaim Stain |
| 88312.0000 | Mallory Collagen Stain |
| 88313.0000 | Methyl Green Stain |
| 88314.0000 | Maxwell Stain |
| 88315.0000 | Stain Group4 |
| 88316.0000 | Papanicolaou Stain |
| 88317.0000 | Wilson Ezrin Stain |
| 88318.0000 | Pentachrome Movat Stain |
| 88319.0000 | Mucicarmine Stain |
| 88320.0000 | Stain Group5 |
| 88321.0000 | Warthin Starry Stain |
| 88322.0000 | Myeloperoxidase Stain |
| 88325.0000 | Stain Group6 |
| 88326.0000 | Stain Only H & E |

VistA Laboratory EPI

Rollup Modifications

Technical and User Manual

| | |
|------------|--------------------------------|
| 88327.0000 | Steiner Stain |
| 88328.0000 | B72.3 |
| 88329.0000 | Ber-Ep4 |
| 88330.0000 | GCDFP-15 |
| 88331.0000 | Properdin |
| 88332.0000 | Dieterle Stain |
| 88333.0000 | Steiner&Steiner |
| 88343.0000 | Case Review Surg or Autopsy |
| 88344.0000 | Case Review Cytology |
| 88350.0000 | Frozen Section Rush Dx |
| 88353.0000 | Frozen Section Add Rush Block |
| 88354.0000 | Frozen Section Not Rush |
| 88355.0000 | Frozen Section Add Section |
| 88356.0000 | Body Brushing |
| 88357.0000 | Body Fluid Exam |
| 88358.0000 | Washing Fluid Exam |
| 88360.0000 | Frozen Section Add Cut |
| 88363.0000 | Sections Plastic Complete |
| 88365.0000 | Sections Paraffin SP Cut |
| 88366.0000 | Thyroid Transcription Factor |
| 88375.0000 | Tissue Processing Plastic Emb |
| 88410.0000 | Chromosome Karotype Stimulated |
| 88420.0000 | Decalcification Tissue |
| 88430.0000 | Photographs Gross Specimen |
| 88435.0000 | Photography Print Enlarge |
| 88493.0000 | Temperature Patient |
| 88499.0000 | Scanning EM Analysis |
| 88500.0000 | Gross Surgical Description Lev |
| 88501.0000 | Gross Surgical Tech Assistance |
| 88502.0000 | Tissue Preparation |
| 88503.0000 | Gross & Microscopic Pathology |
| 88504.0000 | Interpretation CytoPath |
| 88505.0000 | Cytopathology Procedures NOS |
| 88506.0000 | Buccal Smear |
| 88507.0000 | Consultation Referred Slides |
| 88508.0000 | Consultation Referred Specimen |
| 88509.0000 | Stain Cytology Extended |
| 88510.0000 | Pathology Surgery Consult |
| 88511.0000 | Gross & Microscopic Pathology |
| 88512.0000 | Gross & Microscopic Pathology |
| 88513.0000 | Gross & Microscopic Pathology |
| 88514.0000 | Gross & Microscopic Pathology |
| 88515.0000 | Surgical Pathology Procedures |
| 88516.0000 | Homogenization Tissue |
| 88517.0000 | Tissue Preparation Drug |
| 88518.0000 | Surgical Pathology Level II |
| 88520.0000 | Surgical Path Init Handling |
| 88522.0000 | Transcription File Search Retr |
| 88524.0000 | Transcription Report Prep only |
| 88526.0000 | Transcription Report Disp |
| 88528.0000 | Sections Paraffin Surg Path |
| 88529.0000 | Autopsy Gross Only |
| 88530.0000 | Stain H&E Automated |
| 88531.0000 | Autopsy Complete w/o Brain |
| 88532.0000 | Autopsy Complete with Brain |
| 88533.0000 | Autopsy Complete with Brain/CN |
| 88534.0000 | Autopsy Limited |
| 88535.0000 | Sections Diagnostic Thick |
| 88536.0000 | Sections Thin EM |

VistA Laboratory EPI

Rollup Modifications

Technical and User Manual

| | |
|------------|--------------------------------|
| 88537.0000 | Fine Needle Consult |
| 88538.0000 | Cytogenetic |
| 88539.0000 | Specimen |
| 88540.0000 | History |
| 88541.0000 | Clinical History |
| 88542.0000 | Brief Clinical History |
| 88543.0000 | Diagnosis |
| 88544.0000 | Diagnosis PreOp |
| 88545.0000 | Findings |
| 88546.0000 | Findings PreOp |
| 88547.0000 | Findings PostOp |
| 88548.0000 | Description |
| 88549.0000 | Description Gross |
| 88550.0000 | Initial Handling Cytology (Gyn |
| 88551.0000 | Surgical Pathology Level I |
| 88552.0000 | Initial Handling Cyto (Non Gyn |
| 88553.0000 | Surgical Pathology Level III |
| 88554.0000 | Stain Cytology Routine |
| 88555.0000 | Surgical Pathology Level IV |
| 88556.0000 | Stain Cyto Membrane Filt Prep |
| 88557.0000 | Surgical Pathology Level V |
| 88558.0000 | Stain Cyto Rapid Pap or H&E |
| 88559.0000 | Surgical Pathology Level VI |
| 88560.0000 | Stain Cyto Romanowski Diff Qui |
| 88561.0000 | Cytology Misc |
| 88562.0000 | File Search Update Cytology |
| 88563.0000 | Description Micro |
| 88564.0000 | Report Record File Cytology |
| 88565.0000 | Section |
| 88566.0000 | Cell Block Cytology |
| 88567.0000 | Coccidioides IgM |
| 88568.0000 | Smear Cyto Prep of Spec Saccom |
| 88569.0000 | Frozen Section |
| 88570.0000 | Smear Cyto Prep of Fluid Centr |
| 88571.0000 | Diagnosis Pathology |
| 88572.0000 | Smear Cyto Cytocentrifugation |
| 88573.0000 | Report Pathology |
| 88574.0000 | Smear Cyto Simple Special Proc |
| 88575.0000 | Report Preliminary |
| 88576.0000 | Smear Cyto Complicated Sp Proc |
| 88577.0000 | Cytology Smear GYN |
| 88578.0000 | Screen Cyto Tech Interp Neg Gy |
| 88579.0000 | Cytology Smears |
| 88580.0000 | Screen Cyto Tech Interp Abn Gy |
| 88581.0000 | Nerve Tissue |
| 88582.0000 | Screen Cyto Tech Interp Memb F |
| 88583.0000 | Report Final |
| 88584.0000 | Screen Cyto NonGyn CMC<50% |
| 88585.0000 | Report Amended |
| 88586.0000 | Screen Cyto NonGyn CMC>50% |
| 88587.0000 | Report Partial |
| 88588.0000 | Screen Cyto Tech Interp Cell B |
| 88589.0000 | Report Supplemental |
| 88590.0000 | Screen Cyto Tech Interp Sp St |
| 88591.0000 | Diagnosis PostOp |
| 88592.0000 | Screen Cyto Tech. Interp. Sp. |
| 88593.0000 | Report Cytology |
| 88594.0000 | Differential Cell Count Cyto |
| 88596.0000 | Screen Cyto Rescreen Neg Gyn (|

VistA Laboratory EPI

Rollup Modifications

Technical and User Manual

| | |
|------------|--------------------------------|
| 88597.0000 | Report Electron Microscopy |
| 88598.0000 | Report Histology |
| 88599.0000 | FISH Interphase |
| 88601.0000 | Report Immunology |
| 88602.0000 | Report Laboratory |
| 88603.0000 | Consultation and Report, Compr |
| 88605.0000 | Cell Block Any Source |
| 88606.0000 | Autopsy Single Organ |
| 88607.0000 | Autopsy Forensic Exam |
| 88608.0000 | Autopsy Exam NOS |
| 88609.0000 | Cytology Smear GYN Auto Thin M |
| 88610.0000 | Cytology Smear GYN Phy Interp |
| 88612.0000 | Cytology Smear non GYN <5 Slid |
| 88613.0000 | Cytology Smear non GYN >5 Slid |
| 88615.0000 | Sudan Black Stain |
| 88616.0000 | Fine Needle Aspirate Deep Guid |
| 88617.0000 | Estrogen/Progesterone Receptor |
| 88618.0000 | Coxsackie |
| 88619.0000 | Sacchromyces |
| 88620.0000 | Sacchromyces Ab |
| 88621.0000 | Sperm Ab |
| 88622.0000 | Sacchromyces Cerevisiae Ab |
| 88623.0000 | Spinocerebellar Ataxia 2 |
| 88624.0000 | Proline Beta Alanine |
| 88625.0000 | Machado Joseph Disease |
| 88626.0000 | Myelin Associated Glycoprotein |
| 88627.0000 | Fascio Scapulo Humoral Dystrop |
| 88628.0000 | Creutzfeldt Jakob Disease |
| 88629.0000 | Echovirus 6 Ab |
| 88630.0000 | Echovirus 7 Ab |
| 88631.0000 | Ethidium Monoazide |
| 88632.0000 | Rast Profile |
| 88633.0000 | Pork |
| 88634.0000 | Wheat Bran Ab IgG |
| 88635.0000 | Milk (cow) |
| 88636.0000 | Milk (cow) Ab IgG |
| 88637.0000 | Wheat |
| 88638.0000 | Corn |
| 88639.0000 | Peanut |
| 88640.0000 | Soybean |
| 88641.0000 | Beef |
| 88642.0000 | Fish/Sea Food |
| 88643.0000 | Shell Fish |
| 88644.0000 | Fish/Shell |
| 88645.0000 | Egg |
| 88646.0000 | Egg White |
| 88647.0000 | Spinocerebellar Ataxia 3 |
| 88648.0000 | Spinocerebellar Ataxia 7 |
| 88649.0000 | Egg White Ab IgG |
| 88650.0000 | Bladder Tumor |
| 88651.0000 | Borrelia Pertussis |
| 88652.0000 | Leptospira Australis |
| 88653.0000 | Leptospira Australis Ab |
| 88654.0000 | Presenilin 1 Allele1 |
| 88655.0000 | Presenilin 1 Allele2 |
| 88656.0000 | Streptococcus Pneumoniae 1 |
| 88657.0000 | Streptococcus Pneumoniae 2 |
| 88658.0000 | Streptococcus Pneumoniae 19 |
| 88659.0000 | Streptococcus Pneumoniae 14 |

VistA Laboratory EPI

Rollup Modifications

Technical and User Manual

| | |
|------------|--------------------------------|
| 88660.0000 | Streptococcus Pneumoniae 23 |
| 88661.0000 | Streptococcus Pneumoniae 51 |
| 88662.0000 | IgG Subsets 2 |
| 88663.0000 | IgG Subsets 3 |
| 88664.0000 | Echovirus 2 Ab |
| 88665.0000 | Echovirus 3 Ab |
| 88666.0000 | Echovirus 8 Ab |
| 88667.0000 | Echovirus 16 |
| 88668.0000 | Fitzgerald Factor |
| 88669.0000 | Fine Needle Aspirate Pathologi |
| 88670.0000 | PAS Stain Micro |
| 88671.0000 | Orcein Giemsa Stain Micro |
| 88672.0000 | Giemsa Stain Micro |
| 88673.0000 | Fite Stain Micro |
| 88674.0000 | Cytology Smear Any Source |
| 88675.0000 | Cytology Smear Auto Rescreen b |
| 88676.0000 | Cytology Smear Computer Rescre |
| 88677.0000 | Cytology Smear Auto Man/Comput |
| 88678.0000 | Cytology Smear Auto by Phy |
| 88679.0000 | Cytology Smear Auto/Man Rescr |
| 88680.0000 | Cytology Smear Bethesda Rescr |
| 88681.0000 | Cytology Smear Bethesda Rescr |
| 88682.0000 | Cytology Smear Bethesda Rescr |
| 88683.0000 | GD1B Elisa |
| 88684.0000 | GQ1B Elisa |
| 88685.0000 | Sensorimotor Neuropathy Profil |
| 88686.0000 | Beta 2 Glycoprotein IgG Ab |
| 88687.0000 | Beta 2 Glycoprotein IgA Ab |
| 88688.0000 | Beta 2 Glycoprotein IgM Ab |
| 88689.0000 | EGFR-Paraffin |
| 88690.0000 | ER-IHC/Paraffin |
| 88691.0000 | PR-IHC/Paraffin |
| 88692.0000 | Micropolyspora faeni Ab |
| 88693.0000 | Aspergillus pullulans Ab |
| 88694.0000 | Toxoplasma IgG Ab, CSF |
| 88695.0000 | Toxoplasma IgM Ab, CSF |
| 88696.0000 | Spinocerebellar Ataxia 8 |
| 88697.0000 | Spinocerebellar Ataxia 10 |
| 88698.0000 | DRPLA DNA |
| 88757.0000 | Cytology Smear non GYN |
| 88885.0000 | Misc Stain 4 |
| 88886.0000 | Misc Stain 5 |
| 88887.0000 | Misc Stain 6 |
| 88888.0000 | Misc Stain 7 |
| 88889.0000 | Misc Stain 8 |
| 88890.0000 | Misc Stain 9 |
| 88891.0000 | Misc Stain 10 |
| 88978.0000 | Febrile Agglutinins Panel |
| 88979.0000 | St Louis Equine Encephalitis I |
| 88980.0000 | St Louis Equine Encephalitis I |
| 88981.0000 | La Crosse Virus IGM |
| 88982.0000 | La Crosse Virus IGG |
| 88983.0000 | La Crosse Virus Ab |
| 88984.0000 | Eastern Equine Encephalitis IG |
| 88985.0000 | Eastern Equine Encephalitis IG |
| 88986.0000 | Dengue Virus Ab IGM |
| 88987.0000 | Dengue Virus Ab IGG |
| 88988.0000 | Galop Auto Ab |
| 88989.0000 | HIV 2 |

VistA Laboratory EPI

Rollup Modifications

Technical and User Manual

| | |
|------------|------------------------------|
| 88990.0000 | HIV Quant |
| 88991.0000 | HIV Qual |
| 88992.0000 | Herpes Virus VI IgG IgM |
| 88993.0000 | Rubella Titer |
| 88995.0000 | APC GENE MUTATION |
| 88996.0000 | Complement Total |
| 88997.0000 | Hepatitis G Ab |
| 88998.0000 | Charcot Marie Tooth Profile |
| 88999.0000 | Interferon Alpha Receptor |
| 89000.0000 | Surface Marker Leu9 |
| 89001.0000 | Surface Marker B4 |
| 89002.0000 | Surface Marker My10 |
| 89003.0000 | Surface Marker KC56 |
| 89004.0000 | Neutrophil Cytoplasm |
| 89005.0000 | Farmer's Lung |
| 89006.0000 | Histone |
| 89007.0000 | Hypersensitivity Aspergillus |
| 89008.0000 | Hypersensitivity Pneumonitis |
| 89009.0000 | Alpha Pituitary G Hormone |
| 89010.0000 | Alphal Antitrypsin Clearance |
| 89011.0000 | Anti Adrenal Ab |
| 89012.0000 | Anti Dnase B |
| 89013.0000 | DS DNA Ab |
| 89014.0000 | Anti Single Stranded DNA |
| 89015.0000 | Anti Thyroglobulin Ab |
| 89016.0000 | Anti Diuretic Hormone |
| 89017.0000 | Antineuronal Nuclear Ab |
| 89018.0000 | Anti Streptolysin O |
| 89019.0000 | Aspergillus Complement Titer |
| 89020.0000 | Blastomyces Complement Titer |
| 89021.0000 | Legionella IFA Ab |
| 89022.0000 | Coccidioides Complement Fix |
| 89023.0000 | Complement C9 |
| 89024.0000 | Febrile Agglutinins |
| 89025.0000 | GM1 Autoantibody |
| 89026.0000 | Immunocytochemistry |
| 89027.0000 | Legionella Ag |
| 89028.0000 | Lupus Anticoagulant |
| 89029.0000 | Lyme Disease |
| 89030.0000 | Measles Rubeola titer |
| 89031.0000 | Monospot Screen |
| 89032.0000 | Polymyositis Ab |
| 89033.0000 | Purkinje Cell Ab |
| 89034.0000 | Rocky Mountain Spotted Fever |
| 89035.0000 | Tetanus Ab EIA |
| 89036.0000 | Tularmia Agglutination |
| 89037.0000 | Typhus Ab Titer |
| 89038.0000 | Anti Microsomal Ab |
| 89039.0000 | Anti Nuclear Ab |
| 89040.0000 | Oligoclonal bands |
| 89041.0000 | Psittacosis |
| 89042.0000 | Endomysial Ab |
| 89043.0000 | Surface Marker CD30 |
| 89044.0000 | Surface Marker CD15 Leu M1 |
| 89045.0000 | Surface Marker CD11c |
| 89046.0000 | Anti Myocardial Ab |
| 89047.0000 | Surface Marker CD25 |
| 89048.0000 | Surface Marker FMC-7 |
| 89049.0000 | Anti Mitochondrial Ab |

VistA Laboratory EPI

Rollup Modifications

Technical and User Manual

| | |
|------------|---------------------------------|
| 89050.0000 | Cell Count Body Fluid |
| 89051.0000 | Cell Count with Film |
| 89052.0000 | Anti Parietal Cell Ab |
| 89053.0000 | Anti Glomerular Basement Membr |
| 89054.0000 | Anti Smooth Muscle Ab |
| 89055.0000 | Anti Cardiolipin Ab |
| 89056.0000 | Anti Viral Ab |
| 89057.0000 | Anti Skin Ab |
| 89058.0000 | Histone Reaction Ab |
| 89059.0000 | Diphtheria Antitoxoid ELISA |
| 89060.0000 | Pneumococcal IgG Vaccine Respo |
| 89061.0000 | Tetanus Antitoxoid ELISA |
| 89062.0000 | HLA DR2 |
| 89063.0000 | Legionella Urinary Ag |
| 89064.0000 | Hepatitis A Ab |
| 89065.0000 | Hepatitis B Core Ab |
| 89066.0000 | Hepatitis B Core Ag |
| 89067.0000 | Hepatitis B Surface Ab |
| 89068.0000 | Hepatitis B Surface Ag |
| 89069.0000 | Hepatitis B Virus DNA |
| 89070.0000 | Hepatitis C Ab |
| 89071.0000 | HIV Ag |
| 89072.0000 | HIV Ab |
| 89073.0000 | CA-15-3 |
| 89074.0000 | MAG Autoantibody |
| 89075.0000 | Protein S activity |
| 89076.0000 | Protein S, Total |
| 89077.0000 | Protein S, free |
| 89078.0000 | RAST test |
| 89079.0000 | Acetylcholine REC Blocking Ab |
| 89080.0000 | Acetylcholine receptor |
| 89081.0000 | T cell subsets |
| 89082.0000 | Cell surface markers |
| 89083.0000 | Hepatitis A IgM Ab |
| 89084.0000 | Immunodiffusion, histoplasmosi |
| 89085.0000 | Immunodiffusion, aspergillosis |
| 89086.0000 | Immunodiffusion, blastomycosis |
| 89087.0000 | Immunodiffusion, candidiosis |
| 89088.0000 | Immunodiffusion, coccidioidiosi |
| 89089.0000 | EIA Clostridium diff tox A or |
| 89090.0000 | Latex agglut Clostridium diffi |
| 89091.0000 | Direct FA, Chlamydia trachomat |
| 89092.0000 | EIA, Chlamydia trachomatis |
| 89093.0000 | Hepatitis B, early Ab |
| 89094.0000 | Hepatitis B, early Ag |
| 89095.0000 | Hepatitis B core IgM Ab |
| 89096.0000 | FTA ABS |
| 89097.0000 | MHA TP |
| 89098.0000 | HIV 1 by EIA |
| 89099.0000 | HIV 1 by Western Blot |
| 89100.0000 | HIV 1 by IFA |
| 89101.0000 | HIV 1 P24 Ag by EIA |
| 89102.0000 | HTLV 1 Ab by EIA |
| 89103.0000 | Lymes Ab by EIA |
| 89104.0000 | Lymes Ab by IFA |
| 89105.0000 | Nordoxepin done by GC |
| 89106.0000 | Rapid Plasma Reagin |
| 89107.0000 | Pneumococcal Ab |
| 89108.0000 | Rabies Ab |

VistA Laboratory EPI

Rollup Modifications

Technical and User Manual

| | |
|------------|-------------------------------|
| 89109.0000 | Poliovirus Ab |
| 89110.0000 | Drug Dependent Ab |
| 89111.0000 | Mumps Immune Status |
| 89112.0000 | Chlamydia Titer |
| 89113.0000 | Helicobacter pylori Serology |
| 89114.0000 | Antitrypsin alpha 1 phenotype |
| 89115.0000 | Heparin dependent Ab |
| 89116.0000 | Viral serology panel |
| 89117.0000 | Striated Muscle Ab |
| 89118.0000 | Misc Immuno Test 1 |
| 89119.0000 | Misc Immuno Test 2 |
| 89120.0000 | Misc Immuno Test 3 |
| 89121.0000 | Misc Immuno Test 4 |
| 89122.0000 | Misc Immuno Test 5 |
| 89123.0000 | Instrument IM Setup |
| 89124.0000 | Hepatitis C RNA by PCR |
| 89125.0000 | Myasthenia Gravis Panel |
| 89126.0000 | Heparin dependent Platelet Ab |
| 89127.0000 | Hepatitis B Delta Ab, IgG |
| 89128.0000 | Hepatitis B Delta Ab, IgM |
| 89129.0000 | Hepatitis B Delta Ag |
| 89130.0000 | Gastric Contents |
| 89131.0000 | Toxoplasma Ab CSF |
| 89132.0000 | Toxoplasma Ab IgG |
| 89133.0000 | Toxoplasma Ab IgM |
| 89134.0000 | Sulfatide Autoantibody |
| 89135.0000 | DNA Ploidy |
| 89136.0000 | Hantavirus |
| 89137.0000 | Multiple Sclerosis Panel |
| 89138.0000 | Complement C3/C4 Panel |
| 89139.0000 | Immunoglobulin Panel NOS |
| 89140.0000 | Report Delivery |
| 89141.0000 | Interleukin 6 Receptor |
| 89142.0000 | Report Charting |
| 89143.0000 | Gowning Degowning |
| 89144.0000 | Specimen Rejection |
| 89145.0000 | Gowning Degowning Only |
| 89146.0000 | Surface Marker Panel |
| 89147.0000 | Gluten Sensitivity Eval |
| 89148.0000 | Hepatitis Immuno Panel |
| 89149.0000 | Varicella Immune Status |
| 89150.0000 | Gloving Degloving |
| 89151.0000 | Hepatitis A, IgG Ab |
| 89152.0000 | Kappa/Lambda Ratio |
| 89153.0000 | Candida Precipitan Ab titer |
| 89154.0000 | FMC7 |
| 89155.0000 | VDRL |
| 89156.0000 | Hepatitis E Ab |
| 89157.0000 | Hepatitis E Ag |
| 89158.0000 | Sjorgren's Ab |
| 89159.0000 | Sjorgren's Ag |
| 89160.0000 | Ribonucleic Protein Ab |
| 89161.0000 | Ribonucleic Protein Ag |
| 89162.0000 | Serology Specimen |
| 89163.0000 | Immuno Specimen |
| 89164.0000 | Flow Specimen |
| 89165.0000 | Sp Flow Specimen |
| 89166.0000 | Ehrlichiosis Ab |
| 89167.0000 | Hemophilus Influenza |

VistA Laboratory EPI

Rollup Modifications

Technical and User Manual

| | |
|------------|--------------------------------|
| 89168.0000 | Ehrlichiosis Ag |
| 89169.0000 | TdT |
| 89170.0000 | HTLV I |
| 89171.0000 | TORCH Ab Panel |
| 89172.0000 | HTLV II |
| 89173.0000 | HTLV I/HTLV II |
| 89174.0000 | Brucella Ab |
| 89175.0000 | Herpes Ab |
| 89176.0000 | Helicobacter pylori Ab |
| 89177.0000 | Leishmania Ab |
| 89178.0000 | Listeria Ab |
| 89179.0000 | Skin Test NOS |
| 89180.0000 | HIV 1 RNA Quant |
| 89181.0000 | Tetanus Ab |
| 89182.0000 | Diphtheria Ab |
| 89183.0000 | Toxoplasma Ab |
| 89184.0000 | CD14/CD45 |
| 89185.0000 | CD2/CD20 |
| 89186.0000 | CD19/CD10 |
| 89187.0000 | CALLA |
| 89188.0000 | CD19/CALLA |
| 89189.0000 | CD3/CD8 |
| 89190.0000 | CD3/CD4 |
| 89191.0000 | CD19/CD5 |
| 89192.0000 | CD22/CD3 |
| 89193.0000 | CD10/CD34 |
| 89194.0000 | CD7/CD13/CD33 |
| 89195.0000 | Flow Cytometry |
| 89196.0000 | Fasciola Hepatica Ab |
| 89197.0000 | Anti Nuclear Ab Quant |
| 89198.0000 | Lyme Ab Quant |
| 89199.0000 | Immunoglobulin Heavy Chain Gen |
| 89200.0000 | HCV Ab Quant |
| 89201.0000 | Lyme Ab |
| 89202.0000 | Lyme Ab IgG |
| 89203.0000 | Lyme Ab IgG Quant |
| 89204.0000 | Lyme Ab IgM |
| 89205.0000 | Lyme Ab IgM Quant |
| 89206.0000 | Rubella Ab |
| 89207.0000 | Rubella Ab Quant |
| 89208.0000 | Extractable Nuclear Ag RNP Qua |
| 89209.0000 | Extractable Nuclear Ag Sci 70 |
| 89210.0000 | Extractable Nuclear Ag Sm Qt |
| 89211.0000 | Mycoplasma Pneumoniae Ab IgG |
| 89212.0000 | Mycoplasma pneumoniae Ab IgM |
| 89213.0000 | Streptozyme Qt |
| 89214.0000 | Leukemia Panel Acute |
| 89215.0000 | Leukemia Panel Chronic |
| 89216.0000 | Leukemia Panel Hairy |
| 89217.0000 | Cancer Ag 27.29 |
| 89218.0000 | Pneumonitis Hypersensitivity |
| 89219.0000 | Gardnerella Vaginalis |
| 89220.0000 | Scleroderma Ab Quant |
| 89221.0000 | Streptozyme Ab Quant |
| 89222.0000 | T Cell Receptor |
| 89223.0000 | Beta 2 Glycoprotein 1 Ab |
| 89224.0000 | Western Blot |
| 89225.0000 | HIV Genotype |
| 89226.0000 | Complexed Prostate Specific Ag |

VistA Laboratory EPI

Rollup Modifications

Technical and User Manual

| | |
|------------|--------------------------------|
| 89227.0000 | Varicella Rapid Culture |
| 89228.0000 | HCV Genotyping |
| 89229.0000 | Cell Viability |
| 89230.0000 | Fat Stain |
| 89231.0000 | Tumor Necrosis Factor |
| 89232.0000 | HIV 1 Proviral DNA PCR |
| 89233.0000 | Toxoplasmosis Ab, IgA&IgM |
| 89234.0000 | Proteinase 3 Ab |
| 89235.0000 | HIV 1 and HIV 2 |
| 89236.0000 | HIV 1 |
| 89237.0000 | Epstein Barr Ab IgG |
| 89238.0000 | Signal Recognition Particle Au |
| 89239.0000 | Epstein Barr Ab IgM |
| 89240.0000 | Proliferating Cell Nuclear Ab |
| 89241.0000 | Herpes Virus VI IgG |
| 89242.0000 | Herpes Virus VI IgM |
| 89243.0000 | Centromere Ab |
| 89244.0000 | von Hippel Lindau |
| 89245.0000 | T Cell Receptor Alpha |
| 89246.0000 | T Cell Receptor Beta |
| 89247.0000 | T Cell Receptor Gamma |
| 89248.0000 | T Cell Receptor Delta |
| 89249.0000 | Centromere Ab Titer |
| 89250.0000 | GM1 IgG |
| 89251.0000 | Asialo GM1 IgG |
| 89252.0000 | GM1 IgM |
| 89253.0000 | Asialo GM1 IgM |
| 89254.0000 | GM1 Panel |
| 89255.0000 | X*Hypersensitive Pneumonitis |
| 89256.0000 | Neocerebellar Degeneration Pro |
| 89257.0000 | HCV 5-1-1 Ab |
| 89258.0000 | HCV C33C Ab |
| 89259.0000 | HCV C22-3 Ab |
| 89260.0000 | HCV NS5 Ab |
| 89261.0000 | HCV RIBA Panel |
| 89262.0000 | HCV Panel Interp |
| 89264.0000 | Lyme Ab IgG/IgM |
| 89265.0000 | Microspordin Stain |
| 89266.0000 | Mumps Ab |
| 89267.0000 | Mumps Ab IgM |
| 89268.0000 | CD3/CD16*CD56 |
| 89269.0000 | Basement Membrane |
| 89270.0000 | Basement Membrane Ab |
| 89272.0000 | CD20 Percent |
| 89273.0000 | Lymphocyte B |
| 89274.0000 | Lymphocyte T Percent |
| 89275.0000 | CA 27 29 |
| 89276.0000 | CA 72-4 |
| 89277.0000 | CD2 Percent |
| 89278.0000 | CD3-CD16+CD56+ Absolute |
| 89279.0000 | CD3-CD16+CD56+ Percent |
| 89280.0000 | Echovirus 4 Ab |
| 89281.0000 | Echovirus 9 Ab |
| 89282.0000 | Echovirus 11 Ab |
| 89283.0000 | Echovirus 30 Ab |
| 89284.0000 | Galop Ab |
| 89285.0000 | Hepatitis C Band c100-3 |
| 89286.0000 | Hepatitis C Band c22p |
| 89287.0000 | Hepatitis C Band hSOD |

VistA Laboratory EPI

Rollup Modifications

Technical and User Manual

| | |
|------------|--------------------------------|
| 89288.0000 | Human Granulocytic Ehrlichiosi |
| 89289.0000 | Human Granulocytic Ehrlichiosi |
| 89290.0000 | Human Granulocytic Ehrlichiosi |
| 89291.0000 | HIV Log |
| 89292.0000 | HIV Log Ultra |
| 89293.0000 | HIV 2 gp105 Ab |
| 89294.0000 | HIV 2 gp120 Ab |
| 89295.0000 | HIV 2 gp34 Ab |
| 89296.0000 | HIV 2 p15 Ab |
| 89297.0000 | HIV 2 p26 Ab |
| 89298.0000 | HIV 2 p31 Ab |
| 89300.0000 | Semen Analysis Sperm |
| 89301.0000 | HIV 2 p58 Ab |
| 89302.0000 | HIV 2 p68 Ab |
| 89303.0000 | HIV 2 Ab Western Blot |
| 89304.0000 | HPV Hybrid Capture Inter High |
| 89305.0000 | HPV Typing, Biopsy |
| 89306.0000 | HPV Hybrid Capture Low Risk |
| 89307.0000 | Herpes Simplex Virus DNA |
| 89308.0000 | Herpes Simplex 1 DNA |
| 89309.0000 | Herpes Simplex 2 DNA |
| 89310.0000 | Herpes Simplex Ab |
| 89311.0000 | Herpes Simplex Ag |
| 89312.0000 | Parainfluenza 1 Ab |
| 89313.0000 | Parainfluenza Ag |
| 89314.0000 | Parainfluenza 1 Ag |
| 89315.0000 | Parainfluenza 2 Ag |
| 89316.0000 | Parainfluenza 3 Ag |
| 89317.0000 | Coxiella Burnetti 1 IgM |
| 89318.0000 | Coxiella Burnetti 2 |
| 89319.0000 | Coxiella Burnetti 2 IgG |
| 89320.0000 | Semen Analysis Count Motil |
| 89321.0000 | Coxiella Burnetti 2 IgM |
| 89322.0000 | Typhus |
| 89323.0000 | Typhus IgG |
| 89324.0000 | Typhus IgM |
| 89325.0000 | Rocky Mountain Spotted Fever I |
| 89326.0000 | Rocky Mountain Spotted Fever I |
| 89328.0000 | RNA Polymerase 1,2,3 Ab |
| 89329.0000 | Varicella Zoster Ab IgG |
| 89330.0000 | Cervical Mucus |
| 89331.0000 | Yersinia Enterocolitica Ab 0:3 |
| 89332.0000 | Yersinia Enterocolitica Ab 0:5 |
| 89333.0000 | Yersinia Enterocolitica Ab 0:8 |
| 89334.0000 | Yersinia Enterocolitica Ab 0:9 |
| 89335.0000 | Capillary Puncture Out Lab |
| 89336.0000 | Capillary Puncture Collection |
| 89337.0000 | Hantavirus Ab |
| 89338.0000 | Microbiological Specimen |
| 89339.0000 | Herpes Simplex 1 Ab |
| 89340.0000 | Urine (coll by lab) |
| 89341.0000 | +Venipuncture Travel Time |
| 89342.0000 | Prep Sterile Venipuncture |
| 89343.0000 | +Venipuncture Outpatient |
| 89344.0000 | Drainage |
| 89345.0000 | Venipuncture <3YR |
| 89346.0000 | Venipuncture (Scalp) |
| 89347.0000 | Venipuncture (Other) |
| 89348.0000 | Specimen Dispatch prep mail |

VistA Laboratory EPI

Rollup Modifications

Technical and User Manual

| | |
|------------|--------------------------------|
| 89349.0000 | Specimen Dispatch Ice |
| 89350.0000 | Arterial Puncture |
| 89351.0000 | Specimen Dispatch w data handl |
| 89352.0000 | Specimen Dispatch Nonal w dat |
| 89353.0000 | Specimen Dispatch w o Data Han |
| 89354.0000 | Specimen Dispatch Non w o data |
| 89355.0000 | Travel Time |
| 89356.0000 | Specimen Handling (Misc) |
| 89357.0000 | Venipuncture Transfusion |
| 89358.0000 | Arterial Catheterization |
| 89359.0000 | Specimen Collection Time |
| 89360.0000 | Chloride Sweat Test Quant |
| 89361.0000 | Tay Sach |
| 89362.0000 | Specimen Preprocessing Airfuge |
| 89363.0000 | Reverse Transcript Mutation |
| 89364.0000 | Specimen Preprocess Sphingo |
| 89365.0000 | Ward Collect Spec |
| 89366.0000 | LEDI Specimen |
| 89367.0000 | Referred Specimen |
| 89368.0000 | DoD Specimen |
| 89369.0000 | Research Specimen |
| 89370.0000 | Fee Basis Specimen |
| 89371.0000 | Contract Specimen |
| 89372.0000 | Hepatitis C RIBA |
| 89373.0000 | Pokeweed Mitogen |
| 89374.0000 | Concanavalin A Mitogen |
| 89375.0000 | Lymphocyte Mitogen Prolif |
| 89376.0000 | c100 5-1-1 Ab |
| 89377.0000 | c33c Ab |
| 89378.0000 | c22 Ab |
| 89379.0000 | NS5 Ab |
| 89380.0000 | Zea Mays Ab IgG |
| 89381.0000 | Arachis Hypogaea Ab IgG |
| 89382.0000 | Chronic Granulomatous Disease |
| 89383.0000 | Glycine Max Ab IgG |
| 89384.0000 | SOD1 DNA |
| 89385.0000 | Familial ALS |
| 89386.0000 | MA1 Ab |
| 89387.0000 | MA2 Ab |
| 89388.0000 | Satratoxin IgG |
| 89389.0000 | Satratoxin IgA |
| 89390.0000 | Satratoxin IgM |
| 89391.0000 | hSOD Ab |
| 89392.0000 | Satratoxin IgE |
| 89393.0000 | Aflatoxin IgG |
| 89394.0000 | Aflatoxin IgA |
| 89395.0000 | Aflatoxin IgM |
| 89396.0000 | Aflatoxin IgE |
| 89397.0000 | Trichothecene IgG |
| 89398.0000 | Trichothecene IgA |
| 89399.0000 | Trichothecene IgM |
| 89400.0000 | Trichothecene IgE |
| 89403.0000 | Hepatitis GBV |
| 89404.0000 | Rh (D) Typing |
| 89405.0000 | HBs Ag |
| 89406.0000 | HBe Ag |
| 89407.0000 | HBe Ab |
| 89408.0000 | HBs Ab |
| 89409.0000 | HBV |

VistA Laboratory EPI

Rollup Modifications

Technical and User Manual

| | |
|------------|--------------------------------|
| 89410.0000 | HBc Ab |
| 89411.0000 | HCV Ab |
| 89412.0000 | HCV Ag |
| 89413.0000 | Cutaneous Ab |
| 89414.0000 | Extractable Nuclear Ag NOS |
| 89415.0000 | Herpes Simplex 2 Ab |
| 89416.0000 | Nuclear Matrix Protein Tumor M |
| 89417.0000 | Leptospira Grippio Ab |
| 89418.0000 | Leptospira Icterohaemorrhiae A |
| 89420.0000 | Leptospira Pomona Ab |
| 89421.0000 | CD1+ Percent |
| 89422.0000 | HLA -DR+DQ Ag |
| 89423.0000 | Mumps Skin Test |
| 89424.0000 | Spinocerebellar Ataxia 1 |
| 89425.0000 | Molecular Cytogenetics Probe |
| 89426.0000 | FISH |
| 89427.0000 | HEREDITARY SPASTIC PARAPARESIS |
| 89428.0000 | Spinocerebellar Ataxia Type 17 |
| 89429.0000 | Spinocerebellar Ataxia Type 1& |
| 89430.0000 | Lyme IB 21kDa |
| 89431.0000 | Lyme IB 23kDa |
| 89432.0000 | Lyme IB 28kDa |
| 89433.0000 | Lyme IB 30kDa |
| 89434.0000 | Lyme IB 39kDa |
| 89435.0000 | Lyme IB 41kDa |
| 89436.0000 | Lyme IB 45kDa |
| 89437.0000 | Lyme IB 58kDa |
| 89438.0000 | Lyme IB 66kDa |
| 89439.0000 | Lyme IB 93kDa |
| 89440.0000 | Hu Ab CSF |
| 89441.0000 | ANA-Atypical Speckled Pattern |
| 89442.0000 | B Cell Gene Rearrangement |
| 89443.0000 | ANA-Homogeneous Pattern |
| 89444.0000 | Inflammatory Bowel Disease Pan |
| 89445.0000 | ANA-Mitotic Spindle Pattern |
| 89446.0000 | ANA-Nuclear Pattern |
| 89447.0000 | ANA-Speckled Pattern |
| 89448.0000 | RET Proto Oncogene Mutations |
| 89449.0000 | Muscular Dystrophy Duchenne Be |
| 89450.0000 | Interleukin 5 Receptor |
| 89451.0000 | Presenilin-1 Analysis |
| 89452.0000 | ApoE Allele 1 |
| 89453.0000 | ApoE Allele 2 |
| 89454.0000 | ApoE Genotype Analysis |
| 89455.0000 | BCL 1 Gene Translocation |
| 89456.0000 | ANA-Peripheral Pattern |
| 89485.0000 | Hepatitis C RNA |
| 89486.0000 | Heparin LMW |
| 89496.0000 | HCV Viral Load |
| 89497.0000 | Aureobasidium Pullans |
| 89498.0000 | HIV Viral Load |
| 89499.0000 | Immunoglobulin Lambda L Mon |
| 89500.0000 | Immunoglobulin Kappa L Mon |
| 89501.0000 | Helminth Ab |
| 89502.0000 | Rubeola Immune Status |
| 89503.0000 | Varicella Zoster Ab |
| 89504.0000 | VDRL Quant |
| 89505.0000 | HSV Ab IgG |
| 89506.0000 | HSV Ab IgM |

VistA Laboratory EPI

Rollup Modifications

Technical and User Manual

| | |
|------------|--------------------------------|
| 89507.0000 | PL-7 Autoantibodies |
| 89508.0000 | PL-12 Autoantibodies |
| 89509.0000 | Mi-2 Autoantibodies |
| 89510.0000 | Ku Autoantibodies |
| 89511.0000 | EJ Autoantibodies |
| 89512.0000 | OJ Autoantibodies |
| 89513.0000 | U2 SnRNP Autoantibodies |
| 89530.0000 | CA-125 Cancer Ag |
| 89531.0000 | Complement C1 Esterase Inhib |
| 89532.0000 | Complement C1q |
| 89533.0000 | Complement C1r |
| 89534.0000 | Complement C1s |
| 89535.0000 | Complement C2 |
| 89536.0000 | Complement C3 |
| 89536.3035 | Complement C3b Inhibitor~DU PO |
| 89537.0000 | Complement C3b Inhibitor |
| 89538.0000 | Complement C3c |
| 89539.0000 | Complement C3 Mobility |
| 89540.0000 | Complement C4 |
| 89540.3035 | Complement C5~DU PONT ACA |
| 89541.0000 | Complement C4 Allotypes |
| 89542.0000 | Complement C5 |
| 89543.0000 | Complement C6 |
| 89544.0000 | Complement C7 |
| 89545.0000 | Complement C8 |
| 89546.0000 | Complement Activation Products |
| 89547.0000 | Complement Decay Rate |
| 89548.0000 | Complement Factor B (C3PA) |
| 89549.0000 | Complement Properidin |
| 89550.0000 | Complement Total (CH50 CH100) |
| 89551.0000 | Immunoglobulin A |
| 89552.0000 | Immunoglobulin D |
| 89553.0000 | Immunoglobulin E |
| 89554.0000 | Immunoglobulin G |
| 89555.0000 | Immunoglobulin G Albumin Index |
| 89556.0000 | Immunoglobulin G Synthesis Rt |
| 89557.0000 | Immunoglobulin G1 |
| 89558.0000 | Immunoglobulin G2 |
| 89559.0000 | Immunoglobulin G3 |
| 89560.0000 | Immunoglobulin G4 |
| 89561.0000 | Immunoglobulin J Chain |
| 89562.0000 | Immunoglobulin Kappa Light Ch |
| 89563.0000 | Immunoglobulin Lambda Light Ch |
| 89564.0000 | Immunoglobulin M |
| 89565.0000 | Immunoglobulin Oligoclonal |
| 89566.0000 | Immunoglobulin G Low Level |
| 89567.0000 | Delta Ab |
| 89568.0000 | Heparin Induced Ab |
| 89569.0000 | HLA DR |
| 89570.0000 | Multiple Serum Proteins |
| 89571.0000 | Molecular Diag Separation |
| 89572.0000 | Helicobacter pylori Ab IgA |
| 89573.0000 | Helicobacter pylori Ag |
| 89574.0000 | EBV-VCA, IgM Quant |
| 89575.0000 | EBV-VCA, IgM |
| 89576.0000 | EBV-VCA, IgG |
| 89577.0000 | EBV-VCA, IgG Quant |
| 89578.0000 | EBV-VCA |
| 89579.0000 | CMV Ab, IgM Quant |

VistA Laboratory EPI

Rollup Modifications

Technical and User Manual

| | |
|------------|--------------------------------|
| 89580.0000 | CMV Ab, IgM |
| 89581.0000 | CMV Ab, IgG Quant |
| 89582.0000 | CMV Ab, IgG |
| 89583.0000 | CMV Ag |
| 89584.0000 | CMV Ab |
| 89585.0000 | Parietal Cell Ab Quant |
| 89586.0000 | Parietal Cell Ab |
| 89587.0000 | Smooth Muscle Ag |
| 89588.0000 | Smooth Muscle Ab Quant |
| 89589.0000 | Gliadin Ab IgA |
| 89590.0000 | DNA Ab Quant |
| 89591.0000 | Varicella Immune status Quant |
| 89592.0000 | Immune Status |
| 89593.0000 | Varicella Ab Quant |
| 89594.0000 | Varicella Ag |
| 89595.0000 | Varicella Ab |
| 89596.0000 | Toxoplasma Ab IgM Quant |
| 89597.0000 | Toxoplasma Ab IgG Quant |
| 89598.0000 | Sulfolglucuronyl paragloboside |
| 89599.0000 | T Cell Receptor Gene |
| 89600.0000 | Deoxyribonucleoprotein Ag |
| 89601.0000 | Deoxyribonucleoprotein Ab |
| 89602.0000 | Acetylcholine Receptor Binding |
| 89603.0000 | Chagas Disease |
| 89604.0000 | Acetylcholine Receptor Blockin |
| 89605.0000 | Polymavirus |
| 89606.0000 | Actin |
| 89607.0000 | Helicobacter pylori Ab IgG |
| 89608.0000 | Adenocarcinoma Surface Ag |
| 89609.0000 | Acute Myeloid Leukemia Panel |
| 89610.0000 | Adrenal Cortex |
| 89611.0000 | Lymphoma Panel |
| 89612.0000 | Bile Canaliculus |
| 89613.0000 | Chronic Leukemia Panel |
| 89614.0000 | Bile Duct |
| 89615.0000 | Acute Leukemia Panel |
| 89616.0000 | Blood Species Specific |
| 89617.0000 | Cat Scratch Fever |
| 89618.0000 | Bovine Milk |
| 89619.0000 | Histochemistry Panel |
| 89620.0000 | Breast Carcinoma Surface Ab |
| 89621.0000 | Lupus Panel |
| 89622.0000 | Brush Border |
| 89623.0000 | Carcinoembryonic Ag Polyclonal |
| 89624.0000 | CA 19 9 Carbohydrate Ag |
| 89625.0000 | Lupus Erythematosus |
| 89626.0000 | CA 125 Ovarian Cancer Ag |
| 89627.0000 | Delta Ag |
| 89628.0000 | Carcinoembryonic Ag |
| 89629.0000 | Genetics Study |
| 89630.0000 | Cardiolipin |
| 89631.0000 | Helicobacter pylori Ab IgM |
| 89632.0000 | Centriole |
| 89633.0000 | Tiech Acid Ab |
| 89634.0000 | Centromere |
| 89635.0000 | Gliadin Ab IgG |
| 89636.0000 | Cold Agglutinins |
| 89637.0000 | Gliadin Ab Panel |
| 89638.0000 | Cold Hemolysins Donath Land |

VistA Laboratory EPI

Rollup Modifications

Technical and User Manual

| | |
|------------|-------------------------------|
| 89639.0000 | Fetoprotein Alpha Stain |
| 89640.0000 | C Reactive Protein |
| 89641.0000 | Herpes I&II Stain |
| 89642.0000 | Cystic Disease Protein (CDP) |
| 89643.0000 | West Nile Virus |
| 89644.0000 | Cytokeratin |
| 89645.0000 | c-erbB-2(HER-2/neu) |
| 89646.0000 | Deoxyribonuclease B |
| 89648.0000 | Deoxyribonucleic Acid Double |
| 89650.0000 | Deoxyribonucleic Acid Quant |
| 89652.0000 | Deoxyribonucleic Acid Single |
| 89654.0000 | Desmin |
| 89656.0000 | Desmosome |
| 89658.0000 | Extractable Nuclear Ag H |
| 89660.0000 | Extractable Nuclear Ag Jo |
| 89661.0000 | Microsomal Ab |
| 89662.0000 | Extractable Nuclear Ag Ku |
| 89663.0000 | Extractable Nuclear Ag MA |
| 89664.0000 | Extractable Nuclear Ag Mi |
| 89666.0000 | Extractable Nuclear Ag PM |
| 89668.0000 | Extractable Nuclear Ag RA |
| 89670.0000 | Extractable Nuclear Ag RNP |
| 89672.0000 | Extractable Nuclear Ag Scl 70 |
| 89674.0000 | Extractable Nuclear Ag Sm |
| 89676.0000 | Extractable Nuclear Ag SS |
| 89677.0000 | Extractable Nuclear Ag SSA |
| 89678.0000 | Extractable Nuclear Ag SSB |
| 89680.0000 | Epithelial Membrane Ag |
| 89682.0000 | Fetoprotein Alpha |
| 89684.0000 | Fibronectin |
| 89686.0000 | Gliadin |
| 89688.0000 | Glial Fibrillary Acidic Prot |
| 89690.0000 | Glomerular Basement Membrane |
| 89691.0000 | Glycoprotein Betal Pregnancy |
| 89692.0000 | IgA |
| 89693.0000 | Histone DNA Complex IgG Ab |
| 89694.0000 | Heterophile |
| 89695.0000 | Machado Joseph Panel |
| 89696.0000 | Hyaluronidase |
| 89697.0000 | Prostatic Specific Ag Free |
| 89698.0000 | Immune Complex Clq Binding |
| 89699.0000 | Hepatitis B Surface Ab Quant |
| 89700.0000 | Immune Complex Polyethylene G |
| 89701.0000 | Rapid Plasma Reagin Quant |
| 89702.0000 | Immune Complex Raji Cell |
| 89703.0000 | Interleukin 2 Receptor |
| 89704.0000 | Intrinsic Factor |
| 89705.0000 | Rheumatoid Factor Quant |
| 89706.0000 | Islet Cell |
| 89707.0000 | Viral Titer |
| 89708.0000 | Keratin Squamous |
| 89709.0000 | DNA Binding |
| 89710.0000 | Keratin Nonsquamous |
| 89711.0000 | Hepatitis D Ag |
| 89712.0000 | Lactalbumin Alpha |
| 89713.0000 | Hepatitis D Ab |
| 89714.0000 | Lactoferrin |
| 89715.0000 | Rochaumaea Ag |
| 89716.0000 | Lung Carcinoma Surface Ag |

VistA Laboratory EPI

Rollup Modifications

Technical and User Manual

| | |
|------------|--------------------------------|
| 89717.0000 | Rochaumaea Ab |
| 89718.0000 | Melanoma Surface Ag |
| 89719.0000 | Microsomes Liver and Kidney |
| 89720.0000 | Microsomes Thyroid |
| 89721.0000 | Schistosoma Ab |
| 89722.0000 | Mitochondria |
| 89723.0000 | Heamophilus Pylorii Stain |
| 89724.0000 | Myelin |
| 89725.0000 | Thyroid Peroxidase Ab |
| 89726.0000 | Myelin Basic Protein |
| 89727.0000 | Hu Auto Ab |
| 89728.0000 | Myocardium |
| 89729.0000 | Yo Auto Ab |
| 89730.0000 | Myosin |
| 89731.0000 | Chlamydia Ab |
| 89732.0000 | Nuclear |
| 89734.0000 | Neurofilament Triplet Pro 200 |
| 89736.0000 | Neurofilament Triplet Pro 160 |
| 89738.0000 | Neurofilament Triplet Protein |
| 89740.0000 | Neuroleptic Receptor |
| 89742.0000 | Neuron Specific Enolase |
| 89744.0000 | Neurophysin |
| 89746.0000 | Panfilament |
| 89748.0000 | Pancreatic Carcinoma |
| 89750.0000 | Pancreatic Onofetal Ag |
| 89752.0000 | Parietal Cell |
| 89754.0000 | Pigeon Serum |
| 89756.0000 | Prekeratin |
| 89758.0000 | Prostatic Carcinoma Surface |
| 89760.0000 | Prostate Specific Ag |
| 89762.0000 | Reticulin |
| 89764.0000 | Rheumatoid Factor |
| 89766.0000 | Ribonuclease |
| 89768.0000 | Ribosome |
| 89770.0000 | S 100 Neural Ag |
| 89772.0000 | Salivary Gland |
| 89773.0000 | Mumps Ab Titer |
| 89774.0000 | Sarcolemma |
| 89776.0000 | Skin |
| 89778.0000 | Smooth Muscle |
| 89780.0000 | Sperm |
| 89782.0000 | Streptokinase |
| 89784.0000 | Anti Streptolysin O (ASO) |
| 89786.0000 | Streptozyyme |
| 89788.0000 | Striated Muscle |
| 89790.0000 | Tamm Horsfall Protein |
| 89792.0000 | Thyroglobulin |
| 89794.0000 | Thyroid Stimulating Immunoglob |
| 89796.0000 | Tubulin |
| 89798.0000 | Vimentin |
| 89801.0000 | Percent Recovery |
| 89802.0000 | Thyroglobulin Panel |
| 89803.0000 | CD3 Absolute |
| 89804.0000 | CD3 Percent |
| 89805.0000 | CD4 Percent |
| 89806.0000 | Bermuda Grass |
| 89807.0000 | Bermuda Grass IgE |
| 89808.0000 | Scleroderma Ab |
| 89809.0000 | Johnson Grass |

VistA Laboratory EPI

Rollup Modifications

Technical and User Manual

| | |
|------------|--------------------------------|
| 89810.0000 | Johnson Grass IgE |
| 89811.0000 | Timothy Grass |
| 89812.0000 | Timothy Grass IgE |
| 89813.0000 | Alternaria tenuis |
| 89814.0000 | Elm Tree |
| 89815.0000 | Mountain Cedar |
| 89816.0000 | Oak Tree |
| 89817.0000 | Sycamore Tree |
| 89819.0000 | Pecan Tree |
| 89820.0000 | Ash Tree |
| 89821.0000 | Privet |
| 89822.0000 | Ragweed Common |
| 89823.0000 | Lamb's Quarters |
| 89824.0000 | Russian Thistle |
| 89825.0000 | Marsh Elder |
| 89826.0000 | Cat Dander |
| 89827.0000 | Dog Dander |
| 89828.0000 | Mites |
| 89829.0000 | Allergy Panel |
| 89830.0000 | Endomysial Ab Titer |
| 89831.0000 | Giardia Ab IFA |
| 89832.0000 | Ribosomal P Protein Ab |
| 89833.0000 | Pneumococcal Sero 3 |
| 89834.0000 | Pneumococcal Sero 7F |
| 89835.0000 | Pneumococcal Sero 9N |
| 89836.0000 | Pneumococcal Sero 14 |
| 89837.0000 | Pneumococcal IgG |
| 89838.0000 | IGF 3 Binding Protein |
| 89839.0000 | Glomerular Basement Membrane A |
| 89840.0000 | Glomerular Basement Membrane A |
| 89841.0000 | Glomerular Basement Membrane A |
| 89842.0000 | Pneumococcal IgG Type 08 |
| 89843.0000 | Pneumococcal IgG Type 12 |
| 89955.0000 | Grass Allergens |
| 89960.0000 | Tree Allergens |
| 89965.0000 | Mold Allergens |
| 89970.0000 | Weed Allergens |
| 89975.0000 | Epithelial Allergens |
| 89980.0000 | Food Allergens |
| 89981.0000 | Chocolate Ab IgG |
| 89982.0000 | Lycopersicon Lycopersicum Ab I |
| 89985.0000 | House Dust Allergens |
| 89990.0000 | House Dust Mite Allergens |
| 89995.0000 | Venom Allergens |
| 91941.0000 | Acetazolamide |

APPENDIX – C

Health Level Seven (HL7) Protocol

Appendix C - Health Level Seven (HL7) Protocol

The EPI Rollup Modification patch LR*5.2*281, utilizes the *VistA* Laboratory, PIMS, Pharmacy, Clinical Reminders, and Social Work databases for the EPI Rollup Modification criteria. The *VistA* HL7 software is used to transmit EPI Rollup Modification data to the AITC database.

3. General Specifications

3.1 Communication Protocol

The electronic *VistA* Mailman software application is used as the communications protocol for sending the EPI HL7 mailman messages between *VistA* database and AITC database.

3.2 Application Processing Rules

The HL7 protocol itself describes the basic rules for application processing by the sending and receiving systems. The HL7 Version 2.2 protocol is used. The Observational Results Unsolicited (ORU) message is sent using the HL7 batch protocol.

3.3 Message

The following HL7 mail message is used to support the exchange of data:

ORU Observational Results Unsolicited

3.4 Segments

The following HL7 segments are used to support the exchange of data:

| HL7 segments | Exchange of Data |
|--------------|-----------------------------|
| DG1 | Diagnosis |
| DSP | Display Data |
| MSH | Message Header |
| NTE | Notes and Comments |
| OBR | Observation Request |
| OBX | Observation Results |
| PID | Patient Identification |
| PV1 | Patient Visit |
| ZXE | Pharmacy Prescription Order |

3.5 Fields

The following HL7 fields are used to support the exchange of data for each of the segments listed in the 3.4 Segments:

| SEGMENT | FIELD SEQUENCE NUMBER | Data Type/Length HL/7 | FIELD ELEMENT NAME | USER/HL7 DEFINED |
|---------|-----------------------------|-----------------------------|---|---------------------|
| DG1 | 1 | 4/SI | Set ID-Diagnosis (Sequence #) | HL7 |
| | 3 | 60/CE | Diagnosis Code (Code(id) ~Text (St.) ~Name of coding system (st) | HL7 |
| | 4 | 19/TS | Admission Date | HL7 |
| | 6 | 2/IS | Diagnosis Type (PR=DXLS) | HL7 |
| MSH | 1 | 1/ST | Field Separator | HL7 |
| | 2 | 4/ST | Encoding Characters | HL7 |
| | 3 | 180/HD | Sending Application | HL7 |
| | 4 | 180/HD | Sending Facility | HL7 |
| | 5 | 180/HD | Receiving Application | HL7 |
| | 6 | 180/HD | Receiving Facility | HL7 |
| | 7 | 19/TS | Date/Time of Message | HL7 |
| | 8 | 40/SY | Security | HL7 |
| | 9 | 7/CM | Message Type | HL7 |
| | 10 | 20/ST | Message Control ID | HL7 |
| | 11 | 3/PT | Processing ID | HL7 |
| | 12 | 8/ID | Version ID | HL7 |
| OBR | 1 | 4/SI | Set ID-Observation Request (Seq #) | HL7 |
| | 4 | 200/CE | Universal Service ID (identifier ~ text ~ name of coding system ~ alt id ~ alt text ~ alt coding system) | HL7 |
| | 7 | 19/TS | Observation Date/Time | HL7 |
| | 15 | 300/CM | Specimen Source (Specimen source code (CE) ~~ text (TX)) | HL7 (Table 0070) |
| | 26 | 400/CM | Parent Results (OBX observation id of parent ^OBX sub ID | HL7 |

3.5 Fields continued

| SEGMENT | FIELD SEQUENCE NUMBER | Data Type/Length HL/7 | FIELD ELEMENT NAME | USER/HL7 DEFINED |
|-----------------|-----------------------------|-----------------------------|--|---------------------|
| NTE | 1 | 4/SI | Set ID (seq. #) | HL7 |
| | 3 | 64K/FT | Comment (five formats exist for this segment, see Note #2) | HL7 |
| OBX | 1 | 4/SI | Set Id-Observational Simple (seq. #) | HL7 |
| | 2 | 2/ID | Value Type | HL7 |
| | | | | |
| New LOINC | 3 | 80/CE | Observation Identifier (identifier ~ text ~ name of coding system ~ alt id ~ alt text ^ alt coding system) | HL7 |
| | | | | |
| | | | | |
| | 4 | 20/ST | Sub Id | HL7 |
| New MIC value | 5 | | Observation Value (Result) | HL7 |
| | 6 | 60/CE | Units (Units) | HL7 |
| | 8 | 10/ID | Abnormal Flags | HL7 (Table 0078) |
| | 14 | 60/CE | Date/Time of the Observation (Verified Date/Time) | HL7 |
| PID | 1 | 4/SI | Set ID – Patient ID | HL7 |
| | 2 | 16/CK | Patient ID (External ID) | HL7 |
| New MPI | 3 | 20/CM | Patient ID (Internal ID) | HL7 |
| | 5 | 48/PN | Patient Name | HL7 |
| | 7 | 19/TS | Date of Birth | HL7 |
| | 8 | 1/ID | Sex | HL7 (Table 0001) |
| New Race | 10 | 1/ID | Race | HL7 (Table VA07) |
| | 11 | 106/AD | Address (Homeless{ where applicable}~Zip Code) | HL7 |
| New County Code | 12 | 4/IS | County Code | HL7 |
| | 19 | 16/ST | SSN | HL7 |
| | | | | |

3.5 Fields continued

| SEGMENT | FIELD SEQUENCE NUMBER | Data Type/Length HL/7 | FIELD ELEMENT NAME | USER/HL7 DEFINED |
|--------------------|-----------------------------|-----------------------------|---|---------------------|
| New Ethnic Group | 22 | 80/CE | Ethnic Group | HL7 |
| | 27 | 60/CE | Veteran's Military Status | HL7 (Table Va011) |
| PV1 | 1 | 4/SI | Set ID - Patient Visit | HL7 |
| | 36 | 3/ID | Discharge Disposition (Type of Disposition {Code}~Type of Disposition {Text}~Source ID {VA45=VA File 45}) | HL7 |
| Servicing Facility | 39 | 2/SI | Servicing Facility | HL7 |
| | 44 | 19/TS | Admit Date/Time (Event Date/Time) | HL7 |
| | 45 | 19/TS | Discharge Date/Time | HL7 |
| DSP | 1 | 2/ID | Set ID | HL7 |
| | 3 | 80/FT | Date~Text Term~Resolved Term~Result~Sourceid | USER |
| | 5 | 2/ID | Result ID (linking DSP and ZXE) | HL7 |
| ZXE | 1 | 20/FT | NDC | USER |
| | 2 | 75/FT | Drug Name~Coding System | USER |
| | 3 | 4/NM | Days Supply | USER |
| | 4 | 19/TS | Release Date/Time | USER |
| | 5 | 19/TS | Fill Date/Time | USER |
| | 6 | 19/TS | Stop Date/Time | USER |
| | 7 | 2/ID | Result ID (linking DSP and ZXE) | USER |

NOTE: The NTE segment is present in four forms. EPI only items tagged with (EPI).

- a. NTE||manual/automatic indicator (Null for automatic, R for Manual)~REPORTING DATE FROM from date TO to date~message number~~software version number (blank for original system/V2 for new system(epi)~Negative Input Indicator (null if input is present, N if negative)
- b. NTE|sequence number|reference number from field .05 (reference number) in 5 (LAB SEARCH/EXTRACT file (#69).
- c. NTE||Totals indicator (T if NTE describes totals for run)~National Lab Test Code~Test Name from LAB TEST file (#60) or (ETIOLOGY FIELD file (#61.2)~Total number of tests performed
- d. NTE||Totals indicator (T if NTE describes totals for run)~National Lab Test Code~ “PATIENTS WITH”_Test Name from LAB TEST file (#60) or ETIOLOGY FIELD file (#61.2)~Number of unique patients receiving this test

Definitions from Austin

| Field Name | Start | End | Length | Properties | |
|-------------------------------------|-------|-----|--------|--------------|-------------------------|
| DG1 SEGMENT | | | | | |
| SET-ID | 94 | 97 | 4 | alphanumeric | |
| DIAG- CODING- METHOD | 98 | 99 | 2 | alphanumeric | |
| DIAG-CODE | 100 | 106 | 7 | alphanumeric | |
| DIAG-TEXT | 107 | 146 | 40 | alphanumeric | |
| DIAG- CODING-SYT | 147 | 156 | 10 | alphanumeric | |
| FILLER | 157 | 467 | 311 | alphanumeric | |
| NTE-SEGMENT | | | | | |
| SET-ID | 94 | 97 | 4 | alphanumeric | |
| ACTION-IND | 98 | 99 | 2 | alphanumeric | valid total indicator T |
| NATIONAL- LAB-TEST- NUM | 100 | 109 | 10 | alphanumeric | |
| BACTERIA | 110 | 144 | 35 | alphanumeric | |
| TOTAL- COUNT | 145 | 149 | 5 | alphanumeric | |
| FILLER | 150 | 467 | 318 | alphanumeric | |
| NTE- SEGMENT (alternate type) | | | | | |
| SET-ID | 94 | 97 | 4 | alphanumeric | |
| ACTION-IND | 98 | 99 | 2 | alphanumeric | |
| FILLER | 100 | 119 | 20 | alphanumeric | |
| FROM-DATE | 120 | 127 | 8 | alphanumeric | |
| FILLER | 128 | 131 | 4 | alphanumeric | |
| TO-DATE | 132 | 139 | 8 | alphanumeric | |
| MSG-SEQ- NUM | 140 | 142 | 3 | alphanumeric | |
| NEGATIVE- INPUT-IND | 143 | 143 | 1 | alphanumeric | |
| FILLER | 144 | 467 | 324 | alphanumeric | |

Continued

| Field Name | Start | End | Length | Properties | |
|-----------------------|-------|-----|--------|--------------|--|
| OBR-SEGMENT | | | | | |
| SET-ID | 94 | 97 | 4 | alphanumeric | |
| PATHOGEN-NAME | 98 | 132 | 35 | alphanumeric | |
| UNIV-SERVICE-ID | 133 | 142 | 10 | alphanumeric | |
| UNIV-SERVICE-TEXT | 143 | 172 | 30 | alphanumeric | |
| UNIV-SERVICE-CODE | 173 | 187 | 15 | alphanumeric | |
| ALT-UNIV-SERVICE-ID | 188 | 202 | 15 | alphanumeric | |
| ALT-UNIV-SERVICE-TEXT | 203 | 232 | 30 | alphanumeric | |
| ALT-UNIV-SERVICE-CODE | 233 | 247 | 15 | alphanumeric | |
| OBSER-DATE | 248 | 255 | 8 | yyyymmdd | |
| OBSER-TIME | 256 | 261 | 6 | hhmmss | |
| OBSER-DATE-A | 262 | 269 | 8 | alphanumeric | |
| SPECIMEN-CODE | 270 | 273 | 4 | alphanumeric | |
| FILLER | 274 | 274 | 1 | alphanumeric | |
| SPECIMEN-CODE-TEXT | 275 | 304 | 30 | alphanumeric | |
| ACCESSION-NUM | 305 | 324 | 20 | alphanumeric | |
| PARENT-OBSER-ID | 335 | 334 | 10 | alphanumeric | |
| PARENT-OBSER-SUB-ID | 355 | 340 | 6 | alphanumeric | |
| PARENT-TEST-SYS | 361 | 350 | 10 | alphanumeric | |
| PARENT-LAB-NUM | 371 | 360 | 10 | alphanumeric | |

Continued

| Field Name | Start | End | Length | Properties | |
|-------------------------------|-------|-----|--------|--------------|--|
| FILLER | 381 | 458 | 98 | alphanumeric | |
| OBX- SEGMENT | | | | | |
| OBR-SET-ID | 94 | 97 | 4 | alphanumeric | |
| OBX-SET-ID | 98 | 101 | 4 | alphanumeric | |
| VALUE-TYPE | 102 | 103 | 2 | alphanumeric | |
| OBSERVATIO N-ID | 104 | 113 | 10 | alphanumeric | |
| OBSERVATIO N-TEXT | 114 | 143 | 30 | alphanumeric | |
| OBSERVATIO N-CODE | 144 | 158 | 15 | alphanumeric | |
| OBSERVATIO N-ID-ALT | 159 | 168 | 10 | alphanumeric | |
| OBSERVATIO N-TEXT-ALT | 169 | 198 | 30 | alphanumeric | |
| OBSERVATIO N-CODE-ALT | 199 | 213 | 15 | alphanumeric | |
| OBSERVATIO N-SUB-ID | 214 | 219 | 6 | alphanumeric | |
| OBSERVATIO N-NAT-LAB | 220 | 229 | 10 | alphanumeric | |
| OBSERVATIO N-VALUE | 230 | 274 | 45 | alphanumeric | |
| OBSERVATIO N-UNITS | 275 | 289 | 15 | alphanumeric | |
| OBSERVATIO N-REF- RANGE | 290 | 304 | 15 | alphanumeric | |
| ABNORMAL- FLAGS | 305 | 314 | 10 | alphanumeric | |
| FINAL- RESULT- DATE | 315 | 322 | 8 | yyyymmdd | |
| FILLER | 323 | 450 | 128 | alphanumeric | |
| PID- SEGMENT | | | | | |
| SET-ID | 94 | 97 | 4 | alphanumeric | |

Continued

| Field Name | Start | End | Length | Properties | |
|------------------------|-------|-----|--------|--------------|---------------------------------|
| PATIENT-EXTERNAL-ID | 98 | 114 | 17 | alphanumeric | |
| PATIENT-INTERNAL-ID | 115 | 135 | 21 | alphanumeric | |
| PATIENT-NAME | 136 | 220 | 85 | alphanumeric | |
| PATIENT-BIRTH-DATE | 221 | 228 | 8 | yyyymmdd | |
| PATIENT-SEX | 229 | 229 | 1 | alphanumeric | |
| PATIENT-RACE | 230 | 230 | 1 | alphanumeric | |
| PATIENT-ADDRESS | 231 | 231 | 1 | alphanumeric | valid patient address H |
| ZIP | 232 | 240 | 9 | alphanumeric | |
| FILLER | 241 | 241 | 1 | alphanumeric | |
| PATIENT-SSN | 242 | 250 | 9 | alphanumeric | |
| PATIENT-PSEUDO | 251 | 251 | 1 | alphanumeric | valid pseudo space or P |
| PATIENT-VETERAN-STATUS | 252 | 253 | 2 | alphanumeric | |
| FILLER | 254 | 450 | 197 | alphanumeric | |
| | | | | | |
| PV1-SEGMENT | | | | | |
| SET-ID | 94 | 97 | 4 | alphanumeric | |
| PATIENT-CLASS | 98 | 98 | 1 | alphanumeric | valid patient class I or O or U |
| DISCHARGE-DISPOSITION | 99 | 133 | 35 | alphanumeric | |
| ADMIT-DATE | 134 | 141 | 8 | yyyymmdd | |
| ADMIT-TIME | 142 | 147 | 6 | hhmmss | |
| DISCHARGE-DATE | 148 | 155 | 8 | yyyymmdd | |
| DISCHARGE-TIME | 156 | 161 | 6 | hhmmss | |
| FILLER | 162 | 450 | 289 | alphanumeric | |

4.0 Transaction Specifications

4.1 General

The VistA software sends an Observational Result Unsolicited (ORU) result type HL7 message whenever one or more of the defined emerging pathogen initiatives are identified.

4.2 Specific Transaction

A. Identified Encounter

When EPI data are identified an EPI Observational Result Unsolicited (ORU) message is sent to the AITC. The EPI ORU message consists of the following segments:

Example: EPI ORU Message

```

ORU      OBSERVATIONAL RESULT UNSOLICITED
MSH      Message Header
NTE      Notes and Comments
PID      Patient Identification
PV1      Patient Visit
NTE      Notes and Comments
DG1      Diagnosis
DSP      Display Data
ZXE      Pharmacy Prescription
OBR      Observation Report
OBX      Results

MSH|~|\&|EPI-XXX|170|EPI-XXX|170|19961018113521||ORU~R01|107|P|2.2|||||USA
NTE|REPORTING DATE FROM 19850101 TO 19961018
PID|1|000-00-
0008~0~M10|5~5~M10||LABPATIENT~EIGHT||19220912|M||7|||||||052167946
PV1|1|O|||||||||||||||||||||||||||||||||19950315151907
NTE|1|Vanc-Res Enterococcus
DG1|1||451.19^DEEP PHLEBITIS-LEG NEC~I9
DG1|2||511.9^PLEURAL EFFUSION NOS~I9
DG1|3||670.02^MAJOR PUERP INF-DEL P/P~I9
DG1|4||331.0^ALZHEIMER'S DISEASE~I9
DG1|5||500.^COAL WORKERS' PNEUMOCON~I9
OBR|1||^CHEMISTRY TEST^VANLT||19950315151907||||||SER^^SERUM
OBX|1|ST|84330.0000^Glucose Quant^VANLT^260^GLUCOSE1^VA60||25|mg/dL|70-125|L*
NTE|2|2^Hepatitis C antibody
OBR|2||^CHEMISTRY TEST^VANLT||19950315151907||||||SER^^SERUM
OBX|1|ST|84330.0000^Glucose Quant^VANLT^260^GLUCOSE1^VA60||25|mg/dL|70-125|L*
PID|2|000-00-
0009~8~M10|7~7~M10||LABPATIENT~NINE||19591229|F||7|||||||023456666
PV1|1|O|||||||||||||||||||||||||||||||||19950315152721
NTE|1|1^Vanc-Res Enterococcus
OBR|1||87999.0000^MICRO CULTURE^VANLT||198612100835||||||^BLOOD
OBX|1|CE|87993.0000^BACTERIOLOGY CULTURE^VANLT|1|^ESCHERICHIA COLI
OBR|2|^ANTIBIOTIC
MIC^VANLT|||198612100835||||||^BLOOD||||||87993.0000^1
OBX|1|ST|81812.0000^Neomycin^VANLT^18^NEOMYCIN^VA62.06||||R
OBX|2|ST|^35^BACTRCN^VA62.06||||R
OBX|3|ST|81852.0000^Penicillin^VANLT^23^PENICLN^VA62.06||||R
OBX|4|ST|81676.0000^Clindamycin^VANLT^3^CLINDAM^VA62.06||||S

```

Table VA011 - Period of Service

| Value | Description |
|-------|---------------------------|
| 0 | KOREAN |
| 1 | WORLD WAR I |
| 2 | WORLD WAR II |
| 3 | SPANISH AMERICAN |
| 4 | PRE-KOREAN |
| 5 | POST-KOREAN |
| 6 | OPERATION DESERT SHIELD |
| 7 | VIETNAM ERA |
| 8 | POST-VIETNAM |
| 9 | OTHER OR NONE |
| A | ARMY--ACTIVE DUTY |
| B | NAVY, MARINE--ACTIVE DUTY |
| C | AIR FORCE--ACTIVE DUTY |
| D | COAST GUARD--ACTIVE DUTY |
| E | RETIRED, UNIFORMED FORCES |
| F | MEDICAL REMEDIAL ENLIST |
| G | MERCHANT SEAMEN--USPHS |
| H | OTHER USPHS BENEFICIARIES |
| I | OBSERVATION/EXAMINATION |
| J | OFFICE OF WORKERS COMP. |
| K | JOB CORPS/PEACE CORPS |
| L | RAILROAD RETIREMENT |
| M | BENEFICIARIES-FOREIGN GOV |
| N | HUMANITARIAN (NON-VET) |
| O | CHAMPUS RESTORE |
| P | OTHER REIMBURS. (NON-VET) |
| Q | OTHER FEDERAL - DEPENDENT |
| R | DONORS (NON-VET) |
| S | SPECIAL STUDIES (NON-VET) |
| T | OTHER NON-VETERANS |
| U | CHAMPVA--SPOUSE, CHILD |
| V | CHAMPUS |
| W | CZECHOSLOVAKIA/POLAND SVC |
| X | PERSIAN GULF WAR |
| Y | CAV/NPS |
| Z | MERCHANT MARINE |

Table 0070 - Specimen Source Codes (continued)

| Abbreviations | Descriptions | Abbreviations | Descriptions | Abbreviations | Descriptions |
|---------------|-----------------------|---------------|------------------------|---------------|------------------------------|
| ABS | Abscess | FLU | Body fluid, unsp | SER | Serum |
| AMN | Amniotic fluid | GAS | Gas | SKN | Skin |
| ASP | Aspirate | GAST | Gastric fluid/contents | SKM | Skeletal muscle |
| BPH | Basophils | GEN | Genital | SPRM | Spermatozoa |
| BIFL | Bile fluid | GENC | Genital cervix | SPT | Sputum |
| BBL | Blood bag | GENV | Genital vaginal | SPTT | Sputum tracheal aspirate |
| BLDC | Blood capillary | HAR | Hair | STON | Stone (use CALC) |
| BPU | Blood product unit | IHG | Inhaled Gas | STL | Stool = Fecal |
| BLDV | Blood venous | IT | Intubation tube | SWT | Sweat |
| BON | Bone | ISLT | Isolate | SNV | Synovial fluid (Joint fluid) |
| BRTH | Breath (use EXHLD) | LAM | Lamella | TEAR | Tears |
| BRO | Bronchial | WBC | Leukocytes | THRT | Throat |
| BRN | Burn | LN | Line | THRB | Thrombocyte (platelet) |
| CALC | Calculus (=Stone) | LNA | Line arterial | TISS | Tissue |
| CDM | Cardiac muscle | LNV | Line venous | TISG | Tissue gall bladder |
| CNL | Cannula | LIQ | Liquid NOS | TLGI | Tissue large intestine |
| CTP | Catheter tip | LYM | Lymphocytes | TLNG | Tissue lung |
| CSF | Cerebral spinal fluid | MAC | Macrophages | TISPL | Tissue placenta |
| CVM | Cervical mucus | MAR | Marrow | TSMI | Tissue small intestine |
| CVX | Cervix | MEC | Meconium | TISU | Tissue ulcer |
| COL | Colostrum | MBLD | Menstrual blood | TUB | Tube NOS |
| CBLD | Cord blood | MLK | Milk | ULC | Ulcer |
| CNJT | Conjunctiva | MILK | Breast milk | UMB | Umbilical blood |
| CUR | Curettage | NAIL | Nail | UMED | Unknown medicine |

Table 0070 - Specimen Source Codes (continued)

| Abbreviations | Descriptions | Abbreviations | Descriptions | Abbreviations | Descriptions |
|---------------|-----------------------|---------------|-----------------------------------|---------------|--|
| CYST | Cyst | NOS | Nose (nasal passage) | URTH | Urethra |
| DIAF | Dialysis fluid | ORH | Other | UR | Urine |
| DOSE | Dose med or substance | PAFL | Pancreatic fluid | URC | Urine clean catch |
| DRN | Drain | PAT | Patient | URT | Urine catheter |
| DUFL | Duodenal fluid | PRT | Peritoneal fluid ascites | URNS | Urine sediment |
| EAR | Ear | PLC | Placenta | USUB | Unknown substance |
| EARW | Ear wax (cerumen) | PLAS | Plasma | VOM | Vomit |
| ELT | Electrode | PLB | Plasma bag | BLD | Whole blood |
| ENDC | Endocardium | PLR | Pleural fluid (thoracentesis fld) | BDY | Whole body |
| ENDM | Endometrium | PMN | Polymorphonuclear neutrophils | WAT | Water |
| EOS | Eosinophils | PPP | Platelet poor plasma | WICK | Wick |
| RBC | Erythrocytes | PRP | Platelet rich plasma | WND | Wound |
| EYE | Eye | PUS | Pus | WNDA | Wound abscess |
| EXHLD | Exhaled gas (breath) | RT | Route of medicine | WNDE | Wound exudate |
| FIB | Fibroblasts | SAL | Saliva | WNDD | Wound drainage |
| FLT | Filter | SEM | Seminal fluid | XXX | To be specified in another part of the message |
| FIST | Fistula | | | | |

Table 0005 – Race:

1ST RACE COMPONENT Identifier comes from table 0005.

2ND COMPONENT Text- comes from table 0005.

| IDENTIFIER | TEXT |
|------------|--|
| 0000-0-SLF | Declined to answer |
| 9999-4-SLF | Unknown by patient |
| 1002-5-SLF | American Indian or Alaska Native (self identified) |
| 1002-5-PRX | American Indian or Alaska Native (proxy identified) |
| 1002-5-OBS | American Indian or Alaska Native (observer identified) |
| 1002-5-UNK | American Indian or Alaska Native (unknown identifier) |
| 2028-9-xxx | Asian (xxx identified) |
| 2054-5-xxx | Black or African American (xxx identified) |
| 2076-8-xxx | Native Hawaiian or other Pacific Islander (xxx identified) |
| 2106-3-xxx | White (xxx identified) |

Table CDC – Race:

3rd RACE COMPONENT Identifier - comes from table CDC.

4th COMPONENT Text - comes from table CDC.

| IDENTIFIER | TEXT |
|------------|---|
| null | Unknown by patient or Declined to answer |
| 1002-5 | American Indian or Alaska Native |
| 2028-9 | Asian |
| 2054-5 | Black or African American |
| 2076-8 | Native Hawaiian or other Pacific Islander |
| 2106-3 | White |

Table 0189 - Ethnic Group

1ST ETHNICITY COMPONENT Identifier - comes from table 0189.

2ND COMPONENT Text - comes from table 0189.

| IDENTIFIER | TEXT |
|------------|--|
| 0000-0-SLF | Declined to answer |
| 9999-4-SLF | Unknown by patient |
| 2135-2-SLF | Hispanic or Latino (self identified) |
| 2135-2-PRX | Hispanic or Latino (proxy identified) |
| 2135-2-OBS | Hispanic or Latino (observer identified) |
| 2135-2-UNK | Hispanic or Latino (unknown identifier) |
| 2186-5-xxx | Not Hispanic or Latino (xxx identified) |

Table CDC - Ethnic Group

3rd ETHNICITY COMPONENT Identifier - comes from table CDC.

4th ETHNICITY COMPONENT Text - comes from table CDC.

| Value | Description |
|--------|--|
| Null | Unknown by patient or Declined to answer |
| 2135-2 | Hispanic or Latino |
| 2186-5 | Not Hispanic or Latino |

Table 0001 - Sex

| Value | Description |
|-------|-------------|
| F | FEMALE |
| M | MALE |
| O | OTHER |

Table 0078 - Abnormal flags

| Value | Description |
|-------------------------------------|--------------------------|
| L | Below low normal |
| H | Above high normal |
| LL | Below lower panic limits |
| HH | Above upper panic limits |
| For microbiology sensitivities only | |
| S | Sensitive |
| R | Resistant |
| I | Intermediate |
| MS | Moderately sensitive |
| VS | Very sensitive |

Table Specimen Source ID Code

| Value | Description |
|--------------|-------------|
| Problem List | 1 |
| Encounter Dx | 2 |
| Discharge DX | 3 |

Table Hepatitis Risk Assessment Resolutions

| Value | Description |
|--------------------------------|-------------|
| Declined Hep C Risk Assessment | 1 |
| No Risk Factors for Hep C | 2 |
| Prev Positive Test for Hep C | 3 |
| Risk Factor for Hepatitis C | 4 |
| Hep C Virus Antibody Positive | 5 |
| Hep C Virus Antibody Negative | 6 |
| Hepatitis C Infection | 7 |

NOTE: Term other than Hepatitis C National Risk Assessment Clinical Reminders resolution term 00

**APPENDIX – D
VHA DIRECTIVE 2001-039
JUNE 27, 2001
IMPLEMENTATION OF LOGICAL
OBSERVATION IDENTIFIERS NAMES
AND CODES (LOINC®) FOR
LABORATORY DATA**

APPENDIX – D

| | |
|--------------------------------|------------------------|
| Department of Veterans Affairs | VHA DIRECTIVE 2001-039 |
| Veterans Health Administration | |
| Washington, DC 20420 | June 27, 2001 |

IMPLEMENTATION OF LOGICAL OBSERVATION IDENTIFIERS NAMES AND CODES (LOINC®) FOR LABORATORY DATA

NOTE: LOINC® is a registered trademark symbol.

1. PURPOSE: This Veterans Health Administration (VHA) Directive defines policies on the need for consistent laboratory test names across the national system within the Veterans Health Information Systems Technology Architecture (VistA) software.

2. BACKGROUND

a. Improving health data is also a high priority that is consistent with VHA's goal of improving the quality and accessibility of medical information for clinicians and veterans. In order to provide optimal clinical care, accurate, comprehensive, accessible, and timely data is necessary. Improvements in the provision and outcomes of VHA health care can only be measured by consistent and valid information.

b. LOINC® is a data system that provides a standard set of universal names and codes for identifying individual laboratory results. Developed as a collaborative effort including VHA's Office of Information (OI) staff, LOINC® codes were first released in April 1996 and have since been formally endorsed by the American Clinical Laboratory Association, the association of large referral laboratories whose membership is responsible for over 60 percent of outpatient laboratory testing in the United States. Numerous private commercial laboratories, health plans and health care provider systems have since adopted this system. LOINC® codes have been incorporated into the National Library of Medicine's Unified Medical Language System and are the basis of the Health Care Financing Administration's (HCFA) proposed International Classification of Diseases, 10th edition (ICD-10), laboratory codes. The codes have been incorporated into HCFA's quality assurance testing pilot programs and adopted by the Centers for Disease Control and Prevention to test reporting of communicable disease information electronically. VHA is represented on the committee responsible for introducing new codes.

c. The primary benefit to the Department of Veterans Affairs (VA) health care is having a system that integrates data across inpatient and outpatient settings and across facilities, allowing easy and timely retrieval of clinically useful information needed to provide efficient, high quality individual patient care. LOINC® allows the aggregation of clinical laboratory data within Veterans Integrated Service Networks (VISNs), and nationally, efforts that are currently encumbered by the high rates of variation in local laboratory test naming. Such mapping provides a way to support multiple, normal ranges based on test, method, specimen, sex, and patient age.

d. Hepatitis C infection, an important public health and medical problem for many veterans, is a high priority for VHA. The Under Secretary for Health has requested the creation of an electronic database to monitor the clinical outcomes of patients in the VA system with Hepatitis C infection and information needed for the oversight and management of the national hepatitis C program. A prerequisite for the implementation of such a registry is the availability of standardized laboratory test result data across VHA.

THIS VHA DIRECTIVE EXPIRES JUNE 30, 2006

e. Patch LR*5.2*215, to Version 5.2 of the Laboratory software application, was released in April 1999. This patch provides a mapping process for linking VA National Laboratory Test (NLT) codes to LOINC®.

3. POLICY: It is VHA policy that VISN and facility Directors must provide a national system for laboratory test names by ensuring the installation, set-up, and maintenance of each facility's laboratory software mapping to LOINC®.

4. ACTION

a. By June 30, 2001, each facility must install Patch LR*5.2*215 to laboratory software version 5.2.

b. By July 16, 2001, each VISN Director must have designated one lead person, to be known as the VISN LOINC® Coordinator, who will be responsible for ensuring that, at each VistA site, the appropriate mapping of NLT to LOINC® codes will be performed. In addition, the VISN LOINC® Coordinator will serve as a VistA corporate liaison between the VISN and VHA Information Technology team responsible for providing training on the use of the mapping tool. **NOTE:** *The VISN LOINC® Coordinators will work to ensure complete implementation of LOINC® coding within their respective VISNs.*

(1) The LOINC® Coordinator needs to have a broad-based knowledge of clinical laboratory medicine, an overall understanding of the VistA Laboratory Service software package, experience using general VistA applications (i.e., FileMan, MailMan), and be able to grasp the analytical concepts to properly encode test results in all areas of laboratory (i.e., serology, chemistry, microbiology, blood bank, and immunology).

(2) VISN LOINC® Coordinators will receive training on the lab linking process and orientation to their roles as LOINC® Coordinators through a series of teleconferences for that purpose. Training will be coordinated through the OI National Training and Education Office. Specific information on the LOINC® training is available at: <http://vaww.vistau.med.va.gov/vistau/loinc/loinc.htm>. Training and support through teleconferences and audio question and answer sessions will be made available to the VistA site clinical laboratory VistA liaison (Laboratory Information Manager (LIM) or Automated Data Processing Application Coordinator (ADPAC)). **NOTE:** *It is requested that facilities do not initiate the mapping process until they have been appropriately trained.*

c. By July 16, 2001, each VISN Director must forward the name and contact information for each VISN LOINC® Coordinator to the National Pathology Enforcement Officer (115), Veterans Health Administration, 810 Vermont Avenue, NW, Washington, DC 20420, or fax to (202) 273-7561.

d. By September 30, 2001, each VISN LOINC® Coordinator must ensure the linking of Hepatitis C-related laboratory tests at each facility and report completion to the VISN Director. **NOTE:** *The actual mapping will be performed by the LIM or ADPAC at all facilities.*

e. By December 31, 2001, VISN LOINC® Coordinators must have completed the full mapping of LOINC® codes within all facility clinical laboratories and report completion of the task to the VISN Director as well as the Pathology Regional Commissioners. Complete mapping for all laboratory test names is required.

5. REFERENCES

a VHA Executive Decision memorandum approved by the Under Secretary for Health on September 20, 2000. <<http://www.va.gov/hepatitisc>>

b. Logical Observation Identifier Names and Codes (LOINC®) User's Guide, January 5, 2001, c/o Regenstrief Institute, Indianapolis, IN. The LOINC® is copyrighted (1995-2001) by Regenstrief Institute and the LOINC® Committee. The Department of Veterans Affairs abides by all copyright restrictions. For further information go to <<http://www.regenstrief.org/loinc/>>.

c. National Laboratory Test (NLT) Mapping to Logical Observation Identifier Names and Codes (LOINC®) Patch LR*5.2*215, Technical, Installation and User Guides, Version 5.2, April 1999, Department of Veterans Affairs, Software Service, Clinical Ancillary Product Line. Further information is at <http://vista.med.va.gov/softserv/clin_nar.row/lab/loinc/loinchm.htm>.

6. FOLLOW-UP RESPONSIBILITY: The Chief Consultant for Public Health, Strategic Healthcare Group (SHG), and Chief Consultant, Diagnostic Services SHG, are responsible for the contents of this Directive. Technical support for the preceding actions will be provided by the OI Software Design and Development Group. Content support will be provided by the Chief Consultant, Diagnostic Services SHG.

7. RECISSIONS: None. This VHA Directive expires June 30, 2006.

| | | |
|---------------|------|--|
| | | S/ Timothy N. Buckley for |
| | | Thomas L. Garthwaite, M.D. |
| | | Under Secretary for Health |
| | | |
| DISTRIBUTION: | CO: | E-mailed 6/27/2001 |
| | FLD: | VISN, MA, DO, OC, OCRO, and 200 - E-mailed 6/27/2001 |